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2Abstract
The serine protease HtrA2 is released  from mitochondria following apoptotic stimuli. 
Once in the cytosol, HtrA2 has been implicated in promoting cell death by a caspase- 
dependent and -independent mechanism.  However, mice lacking expression of HtrA2 
show no evidence of reduced rates of cell death. On the contrary, loss of HtrA2 causes 
mitochondrial  dysfunction  leading to a neurodegenerative disorder with parkinsonian 
features. This suggests that the protease function of HtrA2 in the mitochondria, and not 
its pro-apoptotic action in the cytosol, is critical. Mammalian HtrA2 is therefore likely 
to function in vivo in a manner similar to its bacterial homologues, which are involved 
in protection against cell stress.
The  bacterial  DegS  homologue  senses  unfolded  proteins,  activating  a  proteolytic 
cascade leading to induction of stress response genes. Transcriptional profiling of wild 
type and HtrA2 knockout (KO) cells identified the stress-inducible transcription factor 
CHOP being differentially  regulated when mitochondrial  stress was triggered.  CHOP 
up-regulation  was  found  in  HtrA2  KO  mouse  brains  but  not  in  other  tissues. 
Transcriptional  profiling  of brain  tissue  revealed  a  number  of putative  ATF4  target 
genes  being  up-regulated  in  HtrA2  KO,  among  these  CHOP.  Promoter  analysis 
identified  a  C/EBP-ATF  composite  site  in  the  majority  of  the  genes  within  this 
signature.  Therefore,  loss  of  HtrA2  might  impact  on  nuclear  gene  expression 
specifically in brain, subverting normal cellular homeostasis leading to disease.
In humans, point mutations in HtrA2 are a susceptibility factor for Parkinson’s disease 
(PD) resulting in partial loss of proteolytic activity. Affinity purification shows that the 
mitochondrial  kinase  PINK1  interacts  with  HtrA2.  PINK1  mutations  are  associated 
with  the  PARK6  PD  susceptibility  locus.  HtrA2  is  phosphorylated  in  a  PINK1- 
dependent  manner  at  residues  adjacent  to  positions  found  mutated  in  PD  patients. 
Phosphorylation  of  HtrA2  and  thereby  modulation  of its  proteolytic  activity  seems 
necessary  for  the  function  of  HtrA2  in  the  mitochondria  contributing  to  increased 
resistance of cells to mitochondrial stress.
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171  Chapter 1: Introduction
1.1  Apoptosis, programmed cell death
Programmed  cell  death,  also  known  as  apoptosis,  is  an  essential  mechanism  in  the 
removal of cells during development and in homeostasis of multi-cellular organisms in 
order to control cell number. During vertebrate life, most newly formed but unwanted 
lymphocytes in the thymus undergo apoptosis.  Apoptosis also plays an important role 
in  a  variety  of  diseases,  including  cancer,  autoimmune  diseases  and  many 
neurodegenerative disorders.
The process of controlled killing by activation of an intracellular death programme was 
first described in 1972, when Kerr and co-workers observed that large numbers of cells 
die  after  hormone  withdrawal  from  hormone-dependent  tumours  (Kerr  et  al.  1972). 
Cells undergoing apoptosis show characteristic morphological changes,  including cell 
shrinkage,  plasma  membrane  blebbing,  DNA  fragmentation  and  chromatin 
condensation  which  eventually  result  in  disassembly  of  the  cell  into  membrane- 
enclosed vesicles, termed apoptotic bodies.  These are then recognised and eliminated 
by  phagocytes or neighbouring cells  without the  release of intracellular components, 
thereby preventing an inflammatory response. At the cell surface phosphatidyl-serine is 
externalised,  which  promotes  recognition  of  the  apoptotic  cell  for  phagocytosis 
(Homburg et al.  1995; Martin et al.  1995). In contrast, cells that die by an uncontrolled 
process,  termed  necrosis,  swell  and  the  organelles  lose  their  integrity.  The  plasma 
membrane  ruptures  and  the  intracellular  contents  are  released,  which  can  elicit  a 
damaging inflammatory response.
The  first  genetic  evidence  for  apoptosis  came  from  studies  using  Caenorhabditis 
elegans: during somatic development, apoptosis normally occurs in  131  cells resulting 
in an adult worm with 959 cells. This made C.  elegans a model organism for studying 
the core components of the cell death machinery (for review (Meier et al. 2000)).
1.1.1  Caspases, central executioners of apoptosis
Studies in C.  elegans led to the identification of genes required for apoptosis, the ced 
genes. One of them was called ced-3 and loss-of-function mutations in ced-3 resulted in
18survival of all  131  doomed cells (Ellis and Horvitz 1986). CED-3 is the prototype of a 
family of cysteine proteases, termed caspases, with specificity for aspartic acid residues 
carboxy-terminal (C-terminal) to the cleavage site in their substrates (Yuan et al.  1993). 
Caspases  are  highly  conserved  throughout  evolution.  They  are  synthesised  as 
enzymatically inert zymogens composed of three domains: an N-terminal pro-domain, 
a large domain containing the active site cysteine and a C-terminal small domain (for 
review (Eamshaw et al.  1999)). The pro-domain is separated from the large domain by 
an aspartate cleavage site.  The large and the small domains are separated by a linker 
region  harbouring  one  or two  aspartate  cleavage  sites.  Based  on  their  structural  and 
functional differences the apoptotic caspases can be divided into two groups. The first 
group comprises caspases with large pro-domains which are involved in the initiation 
of the  apoptotic  response  and  are  therefore  named  initiator  caspases.  Two  types  of 
protein-protein interaction motifs have been identified in their pro-domains: capsase-8 
and  -10  each  contain  two  death  effector  domains  (DED),  while  caspase-2  and  -9 
contain  caspase  recruitment  domains  (CARD).  These  domains  enable  them  to  bind 
adaptor  molecules  containing  similar  domains,  a  process  which  is  required  for their 
activation.  The second group of caspases comprises caspases with short pro-domains 
such as caspase-3 and -7. They are activated by the initiator caspases and are therefore 
termed effector caspases.
Caspases are ubiquitously expressed in most cells, however, as zymogens they exhibit 
low  intrinsic  enzymatic  activity.  Upon  a  pro-apoptotic  stimulus,  pro-caspases  are 
activated  by  proteolytic  cleavage  either  through  an  autocatalyic  process  or  through 
other caspases. A first proteolytic cleavage in the linker region divides the pro-caspase 
into a large and a small caspase subunit and a second cleavage removes the N-terminal 
pro-domain. The active caspases are heterotetramers composed of two identical  small 
and two identical large subunits with two active sites.
Currently, two major pathways are described by which different initiator pro-caspases 
can be activated. One is dependent on a cell surface stimulus and therefore termed the 
extrinsic pathway:  the apoptotic  signal  is transduced through the binding of an extra­
cellular  death  ligand  to  its  death  receptor,  such  as  CD95,  TRAIL-R1  or  TRAIL-R2 
(Ashkenazi  and  Dixit  1998).  This results in the activation of pro-caspase-8,  which  is 
mediated by recruitment to the adaptor protein FADD (Figure  1-1 A). The other major
19pathway  for  pro-caspase  activation  occurs  via  intrinsic  stimuli  as  a  consequence  of 
cellular stress such as irradiation, cytotoxic drugs, and growth factor withdrawal. This 
involves release of cytochrome c from mitochondria which is required for activation of 
the adaptor protein bound initiator caspase-9 (Figure 1  -IB). Once initiator caspases are 
activated, they target and activate effector caspases such as caspase-3 and -7, thereby 
initiating a complex amplification cascade.
1.2  Cellular substrates of caspases
Once  active,  caspases  can  cleave  a  variety  of  intra-cellular  substrates,  including 
structural components, protein kinases and components of the DNA repair machinery. 
This results in inhibition of cellular survival pathways and destruction of cell structure 
and commitment to cell death (for review (Eamshaw et al. 1999)).
Another important feature of apoptosis is the disassembly of the nucleus. The inhibitor 
of the  nuclease  CAD  (ICAD)  is  cleaved  by  caspase-3  (Liu  et  al.  1997),  leading  to 
activation  of DNA  fragmentation  and  nuclear  chromatin  condensation  (Enari  et  al. 
1998).  Mediators of DNA repair, such as PARP, DNA-PKs and hsRAD51  are among 
the  earliest  proteins  to  be  cleaved  in the  apoptotic  cell,  which prevents  DNA  repair 
allowing  accumulation  of  fragmented  DNA.  Cleavage  of  major  structural  nuclear 
proteins,  including the  laminins,  are essential  for disassembling the nuclear  structure 
required for nuclear shrinkage (Rao et al.  1996).
1.2.1  Formation of the apoptosome
Cytochrome  c  release  from  mitochondria  into  the  cytosol  plays  a crucial  role  in the 
amplification of apoptotic signals. Cytochrome c is essential for the intrinsic initiation 
of a caspase cascade by causing formation of the apoptosome (for review (Green and 
Reed  1998;  Desagher and Martinou 2000)). Normally, cytochrome c is located in the 
mitochondrial  intermembrane  space,  where  it  serves  an  essential  function  in  the 
respiratory chain. During apoptosis, cytochrome c release from the mitochondria leads 
to oligomerisation with the adaptor protein Apaf-1.  In the presence of ATP, this leads 
to conformational changes, which unmask the CARD domain of Apaf-1.  Via CARD- 
CARD interaction, pro-caspase-9 is recruited into this protein complex (Li et al.  1997), 
forming the apoptosome (Cain et al.  1999). Aggregation of pro-caspase-9 facilitates its
20autoactivation, which then leads to activation of downstream caspases, such as effector 
caspase-3  and  -7.  In the absence of an apoptosis  signal,  the CARD of Apaf-1  is not 
exposed and therefore unable to bind to pro-caspase-9.
Besides  cytochrome  c,  other  proteins  are  released  from  the  mitochondria  during 
apoptosis.  Smac  and  HtrA2  are  released  from  the  intermembrane  space,  and  their 
function will be discussed later.  Apoptosis-inducing factor (AIF) and endonuclease G 
are released after a cell  has committed to die and their release is dependent on post- 
mitochondrial caspase activity (Amoult et al.  2003).  AIF  was initially described as a 
pro-apoptotic  protein  to  function  as  a  protease  and  flavoprotein  (Susin  et  al.  1996; 
Susin et al.  1999), however, mice deficient for AIF die during embryogenesis without 
an over-abundance of cells (Joza et al.  2001), and mice hypomorph for AIF are more 
sensitive to induction of apoptosis rather than showing increased resistance (Klein et al.
2002). Endonuclease G mediates nucleosomal DNA fragmentation during apoptosis (Li 
et al. 2001).
1.2.2  Bcl-2 proteins
There is a large body of evidence that release of mitochondrial proteins is controlled by 
members of the Bcl-2 family. Over time, a large number of Bcl-2 family members have 
been  identified,  which  can  be  divided  into  three  groups  based  on  structural  and 
functional  differences.  Members  of  group  I,  such  as  Bcl-2  and  Bcl-XL  are  anti- 
apoptotic. They contain four short conserved Bcl-2 homology (BH) domains and a C- 
terminal hydrophobic sequence, which localises the proteins predominantly to the outer 
surface of the mitochondria, but also to the endoplasmic reticulum (ER) membrane and 
outer  nuclear  membrane  (Krajewski  et  al.  1993;  Akao  et  al.  1994).  In  contrast, 
members of group II and III have pro-apoptotic activity (for review (Adams and Cory
1998)).  Members of group II, including Bax and Bak, are similar in structure to Bcl-2 
and  Bcl-XL.  They  also  contain  the  C-terminal  hydrophobic  tail,  but  only  three  BH 
domains. Group III consists of a large and diverse group of proteins including Bid, Bad 
and Bim, whose only common feature is the presence of a BH3 domain. These BH3- 
only proteins are essential initiators of apoptosis (Huang and Strasser 2000).
Pro-apoptotic Bcl-2 members were found to localise to the cytosol or cytoskeleton prior 
to a death signal. Upon an apoptotic stimulus they are activated and translocate to the
21mitochondria, where they can dimerise with and neutralise Bcl-2 or Bcl-XL and induce 
cytochrome  c  release  (for  review  (Desagher  and  Martinou  2000)).  The  principal 
mechanism  by  which  Bcl-2  family  proteins  regulate  apoptosis  is  by  controlling 
cytochrome c release from the mitochondria  Once the apoptotic process gets past the 
mitochondria, Bcl-2 and Bcl-XL have no protective effect (Moriishi et al.  1999).
1.2.3  Inhibitor of Apoptosis proteins
Inhibitor of Apoptosis (1AP) proteins were first discovered in baculovirus through their 
ability to inhibit apoptosis of insect cells upon viral infection (Clem et al.  1991; Bump 
et  al.  1995;  Uren  et  al.  1998).  They  were  found to  suppress  caspase  activation  and 
apoptosis induced by a variety of stimuli, including TNF, CD95L/FasL, staurosporine, 
etoposide and growth factor withdrawal (for review (Salvesen and Duckett 2002)). The 
human members of the IAP family, X-linked IAP (XIAP), cIAPl, cIAP2, neuronal IAP 
(NIAP),  ILP2,  ML-IAP,  Survivin  and  Bruce  contain  one  to  three  BIR  (baculovirus 
IAP-repeat)  motifs.  Some  IAP  members  also  contain  additional  protein-protein 
interaction  domains,  such  as  a  RING  and  a  CARD  domain.  IAPs  appear  to  inhibit 
apoptosis  through  direct  interaction  with  caspases.  XIAP,  which  is  the  most  potent 
inhibitor,  can  specifically  bind  and  inhibit  caspase-3,  -7  and  -9  in  vitro,  thereby 
blocking the apoptotic process (Deveraux et al.  1997; Deveraux et al.  1998). The RING 
domain, which recruits E2 ubiquitin-conjugating enzymes, mediates ubiquitylation and 
destruction  of  IAP  interacting  proteins  as  well  as  IAPs  themselves  by  the  26S 
proteasome (Yang et al. 2000).
On  activation,  caspases  are  proteolytically  processed  between  their  large  and  small 
subunits  as  a  result  of either  autocatalytic  processing  following  dimerisation  or  the 
activity  of  upstream  proteases.  For  caspase-3,  -7  and  -9,  the  newly  generated  N- 
terminus  of  the  small  subunit  constitutes  an  IAP-binding  motif  (IBM)  which  is 
characterised  by  an  alanine  at  position  PL  The  IBM  is  then  bound  by  the  IBM- 
interaction grove in the BIR2 (caspase-3, -7) or BIR3 (caspase-9) domain of XIAP. In 
addition, a peptide strand preceding the BIR2 domain stretches across the catalytic cleft 
of caspase-3  and  -7,  leading  to  tight  inhibition  of their  catalytic  activity  (Sun  et  al.
1999).  In  addition to  interaction  of the  IBM  of caspase-9  with  the  BIR3  domain  of 
XIAP, a helix immediately after the BIR3  domain binds to the dimer interface of the
22caspase, thereby preventing it from dimerising and becoming catalytically active (Sun 
et al.  2000;  Shiozaki  et al.  2003).  Intriguingly,  those elements of XIAP  required for 
caspase  inhibition  are  not  conserved  among  other  mammalian  IAPs  (for  review 
(Eckelman et al. 2006)). Therefore, it seems that XIAP is the only mammalian IAP that 
directly  inhibits caspase activity,  and the mechanism by  which the other mammalian 
IAPs attenuate apoptosis is less clear.
1.2.4  IAP antagonists
In D.  melanogaster,  the cytoplasmic  IAP antagonists Reaper,  Grim,  HID,  Sickle and 
Jaffac2 promote apoptosis by interacting with the BIR domains of IAPs through their 
N-terminal  IBMs,  thereby  excluding  active  caspases  from  these  complexes  (Abrams 
1999;  Goyal  et  al.  2000;  Christich  et  al.  2002;  Srinivasula et  al.  2002;  Tenev  et  al. 
2002; Wing et al. 2002). Initially, two mammalian proteins with N-terminal IBMs have 
been identified: Smac (also known as DIABLO) (Du et al. 2000; Verhagen et al. 2000; 
Ekert et al.  2001) and  HtrA2 (also known as Omi)  (Suzuki et al. 2001;  Hegde et al. 
2002; Martins et al. 2002; van Loo et al. 2002; Verhagen et al. 2002). They appear to 
be able to act through a mechanism  similar to the Reaper family  proteins in flies by 
interacting with the BIR domains of mammalian IAPs through their N-terminal IBMs. 
Concomitantly,  other proteins were  identified to contain  IBMs and  many are able to 
antagonise XIAP inhibition of caspase-3  in vitro  (Hegde et al.  2003; Verhagen et al. 
2007).  In mammalian cells, apoptotic stimuli result in the release of Smac and HtrA2 
from  the  mitochondrial  intermembrane  space  into  the  cytosol,  along  with  other 
apoptosis regulatory  molecules  such as cytochrome c, AIF  and endonuclease  G (van 
Loo et al. 2002). Since IAPs are localised in the cytosol, the release of Smac and HtrA2 
will result in displacement of IAPs from caspases and loss of their suppressive effect on 
caspase activity.
1.2.5  Identification of HtrA2 as a Reaper-related protein
HtrA2  is  synthesised  as  a  49kD  precursor  containing  a  mitochondrial  targeting 
sequence  at  its  N-terminus  (amino  acids  1-31),  which  gets  cleaved  off  upon 
translocation into the mitochondrial  matrix.  Further,  HtrA2 possesses a central  serine 
protease domain (amino acids  166-342) and a C-terminal PDZ binding domain (amino 
acids 364-445) (Figure  1-2A). Following import into mitochondria, HtrA2 is anchored
23into the inner mitochondrial membrane through an N-terminal transmembrane domain. 
In addition, this enzyme also exists in the intermembrane space of mitochondria as a 
more  abundant  non-anchored  form  that  results  from  cleavage  C-terminal  of  the 
transmembrane  domain.  Processing  of  HtrA2  was  thought  to  occur  through 
autoproteolytic  cleavage,  and  in  vitro  HtrA2  can  process  itself (Seong  et  al.  2004). 
However,  mice with proteolytically  inactive  HtrA2  show that  the mutant HtrA2  was 
correctly  processed  into the  mature  form  in vivo  (Jones et  al.  2003),  suggesting  that 
processing of HtrA2 into the mature form is probably catalysed by other mitochondrial 
proteases.  The  36kD  mature  HtrA2  (amino  acids  134-458)  exposes  an  IBM  at  the 
newly generated N-terminus, and gets released into the cytosol following an apoptotic 
stimulus.
HtrA2 was the second mitochondrial protein identified to bind to XIAP (Suzuki et al. 
2001;  Hegde  et  al.  2002;  Martins  et  al.  2002;  van  Loo  et  al.  2002;  Verhagen  et  al.
2002). Binding of HtrA2 to IAPs suppresses their inhibitory activity towards caspases. 
This binding results in the increase of the proteolytic activity of HtrA2 (Martins et al.
2003)  and  has  also  been  reported  to  cause  proteolytic  degradation  of bound  IAPs 
(Srinivasula et al. 2003; Yang et al. 2003). HtrA2 has therefore been proposed to be a 
pro-apoptotic  protein  analogous  to  the  Reaper  family  proteins  that  removes  the 
protective  effect  of IAPs and  thus  potentiates  the  ability  of cytochrome  c  to  trigger 
caspase activation (Martins et al. 2002; van Loo et al. 2002; Wolf and Green 2002; van 
Gurp et  al.  2003).  To achieve a complete antagonism of XIAP-mediated  survival  by 
HtrA2, both its IBM and its protease activity were required, as mutations at either the 
N-terminal  alanine  of the  IBM  (A 134)  or  the  catalytic  serine  (S306)  reduced  its 
potency to promote cell death (Verhagen et al. 2002). Interaction of the N-terminus of 
mature HtrA2 with the BIR2 and BIR3 domains of XIAP is responsible for the caspase- 
dependent  death  induced  by  HtrA2.  Mutation  of alanine  134  to  glycine  in  HtrA2 
abolishes  the  IBM  and  prevents  interaction  with  XIAP  causing  cell  death  that  is 
independent  of caspase  activation  (Verhagen  et  al.  2002),  therefore  mediating  cell 
death through its own serine protease activity (Suzuki et al. 2001; Hegde et al. 2002).
At  the  commencement  of this  work,  mice  with  deleted  HtrA2  genes  had just  been 
generated. These mice showed a severe phenotype and died early during development. 
Although the severity of the phenotype of the HtrA2 deficient mice suggested a crucial
24role  for  this  protease,  it  was  unclear  if this  was  due  to  an  apoptotic  defect  or  an 
essential role for HtrA2 in the mitochondria of healthy cells. In contrast, deletion of the 
other mammalian Reaper homologue Smac in mice has no detectable effect other than 
relatively slow activation of caspase-3 in vitro (Okada et al. 2002). Little else is known 
about the function of Smac and close homologues have not been characterised in non­
mammalian  species.  Similarly,  mice  deleted  for  the  broadly  expressed  IAP  family 
member XIAP  show  no abnormal  phenotype  (Harlin et al.  2001).  It  is possible that 
IAPs and their antagonists play relatively minor roles in the regulation of apoptosis in 
mammals, unlike in flies. Alternatively, the high degree of redundancy amongst IAPs, 
and  possibly  also  IBM-containing proteins,  may  make their  in vivo  function  hard to 
analyse by single gene deletion experiments.
1.3  HtrA2 belongs to the HtrA family of serine proteases
HtrA2  belongs  to  the  HtrA  family  of serine  proteases,  which  is  conserved  across 
eukaryotic and prokaryotic species (Clausen et al. 2002).  Initially, mammalian HtrA2 
was  identified  as a homologue  of the Escherichia coli protein  HtrA  (also  known  as 
DegP),  and  was  reported  to  be  up-regulated  in conditions  of cellular  stress  such  as 
ischemia-reperfusion, heat shock, and ER stress (Faccio et al. 2000; Gray et al. 2000). 
However,  whereas  bacterial  DegP  protease  possesses  two  PDZ  (protein/discs-large 
protein/zonula)  domains  and  forms  a  hexamer  (Krojer  et  al.  2002),  bacterial  DegS 
protease  is  structurally  closer  to  mammalian  HtrA2  in  that  it  has  a  similar  domain 
structure with only one PDZ domain and forms a trimer (Li et al. 2002;  Wilken et al.
2004)  (Figure 1-2B and Figure 1-3B, C and D).
HtrA2  is the only  member of the  family of four mammalian HtrA proteases that has 
been found in the mitochondria and the only one that has been shown to be processed 
to reveal a Reaper-like N-terminal IBM. HtrAl  and HtrA3 are reported to be secreted 
from cells (Hu et al.  1998; Nie et al. 2003; Tocharus et al. 2004), the same seems to be 
the case  for HtrA4.  Neither of those three possesses a TM domain,  but  instead their 
sequences are characterised through a signal  sequence (SS)  found at the N-terminus, 
followed  by  an  insulin  growth  factor  binding  domain  (IGFBP)  and  a  kazal-protease 
inhibitor (KI) domain (Figure 1-2B).
251.3.1  HtrA2 structure and regulation of its protease activity
The  crystal  structure  of  mature  HtrA2  revealed  a  trimeric  structure  mediated 
exclusively  by  the  serine  protease  domains.  In  addition,  mutational  analysis 
demonstrated that monomeric HtrA2 mutants are  unable to induce cell death and are 
deficient in protease activity (Li et al. 2002). In the crystal structure, the PDZ domains 
are oriented inwards and cover the catalytic centre of the protease (Figure 1-3 A and B). 
The  peptide-binding  pocket  of the  PDZ  domain  is  buried  in  the  intimate  interface 
between  the  PDZ  and  the  protease  domains.  Interestingly,  the  topology  of the  PDZ 
domain  of HtrA2  exhibits  a  circular  permutation,  which  has  been  observed  only  in 
bacterially  derived  PDZ-like  sequences  (Liao  et  al.  2000).  Thus,  the  evolutionary 
conservation is manifested in both primary sequence and three-dimensional  fold. The 
N-terminal  IBM  is  flexible  in  solution  and disordered  in  the  HtrA2  crystals  (Figure 
1  -3A). However, in contrast to Smac, the N-termini of the three HtrA2 monomers are 
close to each other (Figure 1-3B), potentially having an adverse effect on IAP binding.
Peptide  library  screening  determined  the  primary  sequence  specificity  for  HtrA2 
proteolytic  activity,  indicating  that the  protease  favours  cleavage  following  aliphatic 
residues (Martins et al.  2003), similar to  its bacterial  homologues DegP (Jones et al. 
2002)  and  DegS  (Walsh et al.  2003).  Secondary  preferences of HtrA2  include  basic 
residues  at  the  P2  and  P3  positions  as  well  as  small  residues  at  PI'  and  aromatic 
residues  at  P2\  The  optimal  cleavage  peptide  was  determined  as  IRRV-SYSF,  this 
substrate can be used in vitro to monitor HtrA2 activity (Martins et al. 2003). It is likely 
that  this  specificity  at  least  partly  determines  the  choice  of sites  selected  by  HtrA2 
within a target protein. However, the selection of target proteins may also be dependent 
on  which  proteins  are  bound  by  the  PDZ  domain  of HtrA2  and  thus  brought  into 
proximity with the activated protease domain.  Binding selectivity of the PDZ domain 
of HtrA2  was  shown  to  favour a C-terminal  valine  or  isoleucine,  preceded  by  three 
residues  rich  in  tyrosine  and  phenylalanine  or  large  aliphatic  groups  (Martins  et  al. 
2003; Gupta et al. 2004).
Mutational  studies  demonstrated  that  the  PDZ  domain  dampens  the  proteolytic  and 
cytotoxic potential of HtrA2 (Li et al. 2002; Martins et al. 2003). Activation of HtrA2 
protease activity  can be accomplished through heat shock,  interactions with the PDZ
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are thought to cause conformational  changes  leading to opening of the  PDZ domain 
and  enabling  access  to  the  catalytic  centre.  Interestingly,  the  proteolytic  activity  of 
DegP is induced at elevated temperatures (Spiess et al.  1999), similarly HtrA2 activity 
is increased  following transient heat  shock.  Peptides binding to the  PDZ domains of 
DegS and DegP were also characterised to activate their proteolytic activity (Jones et 
al. 2002; Walsh et al. 2003).
1.3.2  E. coli DegP can function as a chaperone or protease
DegP is an essential protein in the E.  coli periplasm and it is necessary for oxidative, 
thermo, and osmotic tolerance. DegP protects cells by degrading damaged or denatured 
proteins  generated  during  heat  or  chemical  stress  (Pallen  and  Wren  1997).  Such 
damaged proteins would otherwise form aggregates that are highly toxic to cells. DegP 
homologues  in  a  number  of pathogenic  bacteria  have  been  shown  to  be  virulence 
factors, helping bacteria survive within the host cell  in part by degrading periplasmic 
proteins  damaged  by  the  host’s  oxidative  defence  system  (Pedersen  et  al.  2001). 
Several years ago, an unusual property of E. coli DegP was reported. It appears that the 
enzyme acts to chaperone unfolded proteins, possibly contributing to their re-folding, 
and degrades them only at high temperatures, when the amount of unfolded proteins in 
the cell  is greatly  increased (Spiess et al.  1999).  Therefore,  DegP exhibits chaperone 
function at normal temperature and protease function at high temperature.
In contrast to mammalian HtrA2, bacterial DegP protease possesses two PDZ domains 
and does not contain a transmembrane domain (TM) (Figure  1-2B). Whereas HtrA2 is 
active  as a trimer,  DegP  forms a hexameric  structure  (Figure  1-3B  and  D).  Another 
striking difference between HtrA2 and DegP  in the environments of their active sites 
emerged from the crystal structures. The proteolytic domains are typical of trypsin-like 
proteases with a classical  aspartate-histidine-serine catalytic triad  located  in a crevice 
between  two  (3-barrel  lobes.  In  HtrA2,  the  proteolytic  active  sites  are  in  an  active 
conformation  poised  for  catalysis  (Li  et  al.  2002).  In  contrast,  in  the  inactive 
conformation, the catalytic centre of DegP is sterically blocked by a trio of loops from 
the  surrounding  protein,  and  the  catalytic  triad  is  distorted  away  from  an  active 
configuration  (Krojer  et  al.  2002).  Once  DegP  is  active  as  a  protease,  it  cleaves
27substrates  which  are  transiently  or  globally  denatured.  DegP  exhibits  preference  for 
aliphatic amino acids at position PI  similar to mammalian HtrA2, however in contrast 
to  HtrA2,  DegP  does  not  show  preference  for  any  specific  amino  acid  at  the  PI* 
position of its substrate (Kolmar et al. 1996).
1.3.3  E. coli DegS is involved in the periplasmic stress response
Interestingly, another bacterial member of the HtrA family of serine proteases,  DegS, 
acts as sensor for unfolded proteins  in the periplasm (Walsh et al.  2003).  DegS,  like 
mammalian HtrA2, possesses only one PDZ domain (Figure  1-2B), and it is anchored 
into  the  inner  bacterial  cell  membrane  facing  the  periplasmic  space  (Figure  1-5). 
Unfolded proteins activate DegS by  binding to its PDZ domain, thereby relieving its 
inhibitory effect. Activated DegS initially cleaves the anti-sigma factor RseA, an inner 
membrane protein that, together with RseB, sequesters the transcriptional regulator oE  
at the cytoplasmic  face  of the  inner  membrane.  The  first  cleavage  of RseA  through 
DegS  allows  a  second  cleavage  by  the  membrane-embedded  metalloprotease  RseP 
(also  known  as  YaeL)  (Alba  et  al.  2002;  Kanehara  et  al.  2002).  This  releases  the 
transcriptional regulator oE  from its sequestering complex with the cytosolic domain of 
RseA,  thereby  allowing  aE   to  associate  with  the  core  RNA  polymerase,  enabling 
transcription  of genes  encoding  periplasmic  chaperones,  folding  catalysts,  proteases 
and proteins involved in cell wall biogenesis (Figure 1-5). Interestingly, DegP is among 
the genes induced through cE-mediated transcription (Erickson and Gross 1989). In this 
envelope  stress  response  the  activation  of  DegS  is  the  first  decisive  step  in  the 
proteolytic cascade, and is tightly controlled by the association of unassembled outer 
membrane porins (OMPs) via a conserved YXF motif located at their C-termini (Walsh 
et  al.  2003).  Crystal  structures  of OMPs  show  that  in  the  fully  assembled  state  this 
motif is  buried  and  therefore  cannot  bind  to  DegS.  Thus,  the  exposure  of the  YXF 
motif of OMPs signals folding stress, leading to activation of DegS and up-regulation 
of the downstream envelope stress response genes.
DegS crystallised as a trimer, where the protease domains form the core and the PDZ 
domains protrude outwards, creating a funnel-like arrangement (Wilken et al. 2004). In 
this  structure,  the  active  sites  of the  protease  domains  are  not  blocked  by  the  PDZ 
domains.  However,  structural  alignments to  several  serine proteases indicate that the
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obtained when the crystals were soaked with an activating peptide resembling the C- 
terminus  of OMPs  (Figure  1-3C).  The  peptide  was  bound  in  a  pocket  of the  PDZ 
domain close to the  interface  with the  protease domain.  Association of the  activator 
peptide  results  in  several  important  conformational  changes  in  the  protease  domain. 
Most  noticeably,  the  flexible  loop  L3,  protruding  from  the  protease  domain  was 
displaced from its previous location in the inactive form and was stabilised by a contact 
to  the  OMP  peptide.  Upon  peptide  association,  several  residues  in  the  active  site 
involved in substrate binding and catalysis, previously blocked or distorted in inactive 
DegS,  become  accessible  for  substrate  binding  and  correctly  aligned  for  catalysis 
(Wilken et al. 2004).
Structural comparison of DegS and HtrA2 clearly indicates that the active site of HtrA2 
is  present  in  a  non-functional  state.  There  is  no  oxyanion  hole  and  most  likely  no 
proper catalytic triad. Consistently, some active site loops of HtrA2 align better to the 
inactive than to the active form of DegS. Since the position of the PDZ domain in the 
HtrA2 crystal structure was strongly influenced by crystal packing constraints (Li et al. 
2002),  in  solution,  the  PDZ  domain  of HtrA2  might  function  similarly  as  in  DegS, 
trapping the flexible loop L3. Upon a proper stimulus, the PDZ domain might reorient, 
thereby  releasing  L3,  which  in  turn  triggers  adjustment  of  the  activation  domain 
yielding a functional active site. In the PDZ deletion mutant of HtrA2, which exhibited 
increased proteolytic  activity  (Li  et al.  2002;  Martins et al.  2003),  loop L3  probably 
cannot be fixed in the domain interface and thus activates the protease.
Activation  of DegP  should  require  larger  conformational  changes than  in  DegS  and 
HtrA2. In its chaperone conformation, the DegP protease was observed in a completely 
inactive  state  and  the  active  site  loops  LI  and  L2  are  severely  distorted  and  attain 
different  conformations.  For  example  the  turn  structure  of loop  LI  that  sets  up  the 
oxyanion hole  is pre-formed in DegS and HtrA2, while it is entirely absent in DegP. 
However, similar to DegS and HtrA2, DegP can be allosterically activated by specific 
peptides that bind to its PDZ domains (Jones et al. 2002) and has a flexible loop L3 that 
is wedged between protease and PDZ domains (Krojer et al. 2002; Kim et al. 2003).
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homologues, DegP and DegS, thus appear to be very different from the proposed pro- 
apoptotic,  Reaper-like  action  of mammalian  HtrA2.  Whether  HtrA2  exerts  a  similar 
function  in  mammals  is  unclear,  however,  the  high  level  of similarity  between  the 
bacterial  proteases  and  mammalian  HtrA2  may  suggest  that  they  do  indeed  share 
similar functions.
1.4  Proteins binding to and cleaved by HtrA2
Since  HtrA2  was discovered  in 2000  (Faccio  et  al.  2000;  Gray  et al.  2000),  several 
binding partners and substrates for its proteolytic activity have been reported.  First of 
all,  HtrA2  was  reported  to  bind  to  XIAP  and  mediate  its  proteolytic  degradation 
(Suzuki  et  al.  2001;  Hegde  et  al.  2002;  Martins  et  al.  2002;  van  Loo  et  al.  2002; 
Verhagen et al. 2002; Srinivasula et al. 2003; Yang et al. 2003).
Amyloid  p,  a  principle  component  of the  cerebral  plaques  found  in  the  brains  of 
patients  with  Alzheimer’s  disease,  was  found  to  bind  to  the  C-terminal  region 
containing  the  PDZ  domain  of HtrA2  by  yeast  two-hybrid  assay  (Park et  al.  2004), 
however, the production or degradation of Amyloid p was not directly altered by HtrA2 
(Liu et al. 2005). Subsequently, HtrA2 was shown to bind to the amyloid p precursor 
protein (APP), which partially localises to mitochondria. APP was cleaved in vitro and 
in vivo by HtrA2, resulting in the C l61   fragment of APP (amino acids 535-695) (Park 
et al. 2006).  Presenilins are important determinants of y-secretase activity responsible 
for proteolytic cleavage of APP. The C-terminal tail of Presenilin l (PS l) was reported 
to bind to the  PDZ domain of HtrA2 and  increase its proteolytic activity, and it was 
suggested that  PS l  may  regulate  HtrA2  proteolytic  activity after its release  from the 
mitochondria during apoptosis (Gupta et al. 2004).
The  anti-apoptotic  protein  ped/pea-15  was  shown  to  interact  with  HtrA2  during 
apoptosis when HtrA2 was released into the cytosol. HtrA2 was implied in degradation 
of ped/pea-15 during apoptosis, and this degradation could be inhibited by the HtrA2 
inhibitor Ucf-lOl (Cilenti et al. 2003; Trencia et al. 2004).
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facilitated  proteasomal  degradation  of  HtrA2,  conversely,  HtrA2  was  capable  of 
cleaving Bruce (Sekine et al. 2005).
WARTS, a tumour suppressor and mitotic regulator was shown to bind to HtrA2’s PDZ 
domain,  enhancing  its  proteolytic  activity  (Kuninaka  et  al.  2005).  Subsequently, 
WARTS was identified to be a substrate for HtrA2 potentially leading to inhibition of 
Gl/S phase progression (Kuninaka et al. 2006).
Peroxiredoxin 1  (Prdxl, also known as Pag) is a cytosolic protein involved in the redox 
regulation  of the  cell.  During  oxidative  stress  Prdxl  expression  is  induced,  which 
causes apoptosis. Prdxl  was shown to bind to the PDZ domain of HtrA2 once released 
from the mitochondria and thereby modulate the proteolytic activity of HtrA2 (Hong et 
al. 2006). All of the proteins interacting with or cleaved by HtrA2 discussed so far are 
cytosolic proteins or, in the case of APP and PS 1, proteins mainly localised to cellular 
membranes such  as plasma,  ER,  and perinuclear membranes.  Only during apoptosis, 
when  HtrA2  is  released  from  the  mitochondria,  can  an  interaction  between  these 
proteins  and  HtrA2  take  place,  suggesting  that  the  increase  in  HtrA2  proteolytic 
activity  mediated  by  binding to  its PDZ domain or the degradation of some of these 
proteins might be necessary for apoptosis.
Interestingly,  one  mitochondrial  protein,  HAX-1,  was  shown to  interact with  HtrA2, 
and this interaction involved both the PDZ and the catalytic domain of HtrA2 (Cilenti 
et al.  2004).  HAX-1  has been  reported to  be an anti-apoptotic  protein (Suzuki  et al. 
1997; Sharp et al. 2002), and its protein levels decreased when cells where stimulated 
with  an  apoptotic  trigger  (Cilenti  et  al.  2004).  Degradation  of  HAX-1  could  be 
prevented with the HtrA2-specific inhibitor Ucf-101  (Cilenti et al. 2004). However, the 
specificity  of this  inhibitor was thrown  into doubt recently  (Klupsch and  Downward
2006), suggesting that HtrA2 possibly interacts with HAX-1, but HtrA2 probably does 
not degrade it. Nevertheless, HAX-1  to date is the only mitochondrial protein shown to 
bind  to  HtrA2.  Recently,  mutations  in  the  HAX-1  gene  were  identified  to  cause 
autosomal recessive severe congenital neutropenia (SCN) (Klein et al. 2007), a primary 
immunodeficiency syndrome associated with increased apoptosis in myeloid cells.
311.5  Cellular stress pathways
Eukaryotic cells recognise and process diverse  stress signals to elicit programmes of 
gene expression that are designed to remediate cellular damage, or alternatively induce 
apoptosis. In the following sub-chapters, an overview about cellular stress pathways is 
given. This does naturally not comprise all stress pathways but a selection of pathways 
and molecules whose understanding is beneficial for readers of this thesis.
1.5.1  The unfolded protein response (UPR)
The  accumulation  of misfolded  proteins  in  the  ER  activates  a  protective  signalling 
cascade  termed  the  unfolded  protein  response  (UPR).  Proximal  transducers  of the 
mammalian UPR,  which include PERK (Shi  et al.  1998;  Harding et al.  1999),  IRE1 
(Tirasophon et al.  1998; Wang et al.  1998), and ATF6 (Haze et al.  1999), are all ER- 
localised transmembrane proteins (Figure  1-6A). Under non-stressed conditions,  they 
are  kept  in  an  inactive  monomeric  state  by  binding  to  the  ER  chaperone  BiP  (also 
called Grp78). During ER stress, misfolded proteins accumulate in the ER, and BiP is 
dissociated  from  the  luminal  domains  of  these  sensor  proteins,  leading  to  their 
activation (Bertolotti et al. 2000; Shen et al. 2002).  For ATF6, dissociation from BiP 
allows  its  translocation  to  the  Golgi,  where  its  cytosolic  domain  encoding  a 
transcription factor (TF), is cleaved by the site 1  (SIP) and site 2 (S2P) proteases (Ye et 
al. 2000). The liberated ATF6 then migrates to the nucleus, where it directly binds to 
and activates the consensus ER stress response element (ERSE) found in the promoters 
of various UPR targets including TFs XBP-1  and CHOP, and ER chaperones like BiP 
and Grp94 (Yoshida et al.  1998; Yoshida et al. 2000). For IRE1, dissociation from BiP 
leads to its dimerisation and activation of the cytosolic kinase domain, which in turn 
stimulates  an  endoribonuclease  activity  located  at  its  C-terminus.  Activated  IRE1 
recognises and cleaves two specific stem loop sequences in the XBP-1  mRNA, which 
are  then  ligated,  resulting  in  a  larger  XBP-1  protein  (spXBP-1)  due  to  a  resulting 
frameshifk  (Shen  et  al.  2001;  Calfon  et  al.  2002).  Spliced  XBP-1  encodes a TF  that 
binds and transactivates the same ERSE site in vitro as ATF6, however, not all ATF6 
and  XBP-1  targets  are  shared  (Yoshida  et  al.  2003).  In  the  case  of  PERK,  BiP 
dissociation  during  UPR  activation  leads  to  oligomerisation  and  activation  of  its 
cytosolic  kinase  domain.  Activated  PERK  phosphorylates  eIF2a,  leading  to  an 
immediate,  yet  transient  protein  synthesis  inhibition  (Harding  et  al.  2000).  Unlike
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consequences  of  PERK  activation  are  shared  with  other  cellular  stress  responses 
including amino acid deprivation,  infection with double-stranded RNA viruses,  haem 
deficiency  and  oxidative  stress  (Figure  1-6B)  (reviewed  in  (Wek  et  al.  2006)). 
Therefore, the mammalian ER stress response can be divided into two main branches: 
one that is downstream of both ATF6 and 1RE1/XBP-1 and is specific to ER stress, and 
another that is downstream of PERK and is shared by other cellular stresses that lead to 
phosphorylation of eIF2a.
1.5.2  elF2a kinases and translational control
An  important  contributor  to  stress  adaptation  is  a  family  of  protein  kinases  that 
phosphorylate  the  a  subunit  of eIF2,  which  leads  to  general  inhibition  of protein 
synthesis.  Yeast cells possess only one eIF2a kinase, whereas mammalian cells have 
four different kinases, namely PERK, PKR, HRI and GCN2, suggesting that the targets 
of these pathways are important in a generalised stress response. In mammals, each of 
the four eIF2a kinases contains unique regulatory regions that recognise a different set 
of stress conditions (Figure  1-6B).  PERK activation by misfolded proteins in the ER 
reduces  the  load  on  the  protein  folding  and  degradation  apparatus  in  the  organelle 
(Harding et al.  1999). PKR activation by double-stranded RNA shuts down the host’s 
protein synthesis machinery, interfering with viral infections (Clemens and Elia 1997). 
HRI  is  activated  by  haem  deprivation,  matching  haemoglobin  synthesis  with  iron 
availability (Chen and London 1995), as well as oxidative and heat stresses in erythroid 
tissues (Lu et al. 2001). In cells deprived of nutrients, activation of mammalian GCN2 
conserves scarce amino acids for use in essential metabolic processes and is activated 
by  elevated  levels  of uncharged  tRNAs  (Berlanga  et  al.  1999;  Sood  et  al.  2000). 
Interestingly,  GCN2  is also activated by  other stresses that are not directly related to 
nutritional deprivation, including proteasome inhibition (Jiang and Wek 2005) and UV 
irradiation (Deng et al. 2002). Phosphorylation of eIF2a impedes recycling of eIF2a to 
its active  GTP-bound  form,  and the accompanying reduction in the levels of eIF2a- 
GTP reduces global  (cap-dependent) translation, allowing cells to conserve resources 
and  to  initiate  a  reconfiguration  of  gene  expression  to  effectively  manage  stress 
conditions.  This  reduction  in  global  protein  synthesis  is  concomitant  with  induced 
translation of selected mRNAs, such as those encoding the bZIP (basic leucine zipper)
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(upstream  open  reading  frames)  located  in  the  5'-leader  of the  ATF4  mRNA  that 
facilitate its translation in response to eIF2a phosphorylation. Elevated levels of ATF4 
lead to induction of additional bZIP TFs, ATF3 (Jiang et al. 2004) and CHOP (Fawcett 
et  al.  1999;  Harding  et  al.  2000),  which  together  induce  a  programme  of  gene 
expression  important  for cellular remediation  and  apoptosis.  The  phosphorylation  of 
elF2a and downstream events are shared with the UPR pathway (Figure 1-6A and B).
1.5.3  CHOP and  Herp are  regulated  by the  ER stress-specific  as 
well as the shared branch of the UPR
CHOP (C/EBP homologous protein, also called Gaddi 53 or Ddit3) is a member of the 
C/EBP  family  of bZIP  TFs that  are  critical  for the  regulation  of various  aspects  of 
cellular  differentiation  and  function  in  multiple  tissues.  CHOP  is  ubiquitously 
expressed at  low levels in proliferating cells,  but when cells are exposed to  stressful 
stimuli the expression of CHOP is increased (for review (Oyadomari and Mori 2004)). 
CHOP has been implicated as a mediator of apoptosis in the contexts of both ER stress 
(Matsumoto et al. 1996; Zinszner et al. 1998; Kawahara et al. 2001; Maytin et al. 2001; 
Gotoh et al. 2002) and oxidative stress (Guyton et al.  1996; Mengesdorf et al. 2002). 
CHOP has a dual role in the regulation of cellular gene expression: as an inhibitor of 
the binding of C/EBP to classical C/EBP target genes (Ron and Habener 1992) and as 
an  activator  of genes  that  have  CHOP-C/EBPp-binding  sites  (Ubeda  et  al.  1996). 
Several genes downstream of CHOP, induced by ER stress (Wang et al.  1998; Sok et 
al.  1999) or mitochondrial stress (Zhao et al. 2002), have been identified to contain this 
CHOP-C/EBPp-binding sequence.  In addition, CHOP interacts with TFs of the AP-1 
family such as JunD, c-Jun and c-Fos, and has been reported to activate transcription of 
their target genes (Ubeda et al. 1999).
CHOP is one of the UPR target genes that has been shown to be dually regulated by 
both the ER stress-specific and the shared branches of the UPR (Ma et al. 2002). The 
CHOP  promoter  contains  both  ERSEs  and  a  C/EBP-ATF  composite  site,  through 
which these two branches act, respectively.  Deletion of either element from a CHOP 
promoter construct leads to a decrease in its transcriptional activity (Ma et al.  2002). 
TFs ATF6 and XBP-1  can bind to ERSEs in vitro, and ATF6 over-expression leads to
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composite site and stimulates CHOP expression in response to various cellular stress 
conditions (Fawcett et al.  1999; Ma et al. 2002).
Herp, an ER localised protein with an N-terminal ubiquitin-like domain is another UPR 
target that is, like CHOP, dually regulated by both the shared and the ER stress-specific 
branches of the UPR pathway (Ma and Hendershot 2004). ATF6 can transactivate the 
Herp gene through the ERSEI and II sites present in its promoter (Kokame et al. 2001). 
In addition, during both amino acid deprivation and ER stress, eIF2a phosphorylation 
causes ATF4 induction, which then directly binds to and transactivates the C/EBP-ATF 
composite site in the Herp promoter (Ma and Hendershot 2004).  Therefore, although 
Herp is an ER localised protein, it can be induced by cellular stress conditions that are 
not thought to affect the ER.
The convergence of two signalling branches of the  ER stress response upon a single 
target  is  a  conserved  feature  of the  UPR,  which  suggests  there  could  be  additional 
targets that are regulated this way. Since the activation of stress-specific eIF2a kinases 
and their common downstream target ATF4 is well-conserved among various cellular 
stress  conditions,  the  ability  of this  pathway  to  transactivate  the  CHOP  and  Herp 
promoters ensures that these genes are also  induced during other stresses that do not 
involve  ATF6 cleavage,  XBP-1  splicing,  and  ERSE  activation  (Figure  1-6B).  These 
dually regulated targets are activated to a much higher level during ER stress than with 
other  cytosolic  stresses  like  hypoxia  (Price  and  Calderwood  1992),  amino  acid 
deprivation (Marten et al. 1994), and oxidative stress (Harding et al. 2000).
1.5.4  ATF3 is induced by multiple stresses
The TF ATF3 has been reported to be induced by a variety of stresses (for review (Hai 
and  Hartman 2001)).  Up-reguation of ATF3  appears to correlate with cellular injury 
and probably leads to detrimental outcomes. The list of conditions that induce ATF3 is 
long:  In  animal  experiments,  the  signals  include  ischemia,  ischemia  coupled  with 
reperfusion,  wounding,  axotomy,  toxicity,  and  seizure;  in  cultured  cells,  the  signals 
include  cytokines,  genotoxic  agents  such  as  UV,  activators  of  JNK  signalling, 
microtubule binding agents, proteasome inhibitors, homocysteine, hydrogen peroxide,
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The increase in ATF3  expression following amino acid deprivation or ER stress was 
demonstrated to occur by mechanisms requiring the eIF2a kinases GCN2 and PERK 
respectively (Jiang et al. 2004). The ATF3 promoter contains an ATF/CRE site and a 
C/EBP-ATF composite site (Liang et al.  1996;  Wolfgang et al.  2000) and ATF4 was 
shown  to  bind  to  the  latter  in  response  to  amino  acid  limitation  (Pan  et  al.  2007), 
leading  to  the  induction  of ATF3.  Its  name  is  slightly  misleading  and  reflects  the 
history of discovery, because ATF3 is more homologous to the Fos proteins (members 
of the AP-1  family) (Meyer and  Habener  1993)  rather than to other members of the 
ATF  family  of TFs.  Homodimers  of ATF3  are  transcriptional  repressors,  however, 
heterodimeric complexes of ATF3 with AP-1 family members have been demonstrated 
to  function as transcriptional  activators.  CHOP,  in addition to being a target gene of 
ATF3  (Wolfgang  et  al.  1997;  Fawcett  et  al.  1999),  also  dimerises  with  ATF3  and 
induces transcription (Hai and Hartman 2001).
Taken together, the ER stress response and the stress pathways leading to activation of 
eIF2a  kinases  overlap  partially  through  the  activation  of PERK  during  ER  stress. 
Therefore, some of the genes induced by ER stress, like CHOP, Herp and ATF3, can 
also be induced by other stresses unrelated to ER stress (Figure  1-6B).  In the case of 
CHOP  and  Herp,  the  ER  stress-specific  branch  (ATF6,  IRE 1/XBP-1)  as well  as the 
shared branch (PERK-eIF2a/ATF4) can lead to their induction. ATF3 expression is not 
up-regulated  by  the  ER  stress-specific  branch,  however,  ATF4  induction  by  eIF2a 
kinases is activating ATF3  expression.  In addition, other stresses like oxidative stress 
and  activation  of p38  MAP  kinase  signalling  modulate  ATF3  expression  (Lu  et  al.
2007),  and  some  of  these  have  also  been  implicated  in  the  activation  of  CHOP, 
although  their  mechanism  has  not  been  studied  extensively  (Kultz  et  al.  1998).  In 
addition, CHOP has been reported to be modulated through phosphorylation by p38 or 
casein  kinase  2,  leading  to  activation  or  inhibition  of  its  transcriptional  activity, 
respectively (Wang and Ron 1996; Ubeda and Habener 2003).
361.6  Parkinson’s disease
Parkinson’s disease (PD), first described by James Parkinson in  1817, is a chronically 
progressive neurodegenerative disease, affecting at least 1% of the population over the 
age of 65, rising to 4-5% over 85 years of age. The aetiology of this disease is likely 
due to combinations of environmental and genetic factors. The main clinical phenotype 
of PD  is parkinsonism,  a movement  disorder that  is characterised  by  resting  tremor, 
rigidity, postural instability, bradykinesia (slowness of movement) and in extreme cases 
akinesia  (absence  of movement)  (Fahn  2003).  At  the  morphological  and  anatomical 
level,  PD  is  characterised  by  degeneration  of the  neural  connection  between  the 
substantia nigra (SN) and the striatum,  two brain regions essential  for normal  motor 
function. The striatum receives its dopaminergic input from neurons of the substantia 
nigra pars compacta (SNpc) via this nigrostriatal pathway. Progressive degeneration of 
the  nigrostriatal  dopaminergic  pathway  results  in  profound  striatal  dopamine 
deficiency, leading to the described motor deficiencies. Often, PD affected brains show 
appearance  of Lewy  bodies  (protein  aggregates)  within  the  surviving  dopaminergic 
neurons. Initially, patients respond well to dopamine replacement therapy but treatment 
is effective for only a limited period and fails to halt disease progression.
1.6.1  Mitochondrial dysfunction in Parkinson’s disease
Mitochondrial dysfunction has long been implicated in the pathogenesis of PD (Figure 
1-8).  Evidence first emerged following the accidental exposure of drug abusers to  1- 
methy 1-4-phenyl-1,2,3,4-tetrahydropyridine  (MPTP)  -   an  environmental  toxin  that 
results in an acute and irreversible parkinsonian syndrome (Langston et al.  1983). The 
active  metabolite  of  MPTP,  the  1  -methyl-4-phenylpyridinium  ion  (MPP+)  is  an 
inhibitor  of  complex  I  of the  respiratory  chain  and  a  substrate  for  the  dopamine 
transporter (DAT). It therefore accumulates in dopaminergic neurons, where it confers 
toxicity and neuronal death through complex I inhibition (Nicklas et al.  1985). This has 
many  deleterious  consequences,  including  increased  oxidative  stress  and  decreased 
ATP  production,  which  causes  increased  intracellular  calcium  concentration, 
excitotoxicity and nitric oxide related cellular damage. Subsequently, administration of 
MPTP to mice was shown to lead to the development of parkinsonism (Sedelis et al.
2001).  Crucially,  a biochemical  link  between MPTP  toxicity  and  idiopathic  PD  was 
established  when complex  I  deficiency  was reported  in the  SN,  skeletal  muscle  and
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2002)).  In  line  with  this,  chronic  administration  of rotenone  in  rats  can  produce  a 
progressive model of parkinsonism (Betarbet et al. 2000; Sherer et al. 2003). In contrast 
to MPTP, which accumulates selectively in dopaminergic neurons, chronic exposure to 
rotenone  can  produce  mild  but  systemic  complex  I  inhibition.  When  a degenerative 
lesion results, it is selective to the nigrostriatal system, indicative of the vulnerability of 
this neuronal population to oxidative stress.  Furthermore,  intracerebral administration 
of the neurotoxin 6-hydroxydopamine (6-OHDA) provides an acute animal model for 
PD (for review (Bove et al.  2005)).  The neurotoxicity  of 6-OHDA  is believed to be 
related  to  production of reactive  oxygen  species  (ROS)  and  inhibition  of complex  I 
activity, which probably induce destruction of SN neurons. In addition, mitochondrial 
involvement and dysfunction has also been reported in numerous studies on the genes 
associated with familial PD (see 1.6.3).
1.6.2  Activation of the UPR in Parkinson’s disease models
Studies  linking activation of the  UPR and  PD  use  neurotoxins to  model  the  disease 
process both  in cell  culture and  in vivo  (Ryu et al.  2002;  Holtz and  O'Malley  2003; 
Silva et al.  2005).  Compounds,  such as 6-OHDA and  MPTP or its active derivative, 
MPP+,  induce  oxidative  stress  and  impair  mitochondrial  respiration  and  energy 
metabolism.  Studies  with  cultured  neuronal  cells,  including  dopaminergic  neurons, 
showed that these compounds trigger activation of the UPR and induce a number of 
genes.  Gene profiling revealed that both ER chaperones and other components of the 
UPR  such  as  the  TF  CHOP  were  up-regulated  in  exposed  cells,  in  addition  to  the 
phosphorylation of the ER stress kinases, IRE1  and PERK, leading to increased ATF4 
translation. These changes were specific for the two PD mimetics and also rotenone, a 
mitochondrial inhibitor that causes degeneration of dopaminergic neurons, but not with 
other agents (Ryu et al. 2002). However, there were some unexpected differences in the 
magnitude and pattern of gene responses induced by 6-OHDA and MPP+ (Holtz and 
O'Malley 2003). The transcriptional changes induced by MPP+ treatment were subtle 
compared to the strong response elicited by stimulation with 6-OHDA. Furthermore, 6- 
OHDA led to the induction of ER chaperones and other genes that are associated with 
the ER stress-specific branch of the UPR, but MPP+ did not. However, both, 6-OHDA 
and  MPP+  caused  transcriptional  up-regulation  of a  set  of genes  that  are  induced
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previously to be induced in response to ER stress dependent on the presence of ATF4 
(Figure  1-6B) (Harding et al.  2003).  Experiments carried out using neuronal cultures 
from  PERK  gene  deleted  mice revealed  an  increased  sensitivity  of the  cells  against 
treatment with 6-OHDA (Ryu et al. 2002). This suggests that neurons lacking PERK 
were  unable  to  mount  a  proper  UPR  and  are  more  vulnerable  to  6-OHDA.  It  also 
supports  the  notion  that  an  early  UPR  response  may  be  neuroprotective  for  the 
dopaminergic neurons, while sustained activation of the UPR leads to an up-regulation 
of gene products that induce cell death. Thus it seems to be the shared branch of the 
UPR that  is  central  in the  response  to  treatment with  such neurotoxins.  In  addition, 
stresses leading to activation of eIF2a kinases other than ER stress might turn out to be 
important in the development of PD.
1.6.3  Genetic forms of Parkinson’s disease
Genetic mutations identified in familial parkinsonism are relatively rare, accounting for 
only  5-10%  of  the  overall  PD  population.  However,  identification  of  the  genes 
associated  with  familial  PD  have  recently  provided  new  tools  to  implicate  and 
understand the molecular pathways affected (Table 1-1). In the past decade, recessively 
inherited  loss-of-function mutations in Parkin,  DJ-1  and  PINK1  were  found to cause 
early-onset  PD.  In  contrast,  dominantly  inherited,  gain-of-function  mutations  in  a- 
synuclein and LRRK2 result in more typical late-onset PD (for review (Farrer 2006)).
1.6.3.1  Parkin, an E3 ligase
Mutations in Parkin are thought to  impair its E3  ubiquitin protein ligase activity and 
result in improper targeting of substrates for proteasomal degradation, and may lead to 
subsequent  neurotoxic  accumulation.  A  number  of  substrates  have  been  reported 
including Pael, a rare glycosylated form of a-synuclein and a subunit of the aminoacyl- 
tRNA  synthetase  complex  (for  review  (Farrer  2006)).  Some  studies  have  localised 
Parkin to the ER, where it has been shown to have a neuroprotective role against ER 
stress  (Takahashi  et  al.  2003).  In  addition,  Parkin  might  have  a role  in  maintaining 
mitochondrial function. It has been localised to the outer mitochondrial membrane, and 
ubiquitylation can also mediate the  insertion of proteins  into the outer mitochondrial
39membrane (Zhaung and McCauley 1989).
1.6.3.2  DJ-1, involved in oxidative stress protection
DJ-1  is a member of the ThiJ/PfpI family of molecular chaperones which are induced 
during  oxidative  stress.  The  protein  exists  predominantly  as  a  dimer  localised  to 
mitochondria,  and  mutations  are  thought  to  cause  PD  via  impaired  oxidative  stress 
protection (Bonifati et al. 2003; Zhang et al. 2005). In mammalian cells exposed to an 
oxidative stressor, such as H2O2, DJ-1  undergoes an acidic shift in pi by modifying its 
cysteine residues,  which quench  ROS  and protect cells against  stress-induced death. 
Ablation  of DJ-1  function  in mice  leads  to  increased  sensitivity  to  MPTP  treatment 
(Kim et al. 2005).
1.6.3.3  PINK1, a mitochondrial kinase
PINK1  was  originally  identified  to  be  transcriptionally  up-regulated  by  the  tumour 
suppressor PTEN in cancer cells, however, PINK1  has not been shown to exhibit any 
effects on PTEN-dependent cell phenotypes (Unoki and Nakamura 2001). In addition, 
it was reported that Pinkl  mRNA is reduced in ovarian tumour samples from patients 
(Unoki and Nakamura 2001). Furthermore, PINK1 mRNA was found to be increased in 
tumour cell lines with high metastatic potential (Nakajima et al. 2003).
PINK1  encodes a ubiquitously expressed 581  amino acid protein, which consists of an 
N-terminal MTS, a highly conserved serine/threonine kinase domain and a C-terminal 
autoregulatory  domain.  Initially,  three  pedigrees  were  described  with  identified 
mutations:  a  G309D  point  substitution  in  one  family  and  a  truncation  mutation 
(W437X) in two additional families (Valente et al. 2004). Subsequently, several studies 
have described other point mutations or truncations (Hatano et al. 2004; Rogaeva et al. 
2004; Rohe et al. 2004; Bonifati et al. 2005; Li et al. 2005). The reported mutations do 
not show any obvious clustering within the gene, and most are distributed throughout 
the kinase domain with a subset located in the N-terminal region between the MTS and 
the kinase domain (Figure  1-7). As the kinase domain is the only functional domain in 
PINK1  and the site of most of the mutations,  disruption of the kinase activity  is the 
most probable disease mechanism. However, studies showing PINK1  kinase activity in 
in vitro autophosphoiylation assays are relatively weak (Beilina et al. 2005; Silvestri et
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significant functional effects of the mutations on kinase activity.  Some functional data 
has  been  obtained  from  indirect  assays,  which  show  that  loss  of PINK1  adversely 
affects mitochondrial function and cell viability under stress. Mitochondrial membrane 
potential  Aq>m  and  levels  of cell  death  were  measured  in  a  neuroblastoma  cell  line 
over-expressing  G309D  PINK1  after  exposure  to  an  exogenous  source  of  cellular 
stress,  MG-132,  a  proteasome  inhibitor.  Cells  over-expressing  G309D  PINK1  had 
significantly  reduced Atpm compared  with the wild type and increased  levels of cell 
death  following  exposure  to  stress,  but  not  under  basal  conditions.  Moreover,  cells 
over-expressing wild type PINK1  had higher A\pm and lower levels of cell death than 
cells transfected with vector alone (Valente et al. 2004). Consistent with these results, 
over-expression of wild type PINK1  was subsequently shown to reduce the release of 
cytochrome  c  from  mitochondria  under  basal  conditions  and  staurosporine-induced 
stress. Significantly, two PINK1 mutations, E240K and L489P, were shown to abrogate 
the protective effect (Petit et al. 2005). Finally, the L347P mutation decreases the half- 
life of PINK1  from approximately 2hrs to 30min, which supports the idea that loss of 
PINK1  function might contribute to PD (Beilina et al. 2005).
In Drosophila melanogaster, loss of PINK1  leads to defects in mitochondrial function 
resulting in male sterility, apoptotic muscle degeneration and minor loss of dopamine 
neurons (Clark et al. 2006; Park et al. 2006; Yang et al. 2006). A similar phenotype has 
been characterised for Parkin loss-of-function mutants of D.  melanogaster (Greene et 
al. 2003). Interestingly, over-expression of Parkin in PINK1 deficient flies rescues their 
phenotype, but over-expression of PINK 1   in Parkin deficient flies does not (Clark et al. 
2006; Park et al. 2006; Yang et al. 2006). Thus, PINK1 appears to function upstream of 
Parkin in a common pathway.
1.6.3.4  HtrA2, a mitochondrial protease
Recently,  two  point-mutations  were  identified  in  the  coding  sequence  of HtrA2.  A 
mutation of G399S located in the PDZ domain was found in four patients with sporadic 
PD, and a polymorphism at A141S close to the mature N-terminus of the protein was 
found at higher frequencies in patients with PD (Strauss et al.  2005).  Both mutations 
are  predicted  to  affect  regulation  of  the  proteolytic  activity  of  HtrA2,  thereby
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increase  susceptibility  to  stress,  as  shown  by  decreased  mitochondrial  membrane 
potential  after  exposure  to  staurosporine.  Subsequently,  the  HtrA2  gene  has  been 
designated as the Parkinson’s disease-13 (PARK 13) locus.
1.6.3.5  ATP13A2, a lysosomal ATPase
ATP13A2  encodes  for a  P-type  ATPase  that  transports  cations  and  other  substrates 
across membranes (Schultheis et al. 2004). Whereas the wild type protein is located in 
the  lysosome  of transiently  transfected  cells,  the  unstable  truncated  mutants  were 
retained  in  the  ER  and  degraded  by  the  proteasome,  potentially  inducing  ER  stress 
(Ramirez et al. 2006).
1.6.3.6  UCHL1, a ubiquitin hydrolase
UCHL1  has  been  associated  with  familial  PD,  but  the  genetic  evidence  for  its 
pathogenicity  is  weak  as  only  a  single  mutation  has  been  identified  in  one  family 
(Leroy  et al.  1998).  UCHL1  functions as a ubiquitin hydrolase,  recycling polymeric 
ubiquitin to its monomeric form.
1.6.3.7  a-synuclein, component of Lewy bodies
a-synuclein is a protein that is expressed throughout the brain and has potential roles in 
learning, synaptic plasticity, vesicle dynamics and dopamine synthesis (Lotharius and 
Brundin 2002; Sidhu et al. 2004). The gene encoding a-synuclein was the first gene to 
be  linked to  familial  PD.  Several  multiplications and three missense  mutations have 
been  described  to  be  dominantly  inherited,  gain-of-function  mutations  (for  review 
(Farrer 2006)).  Given that a-synuclein assumes a fibrillar p-pleated sheet structure in 
Lewy  bodies  in  PD  and  related  a-synucleinopathies  (Spillantini  et  al.  1998),  the 
leading  hypothesis  for  its  pathogenicity  is  the  formation  of  toxic  aggregates,  a- 
synuclein has been shown to bind synaptic vesicles, and protofibrils can form pores that 
could  lead  to  permeabilisation  of the  vesicle  membranes,  thereby  releasing  excess 
dopamine into the cytosol (Lashuel et al. 2002). Formation of protofibrils is enhanced 
and stabilised by dopamine quinones derived from the oxidation of dopamine, and this 
could account for the selective toxicity of a-synuclein in the substantia nigra (Conway 
et  al.  2001).  There  is  accumulating  evidence  for  a  close  relationship  between  a-
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neurons to oxidative stress and damage by dopamine and mitochondrial toxins such as 
MPTP  and  6-hydroxydopamine  (6-OHDA),  resulting  in  increased  protein 
carbonylation and lipid peroxidation in vitro and in vivo (Tabrizi et al. 2000).
1.6.3.8  LRRK2, leucine-rich repeat kinase 2
Mutations  in  LRRK2  have  only  recently  been  identified  (Zimprich  et  al.  2004). 
Strikingly, they account for 0.5-2.0% of cases of sporadic PD and 5% of familial PD. 
In  Ashkenazi  Jews  and  North  African  Arab  populations  this  mutation  might  even 
account  for  18-30%  of  PD  cases,  therefore  LRRK2  is  the  gene  most  frequently 
associated  with  familial  PD  (for review  (Farrer  2006)).  LRRK2  encodes  a  complex 
multi-domain  protein  that  consists  of  N-terminal  leucine-rich  repeats,  a  GTPase 
domain,  a  MAPKKK  and  C-terminal  WD40  repeats.  LRRK2  mutations  increase  its 
kinase activity (West et al. 2005; Gloeckner et al. 2006). It might be associated with the 
outer  mitochondrial  membrane  and  can  bind  Parkin.  In  addition,  over-expression  of 
mutant  LRRK2  was  sufficient  to  induce  neuronal  degeneration  in  mouse  primary 
cortical neurons (Smith et al. 2005).
1.6.4  Common themes in Parkinson’s disease
The diverse causes of PD may be related mechanistically  (Figure  1-8).  As expected, 
normal  mitochondrial  activity  may  be  affected  by  environmental  chemicals, 
mitochondrial  DNA  polymorphisms  (Schapira  2006)  and  nuclear  genes  (see  1.6.3). 
Less  expected  are  the  findings that  a-synuclein  over-expression  and  inactivation  of 
Parkin can also cause mitochondrial dysfunction (Beal 2004; Palacino et al.  2004). A 
common  by-product  of  many  types  of  mitochondrial  impairment  is  increased 
production of ROS, and this may be the source of the oxidative damage found in PD 
brains.  Inhibition  of  mitochondrial  complex  I  leads  to  increased  production  and 
aggregation of a-synuclein (Sherer et al. 2002).  In dopaminergic neurons, aggregation 
may  be promoted by  dopamine metabolites and, perhaps,  by  the formation of highly 
reactive  dopamine-quinones.  The  latter  can  form  adducts  with  proteins,  such  as  a- 
synuclein  (Conway  et  al.  2001),  cross-link  them,  and  facilitate  their  aggregation.  In 
addition to aberrant protein modification, dopamine oxidation can affect mitochondrial 
function  (Berman  and  Hastings  1999)  and  increase  oxidative  stress.  Inhibition  of
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yielding  ROS  that  cause  oxidative  damage  to  proteins,  perhaps  including  the 
components of proteasomes (Shamoto-Nagai et al. 2003). The normal versions of DJ-1 
and PINK1  seem to protect against oxidative stress, but the mutant proteins associated 
with PD do not (Petit et al.  2005; Zhang et al. 2005).  Studies using D.  melanogaster 
mutants demonstrate that PINK1  might function upstream of Parkin and therefore be 
linked in a common pathway (Clark et al.  2006;  Park et al. 2006;  Yang et al.  2006). 
Furthermore, Parkin has been localised to the ER, where it has been shown to have a 
neuroprotective role against ER stress (Takahashi et al. 2003), and oxidative stress was 
demonstrated to activate the UPR (Holtz et al. 2006). The ER and proteasome system 
are  intimately  linked,  since  proteins targeted  for degradation  in the  ER are exported 
into the cytosol to be further processed by the UPS. However, when misfolded proteins 
accumulate in the ER, the UPR is activated. Therefore, disturbance of any of the two, 
UPR or UPS, will impact on the other.
Thus, although there seem to be multiple, divergent causes of PD, yet the pathogenesis 
of this  disease  appears  to  be  converging  on  common  mechanisms  -   mitochondrial 
impairment, oxidative stress, and protein mishandling, all of which are tightly linked.
1.7  Outline of subsequent chapters
Apoptosis  plays  an  essential  role  in  metazoan  development  and  tissue  homeostasis. 
Apart  from  their  function  in  respiration,  during  apoptosis  mitochondria  integrate  a 
variety of cellular stress stimuli. In most cases apoptotic insults are translated into the 
release  of  pro-apoptotic  factors  from  mitochondria  into  the  cytosol  and  nucleus, 
resulting in the organised demise of the cell. One of these proteins is the serine protease 
HtrA2. The role of HtrA2 in vivo is examined in Chapter 3  by studying mice lacking 
HtrA2. The phenotype of these animals and cells derived from them do not support a 
pro-apoptotic function for HtrA2 in vivo, but rather suggest the opposite, a protective 
role for HtrA2. Cells lacking HtrA2 exhibit increased sensitivity to some death stimuli 
and  mice deficient for HtrA2  develop a parkinsonian syndrome.  Interestingly,  HtrA2 
shows homology to bacterial proteases involved in a stress response pathway leading to 
the attractive hypothesis that mammalian  HtrA2  may  exert  its protective  function by 
signalling  in  a  mitochondrial  stress  response  pathway.  In  Chapter  4,  transcriptional
44changes resulting from loss of HtrA2 are investigated, leading to characterisation of a 
stress  signature  in  brain  tissue  of  HtrA2  deficient  animals.  Subsequently,  the 
mitochondrial  kinase  PINK1  is  identified  as  a  novel  binding  partner  of HtrA2  in 
Chapter  5.  PINK 1-dependent  phosphorylation  of  HtrA2  appears  to  regulate  HtrA2 
protease activity, placing PINK1 upstream of HtrA2.
45Figure 1-1. Extrinsic and intrinsic apoptotic pathways.
Apoptosis  can  be  initiated  through  either  extrinsic  or  intrinsic  apoptotic 
signalling  pathways.  (A)  Activation  of  the  extrinsic  pathway  is  triggered  by 
ligation  of  death  receptors  and  results  in  formation  of  the  DISC  complex, 
activation  of  caspase-8  and  subsequently  of  effector  caspases  leading  to 
apoptosis.  Bid  cleavage  by  caspase-8  provides  cross-talk  with  the 
mitochondrial pathway. (B) Activation of the intrinsic (mitochondrial) pathway is 
triggered  by  BH3-only  proteins  and  results  in  Bax-mediated  mitochondrial 
dysfunction,  leading  to  the  release  of  cytochrome  c,  activation  of  the 
apoptosome  caspase-9  complex  and  then  effector  caspases  leading  to 
apoptosis.  Release of Reaper-like  proteins such  as  Smac and  HtrA2 from the 
mitochondria lead to inhibition of IAPs.  Figure taken from (Igney and  Krammer 
2002).
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and comparison to its homologues.
(A)  Domain  structure  of  HtrA2  showing  the  MTS  (amino  acids  1-31),  the  TM 
(amino  acids  105-125),  the  trypsin-like  serine  protease  domain  (amino  acids 
166-342)  and  the  C-terminal  PDZ  domain  (amino  acids  364-445).  Within  the 
protease domain is the catalytic triad, consisting of histidine 198, aspartate 228 
and serine 306. Proteolytic processing reveals an IBM at the new N-terminus of 
mature HtrA2 which starts at amino acid  134. The positions of the amino acids 
are derived from the human sequence of HtrA2. (B) Comparison of the domain 
structure of E.  co// proteases  DegP and  DegS,  all four H.  sapiens  HtrA family 
members  and  D.  melanogaster  dHtrA2.  Domains:  SS,  signal  peptide;  TM, 
transmembrane domain;  IGFBP,  insulin growth factor binding domain;  Kl, kazal 
protease  inhibitor  domain;  protease,  trypsin-like  protease  domain;  PDZ,  PDZ 
domain. The exact position  of the domains cannot be taken from the diagram, 
only  their  relative  position.  SwissProt/TREMBL  accession  numbers  are  DegP 
(P09376),  DegS (P31137),  HtrA1  (Q92743),  HtrA2  (Q43464),  HtrA3 (P83110), 
HtrA4 (P83105), and dHtrA2 (Q9VFJ3).
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DegS E. coli 355
DegP E. coli 448
HtrA1 H. sapiens 458
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□— u -b hFigure 1-3. Crystal structure of HtrA2,  DegS and DegP proteases.
(A)  Crystal  structure  of an  inactive  HtrA2  monomer  shown  as  a  ribbon.  The 
PDZ  domain  is  folded  onto  the  protease  domain.  The  catalytic  serine  306  is 
indicated.  The  N-terminal  IBM  is  exposed  and  unstructured.  (B)  Crystal 
structure of an  HtrA2 trimer as side or top view.  The  PDZ domains are yellow 
and the catalytic serine is highlighted  in  red.  (C) Crystal structure of the active 
DegS trimer from side or top view. The catalytic serine is highlighted in red, the 
PDZ  domain  in  yellow.  (D)  Crystal  structure  of the  proteolytically  active  and 
inactive  DegP  hexamer  from  side  view.  The  PDZ  domains  are  yellow.  The 
structural  information are taken from  (Krojer et al.  2002;  Li et al.  2002;  Wilken 
et al. 2004).
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Model illustrating the activation of HtrA2 proteolytic activity. The mature inactive 
enzyme can be activated by heat shock (temperature increase), by IAP binding 
to the N-terminal  IBM,  or by interaction of binding  partners with the C-terminal 
PDZ domain. All these mechanisms are  proposed to  lead to the displacement 
of the PDZ domain from the active site area. Taken from (Martins et al. 2003).
Figure 1-5. The bacterial stress response pathway involving DegS.
The  bacterial  periplasmic stress  response  involving  DegS as a stress sensor. 
The stress signal  is sensed  in the periplasmic space of the bacterial envelope 
and the signal must cross the inner membrane,  requiring a more sophisticated 
pathway. The transcriptional regulator of the periplasmic stress response is aE, 
which  is  normally  held  in  an  inactive  complex  bound  to  the  cytoplasmic 
domains  of  the  inner  membrane  proteins  RseA  and  RseB.  Upon  external 
stress,  the  periplasmic  DegS  protease  is activated  by  unfolded  porins  located 
in  the  outer  membrane.  The  C-terminus  of the  porins  ends  in  a  PDZ  binding 
motif (YXF) that binds to the PDZ domain of DegS leading to its activation. The 
periplasmic  domain  of  RseA  is  efficiently  cleaved  by  DegS,  which  allows  a 
further  proteolytic  cleavage  of  RseA  by  the  rhomboid-like  metallo  protease 
RseP (also known  as YaeL)  in the  inner membrane.  These proteolysis events 
are thought to destabilise RseA's cytoplasmic domain,  releasing oE  to activate 
transcription  of  the  appropriate  genes  to  help  the  bacteria  to  cope  with  the 
stress.  One of the genes that is induced  encodes for the  periplasmic protease 
DegP  which  is  active  as  a  chaperone  as  well  as  a  protease.  Adapted  from 
(Young and Hartl 2003).
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activation of elF2a kinases.
(A) The three  branches  of the  metazoan  UPR.  The three  types  of  ER  stress 
transducers -  PERK, ATF6, and  IRE1  -  sense the levels of unfolded protein in 
the lumen of the ER and communicate this information across the membrane to 
activate  cognate  bZip  TFs  via  regulation  of  translational  control,  regulated 
proteolysis,  and  regulated  mRNA  splicing,  respectively.  In  mammalian  cells, 
ATF6  up-regulates  expression  of XBP-1  mRNA  (indicated  by  plus  sign).  The 
output of the TFs is integrated through their combinatorial action on UPR target 
genes,  whose  products  increase  the  protein  folding  capacity  of the  cell  and 
hence  help the  system  re-establish  homeostasis.  PERK also  reduces general 
translation  in  cells,  thereby  reducing  the  protein  influx  into  the  ER.  If 
homeostasis in  ER protein folding cannot be reached, cells undergo apoptosis. 
Abbreviations:  K,  kinase  domain;  R,  ribonuclease  domain.  Adapted  from 
(Bernales et al.  2006). (B) Cellular stress  pathways  involving  the activation of 
elF2a kinases. GCN2, PKR, HRI and PERK are activated through the indicated 
stresses  and  phosphorylate  the  translation  elongation  factor elF2a  on  serine 
51.  This  leads  to  inhibition  of general  (cap-dependent  translation).  However, 
ATF4  mRNA  possesses  uORFs  that  facilitate  its  translation  under  these 
conditions.  Therefore,  ATF4  protein  levels  increase  following  elF2a 
phosphorylation. ATF4  is a TF that activates transcription of ATF3,  CHOP and 
Herp.  ATF3  itself  can  also  activate  CHOP  transcription.  ATF4  can  be 
phosphorylated and thereby be targeted to proteasomal degradation (Lassot et 
al. 2001).
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Locus Chromosome Gene Inheritance Function
PARK1, PARK4 4q21-q23 a-synuclein AD
involved in synaptic 
vesicle formation
PARK2 6q25.2-q27 Parkin AR E3 ligase
PARK3 2p13 AD
PARK5 4p14 UCHL1 ?
AD?/
susceptibility
ubiquitin-protein
hydrolase
PARK6 1  p35-p36 PINK1 AR mitochondrial kinase
PARK7 1p36 DJ-1 AR
involved in oxidative 
stress response
PARK8 12p11 2-q13.1 LRRK2 AD protein kinase
PARK9 1p36 ATP13A2 AR
P-type ATPase, 
lysosomal
PARK10 1p32 susceptibility
PARK11 2q36-q37 susceptibility
PARK12 Xq21-q25
PARK13 2p12 HtrA2
AD?/
sporadic mitochondrial protease
Table 1-1.  Genetic loci for Parkinson’s disease.
It  is  unclear  whether  UCHL1  is  a  real  PD  gene,  since 
mutations  were  only  found  in  two  siblings  and  have  never 
been  reproduced. The  inheritance  pattern for  HtrA2  in  PD  is 
not clear, since the mutation has been identified in apparently 
sporadic cases.
AR: autosomal recessive; AD: autosomal dominantFigure 1-7. Domain structure of PINK1
Domain structure of PINK1  showing the kinase domain (amino acids  156-509). 
The coding  regions for each  of the eight exons are numbered  in amino acids. 
Mutations found in familial PD are indicated above the domain structure.
Figure 1-8. Common themes in Parkinson’s disease.
Mutations  in  seven  genes  encoding  a-synuclein,  Parkin,  UCHL1,  LRRK2, 
PINK1,  HtrA2  and  DJ-1  are  associated  with  familial  forms  of  PD  through 
pathogenic pathways that may commonly  lead  to deficits  in  mitochondrial  and 
UPS  function.  PINK1,  Parkin,  HtrA2,  LRRK2  and  DJ-1  may  play  a  role  in 
normal  mitochondrial  function,  whereas  Parkin,  UCHL1,  and  DJ-1  may  be 
involved  in  normal  UPS  function.  Parkin  may  protect  against  ER  stress, 
whereas  oxidative  stress  leads  to  activation  of  the  UPR.  a-synuclein 
fibrillisation  and  aggregation  is  promoted  by  pathogenic  mutations,  oxidative 
stress,  and  oxidation  of  cytosolic  dopamine  (DA),  leading  to  impaired  UPS 
function  and  possibly  mitochondrial  damage,  a-synuclein  may  normally  be 
degraded by the UPS. UPS dysfunction can activate the UPR, and activation of 
the UPR enhances the demand for functional UPS.  Some environmental toxins 
and  pesticides  can  inhibit  complex  I  and  lead  to  mitochondrial  dysfunction, 
whereas  alterations  in  mitochondrial  DNA  (mtDNA)  may  influence 
mitochondrial  function.  Impaired  mitochondrial  function  leads  to  oxidative 
stress,  deficits  in  ATP  synthesis,  and  a-synuclein  aggregation,  which  may 
contribute  to  UPS  dysfunction.  Oxidative  stress  may  also  influence  the 
antioxidant function of DJ-1, can impair Parkin function through S-nitrosylation, 
and  may  promote  DA oxidation.  Excess  DA  metabolism  may further  promote 
oxidative  stress.  Red  lines  indicate  inhibitory  effects,  green  arrows  depict 
defined  relationships  between  components  or  systems,  and  blue  dashed 
arrows indicate proposed or putative relationships. Adapted from  (Moore et al. 
2005).
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UPS2  Chapter 2: Materials and Methods
2.1  Materials
2.1.1  Reagents
CCCP, etoposide, N-acetyl-L-cysteine (NAC), MG-132 in solution, staurosporine, and 
the  HtrA2  inhibitor  Ucf-101  were  purchased  from  Calbiochem.  ATP,  NADH,  H2O2, 
rotenone,  thapsigargin,  tunicamycin,  6-hydroxydopamine  (6-OHDA),  4-hydroxy- 
tamoxifen (40H-Tx), glutamate, CHAPS, Percoll and Proteinase K were obtained from 
Sigma. Protease inhibitor cocktail tablets (complete, EDTA-free) were purchased from 
Roche.  Protein  phospatase  2A  (PP2A)  was  obtained  from  Upstate,  and  X  protein 
phosphatase (k PPase)  was purchased from New England Biolabs (NEB).  Redivue™ 
L-[35S] methionine was from Amersham. Active tobacco etch virus protease (TEV) was 
from Invitrogen, recombinant full length XIAP from R&D Systems. The p38 inhibitor 
BIRB796 was from Ana Cuenda (Kuma et al. 2005). For the 2D DIGE, CyDye DIGE 
Fluors,  Immobiline  DryStrips,  Pharmalytes  (IPG  buffer),  DeStreak  rehydration 
solution,  urea,  thiourea,  CHAPS,  dithiothreitol  (DTT),  iodoacetamide  (IAA)  were 
purchased  from  GE  Healthcare  (formerly  Amersham).  Anhydrous  99.8% 
Dimethylformamide (DMF) was purchased from Sigma. Millipore purified, autoclaved 
distilled  water (dd^O),  and  PBS  was prepared  by  Cancer  Research UK  central  cell 
services.
2.1.2  Antibodies
Actin, C-11, goat polyclonal (Santa Cruz Biotechnology)
P-Akt (Ser473), rabbit polyclonal (Cell Signaling)
Annexin V Alexa Fluor 647 (Molecular Probes)
ANT, N-19 and Q-18, both goat polyclonal (Santa Cruz Biotechnology)
BAD,  C-20  rabbit  polyclonal  (Santa  Cruz  Biotechnology)  and  clone-48  mouse 
monoclonal (BD Transduction Laboratories)
59Bak, clone2-14 rabbit polyclonal (Stressgen) and Ab-1  (Calbiochem)
Bax,  clone  YTH-6A7  mouse  monoclonal  (Mito  Science)  and  rabbit  polyclonal 
(Imgenex)
Bcl-2, N-19 rabbit polyclonal (Santa Cruz Biotechnology) and 4D7 mouse monoclonal 
(Pharmingen)
Bcl-XL, clone64 rabbit polyclonal (BD Transduction Laboratories)
Bifl, 30A882.1.1 mouse monoclonal (Abeam)
Bik, FL-160 rabbit and N-19 goat polyclonal (Santa Cruz Biotechnology)
Bim, N-20, goat polyclonal (Santa Cruz Biotechnology)
Bnip3L, clone 77-92 rabbit polyclonal (Calbiochem)
Cathepsin D, C-20, goat polyclonal (Santa Cruz Biotechnology), lysosomal marker 
Complex I  17kD subunit, clone 21C11, mouse monoclonal (Molecular Probes) 
Complex III UQCRCL 2E3, mouse monoclonal (Molecular Probes)
ComplexV subunit alpha, 7H10, mouse monoclonal (Molecular Probes)
ComplexV subunit beta, 3D5, mouse monoclonal (Molecular Probes)
ComplexV subunit d. 7F9. mouse monoclonal (Molecular Probes)
ComplexV subunit OSCP, 4C11, mouse monoclonal (Molecular Probes)
ComplexV inhibitory Protein, 5E2. mouse monoclonal (Molecular Probes)
Complex V,  12F4AD8AF8, mouse monoclonal (Mito Science)
60CPS1, rabbit polyclonal (Abeam)
Cytochome c, 7H8.2C12, mouse monoclonal (Pharmingen)
DJ-1, gift from Valina Dawson, rabbit polyclonal, 1:5000 dilution for Western blotting
P-eIF2a (Ser51), rabbit polyclonal (Cell Signaling)
P-ERK1/2 (Thr202/Tyr204), E10, mouse monoclonal (Cell Signaling)
FLAG, M2 antibody and affinity gel, mouse monoclonal (Sigma)
Grp75,  clone  30A5,  mouse  monoclonal  (Stressgen),  1:5000  dilution  for  Western 
blotting
HA-HRP, 3F10, rat (Roche), 1:1000 dilution for Western blotting
HAX-1,  clone52,  mouse  monoclonal  (BD  Transduction  Laboratories),  1:300  dilution 
for Western blotting
Hrk, N-20, goat polyclonal (Santa Cruz Biotechnology)
Hsp60, clone Mabl 1-13, monoclonal (Stressgen),  1:1000 dilution for Western blotting
HtrA2,  rabbit polyclonal  (Alexis),  which is raised against recombinant mature HtrA2 
and was used at 1:2000 to 1:5000 for Western blotting
P-S142 HtrA2, rabbit polyclonal,  1:1000 for Western blotting. This antibody was raised 
against the phosphorylated peptide SPPPASPRSQYC of human HtrA2 by coupling an 
additional  N-terminal  C  to  keyhole  limpet  hemacyanin  (KLH)  using  malemeide  and 
injection  into a rabbit at  Harlan  Bioproducts for Science,  UK.  The  P-HtrA2  antibody 
was  characterised  by  Western  blotting  cellular  lysates  where  either  WT  or  SI42A 
HtrA2  was  over-expressed,  verifying  that  this  antibody  does  not  detect  HtrA2  that 
cannot be phosphorylated on SI42 (Figure 5-3C and D).
61IkBq, C-21, rabbit polyclonal (Santa Cruz Biotechnology)
P-IkB<x (Ser32/36), 5A5, mouse monoclonal (Cell Signaling)
P-JNK (Thrl83/Tyrl85), rabbit polyclonal (Cell Signaling)
KDEL, clone 10C3, mouse monoclonal (Stressgen), endoplasmic reticulum marker 
Lamin Bl, C-20, goat polyclonal (Santa Cruz Biotechnology)
Myc, 9E10, mouse monoclonal (Evan et al. 1985)
P-p38 (Thrl80/Tyrl82), rabbit polyclonal (Cell Signaling)
PINK1,  rabbit  polyclonal,  1:1000  dilution  for  Western  blotting.  This  antibody  was 
raised  against  peptide  KSKPGPDPLDTRRLQ  of  human  PINK1  by  coupling  an 
additional N-terminal C to KLH using malemeide and injection into a rabbit at Harlan 
Bioproducts  for  Science,  UK.  The  PINK1  antibody  was  biotinylated  using  the  EZ- 
linkR NHS-PEO Biotinylation kit (Pierce). The PINK1  antibody was characterised by 
Western blotting cellular lysates where PINK1  had been down-regulated using siRNA 
(Figure 5-3A) or where PINK1 was over-expressed (Figure 5-ID).
Prohibitin, 11-14-10, mouse monoclonal (Abeam)
Smac,  rabbit  polyclonal,  generated  against  the  C-terminal  sequence  of human  Smac 
(EQEAYLRED) (Vyas et al. 2004)
VDAC / Porin, clone 31HL, mouse monoclonal (Calbiochem)
VDAC2, C-17, goat polyclonal (Santa Cruz Biotechnology)
XIAP, clone-48, mouse monoclonal (BD Transduction Laboratories)
All  primary  antibodies  were  used  at  dilutions  recommended  by  the  manufacturer’s, 
unless otherwise  indicated.  Secondary  anti-mouse and rabbit antibodies (Amersham) 
coupled  to  horseradish  peroxidase  (HRP)  were  used  at  dilution  1:4000.  1:30,000
62dilution  of  streptavidin  conjugated  to  peroxidase  (DAKO)  was  required  for  the 
detection of biotinylated antibodies.
2.1.3  Plasmids
The  expression  construct  pCMV-SPORT  HtrA2  was  from  GlaxoSmithKline,  and 
HtrA2 S306A was generated by introduction of a single point mutation by site-directed 
mutagenesis  using  the  QuickChange  kit  (Stratagene)  and  confirmed  by  DNA 
sequencing.  HtrA2-Flag was cloned  by  PCR into pcDNA3  (Invitrogen),  inserting an 
Kpnl site at the 5' end and a Xhol site after the Flag at the 3' end. All of this was done 
from  a plasmid  of HtrA2  which  had  the  EcoRI  and  BamHI  sites  within  the  HtrA2 
cDNA removed. The expression construct encoding S306A HtrA2-TAP was generated 
by sub-cloning into pZOMEIC (Cellzome) using BamHI restriction sites to fuse HtrA2 
to  a  C-terminal  TAP  tag.  SI42A,  SI42A/  S400A,  and  S400D  HtrA2-Flag  were 
generated by introduction of a single point mutation by site-directed mutagenesis using 
the  QuickChange  kit  (Stratagene)  and  confirmed  by  DNA  sequencing.  Full  length 
untagged  HtrA2  was  cloned  into  the  lentiviral  vector  pRRLsin-cPPT-PGK-GFP-W 
(Tronolab, Ecole Polytechnique Federale de Lausanne) (Klages et al. 2000), where the 
GFP was removed and replaced with HtrA2.
The  pEGFP-2  expression  vector  encoding  enhanced  green  fluorescence  protein  and 
pcDNA3  (both  Invitrogen)  were  used  as  control  vectors.  The  pEGFP-F  vector  was 
obtained  from  Invitrogen.  The  pRK5  vector encoding  Myc-PINKl  were  a  gift from 
Robert  Harvey  (University  College  London)  and  pcDNA3  PINK1  came  from  the 
Institute  of Neurology.  The  pBabe  Puro  SV40LT  was  from  Miguel  Martins.  The 
pBP3:hbER*  vector  encoding  human  AMEKK3:ER*  was  a  gift  from  Simon  Cook 
(Gamer et al. 2002). The HA-ETHE1  and ETHEl-Flag constructs were generous gifts 
of Jun  Fujita,  Kyoto  University,  Japan  (Higashitsuji  et  al.  2002).  The  pCAGGS  rat 
OTC  plasmid  was  contributed  by  Nicholas  Hoogenraad,  La  Trobe  University, 
Melbourne, Australia (Zhao et al. 2002) and PCR cloned into pcDNA3. A full length 
clone  for Riken2410005016  was ordered  from  RZPD  (German  Resource  Center for 
Genome Research) and verified by DNA sequencing.
632.1.4  Primers
All primers are 5’-3\
2.1.4.1  Cloning primers
To generate HtrA2 with BamHI restriction sites 5’ and 3’ to sub-clone into pZOMEIC 
Fwd: TTTAAGGATCCATGGCCTGCGCCGAGGGCGGG 
Rev: AATTGGATCCGCCCAAGCTTACGCGT
To generate HtrA2-Flag by PCR,
5’ end, Fwd: (random, Kpnl site, Kozak, HtrA2 sequence) 
CGAGCCGGTACCACCACCATGGCTGCGCCGAGGGCGGG 
3’ end, Rev: (random, Xhol site, Stop codon, Flag tag, HtrA2 sequence)
GGCT CGCTCGAGTC ATT  GT C GT  CAT  C GTCTTT  GT AGT CTTCTGTGACCTCAG 
GG
QuickChange primer to silence EcoRI site in HtrA2 coding sequence,
Fwd: GGGGAAAAGAAGAACTCCTCCTCCGG 
Rev: CCGGAGGAGGAGTTCTTCTTTTCCCC
QuickChange primer to silence BamHI site in HtrA2 coding sequence,
Fwd: GGT  C  AC  AGCT  GT  GG  ACCCCGT  GGC AG 
Rev: CT  GCC  ACGGGTCC  AC  AGCT  GT  G  ACC
QuickChange primer to mutate A306S of HtrA2,
Fwd: GCT  ATT  G  ATTTT  GG  AAACT  CT  GG  AGGT  CCCC 
Rev: GGGG  ACCT  CC  AG  AGTTT  CC  AAAAT  C AAT  AGC
QuickChange primer to mutate S142A of HtrA2,
Fwd: GCCCGCCGCCCGCTGCTCCCCGGAGTCAG 
Rev: CTGACTCCGGGGAGCAGCGGGCGGCGGGC
QuickChange primer to mutate S400A of HtrA2,
Fwd: GT  CAT  CCT  GGGCGCCCCT  GC AC ACCGG 
Rev: CCGGT  GT  GC  AGGGGCGCCC AGGAT  GAC
64To PCR OTC out of pCAGGS and insert into pcDNA3,
5’ end, Fwd: (random, EcoRI site, Kozak, OTC sequence)
T  G AC AG  AATT  CGCC ACC  AT  GCT  GTCT  AATTT  G  AGG  ATCCT  GCTC AAC  AAT  G 
C
3’ end, Rev: (random, Notl site, Stop codon, OTC sequence) 
ACTGTGCGGCCGCTCAAAACTTTGGCTTCTGGAGCACAGGTG
2.1.4.2  Genotyping primer
Neo-Fwd, CCGGCCGCTT  GGGT  GG  AG  AGG,
Neo-Rev TCGGC  AGG  AGC  AAGGT  GAG  AT  G  AC A
HtrA2-Fwd CCCCGGATCTCTGGGCACGATTGAAT,
HtrA2-Rev ATCCCCGCTAGGCAGCCTCACTCGTA
2.1.4.3  Real-time PCR primer
Mouse Actin y, Fwd: CTCTTCCAGCCTTCCTTCCT,
Rev: T  GCT  AGGGCT  GT  GAT  CTCCT
Human Actin y, Fwd: AAATCGTGCGCGACATCAA,
Rev: GG  AACCGCT  C  ATT  GCC  A  AT
Mouse and human 18S rRNA, Fwd: CGGCTTAATTTGACTCAACACG,
Rev: TT  AGC  AT  GCC AG  AGT  CT  CGTT  C
Mouse HtrA2, Fwd: CCCT  G  ACT  CCC AGC  AT  CCTT  AT,
Rev: CCC  AAT  GGCC  AAG  AT  C  AC  AT
Mouse HtrAl, Fwd: CCTTCGCAATTCCATCCGAT,
Rev: T  GGCTTT  GCT  AG  AT  GT  G  AGCG
Mouse HtrA3, Fwd: ATCCCCTCAGATCGCATCA,
Rev: TT  C  AGTT  CCT  CC  ACC  AAACTT  G
65Mouse HtrA4, Fwd: G  ACGG  AT  GCC  AT  C  ATT  AACC A, 
Rev: T  GGCGCT  CAT  GAT  AGT  CTTCC
Mouse CHOP, Fwd: AAAGCCCT  CGCT  CT  CC  AG  ATT, 
Rev: CCTTCTCCTTCATGCGTTGCT
Mouse ATF3, Fwd: GCG  AAG  ACT  GG  AGC  AAA  AT  G  A, 
Rev: AT  GGCG  AAT  CT  C  AGCT  CTT  CC
Mouse Herp, Fwd: TGCTGTTGGATCACCAGTGTC, 
Rev: T  GT  GG  ATT  C  AGC  ACCCTTT  G
Mouse KLF5, Fwd: C  ACGT  AC  ACC  AT  GCC AAGT  C  A, 
Rev: GGAAGC  AATT  GT  AGCGGC  AT  A
Mouse Hsp60, Fwd: CGCTGGTTTTGAACAGGCTAA, 
Rev: TCAACCCCTCTTCTCCAAACAC
Mouse MMP9, Fwd: GCGT  GTCT  GG  AG  ATT  CG  ACTT  G, 
Rev: CTCACACGCCAGAAGAATTTGC
Mouse AQP1, Fwd: ATT  GGC  ACT  CT  GC  AGCT  GGT  A, 
Rev: C  AGT  GT  AGT  C  AAT  CGCC AGC  A
Mouse MASP1, Fwd: C AGGT  GCT  GGC  AACCTTTT  GT, 
Rev: CGTCGAAGCCTGTGAATCGTT
Mouse CAV2, Fwd: TCT  GG  AT  CCT  GAT  GCCTTTT  G, 
Rev: T  GC AT  GCT  G  ACCG  AT  GAGA
Mouse NPNT, Fwd: AACCCCAGAAAGGCCATCTAC, 
Rev: CT  GCCGT  GG  AAT  G  AAC  AC  AT
Human PINK1, Fwd: TGAAAGCCGCAGCTACCAAGA, 
Rev: GATGAAGCACATTTGCGGCTA
662.1.5  siRNA oligos
2.1.5.1  Ambion
Silencer Negative Control, catalogue number 4615
GFP, catalogue number 16106, 5’-3’: GACCCGCGCCGAGGUGAAGtt
Human  PINK1,  catalogue  number  51323,  ID  1294,  5’-3’:
GGCAAUUUUUACCCAGAAAtt
2.1.5.2  Dharmacon
siGLO Lamin A/C, catalogue number 001620
siCONTROL Non-Targeting siRNA SmartPool, catalogue number 001206
Human GAPDH SmartPool, catalogue number 004253,
5’-3’ oligo 1: CAACGGAUUUGGUCGUAUUUU, 
oligo 2: GACCUGACCUGCCGUCUAGUU, 
oligo 3: CAAUAUGAUUCCACCCAUGUU, 
oligo 4: GCGAUGCUGGCGCUGAGUAUU
Mouse HtrA2 SmartPool, catalogue number 050725 (OTP),
5’-3’ oligo 1: UCAGACCGAUGCAGCUAUUUU, 
oligo 2: GCAGAUCUGACGUCUAGGAUU, 
oligo 3: CAGCAUCCUUACCGAACUAUU, 
oligo 4: AAACGGAUCAGGAUUCGUAUU
2.2  Mouse techniques
2.2.1  Generation of HtrA2 deficient mice
The HtrA2  locus was targeted in mouse  El4.1  (129/Ola) embryonic stem cells using 
standard  ES  cell  culture  and  gene  targeting  techniques  (Hogan  et  al.  1994;  Joyner 
1999). The targeting vector was generated using DNA fragments from a 129/sv mouse 
Bac genomic clone (Invitrogen). The 5’ arm of homology was isolated as a 2.7kb Xhol- 
Bglll fragment and the 3' arm as a 2.1 kb Hindlll-Xhol fragment. Targeting the HtrA2
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PGK  promoter  (PGK-neo),  in  the  first  coding  HtrA2  exon  at  a  position  140bp 
downstream of the translational start codon. The PGK-neo gene replaces part of exon 1, 
exon 2-6, and part of exon 7 as well as intervening intronic sequences. This removes 
83% of the mHtrA2 coding sequence including the proteolytic catalytic site of HtrA2. 
The targeting construct was linearised with Pmel  and transfected into ES  cells (Bio- 
Rad GenePulser; 230kV, 500pF). Transfected clones were selected in  180jig/ml G418 
(Sigma). A total of 300 G418-resistant ES cell colonies were isolated and screened for 
homologous  recombination  by  Southern  blot  analysis.  Two  targeted  clones  were 
injected into C57B16/J-derived blastocysts. High percentage male chimaeras from both 
clones were crossed with C57B16/J females to produce N1F0 offspring. Heterozygous 
HtrA2 offspring derived from one of the targeted ES cell clones were backcrossed for 
at least 5 generations onto the C57B16/J strain.  Mutant heterozygote FI  crosses were 
set up to generate study populations of animals containing all three possible genotypes 
(wild  type  (WT),  heterozygous  (Het)  and  homozygous  (KO)  mutant).  The  HtrA2 
mutant mice were generated by GlaxoSmithKline UK.
2.2.2  Maintenance and breeding of mice
Animal  husbandry  and  experimental  procedures  were  performed  in  full  compliance 
with  the  UK  Animal  (Scientific  Procedures)  Act  1986,  and  were  approved  by  the 
Cancer  Research  UK  procedures  panel.  Genotypes  of  HtrA2  mutant  mice  were 
confirmed by PCR as shown in (Figure 3-1 A). Primers Neo-Fwd and Neo-Rev specific 
for neomycin gene were used to detect the mutant allele, generating a PCR product of 
300bp. Primers HtrA2-Fwd and HtrA2-Rev that located in sequences within exons 1  to 
2  respectively  were used to  detect  the  HtrA2  WT  allele,  yielding a PCR product of 
500bp.  Post-natal days are abbreviated as P (post-natal day  18  is PI8), as commonly 
accepted.
2.2.3  Inclined platform test
Mice  around  P30  were  placed  in the  middle  portion  of a 60°  inclined  platform  and 
evaluation was performed as previously described (Schaefer et al. 2000).
682.2.4  Rotarod test
The  rotarod  apparatus  (AccuScan  Instruments  Inc.)  was  used  to  measure  fore-  and 
hindlimb motor coordination and balance of the mice.  WT and HtrA2 Het mice were 
initially trained on the rotarod for four consecutive days, using the same settings as for 
the  experiments  which  started  one  month  later.  During  this  training  period,  no 
difference between WT and HtrA2  Het mice could be detected.  Then the mice were 
monitored every two months at 10, 12, 14, and 16 months of age and were tested on the 
rotarod on three consecutive days. The latency to fall was measured and is displayed in 
seconds in the graphs. Rotarod settings were continuous acceleration from 0 to 40rpm 
in 570 seconds. WT n=10, Het n=10.
2.2.5  Anti-oxidant treatment of mice
HtrA2 Het x Het breeding pairs were set up for control and NAC treatment. When the 
females were pregnant the males were taken out of the experiment. When the mothers 
gave birth they started receiving NAC at  1  mg/ml in drinking water. At the same time 
the pups started receiving NAC from day 5 with oral administration at 200mg/kg body 
every day. The pups in the control litters received normal water as oral administration 
in similar volumes. After weaning at P20 the animals received NAC at  1  mg/ml in the 
drinking water.  Following anti-oxidant administration the animals were observed and 
body  weights recorded every 3-5 days. Animals were followed until they reached 30-35 
days of age. If they showed signs of distress including vocalisation, breathing difficulty 
or seizures they were culled by schedule 1  methods.
2.3  Pathology
2.3.1  Histology and immunohistochemistry
Brain  tissues  were  harvested  from  P20  and  P30  mice  and  fixed  in  10%  formalin, 
embedded  in  paraffin,  cut  into  3 pm  sections  and  processed  for  haematoxylin-eosin 
(H&E) staining. In addition, the following immunostains were carried out according to 
the manufacturer’s instructions: GFAP (glial fibrillary acidic protein; rabbit polyclonal 
antibody,  1:300;  DAKO),  NeuN  (anti-neuronal  nuclei;  mouse  monoclonal  antibody, 
1:4000;  Chemicon),  MAP-2  (;  microtubule-associated  protein-2  mouse  monoclonal 
antibody,  1:500; Chemicon), calbindin (Calbindin; rabbit polyclonal antiserum,  1:200;
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Chemicon).
Biotinylated secondary antibodies were used for all staining and visualisation was with 
a horseradish peroxidase-conjugated streptavidin complex and diaminobenzidine as a 
chromogen. All immunostainings were carried out using the automated Nexus staining 
apparatus  (Ventana  Medical  Systems;  www.ventanamed.com),  following  the 
manufacturers’  guidelines.  Photographs  were  obtained  on  a  Color  View  II  digital 
camera  (www.sofl-imaging.de)  mounted  on  a  ZEISS  Axioplan  microscope  and 
composed in Adobe Photoshop.
2.3.2  Stereological cell counts
Immunohistochemistry was performed on serial sections (50pm) of the striatum after 
the tissue had been fixed with paraformaldehyde cryoprotected in 30% (w/v) sucrose in 
phosphate buffer and frozen rapidly  in liquid isopentane.  Counts were performed by 
using  the  optical  fractionator  method  as  described  previously  (Xia  et  al.  2001).  In 
agreement with this method, NeuN positive neurons were counted in the left striatum of 
every  third  section  throughout  the  entire  extent  of the  striatum.  Each  section  was 
viewed at low power (x 2.5 objective), and the striatum was outlined. Then the number 
of NeuN positive cells were counted at high power (x 63 oil) in the various groups of 
animals. In another set the first and fourth section from the striatum, just lateral of the 
thalamus, in a relatively posterio-medial portion of the basal ganglia were outlined and 
cells in the lower half were counted with the stereological program (Stereolnvestigator, 
Microbrightfield,  IN).  TH  immunostaining  was  carried  out  on  striatal  and  midbrain 
sections and the TH-stained SNpc neurons were counted by stereology using the optical 
fractionator method.  The  striatal  density  of TH  immunoreactivity  was determined  as 
described (Teismann et al. 2003).
2.4  Mammalian cell culture
2.4.1  Cell lines and culture conditions
HEK293  and Neuro-2a, a gift from Giampietro Schiavo (Cancer Research UK), cells 
were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% 
foetal bovine serum (FBS). NIH 3T3 cells were cultured in DMEM supplemented with
7010%  donor  calf serum  (DCS).  SH-SY5Y  cells,  a  gift  from  Samantha  Loh  (MRC 
Leicester),  were  cultured  in  DMEM  and  Ham’s  nutrient  mixture  F12  (1:1) 
supplemented with 10 % (FBS). The Phoenix ecotropic retrovirus packaging cell line is 
a 293-based cell line and a gift from Gary Nolan (Stanford). The HEK293 TAP control 
cell line was a gift from Miguel Martins (MRC  Leicester) (Martins et al.  2002).  The 
NIH  3T3  myrAkt:ER (Kohn et al.  1996) and ARaf-DD:ER (Woods et al.  1997) cell 
lines were a gift from Almut Schulze (unpublished, Cancer Research UK). All media 
formulations were prepared by Cancer Research UK central cell services.
2.4.2  Culture of primary cortical neurons
Primary cortical neurons were isolated from El4.5 embryos and seeded at a density of 
5 x  105  per well in  12-well plates coated with poly-L-lysine. Cells were maintained in 
Neurobasal  medium  (Invitrogen)  supplemented  with  B27,  Glutamax  and 
Penicillin/Streptomycin (Invitrogen). Following 3 days in culture, contamination from 
fibroblasts  and  glial  cells  was  reduced  by  supplementing  culture  media with  IOjiM 
cytosine arabinoside (Sigma). Cells were cultured for  10 days, with exchange of 50% 
of the  media  volume  with  fresh  media  every  two  days  before  treatment  with  toxic 
stimuli.
2.4.3  Isolation and immortalisation of MEFs
Primary  mouse  embryo  fibroblasts  (MEFs)  were  established  from  El4.5  embryos 
according to  standard procedures (Hogan  et al.  1994).  The cells were maintained  in 
DMEM  supplemented  with  10%  FBS,  L-glutamine  and  antibiotics.  To  establish 
immortalised MEFs over-expressing SV40 large T antigen (SV40LT), primary MEFs 
were cultured in the presence of viral supernatants prepared by transfecting the Phoenix 
ecotropic retrovirus packaging cell line with pBabe Puro SV40LT. Cells that integrated 
the  virus were  selected  in medium  containing  2pg/ml  of puromycin  (Sigma).  HtrA2 
expression  was  restored  in  HtrA2  KO  MEFs,  by  lentiviral  infected  with  pRRLsin- 
cPPT-PGK-HtrA2 as previously described (Klages et al. 2000).
712.4.4  Transfection methods
2.4.4.1  DNA transfection
HEK293, SH-SY5Y, and MEFs were transiently transfected using Effectene (Qiagen), 
Lipofectamine2000  (Life  Technologies),  and  Genejuice  (Novagen),  respectively, 
according to manufacturer's guidelines. The HEK293 HtrA2-TAP stable cell line was 
selected with 0.5mg/ml G418 (Calbiochem), and single colonies were then assayed for 
Protein  A  epitope  expression.  The  AMEKK3:ER  stable  cell  line  was  selected  with 
1  pg/ml puromycin (Sigma).
2.4.4.2  siRNA transfection
Delivery  of  siRNA  into  Neuro-2a  and  immortalised  MEFs  was  performed  using 
Dharmafect2  according  to  the  manufacturer’s  guidelines  (Dharmacon).  Optimisation 
was  performed  with  the  Dharmacon  siGlo  oligo  and  transfection  efficiency  was 
determined  using  FACS.  Following  optimisation,  cells  were  transfected  on  two 
consecutive days (day  1   + 2) with either Non-Targeting siRNA SmartPool,  GAPDH 
siRNA  SmartPool  or  HtrA2  siRNA  SmartPool  against  mouse  HtrA2  (all  from 
Dharmacon) at a final concentration of 30nM. 6hrs following transfection the medium 
was replaced to fresh medium. 48hrs after the 2nd transfection, the cells were harvested 
and assayed.
SH-SY5Y cells were transfected with  siRNA oligos against human  PINK1,  Silencer 
Negative Control or GFP-specific siRNA (all from Ambion) at a final concentration of 
50nM  using  Lipofectamine2000,  according  to  the  manufacturer's  instructions.  After 
48hrs, cells were harvested for Western blotting.
2.4.5  Proliferation assay
Primary MEFs at passage 2 and immortalised MEFs were seeded at  1   x  105  cells/well 
of  a  6-well  plate.  Every  two  days  a  well  was  trypsinised  and  counted  using  a 
haemocytometer and the total number of cells was calculated.
2.4.6  Metabolic activity assay
Primary MEFs at passage 2 were seeded at 4000 cells/well of a 96-well plate. The next
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rotenone, CCCP, tunicamycin for 6hrs or 24hrs. The MTT assay (Cell Proliferation Kit 
I,  Roche)  was  performed  according  to  the  manufacturer’s  instructions.  The 
spectrophotometric absorbance was measured at 600nm wavelength.
2.5  DNA techniques
2.5.1  Basic DNA manipulations
DNA  amplification  by  polymerase  chain  reaction  (PCR)  was  performed  in  a  50pl 
reaction according to the general scheme:  lOOng DNA template,  0.5pM forward and 
reverse primers,  200pM of each deoxynucleoside triphosphate (dATP, dCTP,  dGTP, 
dTTP) and 2.5U Pfu or TaqPlusPrecision polymerase (both Stratagene)  in a reaction 
buffer appropriate for the enzyme. The TaqPlusPrecision polymerase usually worked 
better  for difficult templates  with  secondary  structure,  such  as  HtrA2.  2.5pi  DMSO 
were added to some PCR reactions to increase the efficiency. Themocycling conditions 
were:  95°C  for  4min  for  initial  denaturation,  then  denaturation  at  95°C  for  45sec, 
annealing at the appropriate temperature for the primers (between  50°C to 60°C) for 
lmin, extension at 72°C for lmin/lkb product (30cycles), then final extension at 72°C 
for lOmin.
Restriction  enzyme  digestions  were  performed  according  to  the  manufacturer’s 
protocol  (NEB)  and  DNA  fragments  were  excised  from  agarose  gels  and  recovered 
using the QIAquick Gel Extraction kit (Qiagen).
DNA  ligation reactions were carried at  15°C  for 2hrs in a volume of lOpl using T4 
DNA ligase (NEB) and  lOOng/pl vector, according to the manufacturer’s protocol. 5pi 
of the ligation reaction were transformed into competent XL-10 gold E. coli.
2.5.2  Plasmid mutagenesis
Plasmid  DNA  mutagenesis  was  performed  by  an  adapted  QuickChange  method 
(Stratagene)  as  a  50pl  reaction:  50ng  parental  DNA  template,  3.2pmol  of  the 
appropriate  forward  and  reverse  primers,  200pM  of  each  dNTP  and  2.5U  of  Pfu 
polymerase  in  Pfu buffer.  Themocycling  conditions were:  95°C  for 4min,  (95°C  for
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enzyme (NEB) was then added to the PCR reaction and incubated for  lh at 37°C to 
digest  methylated  parental  DNA  strands.  1  pi  of the  resulting  reaction  was  used  to 
transform competend E. coli. A control reaction with no Pfu polymerase was performed 
in  parallel  and  colonies  only  picked  for  analysis  if the  control  plate  was  clear  of 
colonies.
2.5.3  DNA gel electrophoresis
Agarose gels were prepared by dissolving 1  -2% agarose (depending on the seize of the 
DNA) in  IX TAE buffer (40mM Tris base, pH 8.0,  ImM EDTA, 20mM acetic acid) 
and  heating  until  boiling.  Ethidium  bromide  was  added  to  a  final  concentration  of 
0.5pg/ml before the gel was cast. Samples were mixed with DNA loading buffer (6X 
buffer containing 40% (w/v)  sucrose,  0.25% bromophenol blue and/or 0.25% xylene 
cyanol  FF)  and  electrophoresis  was  at  5-10  V/cm  in  TAE  buffer.  DNA  molecular 
weight markers (lOObp or  lkb Plus ladder, Invitrogen) were included on all gels and 
bands were visualised on a UV transilluminator.
2.5.4  Transformation of E. coli by heat shock
20ng of plasmid DNA,  5 pi of ligation reactions or  lpl of mutagenesis reactions was 
incubated  with  30pl  competent  XL-10  gold  E.  coli  bacteria  (Stratagene)  on  ice  for 
30min. The bacteria were then heat shocked by transfer to a 42°C water-bath for 45sec 
and  then  returned  to  ice  for  a  further  2min.  1ml  fresh  LB  medium  was  added  and 
bacteria were allowed to recover by lh incubation at 37°C gentle shaking. Bacteria wre 
then pelleted in a microcentrifuge, resuspended in  1  OOpl LB medium and spread onto 
LB agar plates containing the appropriate selective antibiotic. Plates were incubated o/n 
at 37°C and then stored at 4°C.
2.5.5  Purification of plasmid DNA
Single  bacterial  colonies  picked  from  LB  agar  plates  containing  the  appropriate 
selection antibiotic were used to inoculate 5ml cultures of LB medium also containing 
antibiotic and incubated o/n at 37°C with shaking. For small scale (mini prep) plasmid 
purification the o/n culture was pelleted by centrifugation and plasmid DNA isolated 
using  DirectPrep  96  MiniPrep  automated  plasmid  purification  system  (Qiagen)
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purification,  a  single  colony  picked  from  LB  agar  plates  containing  the  appropriate 
selection antibiotic were used to inoculate 300ml cultures of LB  medium / antibiotic 
and incubated o/n at 37°C  with shaking.  Cells were harvested by  centrifugation and 
used for Maxi-prep plasmid purification kit (Qiagen) according to the manufacturer’s 
instructions.  Purified plasmid DNA was resuspended in ddFLO and the concentration 
and  purity  was assessed  using  a NanoDrop  spectrophotometer by  measuring  optical 
density  at 260nm  (OD260nm)  and 280nM (OD280nm).  An OD260nm   of 1   corresponds to 
50ng/ml  double  stranded  DNA  and  33p,g/ml  single  stranded  DNA.  The  ratio 
OD260/280nm  provides an estimate of the purity of the DNA solutions and should be ~1.8 
for DNA preparations. DNA was stored at -20°C.
2.5.6  DNA sequencing
Sequencing PCR reactions were performed according to the general scheme: 8pl of Big 
Dye Terminator reaction mix (Perkin Elmer), 3.2pmol of primer,  150-200ng of double 
stranded DNA template  in a total reactin volume of 20pl.  Thermocycling conditions 
were: denaturation at 96°C for lOsec, annealing at 50°C for 5sec, extension at 60°C for 
4min (25 cycles). Dye-terminator removal was achieved with DyeEx2.0 spin columns 
(Qiagen), according to the manufacturer’s instructions. Finally samples were dried in a 
Speed  Vac  microcentrifuge  and  stroed  at  -20°C  until  run.  Sequences  were  read  by 
capillary sequencing using and ABI Prism 3730 DNA analyser (Applied Biosystems).
2.5.7  In vitro translation assay
In vitro coupled transcription/translation was performed following the protocol by the 
supplier  (TNT  T7  Coupled  Reticulocyte  Lysate  System,  Promega).  Reactions  were 
carried out in a total volume of 50pl containing lpg plasmid DNA. 2pl of that reaction 
were run for SDS-PAGE and 5pl for mitochondria import assay.
2.6  RNA techniques
2.6.1  Isolation of RNA
Total  RNA  from  cells  was  isolated  using  the  RNeasy  kit  (Qiagen)  according  to  the 
manufacturer’s instructions. Briefly, 350ptl RLT buffer was added per well of a 6-well
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the DNA.  RNA was isolated by using the RNeasy  spin columns,  DNA was digested 
using the RNase-free DNase set (Qiagen) and eluted in 30pl RNase-free water.
Total  RNA from tissue was also isolated using the RNeasy kit (Qiagen),  600pl RLT 
buffer / 30pg of tissue were  first homogenised by  pipetting or using a glass dounce 
homogeniser,  then  using  a  QIAshredder  (Qiagen),  and  the  following  steps  were  as 
detailed before.
The  concentration  and  purity  of  RNA  was  assessed  using  a  NanoDrop 
spectrophotometer  by  measuring  optical  density  at  260nm  (OD260nm)  and  280nM 
( O D 280nm).  An  O D 260nm  of  1   corresponds  to  40pg/ml  RNA.  The  ratio  O D 26o/280nm 
provides an estimate of the purity of the RNA solutions and should be -2.0 for RNA 
preparations. RNA was stored at -80°C.
2.6.2  RNA gel electrophoresis
The quality of total RNA was analysed on a 1.2% formaldehyde agarose gel in FA gel 
buffer (20mM Mops, 2mM sodium acetate, ImM EDTA, pH 7). Ethidium bromide was 
added to a final concentration of 0.5pl/ml.  lpg of RNA was mixed with loading buffer 
(5X  buffer  containing  0.25%  bromophenolblue,  4mM  EDTA,  7.2%  (v/v)  of  37% 
(12.3M)  formaldehyde,  20%  (v/v)  glycerol,  40%  (v/v)  FA  gel  buffer,  30.84%  (v/v) 
formamide), incubated at 65°C for 5min and electrophoresed at 5 V/cm in FA running 
buffer (20mM  Mops,  5mM  sodium acetate,  ImM  EDTA,  2%  (v/v)  of 37% (12.3M) 
formamide).  0.24-9.5kb  RNA  ladder  and  RNA  century  markers  (Invitrogen)  were 
included on the gels.  Alternatively, the RNA was run on a Agilent Bioanalyser.  The 
28S ribosomal RNA band should be present at approximately twice the amounts of the 
18S rRNA.
2.6.3  Complementary (cDNA) synthesis
cDNA  was  synthesised  from  total  RNA  with  the  Superscript  III  kit  (Invitrogen) 
according to the manufacturer’s protocol using oligo dT2o primer.
762.6.4  Quantitative real-time PCR
cDNA was used as a template for quantitative PCR analysis monitoring the real-time 
increase in fluorescence of SYBR Green (Applied Biosystems) on a Chromo4 detector 
system (Bio-Rad, formerly MJ Research). Gene-specific primers were designed using 
PrimerExpress software (Applied Biosystems). Relative transcript levels of target genes 
are normalised to Actin y RNA levels. Primer sequences are listed in 2.1.4.2. Usually, 
50ng of cDNA and 300nM of each primer were used in a final reaction volume of 25pl. 
Thermocycling conditions were: first denaturation at 95°C for lOmin, then denaturation 
at  95°C  for  15sec,  annealing  and  extension  at  60°C  for  lmin  (40  cycles),  and  a 
dissociation curve profile was performed at the end of each run: denaturation at 95°C 
for  15sec, annealing and extension at 60°C for 20sec, and then slowly increasing the 
temperature  to  95°C  and  taking  measurements  every  1°C  increase.  Thereby  a 
dissociation curve can be plotted for each primer pair, a single peak should be visible 
representing the generation of only one product. The comparative Cy method (AACy) 
was employed to measure relative transcript levels (Livak and Schmittgen 2001). For 
this  calculation  to  be  valid,  the  efficiency  of the  target  amplification  (eg.  HtrA2, 
CHOP) and the efficiency of the reference amplification (eg. Actin y,  18S rRNA) must 
be approximately equal. Therefore, a standard curve with dilution of the template was 
performed and the ACy (which is Cy target -  Cy reference) values were plotted against 
each template concentration. If the efficiencies of the two amplicons are approximately 
equal, the plot of log input (template) versus ACy has a slope of approximately zero.
2.7  Microarray techniques
2.7.1  Microarray sample preparation
The detailed protocol for the sample preparation and microarray processing is available 
from  Affymetrix  (Santa Clara,  CA,  USA).  Briefly,  lOpg  purified  RNA  was  reverse 
transcribed by  Superscript II  reverse transcriptase (Invitrogen)  using T7(dT)24 primer 
containing a T7 RNA polymerase promoter (Affymetrix). After synthesis of the second 
cDNA strand and double stranded cDNA cleanup (GeneChip Sample Cleanup Module 
(Affymetrix)),  this product  was used  in an in vitro transcription reaction to generate 
biotinylated  complementary  RNA  (cRNA)  carried out with the Enzo  Bio  Array  High 
Yield  Transcript  Labelling  Kit  (Affymetrix).  The  cRNA  was  cleaned  using  the
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2.7.2  Hybridisation to GeneChip
MOE430A GeneChips comprise about 22,000 probe sets, representing approximately 
14,000  genes,  therefore  some  genes  are  represented  by  more  than  one  probe  set. 
Affymetrix Mouse Genome 2.0 GeneChips comprise about 39,000 probe sets and some 
genes are represented by more than one probe set.
15^g of fragmented cRNA was hybridised to MOE430A (MEF) or Mouse Genome 2.0 
(brain cortex) GeneChip arrays (Affymetrix) for 16hrs at 45°C with constant rotation at 
60rpm  according  to  the  Affymetrix  protocol.  Each  microarray  was  used  to  assay  a 
single  sample.  After  hybridisation,  the  microarray  was  washed  and  stained  on  an 
Affymetrix fluidics station and scanned with an argon ion confocal laser, with a 488nm 
emission wavelength and detection at 570nm. The fluorescence intensity was measured 
for each microarray.
2.7.3  Data analysis
Probe level intensities were quantile normalised and quantified using RMA (Irizarry et 
al.  2003).  Data  analysis  was  performed  with  the  Genespring  software  version  3.0 
(Silicon Genetics, now Agilent) or Bioconductor software (Gentleman et al. 2004) for 
the MEF or cortex brain array, respectively.
Probe  sets  differentially  expressed  in  rotenone  treated  WT  MEFs  compared  to 
untreated WT MEFs were identified using one-way analysis of variance (ANOVA) and 
a  false  discovery  rate  (FDR)  of  0.15.  A  lower  FDR  rate  did  not  result  in  the 
identification  of any  probe  sets  that  were  differentially  regulated  by  treatment  with 
rotenone in WT MEFs. Similary, probe sets differentially expressed in rotenone treated 
HtrA2 KO MEFs compared to untreated HtrA2 KO MEFs were identified by applying 
a FDR of 0.15, however, even a FDR of 0.07 did return differentially regulated probe 
sets.  In  order to  identify  probe  sets that  were  differentially  expressed  in  HtrA2  KO 
MEFs compared to  WT,  the untreated  samples  for each genotype were  subjected to 
one-way ANOVA using a FDR of 0.05.
Probe sets differentially expressed in HtrA2 KO cortex tissue compared to WT cortex
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probe sets. Application of a FDR of 0.01 did result in the identification of 79 probe sets 
differentially expressed in HtrA2 KO cortex tissue.
2.8  Protein techniques
2.8.1  Determination of protein concentrations
Protein concentrations were determined using the Bio-Rad Protein Assay reagent based 
on the method of (Bradford 1976). Sample dilutions and BSA standards were made in 
0.8ml water, incubated with 0.2ml Bio-Rad Protein Assay for 5min and the absorption 
was measured at 595nm in a plate reader and protein concentrations were determined in 
the relation to the BSA standard curve.
2.8.2  Lysis of cells
Cells were scraped on ice into lysis buffer containing 50mM Tris base, pH 8,  150mM 
NaCl, 2mM EGTA, 5% (v/v) Glycerol, complete protease inhibitor tablet (EDTA-ffee, 
Roche),  and  1-2%  CHAPS  or  1%  Triton X-100.  Cells were  lysed  by  vortexing and 
leaving on ice  for  lOmin.  The lysate was then cleared of nuclei by  centrifugation at 
14,000rpm  for  lOmin  at  4°C  in  a  microcentrifuge.  Protein  concentration  was  then 
assessed using the Bradford assay (Bio-Rad). Cell lines were also lysed directly into IX 
LDS  sample  buffer  (Invitrogen),  sonicated  and  heated  at  70°C  for  lOmin  before 
resolving  the  samples  by  SDS-PAGE.  Cytosol  and  mitochondria-enriched  fractions 
were obtained as described previously (Rytomaa et al. 2000).
2.8.3  Human brains
Brain  tissue  was  obtained  from  the  Queen  Square  Brain  Bank  (where  it  had  been 
donated  with  the  informed consent  of next  of kin)  with  approval  from  the National 
Hospital for Neurology and Neurosurgery/Institute of Neurology Joint Research Ethics 
Committee.  Two  flash-frozen  post-mortem  brains  with  classical  neuropathological 
appearances of PD,  associated with heterozygous mutations in the PINK1  gene were 
originally identified in an extensive mutation screen (Abou-Sleiman et al. 2006). Four 
flash-frozen  brains  with  idiopathic  PD  were  used  as  age-matched  and  pH-matched 
controls. Frozen sections from the basal ganglia of six brains were cut using a cryostat
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in lOmM Tris base, pH 7.6, 5mM EDTA, 50mM NaCl, 30mM sodium pyrophosphate, 
50mM sodium fluoride,  ImM sodium orthovanadate and 2% CHAPS, incubated on ice 
for 45min,  and centrifuged at  13,000g for  15min at 4  °C.  Protein concentration was 
determined using the Bradford assay decribed before (Bio-Rad).
2.8.4  SDS-PAGE and Western blotting
Protein samples were mixed with loading buffer (LDS sample buffer, Invitrogen), were 
separated  by  SDS-PAGE  on 4-12%  gradient  Bis-Tris NuPAGE  gels  in  MES  buffer 
(Invitrogen) at 165 V for lh. Full range pre-stained molecular weight markers (Rainbow 
Markers,  Amersham)  were  included on  all  gels.  For regular 2D  gel  electrophoresis, 
samples were lysed in buffer containing 8M urea, 2% CHAPS (w/v), 5% glycerol (v/v), 
and  ImM  DTT,  resolved  by  isoelectric  focusing  on  immobilised  pH  3-10  gradient 
strips in the IPGPhor system (Amersham) according to manufacturer's guidelines. The 
strips  were  then  subjected  to  SDS-PAGE  using  pre-cast  4-12%  gradient  Bis-Tris 
NuPAGE gels (Novex).
Following separation, proteins were transferred onto Immobilon™ polyvenylfluoridine 
(PVDF) membranes (Millipore) using mini-gel wet transfer apparatus (Bio-Rad) in a 
buffer containing 25mM Tris base, 250mM glycine, pH 8.3, 20% methanol) at 300mA 
for 1.25hrs at 4°C.
Membranes  were  blocked  in  5%  milk  in  TBST  (20mM  Tris  base,  pH  7.4,  150mM 
NaCl,  0.1%  Tween20)  for  lh  at  room  temperature  (RT)  and  then  incubated  with 
primary  antibodies  diluted  in  3%  BSA  in  TBST  at  4°C  o/n  with  gentle  shaking. 
Membranes  were  washed  three  times  for  lOmin  in  TBST  and  incubated  with  the 
secondary antibody or avidin-labelled with peroxidase diluted in 5% milk in TBST for 
45min  at  RT.  Finally  membranes  were  washed  three  times  for  lOmin  in  TBST. 
Immunoreactive proteins were visualised by enhanced chemiluminescence according to 
the  manufacturer’s  instructions  (ECL,  Amersham)  and  exposed  to  X-ray  film 
(FujiFilm).  Where  indicated,  membranes were  stripped  in 0.1M glycine pH  2.5,  and 
neutralised in 1M Tris base pH 7.6 before re-blotting.
802.8.5  Immunoprecipitation
For co-immunoprecipitation, cells were lysed in lOmM Tris base, pH7.6, 5mM EDTA, 
50mM  NaCl,  30mM  sodium  pyrophosphate,  50mM  sodium  fluoride,  ImM  sodium 
orthovanadate and 2% CHAPS (v/v). After pelleting insoluble material by spinning at 
14,000rpm  for  lOmin  at  4°C,  the  appropriate  antibody  was  added  for 
immunoprecipitation and lysates were rotated at 4°C o/n. Complexes were then isolated 
by adding protein A sepharose beads rotating at 4°C for 2hrs. Beads were recovered by 
centrifugation at  1000 x g for 2min at 4°C and washed three times with  1ml of lysis 
buffer.  Following the  final  wash immunoprecipitated and co-purifying proteins were 
eluted  by the  addition of LDS  sample  buffer  (Invitrogen)  and heating  for  lOmin at 
70°C.
For immunoprecipitation of HtrA2 to assess its proteolytic activity cells were lysed in 
lysis buffer containing 1% CHAPS (600pl / 10cm dish), and the cleared lysate of two 
10cm  dishes  was  pooled.  3 pi  anti-HtrA2  antibody  (Alexis)  were  added  and 
immunoprecipitated  for  4-6hrs  at  4°C  with  rotation.  40pl  of a  50%  suspension  of 
Protein A beads (Sigma) were added and rotated at 4°C for another 2hrs. Beads were 
then recovered by centrifugation at  1000 x g for 2min and washed three times (lx in 
lysis buffer and 2x in a buffer containing 50mM Tris base, pH8, 0.5mM EDTA,  ImM 
DTT).  While the beads were  in suspension of the third wash, they were split in two 
tubes  (for  assessing  the  proteolytic  activity  of  HtrA2  with  or  without  a  further 
stimulus).
2.8.6  Recombinant proteins
Mature, C-terminal His6-tagged HtrA2 proteins (A133HtrA2 WT, S142D and S400D) 
in  pET-20b  (Novagen)  were  expressed  in  the  E.  coli  strain  BL21(DE3)pLysS 
(Novagen).  The  point  mutations  were  generated  by  quickchange  PCR  mutagenesis. 
Protein expression was induced by  culturing cells at  16°C  for  16h in the presence of 
0.5mM  isopropyl-p-D-l-thiogalactopyranoside  (IPTG).  Cells  were  lysed  by  freezing 
and thawing in lysis buffer (50mM HEPES, pH 8.0, 300mM NaCl,  lOmM imidazole, 
1%  (v/v)  Triton  X-100).  Lysates  were  cleared  by  centrifugation  at  10,000  x  g  for 
15min. Supernatants were incubated with nickel-nitrilotriacetic acid beads (Qiagen) for 
lh  at  4°C.  Bound  protein  was  washed  with  wash  buffer  (50mM  HEPES,  pH  8.0,
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imidazole  gradient  (20-300mM)  in  elution  buffer  (50mM  HEPES,  pH  8.0,  150mM 
NaCl,  20%  (v/v)  glycerol).  Eluted  protein  was  dialysed  o/n  against  storage  buffer 
(50mM HEPES, pH 8.0,  150mM NaCl, 20% (v/v) Glycerol,  ImM DTT) and stored in 
aliquots at -80 °C.
2.8.7  HtrA2 protease assay
Recombinant  HtrA2  prepped  from  E.  coli  was  further  fractionated  by  gel  filtration 
chromatography  (Superdex  75  prep  grade  column,  GE  Healthcare)  to  separate 
aggregated proteins from natively folded. Two fractions corresponding to the peak of 
WT  HtrA2  were  selected  from  each  of the  recombinant  HtrA2  proteins.  Purity  and 
concentration  of recombinant  proteins  were  controlled  by  SDS-PAGE  analysis  and 
Bradford  assay  (Bio-Rad).  The  HtrA2  optimal  substrate  peptide  (Mca- 
IRRVSYSF(Dnp)KK (where Mca is 7-methoxycoumarin-4-acetic acid and Dnp is N- 
dinitrophenyldiaminopropionic  acid)),  and  the  PDZ-binding  peptide  PDZopt 
(GQYYFV) were synthesised at the Tufts University Core Facility. Usually, 50nM or 
lOOnM  HtrA2  were  incubated  with  lOpM  optimal  substrate  at  30°C  in  a  buffer 
containing  50mM  Tris  base,  pH8,  0.5mM  EDTA,  ImM  DTT.  Fluorescence  was 
monitored on a CytoFluor multi-well plate reader (PerSeptive Biosystems). In order to 
achieve  similar  activity  kinetics  for  WT  and  S400D  HtrA2  (Figure  5-4B),  S400D 
HtrA2 was diluted until it displayed a similar activity curve. When Ucf-101  was used 
to inhibit HtrA2 activity, HtrA2 and its inhibitor were incubated on ice for 15min prior 
to addition of the fluorescent substrate and measurement of kinetics. Similarly, 500pM 
of PDZopt  peptide,  150nM  recombinant  full  length  XIAP  (R&D  Systems)  or  BSA 
were  pre-incubated  for  15min  with  HtrA2  at  RT  before  addition  of the  fluorescent 
peptide  to  determine  the  maximal  activation.  Reaction  rates  (velocity  (V)  (arbitrary 
fluorescence  units  (AFU)/min)  were  determined  by  linear  regression  analysis of the 
data  points  corresponding  to  the  maximum  reaction  rates  for  each  assay  condition. 
Assays are representative of at least three independent experiments.
2.8.8  TAP-tagged protein purification
HEK293 cells expressing HtrA2-TAP or TAP were grown in 15cm culture dishes and 
20 plates were used per purification column. The growth media was removed and cells
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collected in PBS and pelleted at  1300rpm in a benchtop centrifuge.  Cell pellets were 
washed in PBS and pelleted again. Then cell pellets were lysed on ice in  10ml of 2% 
CHAPS lysis buffer (50mM Tris base, pH 8, 150mM NaCl, 2% CHAPS, 2mM EGTA, 
5%  (v/v)  Glycerol,  complete  protease  inhibitor tablet  (EDTA-free,  Roche))  with  10 
strokes in a glass dounce homogeniser. The lysate was then cleared of nuclei and large 
fragments by centrifugation at 4300 x g for 20min at 4°C and then added to a 15ml tube 
containing 500pl of a 50% suspension of pre-washed IgG-linked agarose (Sigma) and 
incubated for 2hrs at 4°C with rotation.  Beads were then recovered by centrifugation 
for 5min at  1600rpm in a benchtop centrifuge and washed 3 x 10ml  1% CHAPS lysis 
buffer and then 1   x 10ml TEV cleavage buffer (lOmM Tris base, pH8,  150mM NaCl, 
0.1% (v/v) CHAPS, 0.5mM EGTA,  ImM DTT). The bead matrix, resuspended in the 
second of these washes, was transferred to a  15 ml Poly-prep chromatography column 
(Bio-Rad) to simplify further handling. After the TEV cleavage buffer wash the base of 
the  column  was  capped  and  1ml  TEV  cleavage  buffer  and  80U  recombinant  TEV 
protease  (Invitrogen)  were  added.  The  column  was  then  capped  at  the  top  and 
incubated for 2hrs at RT with rotation. Flollowing TEV cleavage the sample was eluted 
directly  into  a  second  column  capped  at  the  base  and  containing  500pl  of a  50% 
suspension of Calmodulin-linked affinity resin (Stratagene). 3.5ml calmodulin binding 
buffer (lOmM Tris base, pH 8,  150mM NaCl, 0.1% CHAPS,  ImM MgAcetate,  ImM 
imidazole,  2mM  CaCh,  lOmM  (3-mercapto-ethanol)  and  3.5pl  1M  CaCh  were then 
added,  the  column  capped  at  the  top  and  incubated  for  2hrs  at  4°C  with  rotation. 
Finally, the calmodulin resin was washed with 3 x 10ml calmodulin binding buffer and 
bound proteins were eluted in 5 x 200pl fractions of calmodulin elution buffer (lOmM 
Tris base, pH 8, 150mM NaCl, 0.1% CHAPS, ImM MgAcetate, ImM imidazole, 2mM 
EGTA,  lOmM  (3-mercapto-ethanol).  At each  step aliquots were  saved  for diagnostic 
Western  blotting.  Final  TAP  eluates  were  concentrated  using  Microcon  YM-10 
columns (Millipore) operating at 5000 x g and 4°C from an initial volume of 1ml to a 
final volume of ~30-100pl. LDS sample buffer (Invitrogen) was added and the sample 
run on 4-12% NuPAGE gels as previously described.
832.9  2D DIGE
2.9.1  Sample preparation
Two sets of 2D DIGE gels were run, each containing four replicates. The first set did 
compare WT and HtrA2 KO mitochondrial proteins (isolated from four pairs of WT 
and  HtrA2  KO  littermates),  and  the  second  set  did  compare  WT  and  HtrA2  KO 
mitochondria  from  two  pairs  of littermates,  where  a  subset of the mitochondria had 
been  treated  with  heat  shock  for  30min  at  42°C  following  30min  at  30°C. 
Mitochondrial pellets were lysed in 2-DE lysis buffer (7M urea, 2M thiourea, 4% (w/v) 
CHAPS,  65mM  DTT,  1%  pharmalytes  pH  3-10)  containing  a  protease  inhibitor 
cocktail (Complete Mini, Roche) and endonuclease (Benzonase, Merck) for lh at RT. 
To  remove  unsolubilised  debris  the  lysates  were  centrifuged  at  4°C  for  5min  at 
14,000rpm in a microfuge. Prior to labeling, all protein samples were cleaned using the
2-D Clean-up kit (GE  Healthcare).  The resulting pellets were resolubilised  in DIGE 
labeling buffer (7M urea, 2M thiourea, 4% (w/v) CHAPS, 30mM Tris base, pH 8.5) to 
give a final protein concentration between 5  and  10 mg/ml. Protein concentrations of 
the  lysates were determined using the  2-D  Quant  Kit (GE  Healthcare)  using a BSA 
standard curve with replicate assays performed for each sample.
2.9.2  CyDye labelling of protein extracts
Lyophilised CyDye DIGE Fluors were reconstituted in anhydrous DMF to a final stock 
solution  concentration  of  lnmol/pl,  and  stored  at  -20°C.  For  labelling  experiments, 
each CyDye was diluted in DMF to a working concentration of 400pmol/pl.  Samples 
were  labelled following the manufacturer’s recommended protocol.  For each sample, 
50pg of protein was labelled at a ratio of 8pmole Cy3 or Cy5 CyDye fluor/pg protein, 
where for replicates 1  and 2 the WT samples were labelled with Cy3 and the HtrA2 KO 
samples  were  labelled  with  Cy5,  and  for  replicates  3  and  4  vice  versa.  A  pooled 
standard  (consisting  of equal  amounts  of each  of the  samples  to  be  analysed)  was 
labelled  with  the  Cy2  fluor  at  the  same  ratio  of  8pmole  CyDye  fluor/pg  protein. 
Labelling  reactions  were  incubated  for  30min  on  ice  in  the  dark  and  stopped  by 
quenching with lOmM lysine, followed by a further lOmin incubation on ice.
842.9.3  2D gel electrophoresis
For the first dimension IEF, 24cm pH 3-10 (linear) Immobiline Dry Strip (IPG) strips 
(GE Healthcare) were re-hydrated with with 450ml DeStreak solution (GE Healthcare) 
at RT o/n in a re-swelling tray.  150pg of CyDye labelled proteins (50pg of each fluor 
Cy2, Cy3 and Cy5) were cuploaded onto the re-swelled IEF strips. Isoelectric focussing 
was performed on an Ettan IPGphor IEF System using the Ettan IPGphor Cup Loading 
Manifold (both GE Healthcare). Focussing was performed for a total of 55kVh at 20°C, 
at  a  maximum  current  of  50pA/strip,  as  described  previously  (Unlu  et  al.  1997). 
Following IEF, for the second dimension SDS-PAGE, the strips were equilibrated for 
15min in equilibration buffer (6M urea, 30% (v/v) glycerol, 2% SDS, 50mM Tris base, 
pH 8.8, and 0.01% (w/v) bromophenol blue) containing 1% DTT, followed by a further 
15min in the same buffer containing 2.5% iodoacetamide (IAA) in place of the DTT as 
described previously (Unlu et al.  1997). Equilibrated IPG strips were transferred onto 
1mm thick 25 x 20cm  12% polyacrylamide gels without a stacking gel, cast between 
low-fluorescence  glass  plates.  The  IEF  strips  were  overlaid  with  0.5%  low melting 
point agarose in 2X  electrophoresis  buffer (50mM Tris base,  384mM glycine,  0.2% 
(w/v) SDS) with bromophenol blue. Gels were electrophoresed in an Ettan Dalt six gel 
tank (GE Healthcare) at 20°C, at 1.5 W/gel constant power (o/n) until the bromophenol 
blue dye front had migrated off the bottom of the gel. A running buffer of 25mM Tris, 
192mM glycine, 0.1% (w/v) SDS was used for the lower chamber. 2X running buffer 
was used for the upper chamber.
2.9.4  Image acquisition and analysis
Following  SDS-PAGE,  fluorescently  labelled  proteins  were  visualised  while  still 
between  the  low-fluorescence  glass  plates  using  a  Typhoon  9400  Variable  Mode 
Imager and Typhoon Scanner Control Software, Version 3.0 (GE Healthcare). For the 
Cy2 images a 488nm laser and an emission filter of 520nm with a band pass (BP) of 40 
nm was used. Cy3 images were obtained using a 532nm laser and an emission filter of 
580 nm/BP30. Cy5 images were obtained using a 633nm laser and an emission filter of 
670 nm/ BP30. For each scan the photomultiplier tube (PMT) voltage was adjusted on 
each channel (Cy2, Cy3  and Cy5) to give a maximum pixel value of between 60,000 
and 80,000 to avoid image saturation (pixel value  100,000). Low-resolution (1000pm 
pixel  size) pre-scans were used to obtain the PMT voltage settings, which were then
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cropped  using  ImageQuant  Tools  to  exclude  non-essential  information  prior  to 
DeCyder analysis.  For image analysis using DeCyder,  images were exported as  .gel 
files, together with a .ds file which links the three separate .gel files for each CyDye 
from  one  gel.  Analysis  of  gel  images  was  performed  using  DeCyder  Differential 
Analysis Software Version 5.0 (GE Healthcare). The software was used to match all 12 
protein spot maps from the 4 gels per set. The Biological  Variation Analysis (BVA) 
module  was  used  to  compare  abundance  changes  across  the  WT  and  HtrA2  KO 
mitochondrial  samples.  DeCyder  performs  Student's  t-tests to  determine  statistically 
significant changes, as well as calculating mean abundance changes between the two 
sample populations.
2.9.5  Preparative gels
Preparative gels for spot picking were prepared by running 400 to 500pg of protein on 
2D gels. Due to the higher protein load,  samples were applied to the first dimension 
strips  using  an  in-gel  re-hydration  method.  Samples  were  diluted  in  re-hydration 
solution (8M urea, 0.5% (w/v) CHAPS, 65mM DTT, 0.5% (v/v) pharmalyte pH 3-10). 
Protein  spots  were  visualised  using  silver  staining  using  a  mass  spectrometry 
compatible  stain  modified  from  (Shevchenko et  al.  1996).  Silver stained preparative 
gels were imaged on a Molecular Dynamics Personal Densitometer SI (GE Healthcare). 
Protein spots of interest were manually excised.
2.10  Mass spectrometry
For mass spectrometry of proteins, the protein spots of interest were excised from SDS- 
PAGE  gels,  destained,  trypsinised  and  MALDI-TOF  mass  spectrometric 
characterisation  was performed  by  the  Protein  Analysis  Service  of Cancer  Research 
UK.
Lipid extraction from purified mitochondria using a Percoll gradient was accomplished 
as described earlier and extracts were analysed by nano-electrospray time of flight mass 
spectrometry using a LCT instrument (Micromass) set in positive ion mode (Sorice et 
al.  2004).  A  few microliters  of the  extracts  were  injected  using  capillary  voltage  at 
2,250  V  and  sample  cone  at  35  V.  Semi-quantitative  evaluation  of lipid  peaks  was
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relationships within multiple  spectra of the  same  sample  and  showed  little  variation 
between  WT  and  HtrA2  KO  samples.  The  data  was  normalised  to  the  major 
phosphatidyl choline, that is PO-PC (mass-to-charge ratio m/z 758), which was in turn 
normalised to other reference ions like C-24 Ceramide (m/z 685) (Sandra et al. 2005).
2.11  Methods to measure cell death
2.11.1  Analysis of DNA content - sub-G1 apoptosis assay
Immortalised MEFs were plated (2 x  105  per well) in 6-well plates and treated  16hrs 
later with CCCP (Calbiochem), rotenone (Sigma), tunicamycin (Sigma) or etoposide 
(Calbiochem) for 27hrs or H2O2, (all Sigma) for 4.5hrs. Immortalised HtrA2 KO and 
HtrA2 KO MEFs restored to express human HtrA2 were treated for 20hrs with MG- 
132  (Calbiochem)  and  6-OHDA  (Sigma)  or  3hrs  with  staurosporine  (Calbiochem). 
Cells were harvested by trypsinisation and washed in PBS. Then cells were fixed with 
ice cold 70% ethanol added dropwise while vortexing. After fixation for at least 30min 
at 4°C, the cells were washed twice in phosphate-citrate buffer (0.2m Na2HP0 4 , 4mM 
citric  acid,  pH  7.8)  and  collected  by  spinning  at 2000rpm  in a benchtop  centrifuge. 
Each  sample  was  then  treated  with  50pl  of  lOOp/ml  RNase  followed  by  200pl  of 
50pg/ml  propidium  iodide  (PI).  Cells  were  then  analysed  by  FACS  using  a 
FACSCalibur instrument (Becton Dickinson) as previously described (Darzynkiewicz 
and Bedner 2000). Debris and cell doublets were excluded from the analysis and the PI 
staining intensity (FL-3) was recorded as a measure of DNA content. For each sample 
at  least  10,000  events  were  acquired  and  data  analysis  was  performed  using  FloJo 
software (TreeStar).
2.11.2  Annexin V staining
Immortalised MEFs were grown in 6-well dishes at 0.7 x 105  cells and transfected with 
lpg  vector or  PINK1  expression  constructs  and,  in  order to  identify  the  transfected 
cells,  0.2pg  of a  plasmid  encoding  famesylated  EGFP  (pEGFP-F)  using  Genejuice 
(Novagen) according to the manufacturer’s guidelines. 24hrs after transfection the cells 
were treated with vehicle or MG-132, and the following day for 3hrs with staurosporine 
before  harvesting  all  cells  and  washing  in  PBS.  Cells  were  then  resuspended  in
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V  antibody  (Molecular  Probes)  in  a  final  volume  of 200pl.  Cells  were  stained  for 
15min at RT in the dark, before placing them on ice and keeping them in the dark. 3pi 
PI were added just before analysis to each sample. Cells were analysed by FACS using 
a  FACSCalibur  instrument  (Becton  Dickinson).  The  instrument  was  configured  to 
measure GFP (FL-1) fluorescence intensity and the analysis was gated on GFP-positive 
cells. The transfected cells were then analysed for AnexinV Alexa 647 (FL-4) and PI 
(FL-2/3).  The  percentage  of GFP-positive  cells  displaying  characteristic  features  of 
apoptotic  cell  death  (ie.  Annexin  V-positive  and  Pi-negative)  was  calculated  as  a 
proportion  of  the  total  GFP-positive  cells  using  CellQuest  software  (Becton 
Dickinson).
Immortalised MEFs were grown in 6-well dishes at 2 x  105  cells. The next day cells 
were pre-treated with vehicle or the HtrA2 inhibitor Ucf-101  (Calbiochem) for 20min 
before addition of vehicle or 2pM staurosporine for 4hrs. Cells were harvested, washed 
in PBS  and  stained with Annexin V Alexa 647 and PI  as described previously.  The 
percentage of Annexin V-positive and Pi-negative cells was calculated as a proportion 
of all cells.
2.11.3  Measurement of chromatin condensation
For  neuron  cell  death  analysis,  cells  were  incubated  in  the  presence  or  absence  of 
glutamate (Sigma) for 4hrs, fixed in 4% paraformaldehyde, stained with Hoechst 33342 
(Molecular Probes) according to the manufacturer’s instructions and nuclear chromatin 
was scored as being condensed or non-condensed by fluorescence microscopy.
2.12  Mitochondria techniques
2.12.1  Morphological analysis of mitochondria
WT  and  HtrA2  KO  MEFs  were  cultivated  in  DMEM  containing  10%  FBS  until 
confluency.  Cells  were  then  subjected  to  the  following  treatments  for  30  minutes: 
25pM  CCCP  (Calbiochem)  or  25pM  rotenone  (Calbiochem).  Following  treatment, 
media  was  replaced  and  cells  were  further  incubated  at  37°C  for  2hrs.  Following 
incubation cells were processed for electron microscopy by gently replacing the culture
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CaCh in 0.2M cacodylate buffer at pH 7.4) and incubating for  lh at RT.  Cells were 
post-fixed with  1% osmium tetroxide/1% potassium ferrocyanide for  lh at RT. Fixed 
cells were stained with 5% aqueous uranyl acetate o/n at RT and harvested by scraping. 
The resulting pellet was dehydrated and embedded in TAAB embedding resin.  Ultra 
thin sections were stained with lead citrate and examined in a Jeol  100-CXII electron 
microscope  equipped  with  a  rotating  stage/eucentric  goniometer.  All  quantitative 
assessments of mitochondrial  morphology  were  based  on  scoring  a minimum  of 25 
cells  for  each  treatment.  For  each  treatment,  the  number  of mitochondria  showing 
specific changes was determined.
2.12.2  Isolation of mitochondria
Mitochondria were purified from mouse livers of WT and HtrA2 KO mice at PI5 to 
P30 using differential centrifugation. In order to achieve high purity, a percoll gradient 
was employed for further purification. The entire procedure was carried out at 4°C. All 
equipment used (dounce homogeniser, tubes) were rinsed with ice cold buffers before 
using.  Mice  were  culled  and  livers  taken  out,  being  careful  not  to  take  any  white 
connective material.  The liver was immediately placed in  10ml  ice cold buffer HSB 
(0.3M sucrose,  lOmM HEPES, pH 7.4). The liver was cut into small cubes using two 
scalpels and a petri dish cooled in an ice bucket as tray. Bring volume to 15ml HSB per 
liver.  The material was homogenised using a  15ml cooled glass dounce homogeniser 
with a loose pestle for 15 strokes or until there were no tissue pieces visible any more. 
The material from two livers could be pooled per sample. The dounce homogeniser was 
washed with another 10ml of HSB and this was pooled with the homogenised material, 
which then was centrifuged at 600 x g for 5min at 4°C to remove cell and tissue debris. 
The  red  blood  cells  did  pellet.  The  supernatant  was  taken  and  the  centrifugation 
repeated.
For purification using a Percoll  gradient, the resulting supernatant was centrifuged at 
8700 x g for  lOmin at 4°C to precipitate the mitochondrial fraction, which should be 
brownish/white. The supernatant was carefully discarded, and 10ml HSB supplemented 
with  ImM PMSF was added. The pellet was gently detached using the tip of a teflon 
prestle,  and  resuspended  using  a  dounce  homogeniser  with  4-5  gentle  strokes.
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resuspended  by  homogenisation  as  before  in  2ml  of buffer  MMB  (0.3M  mannitol, 
5mM Mops,  pH  7.2)  using a small  1.5ml dounce homogeniser.  The  suspension was 
deposited on the top of the following Percoll gradient using a pasteur pipette:  1.5ml of 
70% Percoll (Sigma) in MMB, 4ml of 30% Percoll in MMB, and 2ml of 10% Percoll in 
MMB (from bottom to top) in Beckmann Ultra-Clear centrifuge tubes (14 x 89mm, cat 
no: 344059). The sample was spun in an ultracentrifuge at 13,500 x g using a swinging 
buckets  rotor  for  35min  at  4°C,  with  the  brake  at  the  zero  position.  The  brownish 
mitochondrial material at the interface of 70-30% Percoll was taken off using a pasteur 
pipette, these are the functional intact mitochondria and everything above is disrupted 
mitos. The mitochondria were washed twice in 10ml cold buffer MSB (0.4M mannitol, 
lOmM NaH2PC> 4, 20mM HEPES, pH 7,4, 0.5mM EGTA), by homogenisation as before 
using a dounce homgeniser and centrifugation at 8700 x g for lOmin at 4°C. The final 
pellet was resuspended in 1ml of MSB, and when necessary flash frozen and stored at - 
80°C.  For heat  shock,  the  freshly  isolated  mitochondria were  incubated  at 42°C  for 
30min and for another 30min at 30°C, before flash freezing.
For  isolation  of  mitchondria  by  differential  centrifugation  only,  the  livers  were 
homogenised  in  HSB  as  before  or  in  buffer  LHM  (0.2M  mannitol,  50mM  sucrose, 
lOmM KC1,  ImM  EGTA,  lOmM HEPES,  pH  7.4).  The  supernatant from the  initial 
spins  at  600  x  g  was  centrifuged  at  3000  x  g  for  lOmin  at  4°C  to  precipitate  the 
mitochondrial  fraction and avoid pelleting  lysosomes.  The  supernatant was carefully 
discarded, and 10ml HSB or LHM was added. The pellet was gently detached using the 
tip of a teflon prestle,  and resuspended using a dounce homogeniser with 4-5  gentle 
strokes. Centrifugation at 3000 x g for lOmin at 4°C did pellet the mitochondria again. 
This wash was repeated, and the final mitochondrial pellet was resuspended in MSB as 
before  or mitochondria import  buffer  (MIB)  (0.3M  mannitol,  0.1 mg/ml  BSA,  2mM 
ATP,  2mM  NADH,  2mM  potassium  phosphate,  pH  7.5,  2mM  p-mercato-ethanol, 
50mM HEPES, pH 7.4) when the mitochondria were used for the in vitro import assay 
of  in  vitro  translated  proteins  into  mitochondria  (see  2.12.3  Mitochondria  import 
assay).  The  purity  of the  isolated  mitochondria  was  routinely  assessed  by  Western 
blotting  using  anti-KDEL  (endoplasmic  reticulum,  Stressgen),  anti-Cathepsin  D 
(lysosomal) and anti-Actin antibodies (cytosolic, both Santa Cruz Biotechnology).
902.12.3  Mitochondria import assay
5pl of in vitro translated protein were incubated with  50pg of mitochondria in 20pl 
MIB (final is 25pl) at 25°C, usually for lh unless otherwise indicated. The import was 
stopped by addition of 225pi of MIB containing 50pg/ml Proteinase K to each sample 
to  digest  proteins  bound  to  the  outer  surface  of  the  mitochondria  (iso-osmotic 
conditions).  In order to achieve hypo-osmotic treatment of the mitochondria resulting 
in  rupture  of the  outer  mitochondrial  membrane  only  retaining  the  matrix  proteins 
(formation  of  mitoplasts),  the  Proteinase  K  treatment  was  performed  in  a  buffer 
containing 20mM HEPES, pH7.4 and 50pg/ml Proteinase K. The digest was incubated 
on  ice  for  15min,  then  750pl  MIB  containing  2.5pl  PMSF  were  added  to  stop  the 
reaction. Mitochondria were pelleted at 8000 x g for 5min at 4°C, then 25 pi  IX LDS 
(Invitrogen) were added to the pellet. Proteins were separated on a 4-12% gradient Bis- 
Tris NuPAGE gel (Novex, Invitrogen), transferred onto PVDF membranes and exposed 
to phosphoimager screen.  In vitro translated mature HtrA2  lacking the mitochondria 
import sequence was included as a negative control, and full length HtrA2 as a positive 
control. Hypo-osmotic treatment of the mitochondria after import of full length HtrA2 
did abolish the HtrA2 signal validating its location in the intermembrane space.
2.13  Statistical analysis
Data are presented as mean values and error bars indicate either the standard deviation, 
the standard error or the range of two determinations (Cumming et al. 2007).  The p- 
values in Figure 4-3C and Figure 4-8 were calculated using a two-tailed unpaired t-test. 
The groups in Figure  5-4A were compared by  one-way  ANOVA using Bonferroni's 
post  test  using  Prism  statistical  analysis  software  (www.graphpad.com).  The 
significance is indicated as *** for P <0.001.
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3.1  Introduction
The  serine  protease  HtrA2  is  released  from  the  mitochondrial  intermembrane  space 
following  apoptotic  stimuli.  Once  in  the  cytosol,  HtrA2  has  been  implicated  in 
promoting cell death by binding to IAPs via its N-terminal IBM, thus inducing caspase 
activity (Suzuki et al. 2001; Hegde et al. 2002; Martins et al. 2002; van Loo et al. 2002; 
Verhagen  et  al.  2002).  In  addition,  HtrA2  has  been  described  to  mediate  caspase- 
independent death through its own protease activity (Suzuki et al.  2001; Hegde et al. 
2002; Martins et al.  2002; Verhagen et al.  2002).  However, these studies used over- 
expressed HtrA2 and probably any protease, when strongly over-expressed, might be 
able to induce cell death. At the commencement of this work, the physiological role of 
HtrA2 in the mitochondrial intermembrane space was poorly understood, physiological 
substrates of HtrA2 had not been identified, and the importance of its role as an IAP- 
interacting protein in apoptosis was the subject of much debate. In this chapter, the role 
of HtrA2 in vivo is illuminated, and mitochondrial substrates of its proteolytic activity 
are studied. The function of HtrA2 is studied by examining the phenotype of HtrA2- 
deficient mice and HtrA2’s involvement in cell  death is tested  in cells derived from 
these mice.  Unexpectedly,  HtrA2  appears not to possess a pro-apoptotic  function in 
vitro, but on the contrary, HtrA2 seems to protect mitochondria from stressful insults.
3.2  Deletion  of  HtrA2  results  in  a  neurological  phenotype 
leading to death at one month post-birth
In order to address the physiological role of HtrA2 in vivo, HtrA2-deficient mice were 
generated.  These  mice  were  made  by  Alastair  Morrison  and  co-workers  at 
GlaxoSmithKline,  Harlow,  Essex.  The  HtrA2  gene  was  disrupted  by  homologous 
recombination  in  129/sv  ES  cells  to  generate  HtrA2  KO  mice  (Figure  3-1 A).  The 
targeting vector was designed such that 83% of the coding region, encompassing part 
of exon  1,  all  of exons  2-6,  and  part  of exon  7  were  replaced  with  the  PGK-neo 
cassette.  Three  independent  ES  cell  clones  carrying  the  mutated  HtrA2  allele  were 
obtained.  Two  of these targeted  ES  cell  clones were  injected  into  C57B16/J-derived 
blastocysts and chimeric mice were bom. High percentage male chimaeras from both 
clones  were  identified  by  their  coat  colour  and  crossed  with  C57B16/J  females  to
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clones were  back-crossed  for at  least  5  generations  onto  the  C57B16/J  strain.  Back- 
crossed  HtrA2  Het  animals  were  then  inter-crossed  to  produce  the  FI  progeny. 
Analysis of genomic DNA prepared from tail biopsy samples by PCR confirmed the 
successful disruption of the HtrA2 gene (Figure 3-1B). To verify that the KO allele was 
a  null  mutation,  RNA  prepared  from  brain  tissue  was  used  to  generate  cDNA  as 
template  for  quantitative  real-time  PCR  (qPCR).  About  50%  reduction  in  HtrA2 
mRNA in Het and no product in HtrA2 KO animals were detected (Figure 3-1C). To 
check the level of HtrA2 protein, MEFs were prepared from HtrA2 WT, Het and KO 
littermates and lysates were subjected to Western blotting to detect HtrA2 expression. 
This analysis revealed the absence of HtrA2 protein in cells derived from KO animals 
and a partial reduction of protein levels in cells derived from embryos heterozygous for 
the HtrA2 locus (Figure 3-ID).
Genotypic analysis of the progeny of HtrA2 Het x Het crosses by PCR revealed that 
out of 157 pups, 40 (25%) were WT, 85 (54%) Het for the mutation and 32 (21%) were 
HtrA2  KO,  consistent with almost normal  Mendelian inheritance and  indicating that 
deletion of the HtrA2 gene does not result in gross embryonic lethality (Figure 3-2A). 
Analysis  of the  resulting  HtrA2  KO  animals  revealed  that  from  PI8  they  began  to 
display striking phenotypic alterations when compared with WT or Het littermates. The 
most dramatic alteration observed was failure to gain weight following weaning at PI8 
(Figure 3-2B),  whereas HtrA2  Het mice did not  show a difference compared to WT 
mice.  The  phenotype  of HtrA2  KO  mice  resulted  in  small  runted  animals  at  P30 
(Figure 3-2C). Animals lacking HtrA2 also  showed a general decrease in organ size. 
The degree of decrease in organ size was variable, being particularly dramatic in the 
case of thymus, heart and spleen (data not shown). Hair loss was also occasionally seen 
in the HtrA2 KO mice.
Examination  of the  behaviour  of HtrA2  KO  animals  revealed  several  neurological 
abnormalities. Animals lacking HtrA2 were characterised by a progressive movement 
disorder  beginning  at  PI8.  They  displayed  decreased  mobility  and  bradykinesia 
(difficulty to  initiate movements),  bended posture and tremor,  and exhibited  lack  of 
coordination.  Such features are characteristic  of a parkinsonian syndrome in humans 
and have also been described in animal models of this disease (Betarbet et al.  2002).
93HtrA2 KO animals died between P30 to P40, mostly due to respiratory failure. In order 
to minimise their suffering, HtrA2 KO mice were routinely euthanised at P30 or earlier. 
All  the  animal  husbandry  and  experimental  procedures  were  carried  out  in  full 
compliance with the United Kingdom Animal Act of 1986 and were approved by the 
Cancer Research UK procedures panel.
In order to test the movement skills of the mice, they were challenged on an inclined 
platform test (Schaefer et al. 2000). This test monitors the ability of the mice to reach 
the top of an inclined platform and has been used previously to examine the onset of 
ataxia  in  mice  developing  a progressive  neurological  disorder  due  to  expression  of 
mutant prion protein (Chiesa et al.  1998). HtrA2 KO mice around P30 demonstrated a 
decreased performance on the inclined platform test,  with only half of the KO mice 
reaching the top of the platform (Figure  3-2D).  In addition,  the fact that HtrA2  KO 
mice that managed to reach the top of the  platform took three times longer (Figure 
3-2E)  than  WT  or  Het  littermates,  suggested  that  deletion  of  HtrA2  results  in 
deficiencies  in  coordination  and/or  strength.  However,  although  some  of  the  KO 
animals failed to stay on the platform for the 60sec trial period, 63% of KO animals 
remained  on  the  platform  for  the  entire trial,  suggesting  that  they  were  not  grossly 
impaired  in  muscle  strength  and  that  disturbances  in  coordination  were  principally 
responsible for their poor performance.
3.3  HtrA2 deletion results in the selective loss of a population 
of striatal neurons
The fact that the phenotype of HtrA2 KO mice was reminiscent of Parkinson’s disease 
(PD), prompted the investigation of whether these animals displayed histopathological 
deficits similar to human PD patients. At the morphological and anatomical level, PD is 
characterised  by  degeneration  of the  neural  connection  between the  substantia nigra 
(SN)  and  the  striatum,  two  brain  regions  essential  for  normal  motor  function  (for 
review (Fahn 2003)). The striatum receives its dopaminergic input from neurons of the 
substantia  nigra  pars  compacta  (SNpc)  via  this  nigrostriatal  pathway.  Progressive 
degeneration  of the  nigrostriatal  dopaminergic  pathway  results  in  profound  striatal 
dopamine deficiency, leading to the described motor deficiencies.
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synaptic  deficits  by  analysing  the  SN  or  post-synaptic  deficits  by  analysing  the 
striatum.  First,  the  neuronal  circuits  in  the  striatum  of  HtrA2  KO  animals  were 
examined.  P30  KO  animals  were  analysed  as  they  displayed  the  most  severe 
phenotypes. Analysis of brains from HtrA2 KO animals revealed a selective loss of a 
neuronal  population  in  the  striatum,  just  lateral  of  the  thalamus  in  a  relatively 
posteriomedial portion of the basal  ganglia (Figure  3-3A).  In the haematoxylin-eosin 
(H&E)  stained  sections  (Figure  3-3B)  focal  loss  of  neurons  was  identified,  with 
occasional ballooned cells and concomitant reaction of the astrocytes, as highlighted in 
a  GFAP  immunostain  (Figure  3-3C).  This  loss  of neurons  is  more  clearly  seen  in 
sections  immunostained  for  the  microtubule-associated  protein  MAP2,  a  neuronal 
marker  (Figure  3-3D).  Occasionally,  apoptotic  cell  bodies  were  detected  (data  not 
shown). In order to rule out a general and widespread loss of neurons in the striatum, 
stereological cell counts of striatal neurons were performed. These results indicated that 
there is no significant change in the overall neuronal density in the striatum of HtrA2 
KO animals, but only in the posterior portion of the basal ganglia (Figure 3-3E). Both 
at  P20,  where  no  phenotypic  alterations  are  detectable,  and  at  P30,  a  decrease  of 
neuronal  density  in  brains  from  HtrA2  KO  animals  was  detected,  suggesting  that 
neuronal  loss  precedes  the  full  development  of  the  parkinsonian  syndrome. 
Concomitant  with  the  neuronal  loss,  a  selective  loss  of terminals,  highlighted  by 
tyrosine hydroxylase staining, of the nigrostriatal pathway in the posterior portion was 
identified  when  compared to the  whole  striatum  (Figure  3-3F).  Analysis  of tyrosine 
hydroxylase positive neurons  in the SNpc of HtrA2 KO animals revealed no loss of 
dopaminergic neurons when compared with WT littermates (Figure 3-3G). At present, 
it is unclear if this loss of terminals is a cause or a consequence of the neuronal loss 
detected.
3.4  HtrA2 Het mice do not develop a late onset phenotype
In the last decade, the identification of several genes that cause rare familial forms of 
PD has revealed novel proteins and pathways that may be involved in the development 
of this disease. The human HtrA2 gene is located on Chromosome 2pl3. This position 
is within the Parkinson’s Disease-3 (PARK3) locus identified in familial PD (Gasser et 
al.  1998). The gene responsible for the development of PD in the PARK3 families has
95not  been  identified  yet,  therefore  HtrA2  could  be  a  potential  candidate.  Since  the 
inheritance pattern for the PARK3 locus is autosomal dominant in the human families, 
the HtrA2 Het mice were examined for the development of late-onset coordination and 
movement disabilities. Groups of 10 WT and 10 HtrA2 Het mice were trained to run on 
a rotarod, a rotating stick, and the time until they fell off was measured. The mice were 
tested on three consecutive days every two months at an age between 10 to 16 months. 
However,  no  difference  in the movement  skills between the  WT  and  Het  mice  was 
apparent at any time (Figure 3-4). Therefore, loss of HtrA2 function, as measured by 
this assay,  seems to be recessively inherited in mice, although it cannot be ruled out 
that the lifespan of inbred mice is too short to detect the development of a phenotype in 
HtrA2 Het animals.
3.5  Deletion  of  HtrA2  does  not  alter  cell  proliferation  or 
metabolic activity, but results in mitochondrial dysfunction
The homozygous deletion of HtrA2  in mice  clearly  leads to a severe phenotype and 
therefore  the  effect  of loss  of HtrA2  at  the  cellular  level  was  studied.  The  rate  of 
proliferation as monitored by cell counting was determined in primary or immortalised 
MEFs derived  from  WT  and  HtrA2  KO  mice.  No  differences were  detected  over a 
three  day  period  (Figure  3-5A  and  B).  Similarly,  the  metabolic  activity  of WT  and 
HtrA2 KO MEFs was not demonstrably different. The MEFs were treated with either 
CCCP, an uncoupler of mitochondrial respiration leading to a collapse of mitochondrial 
membrane potential, or rotenone, an inhibitor of complex I of the respiratory chain, or 
tunicamycin,  an  inhibitor  of N-linked  glycosylation  in  the  endoplasmatic  reticulum 
(ER)  causing  accumulation  of proteins  in  the  ER.  These  drugs  did  impact  on  the 
metabolic activity of the MEFs, however, there was no discernible difference between 
the WT and HtrA2 KO MEFs (Figure 3-5C, D, and E).
Given  that  the  serine  protease  HtrA2  is  localised  to  the  intermembrane  space  of 
mitochondria in healthy cells, the effect of HtrA2 loss could impinge on mitochondria 
without notably affecting overall cellular metabolic activity. To test this possibility, the 
mitochondrial morphology was examined at the ultra structural level in WT and HtrA2 
KO  MEFs  following  treatment  with  mitochondrial  stress-inducing  agents.  These 
experiments  were  performed  by  Valentina  Fedele  at  the  MRC  Toxicology  Unit  in
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described  mitochondrial  morphologies  in  untreated  cells  were  observed  (Ghadially 
1982): normal mitochondria, mitochondria displaying ballooning of cristae (intracristal 
swelling) and mitochondria with abnormal form (the latter only detected in cells from 
KO animals) (Figure 3-6A). When cells were subjected to mitochondrial stresses in the 
form of the complex I  inhibitor rotenone and the mitochondrial  membrane potential 
uncoupler  CCCP,  cells  lacking  HtrA2  contained  an  increased  percentage  of 
mitochondria characterised  by  abnormal  morphological  alterations (Figure  3-6B  and 
C).  Therefore,  deletion  of  HtrA2  may  confer  upon  mitochondria  an  increased 
sensitivity to stress.
3.6  Deletion of HtrA2 results in increased susceptibility to cell 
death stimuli
It is possible that the increased susceptibility of HtrA2 KO mitochondria to stress could 
affect cell viability. To test this, immortalised WT or HtrA2 KO MEFs were subjected 
to  apoptosis-inducing  agents  and  the  population  of sub-Gl  cells  was  measured  by 
FACS (Figure 3-7A). Loss of HtrA2 led to increased sensitivity to agents that perturb 
mitochondrial function, such as CCCP and rotenone, as well as agents that cause both 
oxidative stress (hydrogen peroxide) and ER stress (tunicamycin). MEFs lacking HtrA2 
did not show an altered sensitivity to the DNA damaging agent etoposide.
In addition to using WT and HtrA2 KO MEFs, human HtrA2 was stably re-expressed 
in  HtrA2  KO  MEFs.  These  restored  MEFs  exhibited  reduced  sensitivity  to  agents 
affecting mitochondrial  function,  shown  here  for 6-hydroxydopamine  which  inhibits 
complex I  of the respiratory chain and leads to oxidative stress, and accumulation of 
proteins  through  the  proteasome  inhibitor  MG-132  (Figure  3-7B).  Staurosporine,  a 
broad-spectrum  kinase  inhibitor that  induces apoptosis very  potently,  did not have  a 
differential effect on restored and HtrA2 KO MEFs similar to etoposide.  The general 
indication  from these  experiments  was  that  cells  lacking  HtrA2  were predominantly 
sensitised  to  stresses  that  have  been  described  in  the  field  of PD  research,  namely 
mitochondrial and oxidative stress, disturbance of the ER, and protein accumulation.
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neurons  isolated  from  KO  mice  might  be  more  sensitive  than  WT  controls  to 
excitotoxic stimuli. Primary cortical neurons were isolated and subjected to glutamate- 
mediated  excitotoxicity.  These  experiments  revealed  a  significant  increase  in  the 
susceptibility  of  neurons  obtained  from  HtrA2  KO  animals  to  excitotoxic  stimuli 
(Figure 3-7C).
Taken together, the results presented  so far indicate that, rather than protecting cells 
from apoptosis, deletion of HtrA2 results in increased sensitivity to a specific subset of 
death stimuli.
3.7  Identification  of  differential  protein  levels  in  HtrA2  KO 
mitochondria
Mammalian HtrA2 has homologues in bacteria, which act to protect the bacteria from 
the accumulation of unfolded proteins, either by cleaving them directly as in the case 
for  DegP  (Spiess et  al.  1999),  or by  activating a transcriptional  stress  response  and 
inducing expression of chaperones as in the case for DegS (Walsh et al. 2003). In order 
to find out if loss of HtrA2 would impact on the mitochondrial proteome, fluorescence 
2D difference gel electrophoresis (2D DIGE) was employed.  2D DIGE is a powerful 
method  for  detecting  protein  expression  differences  with  high  accuracy  and 
reproducibility. It uses molecular weight- and pi-matched, spectrally resolvable dyes to 
label protein samples prior to 2D electrophoresis on the same gel (Unlu et al.  1997). 
This  method  has  been  successfully  used  to  identify  alterations  in  the  mitochondrial 
proteome,  both  from  cell  culture  (Lehr  et  al.  2005)  and  mouse  models  of  stress 
(Douette et al. 2005).
Liver mitochondria were isolated to high purity from four pairs of WT and HtrA2 KO 
littermates for the first set of 2D DIGE gels with 4 replicates. In addition, half of the 
isolated mitochondria were subjected to heat shock at 42°C for 30 minutes to be run on 
a  second  set  of 2D  DIGE  gels,  comparing  untreated  with  heat  shocked  condition 
between WT and HtrA2 KO mitochondria. HtrA2 proteolytic activity can be increased 
by heat shock (Martins et al. 2003), therefore comparing heat shocked WT and HtrA2 
KO mitochondria might enhance the differences between those genotypes.
98Four  replicate  groups  were  run  per  2D  DIGE  set,  but  no  gross  overall  changes  in 
protein level were detected (Figure 3-8A) between WT and HtrA2 KO mitochondria in 
both untreated and heat shocked conditions. The presence and absence of HtrA2 was 
confirmed by  Western blot (Figure  3-9A),  however it could not be  identified  in the 
fluorescent 2D DIGE gel images. The DeCyder software from Amersham was used to 
detect and analyse the protein spots on the 2D DIGE gels. Only two areas around pH6- 
7 and molecular weights of 66kDa and 30kDa appeared to be differential, these areas 
are shown enlarged in Figure 3-8A and labelled as spots 1, 8 and 9 in Figure 3-8B. In 
addition within the software, all protein spots were sorted on the mean ratio of change 
between  WT  and  HtrA2  KO  and then  manually  investigated  for  the  reproducibility 
across  the  replicate  groups  and  examined  for  their  behaviour  in  the  heat  shocked 
samples. Spots found to show a greater difference in the heat shocked samples than in 
the untreated were of particular interest, because these might possibly comprise HtrA2 
substrates. All spots picked and analysed by mass spectrometry were labelled in Figure
3-8B and their identities are listed in Table 3-1. It is notable that, unlike in publications 
detecting strong differences by 2D DIGE (for example (Douette et al. 2005; Lehr et al. 
2005;  Henkel et al. 2006)), none of the spots identified here were very convincingly 
differential between WT and HtrA2 KO mitochondria.
The  catalytic  centre  of HtrA2  is  in  the  intermembrane  space  of the  mitochondria. 
Therefore, proteins localised in the matrix were deemed to be unlikely HtrA2 substrates 
and  not  followed  up  (dimethylglycine  dehydrogenase,  DMGDH;  succinyl-CoA 
synthase  p  subunit,  SUCLA2;  electron  transfer  flavoprotein  a  subunit,  ETFA). 
Similarly, succinate dehydrogenase flavoprotein subunit, SDHA, belonging to complex 
II  of the respiratory chain, which is inserted into the inner membrane and facing the 
mitochondrial matrix, is an improbable substrate of HtrA2.
3.7.1  Grp75y  chaperone of the Hsp70 family
Grp75  belongs to the  Hsp70  chaperone  family  and assists the re-folding of proteins 
translocated  into  the  mitochondrial  matrix.  The  spot  identified  as  Grp75  by  mass 
spectrometry  seemed  to  exhibit  a  slightly  basic  shift  in  HtrA2  KO  mitochondria. 
Sample pairs from the 2D DIGE replicates as well as another pair of WT and HtrA2 
KO  mitochondria  treated  in  the  same  way,  were  separated  on  2D  SDS-PAGE  and
99Grp75 was detected by Western blot (Figure 3-9B). However, no differences in Grp75 
level or isoelectric point could be confirmed.
3.7.2  UQCRC1, respiratory chain complex III core complex I
Ubinquinol cytochrome C reductase core complex I, UQCRC1, was identified on the 
2D DIGE gels to potentially show a reduction in response to heat shock in WT, but not 
HtrA2  KO  mitochondria.  When  mitochondrial  samples  were  separated  by  2D  SDS- 
PAGE  (data not  shown)  or  ID  SDS-PAGE  (Figure  3-9C),  no  changes  in  UQCRC1 
levels could be determined by Western blot.
3.7.3  CPS1, urea cycle enzyme
Carbamoyl phosphate synthetase 1, CPS1, is the rate-limiting enzyme that catalyses the 
first committed step of the hepatic urea cycle, playing an extremely important role in 
removing excess of ammonia from the cells. CPS 1   is primarily expressed in the liver 
and small intestine. The full-length enzyme is 165kDa, however, the spot detected to be 
CPS1  on 2D DIGE ran at 66kDa (see enlargement of the 66kDa area in Figure 3-8A) 
and was found to be more abundant in HtrA2 KO mitochondria. Sample pairs from the 
2D DIGE replicates, as well as another pair of WT and HtrA2 KO mitochondria treated 
in the same way, were separated on 2D SDS-PAGE and CPS1 was detected by Western 
blot. No changes in full-length CPS 1  could be detected (data not shown), however, two 
spots appeared  in the  66kDa region  (Figure  3-9D)  as before  on the  2D  DIGE  gels. 
These probably represent degradation products of CPS1, because the antibody used was 
raised against the full-length protein and could therefore also detect smaller fragments. 
The more basic spot at 66kDa was clearly more intense in HtrA2 KO mitochondria, 
whereas the  more acidic  spot at the  same molecular weight increased  in  HtrA2  KO 
mitochondria  upon  heat  shock  treatment.  The  accumulation  of a  fragment  of CPS1 
could  either  be  a  consequence  of the  mitochondrial  dysfunction  due  to  absence  of 
HtrA2 or alternatively HtrA2 could be involved in the clearance of abnormal proteins 
and  therefore  in  its  absence  such  abnormal  proteins  could  be  detected.  The  latter 
hypothesis fits with the observation that heat shock treatment enhanced the appearance 
of 66kDa fragments of CPS1.
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ETHEl  was previously known as HSCO, hepatoma subtracted clone one, found to be 
over-expressed in human hepatoma cell cultures and shown to sequester NF-kB in the 
cytoplasm  therefore  inhibiting  apoptosis  (Higashitsuji  et  al.  2002).  Subsequently, 
mutations  in  the  gene  encoding  ETHEl  were  identified  in  patients  suffering  from 
Ethylmalonic Encephalopathy, a devastating infantile metabolic disorder affecting the 
brain,  gastrointestinal  tract  and  peripheral  vessels  (Tiranti  et al.  2004).  ETHEl  was 
shown to localise to the mitochondrial matrix (Tiranti et al. 2004). To investigate the 
subcellular localisation of ETHEl, N- and C-terminally tagged ETHEl were expressed 
in SH-SY5Y cells, separated by SDS-PAGE and detected by Western blot using anti- 
HA and anti-Flag antibodies,  respectively  (Figure  3-9E).  HA-ETHE1  appeared  as  a 
single  band,  whereas  ETHEl-Flag  showed  two  bands,  probably  reflecting 
mitochondrial  import  and  processing,  which  is prevented  by  the  N-termial  HA-tag. 
ETHEl  was  slightly  increased  in  HtrA2  KO  mitochondria.  A  polyclonal  antibody 
against  ETHEl  was  kindly  provided  by  Jun  Fujita  (Kyoto  University,  Japan), 
unfortunately, detection of endogenous ETHEl in the mitochondrial samples was never 
successful (data not shown). Therefore, accumulation of ETHEl  in WT versus HtrA2 
KO mitochondria was monitored following import of in vitro translated ETHEl  into 
mitochondria (Figure 3-9F). Imported ETHEl  was resistant to Proteinase K treatment, 
verifying the mitochondrial  localisation, but no differences could be detected in  WT 
and  HtrA2  KO  mitochondria.  Imported  ETHEl  was processed  similarly  to  ETHEl - 
Flag  in Figure  3-9E,  although this  is  not  clearly visible  in the  image  shown  due to 
limited  resolution  on  the  gradient  gel.  Certainly,  it  cannot  be  ruled  out  from  these 
experiments  that  endogenous  ETHEl  accumulates  in  HtrA2  KO  mitochondria.  The 
matrix  localisation of EHTE1  taken together with  a  similar rate  of accumulation  of 
imported ETHEl  in the mitochondria in vitro, however, makes it a relatively unlikely 
substrate for HtrA2.
3.7.5  Riken 2410005016, unknown mitochondrial protein
Riken  2410005016  encodes  for  a  35kDa protein  and  predicted  to  be  mitochondrial 
with high probability by the pSORT II algorithm (http://psort.nibb.ac.jp). A clone for 
Riken 2410005016 was obtained from RZPD (German Resource Center for Genome 
Research), and three mutations were discovered in the predicted DNA sequence: G to
101A at base pair (bp) 70 resulting in glycine to serine at amino acid 24, and C to G at bp 
91  and G to  C at bp92  which is  a silent mutation.  The  2D DIGE  spot identified as 
Riken 2410005016 by mass spectrometry was found at 30kDa, which could potentially 
represent the processed Riken 2410005016 protein without the mitochondrial targeting 
sequence. A motif for the mitochondrial processing peptidase, MPP, is found at amino 
acid 50 and cleavage there would result in a 30kDa protein with a pi of 5.95. To test if 
Riken 2410005016 is indeed a mitochondrial protein,  in vitro translated protein was 
imported into mitochondria (Figure 3-9G). Full length Riken 2410005016, running at 
35kDa,  was  found  to  a  small  degree  inside  the  mitochondria,  since  most  of it  was 
degraded by Proteinase K treatment. However, a processed form of Riken 2410005016 
rapidly accumulated at 25kDa which was totally unaffected by Proteinase K treatment. 
It seems likely, therefore, that the pre-sequence that is proteolytically removed from 
Riken 2410005016 in the mitochondria is longer than the one predicted by pSORT. 
Inevitably, the 30kDa form of Riken 2410005016 identified in the 2D DIGE, cannot be 
a major  isoform.  No  differences  were  detected  in  WT  and  HtrA2  KO mitochondria 
(data not shown).
Taken together, few significant changes could be detected in the proteome of WT and 
HtrA2  KO mitochondria using  2D  DIGE.  The  accumulation of 66kDa fragments of 
CPS1  in  HtrA2  KO  mitochondria  was  the  only  reproducible  change  that  could  be 
validated with a subsequent approach to the 2D DIGE.  CPS1  is mainly expressed in 
liver  mitochondria  (Gene  Cards:  http://www.genecards.org/cgi-
bin/carddisp.pl?gene=CPSl&search=cpsl&suff=txt) and therefore it seems an unlikely 
target of HtrA2  that  could  explain  the phenotype  of the  KO  mice.  However,  CPS1 
represents the first piece of data supporting a DegP-like role for HtrA2 in mitochondria, 
namely the degradation of unwanted proteins.
3.8  Discussion
When the mammalian IBM-containing proteins Smac and HtrA2 were first identified 
through  their  ability  to  interact  with  XIAP  (Du  et  al.  2000;  Verhagen  et  al.  2000; 
Suzuki  et  al.  2001;  Hegde  et  al.  2002;  Martins  et  al.  2002;  van  Loo  et  al.  2002; 
Verhagen  et  al.  2002),  it  appeared  likely  that  the  pro-apoptotic  function  of these 
proteins  involved  release  from mitochondria following  apoptotic  insult.  Once  in the
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thus promoting  caspase  activation and  apoptosis.  While  over-expression of Smac  or 
HtrA2  certainly  promotes caspase-mediated  apoptotic  death and  also,  in the  case  of 
HtrA2, caspase-independent cell death, the significance of the endogenous proteins in 
these  pathways has been  much  less  clear.  The  data presented  here  indicate that the 
complete loss of expression of HtrA2 protein,  including its IBM, does not obviously 
perturb mouse development and health beyond the effects seen due to loss of only the 
serine protease activity of HtrA2 due to point mutation: the phenotype of the HtrA2 KO 
mouse is very similar to that of the Mnd2 mouse (Jones et al. 2003). The mouse mutant 
Mnd2  (motor  neuron  degeneration  2)  was  identified  in  1990  as  a  spontaneous, 
recessively inherited mutation that arose on the C57BL/6J inbred background (Jones et 
sd.  1993).  Subsequently, the Mnd2 mutation was identified as the missense mutation 
S276C in the protease domain of HtrA2 (Jones et al. 2003). Therefore, the proteolytic 
activity  of HtrA2  rather  than  the  its  IAP-binding  activity  seems  to  be  the  critical 
element. Similarly, total loss of Smac expression has no effect on mouse development 
or  function  (Okada  et  al.  2002).  Mice  completely  lacking  both  HtrA2  and  Smac 
expression display a phenotype identical to HtrA2 KO animals and cells derived from 
these mice fail to show enhanced resistance to apoptotic stimuli (Martins et al. 2004). 
Thus,  loss of both major XIAP-binding proteins does not have any obvious effect on 
the  phenotype  of mice  that  can  be  detected  within  the  limited  lifespan  of animals 
lacking HtrA2  serine protease activity.  It has been reported that many mitochondrial 
proteins  might  have  an  N-terminal  IBM  (Verhagen  et  al.  2007).  Therefore,  severe 
mitochondrial  damage  would  cause  release  of  many  proteins  with  the  ability  to 
antagonise I APs, in addition to just Smac and HtrA2, so that loss of the IBMs of these 
two proteins may have little detectable impact on IAP activity.
HtrA2 KO and Mnd2 mice both die prematurely at around 30 to 40 days of age due to a 
progressive neurological  disorder caused by death of a population of striatal  neurons 
(Jones et al.  2003;  Martins et al.  2004),  no differences in their phenotypes could be 
found.  The  phenotype  of  these  mice  displays  some  similarity  to  patients  with 
parkinsonian neurodegeneration. Indeed, in human PD patients, a polymorphism and a 
mutation in HtrA2 linked to the disorder have been identified and characterised.  The 
effect  of  these  single  amino  acid  changes  is  to  reduce  the  activation  of  HtrA2
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of the PARK3 locus identified in familial PD (Gasser et al.  1998), later however, the 
chromosomal region harbouring the PARK3  locus in the respective families could be 
narrowed and does no longer include HtrA2 (West et al.  2001). Recently, the HtrA2 
gene  has  been  designated  as  an  independent  locus,  the  PARK 13  locus 
(http://www.ncbi.nlm.nih. gov/entrez/dispomim.cgi?id=610297).
Neuronal cell populations isolated from HtrA2 KO mice were more sensitive than WT 
controls to excitotoxicity-induced death in response to glutamate (Figure 3-7C). Non­
neuronal cell types such as fibroblasts and T lymphocytes from the HtrA2  KO mice 
also  showed  increased  sensitivity  to  induction of cell  death by  drugs that target the 
mitochondria, for instance the complex I  inhibitor rotenone and the uncoupler CCCP 
(data  not  shown).  Primary  WT  or  HtrA2  KO  MEFs  did  not  exhibit  differences  in 
metabolic activity when challenged with CCCP, rotenone or tunicamycin as determined 
by an MTT assay (Figure 3-5C-E). The principle of this assay is the cleavage of MTT 
in metabolically active cells only, given that NADH and NADPH are required as co­
factors for this cleavage to occur. Therefore, the MTT assay could be considered as a 
measure of cell number and could reflect the increased sensitivity of HtrA2 KO MEFs 
to these drugs as seen in Figure 3-7A using FACS to determine the number of sub-Gl 
cells.  The  MTT  assay  already  showed  reduced  metabolic  activity  after only  6hrs  of 
incubation with the drugs, this time is probably too short to impact significantly on cell 
death.  After 24hrs of incubation with the drugs, however, the metabolic activity and 
likely also the cell number of WT and HtrA2 KO cells is greatly reduced even with the 
lowest drug concentrations. Therefore this time-point might possibly be too long or the 
drug concentration still too high to record differences in cell number with this assay. In 
contrast,  measurement  of apoptotic  cells  by  sub-Gl  analysis  and  also  AnnexinV-PI 
staining did reveal increased cell death in HtrA2 KO MEFs when treated with CCCP, 
rotenone or tunicamycin (Figure 3-7A).
The increase in cell death in animals lacking HtrA2 function and absence of protection 
from  apoptosis  suggests  that  HtrA2  is  an  essential  gene  required  for  mitochondrial 
function, rather than a pro-apoptotic regulator. Since the Mnd2 mice display the same 
phenotype as the HtrA2 KO mice, it appears that the proteolytic activity of HtrA2 is 
critical  for  correct  mitochondrial  function.  It  is  likely  that  HtrA2  acts  to  protect
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adaptive proteins DegP and DegS  in bacteria.  If HtrA2 acts like DegS (Walsh et al. 
2003),  loss of HtrA2  may result  in an  inability to mount an adaptive transcriptional 
response under stress conditions that cause protein unfolding, leaving the mitochondria 
of striatal neurons unable to maintain their membrane potential and rendering the cells 
prone  to  either  necrotic  or  apoptotic  death.  Alternatively,  if  HtrA2  functions  like 
bacterial  DegP  (Spiess  et al.  1999),  mitochondria  from  KO  mice  may  be  unable to 
degrade unfolded proteins in the intermembrane space under conditions of cell  stress 
and these could form aggregates that would directly compromise the maintenance of 
the  mitochondrial  membrane  potential.  Which  of these  different  models  of HtrA2’s 
neuroprotective  function  is  correct  may  be  clarified  once  its  mitochondrial  binding 
partners  and  substrates  are  identified  and  once  differences  in  stress-induced 
transcriptional responses are determined.
The identification of mitochondrial substrates of HtrA2 using the 2D DIGE approach 
revealed few proteins that were possibly differentially expressed in WT and HtrA2 KO 
mitochondria  (Table  3-1),  however,  none  of  the  proteins  held  up  on  further 
investigation (Figure 3-9). This probably points to the limitations of the methodology: 
either incorrect protein spots were being picked on the preparative gel for identification 
by mass spectrometry or the differences detected were random variations. The latter is 
probably true for all spots except 1, 8 and 9 (Figure 3-8B), since only these spots were 
detected  as  differentially  expressed  by  the  DeCyder  software  across  all  replicates. 
However, picking these spots from the preparative gel was difficult, especially for spot 
8 and 9, due to a number of low abundance protein spots being very close to each other.
Proteins with the highest level of expression among the mitochondrial proteome are the 
proteins  with  conserved  metabolic  functions,  many  of these  are  matrix  proteins and 
inner membrane proteins.  HtrA2  is located in the intermembrane space and therefore 
matrix proteins are unlikely to be HtrA2 substrates. It is possible that differences in WT 
and HtrA2 KO mitochondria in low abundance proteins do exist, although these might 
not be visible on 2D DIGE due to the high abundance proteins. Moreover, HtrA2 itself 
was not detectable by fluorescence on 2D DIGE and the presence or absence of HtrA2 
could only be detected by  Western blot (Figure 3-9A).  Whereas hydrophilic proteins 
are easily resolved by 2D gel electrophoresis, membrane proteins often precipitate at
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could  be  potential  targets  of  HtrA2  might  be  missed  using  conventional  2D  gel 
electrophoresis.  Performing  blue  native  2D  gel  electrophoresis  would  allow  better 
separation of membrane proteins.
If HtrA2 has a DegP-like function in mammalian mitochondria and is responsible for 
the  degradation  of  unfolded  proteins  in  the  intermembrane  space,  these  should 
accumulate  in  HtrA2  KO  mitochondria.  However,  other  proteases  might  have  a 
partially overlapping set of substrates to HtrA2 and, therefore, such substrates might be 
taken care of by other proteases in HtrA2 KO mitochondria under normal conditions. 
Perhaps only under particular stressful conditions would certain proteins accumulate in 
HtrA2 KO mitochondria, such as those conditions in the striatum that ultimately cause 
the neurons to die.
The results presented in this chapter reveal a protective role for HtrA2 in mitochondrial 
function,  which,  when  lost,  leads  to  neurodegeneration  and  development  of  a 
parkinsonian  syndrome  in  mice.  However,  gross  changes  in  the  mitochondrial 
proteome could not be unequivocally identified.
106Figure 3-1. Targeting the HtrA2 gene by homologous recombination.
(A)  Schematic  representation  of  the  WT  mouse  HtrA2  locus,  the  targeting 
construct  and  the  targeted  HtrA2  allele.  These  mice  were  generated  at 
GlaxoSmithKline  UK  (see  2.2.1  for  details).  (B)  Genotyping  of the  WT  and 
mutant HtrA2 locus by PCR using the primers indicated in A. (C) Reduced and 
absent HtrA2 mRNA in  Het and  KO mice,  respectively.  Reverse transcriptase 
(RT)  qPCR was performed  to  measure the mRNA levels of HtrA2.  RNA was 
isolated  from  brain  tissue.  Data  shown  are  normalised  to  the  relative  HtrA2 
mRNA  level  in  WT.  Error  bars  represent  ±  standard  deviation,  n=3.  (D) 
Reduced and absent HtrA2 protein in Het and KO mice,  respectively. Western 
blot analysis of protein lysates obtained from WT,  Het and KO MEFs. Western 
blot analysis for Grp75 were used as a protein loading control.
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75 - G rp 7 5Figure 3-2. Phenotypic alterations of HtrA2 KO mice.
(A) HtrA2 mice are bom with nearly Mendelian ratio.  Percent of mice born for 
each genotype.  157 mice in total were scored.  (B) HtrA2  KO mice fail to gain 
weight from P18. Body weights of WT, Het and KO littermates were measured 
until P33. Data shown are means ± standard deviations of at least 6 animals for 
each point. (C) Appearance of HtrA2 KO and littermate control WT animals at 
P23 and P30. (D) HtrA2 KO mice show decreased coordination. Percentage of 
mice that climbed to the top of a 60°  inclined  platform. WT (n=8),  Het (n=20) 
and KO (n=16) littermates were compared. (E) Average elapsed time for mice 
to climb to the top of the platform.  Data are means ± standard deviations of a 
minimum of 8 trials.  D and  E were performed  by Victoria Cowling and  Miguel 
Martins.
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HtrA2 KO mice.
(A) Diagram  of a  mouse  brain  in  sagital  orientation  indicating  area  of striatal 
degeneration  (red  box)  in  the  striatum.  (B)  Hematoxylin  and  eosin  (H&E) 
staining  showing  focal  loss  of  neurons  and  occasional  ballooning  in  the 
striatum of HtrA2 KO animals (right) compared to WT controls (left). (C) GFAP 
immunohistochemistry  revealing  reaction  of astrocytes  in  HtrA2  KO  animals. 
(D) MAP2 immunohistochemistry revealing loss of this protein in sections from 
HtrA2 KO animals. (E) Density of NeuN positive neurons in the striatum of WT 
and  HtrA2  KO scored  in both the whole striatum (total basal ganglia) and the 
area where localised degeneration was observed (posterior portion of the basal 
ganglia).  Analysis was performed  in  both  P20  and  P30  animals.  (F) Average 
optical  density  of tyrosine  hydroxylase  (TH)  staining  in  both  the  total  basal 
ganglia  and  the  area  where  localised  degeneration  was  observed  (posterior 
portion of the basal ganglia) (G) Average number of TH-positive neurons in the 
substantia nigra pars compacta (SNpc) of WT and HtrA2 KO animals. This data 
was generated by Sebastian Brandner, Institute of Neurology, London.
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life.
Het  HtrA2  mice  do  not  develop  late-onset  coordination  and  movement 
disabilities.  WT  and  HtrA2  Het  mice  were  tested  on  a  rotarod  on  three 
consecutive  days.  The  latency  to  fall  was  measured  and  is  displayed  in 
seconds.  Mice  were  tested  at  10,  12,  14,  and  16  months  of  age.  Rotarod 
settings were  continuous acceleration from  0 to 40rpm  in  570  seconds.  Data 
are means ± standard errors, WT n=10, Het n=10.
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training dayFigure 3-5. Cell proliferation and metabolic activity of HtrA2 MEFs.
(A) Primary MEFs and (B) immortalised MEFs derived from WT and  HtrA2 KO 
littermates display similar proliferation rates. Cells were seeded at 1   x 105 and 
counted for the following three days using a haemocytometer.  Data are means 
± standard deviations of duplicates. (C-E) Metabolic activity of primary WT and 
HtrA2 KO MEFs is not differentially altered in response to drugs. Metabolically 
active cells were measured  using the Cell  Proliferation  Kit I  (MTT assay) from 
Roche which is related to NAD(P)H  production in the cells. Cells were seeded 
and treated with a range of concentrations of (C) CCCP, (D) rotenone, and (E) 
tunicamycin  the  following  day  for  6hrs  or  24hrs.  Assays  were  performed 
according  to  the  manufacturer’s  instructions.  Raw  data  was  normalised  to 
untreated  samples  and  is  displayed  on  the  Y-axis  (metabolic  activity).  Data 
shown are means ± standard errors, n=3.
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(A) Ultrastructural features of mitochondria present in cells from WT and HtrA2 
KO  animals,  scale  bars  correspond  to  500nm.  (B)  and  (C)  Quantification  of 
mitochondrial  morphological  abnormalities detected  in  MEFs  before  and  after 
treatment with mitochondrial stress stimuli.  Results are representative of three 
independent  experiments.  (B)  Percent  of  total  mitochondria  with  ballooned 
cristae.  (C)  Percent  of  total  mitochondria  with  abnormal  shape.  These 
experiments were performed by Valentina Fedele, MRC Leicester.
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6Figure 3-7. Deletion of HtrA2 results in increased sensitivity to cell death- 
inducing agents.
(A) Loss of HtrA2 increases apoptosis in response to cell death stimuli. Viability 
of  immortalised  MEFs  derived  from  WT  and  HtrA2  KO  mice,  determined  by 
measurement of sub-G1  cell populations by flow-cytometry.  Cells were treated 
with  CCCP  (25pM),  rotenone  (Rot,  25pM),  tunicamycin  (Tunic,  2.5pg/ml), 
etoposide  (Etop,  170pM,  all  for 27hrs)  or  hydrogen  peroxide  (H2O2,  3pM  for 
4.5hrs)  and  compared  to  untreated  controls.  Results  show  the  means  ±  the 
range of two determinations.  Results  are  representative of three  independent 
experiments.  Insert shows Western blot for HtrA2 on cell lysate. (B) Viability of 
immortalised  HtrA2  KO  MEFs  re-expressing  human  HtrA2  (KO+HtrA2) 
compared to vector alone HtrA2 KO, following treatment with MG-132 (250nM), 
6-hydroxydopamine  (6-OHDA,  25pM)  both  for  20hrs,  or  2pM  staurosporine 
(STS) for 3hrs.  Insert shows Western blot for HtrA2 on lysate from these cells. 
(C)  Neuronal  response  to  glutamate-induced  cytotoxicity  was  determined  in 
primary neurons  isolated from day  14.5 embryos cultured  in vitro for  10 days. 
Following  incubation  with  the  indicated  concentrations  of glutamate  for 4hrs, 
cells  were  stained  with  Hoechst  33342  and  nuclear  morphology  was 
determined. Results show the means ± standard deviations of two independent 
experiments where  6  fields with  at  least 40  cells were  scored  for each  data 
point.  Experiments  for  C,  neuronal  exitotoxicity,  were  performed  in 
collaboration with Miguel Martins, MRC Leicester.
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7Figure 3-8. 2D DIGE experiment to identify changes in the proteome of 
HtrA2 KO mitochondria.
(A)  Representative picture  of an  overlay of two dye  scan  images.  Red  spots 
show  a  relative  decrease  in  HtrA2  KO  mitochondria,  green  spots  a  relative 
decrease  in  WT  mitochondria,  and  yellows  spots  no  changes  between  both. 
66kDa and 31kDa regions are shown enlarged. (B) 2D DIGE gel image shown 
in black/white, red circles and numbers denote spots that were picked for mass 
spectrometry  analysis.  The  2D  DIGE  experiments  were  performed  in 
collaboration  with  David  Frith  in  the  2D  Gel  Electrophoresis  Laboratory  at 
Cancer Research UK.
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21.5Function Localisation MW(kD) pl (pH) MW spot number
Carboamyl-Phosphate Synthetasel CPS1 urea cycle mito 165 6.33 -66 1
DiMethylGlycine Dehydrogenase DMGDH AA metabolism matrix 97 7.69 similar 2
Heat Shock Protein A / Grp75 Grp75 chaperone matrix 73 5.81 similar 3
Succinate Dehydrogenase Fp Subu. SDHA respiratory chain, complex II inner membrane 72 7.6 similar 4
Ubiquinol-CytC Reductase Core Complexl UQCRC1 respiratory chain, complex III inner membrane 53kD 5.75 similar 5
ATP-sp. Succinyl-CoA Synthetase b subu. SUCLA2 TCA cycle matrix 46 5.65 similar 6
Electron Transfer Flavoprotein a subu. ETFA electron transfer matrix 35 8.62 -40 7
Riken 2410005016 ? pSORT: mito 35 8.85 -30 8
Ethylmalonic-Encephalopathyl / ETHE1/ mutated in AR metab. disorder / mito / 28 6.78 similar 9
Hepatoma Subtracted Clone One HSCO inhib. p53-apoptosis, binds NF-kB cyto / nucleus
Table 3-1. Proteins identified in 2D DIGE from wildtype and HtrA2 knock out mitochondria.
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(A)  Western  blot  for  HtrA2  in  WT  and  HtrA2  KO  mitochondria  verifying  the 
presence  and  absence  of this  protein.  HtrA2  runs  at  35kDa  with  pi  6.1.  (B) 
Grp75  levels  and  isoelectric  point  are  not  dissimilar  in  WT  and  HtrA2  KO 
mitochondria.  Samples  were  separated  on  2D  SDS-PAGE  and  probed  with 
anti-Grp75 antibody. Grp75 runs at 75kDa and pi 5.8.  (C) UQCRC1  levels are 
not different in  WT and  HtrA2  KO  mitochondria.  Samples were  separated  on 
1D  SDS-PAGE  and  probed  with  anti-UQCRC1  antibody.  UQCRC1  runs  at 
51kDa.  (D)  66kDa fragments of CPS1  accumulate  in  HtrA2  KO  mitochondria. 
Samples  were  separated  on  2D  SDS-PAGE  and  probed  with  anti-CPS1 
antibody. The CPS1  fragments run at 66kDa and pi 6.6. (E) ETHE1  expressed 
in  SH-SY5Y  cells  revealing  N-terminal  processing.  HA-ETHE1  and  ETHE1- 
Flag  expression  in  cell  lysates  were  detected  by  anti-HA  and  anti-Flag 
antibodies,  respectively.  (F)  Mitochondrial accumulation  of ETHE1  in  WT and 
HtrA2  KO  is similar.  In vitro translated  35S-labelled  ETHE1-Flag was  imported 
into  mitochondria  isolated  from  WT and  HtrA2  KO  mouse  livers.  After  import 
mitochondria were treated with  Proteinase  K to  remove proteins bound to the 
outside  of  the  mitochondria.  Lysates  were  separated  on  SDS-PAGE  and 
visualised by exposure to Phosphorlmager screen. Ornithine transcarbamylase 
(OTC)  is  a  matrix  protein  used  as  control.  Asterisk  denotes  unspecific  band. 
(G)  Riken  2410005016  protein  is  imported  into  mitochondria  and  rapidly 
processed to a 25kDa form. In vitro translated 35S-labelled  Riken 2410005016 
was  imported  into  mitochondria  isolated  from  WT  mouse  livers.  After  import, 
half  of  the  mitochondria  were  treated  with  Proteinase  K.  Lysates  were 
separated  on  SDS-PAGE  and  visualised  by  exposure  to  Phosphorlmager 
screen.
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2 5 —    —   — mature4  Chapter 4:  Stress-induced transcriptional response 
upon loss of HtrA2
4.1  Introduction
While HtrA2 is ubiquitously expressed, neurons in particular seem to depend heavily 
on its protease function. A localised population of striatal neurons are the first neurons 
to die in HtrA2 KO mice. It is possible such cells are subjected to high metabolic stress 
and  therefore  more  dependent  on  the  function  of HtrA2.  Stresses  that  have  been 
implicated in the death of neurons in vivo include oxidative stress, excitotoxic stress 
and accumulation of denatured proteins including those with expanded polyglutamine 
repeats (for review (Bredesen et al. 2006)). Due to its mitochondrial localisation, HtrA2 
is  probably  acting  to  protect  these  organelles,  and  in  particular  the  mitochondrial 
intermembrane compartment, from damage resulting from the stresses to which striatal 
neurons are normally exposed.
Mitochondria operate a sensitive feedback system, which acts to calibrate and adjust 
their performance in the cellular context. This pathway is referred to as mitochondrial 
retrograde  signalling  or  mitochondrial  stress  signalling,  and  is  a  mean  of 
communication  from  the  mitochondria  to  the  nucleus  (reviewed  in  (Butow  and 
Avadhani  2004)).  Originally,  the  pathway  was  discovered  in  yeast,  however,  a 
mitochondria-specific  stress response  has been reported to  exist in mammalian  cells 
(Zhao  et  al.  2002).  In  this  study,  the  authors  used  a  mutant  version  of ornithine 
transcarbamylase,  OTC,  that could  not  fold properly.  Accumulation of the unfolded 
protein within the mitochondrial matrix resulted in the transcriptional up-regulation of 
nuclear genes encoding mitochondrial  stress proteins such as Hsp60,  HsplO, mtDnaJ 
and  ClpP,  but  not  those  encoding  stress  proteins  of  the  ER.  Analysis  of  the 
Hsp60/Hspl0 bidirectional promoter identified a CHOP element as the mitochondrial 
stress response element. The TF CHOP was shown to regulate the expression of those 
mitochondrial stress proteins in association with C/EBPp (Zhao et al. 2002).
The  structural  similarity  of  mammalian  HtrA2  to  the  bacterial  DegS  protease  is 
particularly striking (see Chapter  1.3,  and Figure  1-2B, Figure  1-3A-D).  DegS has a 
domain structure similar to HtrA2 with only one PDZ domain and the crystal structure
127reveals  that  both  proteases  form  trimers.  The  catalytic  centre  of both  proteases  is 
distorted in the inactive conformation, and their catalytic activity can be regulated by 
the PDZ domains (Li et al. 2002; Wilken et al. 2004). In addition, DegS is localised in 
the periplasmic space between the inner and outer bacterial cell membranes, with its N- 
terminal region inserted into the inner membrane: this localisation is clearly analogous 
to that of full length HtrA2 within the mitochondria. The appearance of the exposed C- 
termini of unfolded porins, outer membrane channel proteins, in the periplasmic space 
results in activation of DegS due their binding to its PDZ domain (Figure  1-5) (Walsh 
et al. 2003). Similarly, engagement of the PDZ domain of HtrA2 results in activation of 
its protease activity (Li et al. 2002; Martins et al. 2003), although in the case of HtrA2 
its natural PDZ-binding partners within the mitochondria remain to be identified. Once 
activated in the bacterial periplasmic  space,  DegS  cleaves RseA, an inner membrane 
protein  that,  together  with  RseB,  sequesters  the  transcriptional  regulator  aE   at  the 
cytoplasmic  face  of the  inner  membrane.  It  is  interesting  to  note that DegS  cleaves 
RseA between a valine and a serine (Walsh et al. 2003). Similarly, human and mouse 
HtrA2  have  a  preference  for  valine  at  PI  position  and  serine  at  PI’  in  an  optimal 
synthetic  peptide  substrate  (Martins  et  al.  2003).  This  suggests  that  conservation 
between DegS and HtrA2 is also present at the biochemical level. Cleavage of RseA by 
DegS leads to further proteolysis by the intramembrane protease RseP, resulting in the 
release of the transcriptional regulator oE  into the cytosol to induce the expression of 
periplasmic  stress response genes (Figure  1-5).  While the structural  and  biochemical 
similarity  between  HtrA2  and  DegS  is  evident,  it  has  so  far  not  been  possible  to 
identify  mitochondrial  mammalian  homologues  of other  downstream  components  of 
the bacterial periplasmic stress response system.
Given  these  observations,  it  seems  possible  that  HtrA2  is  a  component  of  a 
mitochondrial stress pathway. Loss of HtrA2 might have two possible outcomes:  1) If 
HtrA2 is actively involved in mitochondrial stress signalling, its absence might lead to 
down-regulation  of  putative  signalling  pathways  that  modulate  nuclear  gene 
expression. Or 2) Even if HtrA2 does not play a direct role in a putative mitochondrial 
stress signalling pathway, its loss might result in the up-regulation of stress-regulated 
genes as a consequence of enhanced mitochondrial stress in cells lacking this protease. 
This  is  an  important  question  to  address  since  it  could  help  to  understand  how  a
128compromised mitochondrial  stress responses might result in cellular dysfunction and 
disease.
In this chapter, differences in stress-induced mitochondrial  signalling in cells derived 
from WT and HtrA2 KO mice are studied by transcriptional profiling using GeneChip 
analysis. HtrA2 KO cells are shown to exhibit greater sensitivity to the induction of a 
specific  stress  response.  Moreover,  this  stress  response  seems  to  be  activated 
specifically in the brains of animals lacking HtrA2 and contains a signature of genes 
that can be induced by the shared branch of the UPR.
4.2  Transcriptional  analysis  of  rotenone-induced  stress 
response in cells lacking HtrA2
In order to test the contribution of mammalian HtrA2 to the transcriptional activation of 
a  stress  response,  primary  MEFs  derived  from  WT  and  HtrA2  KO  mice  were 
challenged with an inducer of mitochondrial  stress and their transcriptional response 
was  monitored  using  microarray  technology  (Asymetrix  GeneChip  array  system). 
MEFs derived from WT and HtrA2 KO animals were chosen for these experiments, as 
these cells had been previously shown to display differential sensitivity to drug-induced 
mitochondrial  stresses  in  terms  of mitochondrial  morphology  as  well  as  cell  death 
(Figure 3-6 and Figure 3-7A). The complex I  inhibitor rotenone was one of the drugs 
exhibiting a differential effect on WT and HtrA2 KO MEFs and therefore was used in 
this study  to  trigger mitochondrial  stress.  Interestingly,  decreased complex  I  activity 
has  been  reported  in  biochemical  and  histological  studies  of the  SN  of PD  patients 
(Schapira et al.  1990). In addition, rotenone has been shown to produce a progressive 
model of parkinsonism in rodents when chronically administered (Betarbet et al. 2000; 
Sherer et al. 2003).
Primary  MEFs at passage 4 were treated with a low dose of rotenone and  RNA was 
isolated 4hrs later. Cells were harvested 4hrs following rotenone treatment in order to 
minimise indirect effects of drug treatment. The purity and quality of total RNA, cRNA 
and fragmented cRNA for each sample were controlled by agarose gel analysis, which 
showed the characteristic bands of 28S and 18S rRNA of total RNA, a smear of cRNA 
at  a  range  of  seizes  and  fragmented  cRNA  around  150bp  (Figure  4-IB).  Three
129experimental  replicates  were  obtained  for  each  condition,  resulting  in  a  total  of  12 
samples that were hybridised to Asymetrix MOE430A GeneChip arrays (3 untreated 
WT,  3  rotenone  WT,  3  untreated  HtrA2  KO,  3  rotenone  HtrA2  KO,  Figure  4-1 A). 
MOE430A GeneChips comprise about 22,000 probe sets, representing approximately
14,000  genes, therefore some genes are represented by more than one probe set.  The 
GeneChip array data analysis was carried out within the Genespring software (Silicon 
Genetics now Agilent Technologies). Probe level intensities were quantile normalised, 
quantified  using  RMA  (Robust  Multi-chip  Average)  (Irizarry  et  al.  2003),  and  a 
restriction on fold change of 1.2-fold was applied to select probe sets that changed in 
expression levels.
4.2.1  Rotenone  induces  a  greater  number  of  transcriptional 
changes in cells lacking HtrA2
First,  genes that were regulated by rotenone treatment in  WT and HtrA2  KO MEFs, 
respectively,  were  identified.  These  comparisons  are  highlighted  in  green  (WT)  and 
blue (HtrA2 KO) in Figure 4-1 A. In order to determine differentially expressed probe 
sets, statistical analysis was performed. The false discovery rate (FDR) is a statistical 
method  used  in  multiple  hypothesis  testing  to  correct  for  multiple  comparisons.  Its 
threshold is determined from the observed p-value distribution, and hence the FDR is 
adaptive to the amount of signal in the data. In WT MEFs, only 130 probe sets changed 
with  rotenone  treatment,  whereas  1038  probe  sets  were  altered  in  HtrA2  KO  MEFs 
upon  treatment  with  rotenone  when  applying  a  less  stringent  FDR  (0.15)  to  both 
comparisons  (Figure  4-2A).  Choosing  a  more  stringent  FDR  to  identify  probe  sets 
significantly changed  upon rotenone treatment did not return any probe  sets for WT 
MEFs, whereas in HtrA2 KO MEFs probe sets could still be identified using 0.07 FDR. 
In  both,  WT  and  HtrA2  KO  MEFs,  the  fold-changes  upon  rotenone  treatment  were 
relatively  subtle  with  the  majority  of changes  ranging  between  1.2-  to  1.5-fold.  27 
probe  sets  in  WT  and  89  probe  sets  in  HtrA2  KO  MEFs  were  more  than  1.5-fold 
regulated  with  rotenone  treatment  (Figure  4-2B).  A  subset  of genes  modulated  by 
rotenone  treatment  in  HtrA2  KO  MEFs  is  listed  in  Table  4-1.  Taken  together  the 
presented  data  indicates  that the  transcriptional  response  to  treatment  with  rotenone 
was much  stronger in HtrA2  KO  MEFs compared to  WT.  Therefore,  loss of HtrA2 
results in an enhanced transcriptional signature in response to a mitochondrial stressor.
130This  is  in  line  with previous  observations  showing that  HtrA2  KO  MEFs  are  more 
susceptible to rotenone-induced changes of mitochondrial morphology (Figure 3-6) and 
cell death (Figure 3-7A).
4.2.2  Rotenone results in enhanced up-regulation of CHOP in cells 
lacking HtrA2 in vitro
The  TF  CHOP  has  been  previously  shown  to  be  up-regulated  by  mitochondrial 
stressors like rotenone (Ryu et al. 2002) as well as other parkinsonism-inducing drugs 
like 6-OHDA and MPP+ in cultured cells (Ryu et al. 2002; Holtz and O'Malley 2003). 
Recently,  CHOP  has  been  reported to  be  up-regulated  in  neurotoxin-induced  rodent 
models of parkinsonism in vivo (Silva et al. 2005). Interestingly, the CHOP transcript 
was significantly induced (1.9-fold) in HtrA2 KO MEFs treated with rotenone, and not 
in WT MEFs treated in the same manner (Table 4-1). This induction of CHOP in cells 
lacking HtrA2 following rotenone treatment could point to an increased level of stress 
in these mitochondria, as CHOP was found to be implicated in a mitochondria-specific 
stress response (Zhao et al. 2002).
In order to confirm the increased induction of CHOP in HtrA2 KO MEFs, RT qPCR 
analysis  was  performed  on  RNA  from  the  samples  of replicate  3  of the  GeneChip 
analysis.  This  revealed  that  rotenone  treatment  caused  a  2-fold  induction  of CHOP 
mRNA  in  cells  lacking  HtrA2,  whereas the  level  remained  unchanged  in  WT  cells 
(Figure  4-3A).  Similarly,  extension  of this  analysis  to  WT  and  HtrA2  KO  MEFs 
immortalised  with  SV40LT  antigen  revealed  that  rotenone  treatment  resulted  in  an 
approximately  2-fold induction of CHOP in cells lacking HtrA2 while no significant 
change  was  detected  in  controls  (Figure  4-3B).  Although  short  incubations  with 
rotenone failed to result in any CHOP up-regulation in WT cells, prolonged incubation 
with  this  drug  led  to  the  induction  of  CHOP  mRNA.  Nevertheless,  the  level  of 
induction was consistently lower to that of HtrA2 KO cells (Figure 4-3B).
Loss of HtrA2 function renders cells more susceptible to the up-regulation of CHOP in 
response  to  rotenone.  However,  the  cells  studied  so  far have  lost  HtrA2  expression 
permanently.  In order to test the effect of transient loss of HtrA2  function on CHOP 
expression,  further experiments  were  performed  in  a mouse  neuroblastoma cell  line 
(Neuro-2a). In these experiments HtrA2 expression was down-regulated transiently by
131siRNA and CHOP levels compared to appropriate controls.  Interestingly, even in the 
absence of additional stress stimuli down-regulation of HtrA2 led to the up-regulation 
of CHOP  mRNA  (Figure  4-3C).  It  is  possible,  that  the  transfection  method  might 
provide  the  stress  stimulus  that  causes  induction  of CHOP  in cells  where  HtrA2  is 
down-regulated.  In  order  to  rule  out  any  off-target  effects  by  the  HtrA2-specific 
siRNA,  control  experiments  were  performed  in  WT  and  HtrA2  KO  MEFs.  Such 
experiments showed that the up-regulation of CHOP is evident in WT MEFs following 
down-regulation of HtrA2  with the  siRNA.  However,  HtrA2-specific siRNA did not 
significantly affect CHOP expression levels in HtrA2 KO MEFs (Figure 4-3C).
4.2.3  Brain-specific  up-regulation  of  CHOP  expression  in  mice 
lacking HtrA2
The  data presented  so  far suggests that permanent  lack of HtrA2  leads to  enhanced 
expression  of CHOP  following  mitochondrial  stress  triggered  by  rotenone,  and  that 
transient loss of HtrA2 itself leads to induction of CHOP without an additional stress 
stimulus.  It  is  possible  that  tissues which  are  under  great  demand for mitochondrial 
function  in  the  HtrA2  KO  mice  might  be  prone  to  the  up-regulation  of  CHOP. 
Mitochondrial stress could be elicited through high rates of electron flow through the 
respiratory chain in highly metabolically active tissues. The hypothesis that only certain 
tissues  are  selectively  vulnerable  to  mitochondrial  stress  is  supported  by  the  rodent 
model  of rotenone-induced  PD  (Betarbet  et  al.  2000;  Sherer  et  al.  2003).  Systemic 
exposure to rotenone  leads to  a degenerative lesion in rats,  which is selective to the 
nigrostriatal  system,  indicative  of  the  vulnerability  of  this  neuronal  population  to 
oxidative  stress.  Therefore,  CHOP  might  be  up-regulated  in  specific  tissues  whose 
mitochondria might be particularly vulnerable to loss of HtrA2.
To  test  this  hypothesis,  CHOP  expression  was  measured  in  different  tissues  from 
HtrA2  KO  mice  and  compared  to  levels  in  WT  mice.  Results  from  this  analysis 
revealed that CHOP mRNA levels were found to be 5-fold greater in brains from mice 
lacking HtrA2 compared to controls. Interestingly, this enhanced expression of CHOP 
was limited to the brain but absent from other examined tissues (Figure 4-4A). Next, to 
determine if increased CHOP expression preceded the development of the parkinsonian 
syndrome of HtrA2  KO mice,  the  levels of CHOP mRNA were monitored  in brains
132isolated between PI5  and P31.  At every age tested,  CHOP expression was higher in 
HtrA2 KO brains compared to controls (Figure 4-4B), proposing that up-regulation of 
CHOP probably precedes phenotypic alterations in mice devoid of HtrA2. Analysis of 
HtrA2  Het  animals  revealed  that  CHOP  expression  was  comparable  to  that  of WT 
animals, suggesting that HtrA2 is not haplosinsufficient with respect to up-regulation of 
CHOP (data not shown). So far, the expression of CHOP was determined using RNA 
prepared  from  whole  brain  homogenates.  In  order  to  determine  whether  CHOP  up- 
regulation  was  specific  to  particular  anatomical  areas  of  the  brain,  samples  were 
prepared from dissected cortex, cerebellum and basal ganglia (for localisation of these 
Figure 3-3A). This analysis revealed a widespread up-regulation of CHOP transcript in 
all the regions tested from HtrA2 KO mice (Figure 4-4C).
Taken  together  these  results  indicate  that  cells  lacking  HtrA2  experience  a  more 
pronounced  transcriptional  up-regulation  of  CHOP  in  response  to  treatment  with 
rotenone than WT cells. Nevertheless, CHOP expression is also induced in WT cells, 
suggesting  that  the  stress  response  in  WT  and  HtrA2  KO  cells  might  ultimately  be 
similar.  However,  HtrA2  KO cells appear to be more  susceptible to the  induction of 
this stress response.  Strikingly, CHOP expression is higher in brain tissue from HtrA2 
KO  mice,  but  not  in  any  other tissue  tested,  suggesting  that the  brain  is  selectively 
vulnerable to mitochondrial stress upon loss of HtrA2 function.
4.2.4  Genes  differentially  expressed  in  cells  lacking  HtrA2  in  the 
absence of any stress stimulus
In  order  to  identify  differentially  transcribed  genes  in  cells  lacking  HtrA2  in  the 
absence of any stress stimulus, the untreated replicate samples for each genotype (WT 
and  HtrA2  KO)  were  analysed  (highlighted  in  orange  in  Figure  4-1 A).  The  total 
number of probe sets differentially regulated was 298, within these,  113 were up- and 
185 were down-regulated in MEFs derived from HtrA2 deficient animals compared to 
WT  (Figure  4-5A).  Similar  to  the  changes  detected  in  rotenone-treated  cells,  the 
majority of probe sets showed a fold-change in the range between 1.2- to 1.5-fold. Only 
10  probe  sets  were  found  to  differ  more  than  2-fold,  with  HtrA2  being  among  the 
strongest differential genes (Figure 4-5B). The strongest up- and down-regulated genes 
in the cells lacking HtrA2 are listed in Table 4-2.
133Five  genes  were  selected  for  further  validation  by  RT  qPCR  analysis.  All  of the 
detected changes in expression were consistent with the data obtained in the GeneChip 
experiment  (Figure  4-5C).  Matrix  metalloproteinase  9  (MMP9)  was  up-regulated  in 
HtrA2 KO MEFs, whereas caveolin 2 (CAV2), nephronectin (NPNT), mannan-binding 
lectin serine peptidase (MASP1) and aquaporin  1   (AQP1) were down-regulated in the 
same cells.  Among the  list of genes differentially  expressed  in untreated  HtrA2  KO 
cells compared to WT, only a small number of genes was also modulated by rotenone 
treatment. Most of these genes, however, were at the border of 1.2-fold difference. For 
example, NPNT was down-regulated in HtrA2 KO MEFs (Figure 4-5C and Table 4-2) 
and also induced by rotenone in HtrA2 KO MEFs (1.3-fold). However, the induction of 
NPNT  by  rotenone  could  not  be  validated by  RT  qPCR analysis  (data not  shown), 
suggesting, that its up-regulation by rotenone treatment is not reproducible.
4.3  Characterisation of a stress response in brain tissue from 
mice lacking HtrA2
The data presented  so  far indicates that loss of HtrA2  leads to activation of a stress 
response characterised by the up-regulation of CHOP. Furthermore, this up-regulation 
seems to occur specifically in the brains of animals lacking HtrA2. Interestingly, CHOP 
has not  only  been  shown  to  respond to  cellular  stresses  leading to  the  induction  of 
apoptosis (Guyton et al.  1996; Matsumoto et al.  1996; Zinszner et al.  1998; Kawahara 
et  al.  2001;  Maytin  et  al.  2001;  Gotoh et  al.  2002;  Mengesdorf et al.  2002),  but  in 
addition to  be  up-regulated  in neurotoxin-induced rodent models of PD  (Silva et al. 
2005). Loss of HtrA2 in mice seems to elicit a similar stress response, and studying this 
stress  response  in  more  detail  might  add  to  understanding  the  molecular  pathways 
involved in the development of PD in the HtrA2 KO mice. In order to characterise this 
stress  response  more  extensively,  transcriptional  profiling  was  performed  on  cortex 
tissue  from  WT  and  HtrA2  KO  mice  (Figure  4-6A).  Previously,  an  increase  in  the 
expression of CHOP was shown to occur in the basal ganglia of HtrA2 KO mice where 
the neurodegeneration  is found,  but also  in the cortex and  cerebellum  of these  mice 
(Figure 4-4C). Since neuronal loss does occur in the striatum (part of the basal ganglia) 
of the  HtrA2  KO  mice,  this  might  be reflected  in the transcriptional  profile.  Cortex 
tissue was chosen for the GeneChip analysis since it does not suffer from cellular loss. 
Therefore, the effect of the stress response could be examined rather than the impact of
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Genome  2.0  GeneChips  were  used  in  this  study.  These  GeneChips  comprise  about
39,000  probe  sets and some  genes are represented by more than one probe set.  The 
quality of the total RNA for each replicate was controlled on an Agilent Bioanalyser, 
showing the characteristic bands of 28S and  18S rRNA of total RNA (Figure 4-6B). 
The  GeneChip array  data analysis was carried out within the  Bioconductor software 
(Gentleman  et  al.  2004).  Probe  level  intensities  were  quantile  normalised  and 
quantified using RMA (Irizarry et al. 2003).
Probe  sets differentially  expressed  between the  WT and  HtrA2  KO replicate  groups 
were identified by applying a 0.05 FDR threshold, and these are highlighted red in the 
volcano plot (Figure 4-6C).  In total  792 probe sets were differentially expressed and 
approximately equal numbers were up- and down-regulated (Figure 4-6D).  When the 
probe sets were ranked upon their absolute fold change, only 11  were more than 3-fold 
different between WT and HtrA2 KO brain samples, and 70 probe sets were between 2- 
to 3-fold up- or down-regulated in the samples from HtrA2 KO brain. The majority of 
probes sets identified by the 0.05  FDR threshold were  in the range of 1.2- to 2-fold 
differentially expressed (Figure 4-6F).
When  a  more  stringent  threshold  of 0.01  FDR  was  applied  to  analyse  probe  sets 
differentially expressed between the WT and HtrA2 KO replicate groups, 79 probe sets 
were identified. 47 of these probe sets were up- and 32 were down-regulated (Figure 
4-6E). Most of the probe sets lost by applying a 0.01  FDR compared to 0.05 FDR were 
regulated  in  the  lower  fold-range  (Figure  4-6F).  Therefore,  the  genes  displaying  a 
greater difference in expression between WT and HtrA2 KO cortex are more likely to 
withstand a more stringent statistical cut-off.
Table 4-3 shows a list of genes passing the 0.05 FDR threshold that are above 2.5-fold 
up-  or down-regulated  in the  brains of mice  lacking  HtrA2.  Genes passing the  0.01 
FDR  threshold  are  highlighted  in  bold  and  italics.  Besides  HtrA2,  only  two  up- 
regulated  genes,  Shmt2  and  Mthfd2,  are  mitochondrial  proteins.  Gene  Ontology 
analysis on all genes identified by 0.05 FDR (792 probe sets, supplementary data CD), 
detected 36 genes that are mitochondrial proteins. Therefore, a relatively small number 
of genes differentially expressed in HtrA2 KO brain encode for mitochondrial proteins.
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were previously shown to be up-regulated in response to mitochondrial stress mediated 
by an unfolded protein (Zhao et al. 2002), were identified to be differentially expressed 
in  HtrA2  KO  brain.  This  observation  suggests  that  the  stress  response  observed  in 
HtrA2  KO  brains  is probably  mediated  by  different  transcriptional  elements  than  a 
CHOP element that was implicated in the up-regulation of Hsp60/Hspl0 (Zhao et al. 
2002).
Next, the results for HtrA2 and CHOP, which could be viewed as negative and positive 
control, were examined in more detail. In Figure 4-7A and B the expression ratio for 
HtrA2 and CHOP, respectively, are plotted for each sample. In the GeneChip analysis, 
HtrA2  was 4.8-fold  down-regulated  in  HtrA2  KO  cortex  and this was the  strongest 
absolute  fold  change  among  all  genes.  CHOP  was  also  among  the  strongest 
differentially expressed genes, being 3.6-fold induced in HtrA2 KO cortex (Table 4-3). 
The relative level of CHOP mRNA within each single sample was also measured by 
RT qPCR (Figure 4-7C).  Although CHOP expression varied between 2.2- to 5.8-fold 
across the  replicates  when  measured  by  RT  qPCR,  the  average  of 3.7-fold  increase 
matched with the data obtained from the GeneChip analysis.
4.3.1  Transcripts modulated in brains lacking HtrA2: a comparative 
analysis  with  the  in  vitro  stress  response  to  rotenone 
treatment
In order to focus on genes that might be part of a stress response in HtrA2 KO brains 
similarly  to  CHOP,  the probe  sets regulated  in MEFs upon rotenone treatment were 
tested against the expression data obtained from WT and HtrA2  KO cortex  samples. 
The significance was tested using gene set enrichment analysis (GSEA) (Subramanian 
et  al.  2005),  which  is  a  computational  method  that  determines  whether  an  a priori 
defined set of genes shows statistically significant, concordant differences between two 
biological conditions.  When all  1099 probe sets regulated upon rotenone treatment in 
MEFs (WT and/or HtrA2  KO) were tested against the data acquired from the cortex 
tissue, the GSEA returned a p-value of 0. Therefore, a significant number of probe sets 
regulated by rotenone were similarly differentially expressed in HtrA2 KO cortex.  In 
contrast, when instead a list of 1099 probe sets was randomly selected from all probe
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of 0.73, which is not significant (data not shown).
Next,  the  probe  sets  in  common  between  the  probe  sets  differentially  expressed  in 
HtrA2 KO brain identified by 0.05  FDR threshold and probe sets regulated in MEFs 
upon rotenone treatment were identified. 68 probe sets were found to be present in both 
conditions (Figure 4-7D). These 68 overlapping probe sets corresponded to 56 genes, 
however, 8 of these exhibited up-regulation in HtrA2 KO brain and down-regulation in 
MEFs  by  rotenone  treatment,  or  vice  versa,  and  these  were  therefore  omitted  from 
further analysis. 23 of the genes were up-regulated in HtrA2 KO cortex as well as upon 
rotenone treatment in MEFs, whereas the expression of 25 genes was down-regulated 
in HtrA2 KO cortex and by treatment of MEFs with rotenone (Table 4-4).  Strikingly, 
applying  a  more  stringent  threshold  of  0.01  FDR  to  identify  genes  differentially 
expressed in WT and HtrA2 KO cortex tissue led to the enrichment of probe sets also 
identified to be regulated by rotenone in MEFs (Figure 4-7E). 20 out of 79 probe sets 
(25.3%)  were  also  present  in the  set  of probe  sets  regulated  by  rotenone  in  MEFs, 
whereas the overlap was 68 probe  sets out of 792  (8.6%) when using the 0.05  FDR 
threshold for the cortex samples. Genes passing the 0.01 FDR threshold are highlighted 
in bold and italics in Table 4-4.
Thus, the signature of transcripts regulated in cells treated with rotenone is similar to 
the genes that are differentially expressed in brains of mice  lacking HtrA2.  Studying 
the genes listed in Table 4-4 and their regulation might possibly lead to identification of 
common upstream signalling events that could be responsible for such transcriptional 
signature.
4.3.2  Heightened  expression  of ATF3  and  Herp  in  brains  of mice 
lacking HtrA2
Markedly, besides CHOP, two other genes reported to be up-regulated following ER 
stress  and  other  stresses  leading  to  activation  of eIF2a  kinases,  were  found  to  be 
expressed  at higher  levels  in  HtrA2  KO  brain  samples compared to  WT:  ATF3  and 
Herp (Jiang et al. 2004; Ma and Hendershot 2004) (link to figure in introduction that 
shows  overview  of this  pathway).  ATF3  was  also  induced  in  MEFs  treated  with 
rotenone  (Table  4-4),  however,  Herp  was not  significantly  induced  by  treatment
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HtrA2 KO brain tissue, RT qPCR was performed on selected genes. ATF3  and Herp 
were included in this analysis, and in addition KLF5 and Hsp60. KLF5 is a TF that was 
also found induced in HtrA2 KO cortex, however, its induction has not been linked to 
the UPR or other stresses leading to activation of eIF2a kinases. Previously, CHOP up- 
regulation  has  been  implicated  in  a mitochondria-specific  stress  response  leading  to 
increased expression of Hsp60 (Zhao et al. 2002). Although Hsp60 was not changing in 
the GeneChip analysis, its transcript levels were also measured by RT qPCR.  CHOP, 
ATF3  and  Herp  were  clearly  up-regulated  in  brain  tissue  from  mice  lacking  HtrA2 
(Figure 4-8),  although the  increase  in Herp mRNA  was small compared to the high 
levels of CHOP and ATF3  mRNA.  Herp expression in brain tissue from HtrA2  KO 
mice was found to be 1.5-fold above WT control levels. KLF5 expression levels did not 
differ  between  WT  and  HtrA2  KO  brain  tissue  in  most  experiments,  and  Hsp60 
transcript  levels  were  never  increased  in  HtrA2  KO  tissue.  Taken  together,  the 
GeneChip data could not be reproducibly validated for KLF5, however, the expression 
levels of CHOP, ATF3 and Herp were increased in brain tissue from mice deficient for 
HtrA2.
4.3.3  Genes  up-regulated  in  brains  from  HtrA2  KO  mice  display 
C/EBP-ATF composite binding sites
Several  of the genes found to  be  up-regulated  in  HtrA2  KO  cortex  and  in  rotenone 
treated MEFs have been previously described to be induced in response to ER stress 
dependent on the TF ATF4 (marked by an arrow next to the gene symbol in Table 4-4) 
(Vallejo et al.  1993; Fawcett et al.  1999; Siu et al. 2002; Harding et al. 2003; Ohoka et 
al.  2005).  In addition,  analysis of the promoter regions of several of these  genes has 
identified  C/EBP-ATF  composite  sites.  Such  genes  include  CHOP  (Wolfgang  et  al. 
1997),  asparagine  synthetase  (ASNS)  (Barbosa-Tessmann  et  al.  2000),  tribbles  3 
(TRB3) (Ohoka et al. 2005), Herp (Ma and Hendershot 2004), and ATF3 (Wolfgang et 
al.  2000).  Heterodimers of C/EBP-related and ATF/CRE-related TFs can bind to this 
composite  site,  which  consists  of half of each,  a palindromic  C/EBP-  and  a variant 
ATF/CRE-binding site, and has been described for the first time in the CHOP promoter 
(Wolfgang et al.  1997) (Figure 4-9). Transcriptional activity is enhanced through this
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result in an increase of ATF4 protein (for review (Wek et al. 2006)).
The  up-regulated  genes  in  Table  4-4  and  15  additional  genes  showing  higher 
expression in HtrA2 KO brain (0.05 FDR) were selected for sequence analysis in order 
to identify putatitve C/EBP-ATF composite binding sites. The 15 additional genes were 
chosen based on their impaired induction following ER stress in ATF4 deficient cells 
(Harding et al. 2003). The genomic sequence of these genes and 4000bp upstream of 
the transcriptional  start  site  (TSS) of each gene were  screened  for the presence of a 
C/EBP-ATF composite site with the consensus sequence: TT(G/T)CATCA. Then, the 
alignment of mouse and human sequence were tested and one mismatch was allowed to 
occur in either of the analysis steps. The analysis showed that out of the 37 genes tested 
only 4 (Bri3, Slc3a2, Lgals3bp, Gas5) did not contain a C/EBP-ATF composite site. 18 
genes  contained  at  least  one  perfect  C/EBP-ATF  composite  site,  with  no  mismatch 
from  the  consensus  sequence  or  between  the  mouse  and  human  alignment  (Table 
4-5A).  Furthermore,  15  genes  contained  C/EBP-ATF  composite  sites  with  one 
mismatch  to  the  consensus  site  (Table  4-5B).  Of these,  TRB3,  H2afy3  and  Sord 
showed  one  mismatch  from  the  consensus  site  in  the  mouse  sequence,  but  the 
corresponding human sequence perfectly matched the consensus sequence, suggesting 
that a mismatch at these positions might not influence the activity of the site. In order 
to rule out the possibility that the conservation of the sites between mouse and human 
is  due  to  their  localisation  in  the  coding  region  of the  genes,  the  locations  of the 
C/EBP-ATF composite sites were determined. All of the sites were within the 5’UTR, 
the promoter or an intron of the genes, only one gene, Vpsl 1, possessed a C/EBP-ATF 
composite site with one mismatch within an exon and did not contain any other sites.
Taken  together,  a  signature  of genes  previously  reported  to  be  up-regulated  in  an 
ATF4-dependent manner in response to ER stress (Harding et al. 2003) was identified 
in  brains  from  mice  lacking  HtrA2.  Strikingly,  sequence  analysis  of  these  genes 
revealed a C/EBP-ATF composite site for their transcriptional regulation in almost all 
of the genes.
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KO phenotype
Mitochondrial  dysfunction  and  oxidative  stress  have  long  been  implicated  in  PD 
(Gandhi and Wood 2005). Neurotoxins such as MPP+, 6-OHDA and rotenone which 
lead to the development of PD in animal models (Jeon et al.  1995; Betarbet et al. 2000; 
Sedelis  et  al.  2001)  and  humans  (Langston  et  al.  1983)  are  known  to  disturb 
mitochondrial  function  and  result  in  enhanced  oxidative  stress.  In  addition,  these 
neurotoxins  induce  changes  in  gene  transcription  associated  with  the  UPR  and 
apoptosis  (Ryu  et  al.  2002;  Holtz  and  O'Malley  2003).  Recently,  oxidative  stress 
caused by 6-OHDA was shown to trigger the UPR and lead to induction of the TFs 
CHOP and ATF3 (Holtz et al. 2006), therefore placing generation of ROS upstream of 
the transcriptional changes.  Intriguingly,  loss of HtrA2  in cells causes mitochondrial 
stress and leads to increased sensitivity to specific death stimuli (Figure 3-6 and Figure
3-7A). In mice, loss of HtrA2 leads to transcriptional changes that are shared between 
the UPR and other cellular stresses, and the development of a parkinsonian syndrome. 
In  addition,  the  bacterial  HtrA2  homologues  DegS  and  DegP  appear  to  confer 
resistance to oxidative  stress (Raivio  2005).  Therefore,  it is possible to propose that 
loss of HtrA2 function in mice might result in enhanced oxidative stress and generation 
of ROS, which would then lead to the increased expression of CHOP.
In  order  to  address  the  level  of  oxidative  stress  upon  loss  of  HtrA2,  the  lipid 
composition of WT and HtrA2 KO mitochondria was analysed by mass spectrometry 
(in  collaboration  with  Mauro  Degli  Esposti,  University  of  Manchester).  Lipid 
peroxidation  is  the  ultimate  noxious  product  of  oxygen  radicals  that  impairs 
mitochondrial and cellular function, fundamentally by damaging membranes (Porter et 
al.  1995). The analysis revealed that mitochondria derived from HtrA2 KO mice have a 
greater amount of peroxidised lipids in their membranes.  These could be detected in 
liver mitochondria (Table 4-6) as well as mitochondria isolated from brain (data not 
shown). Therefore, HtrA2 KO mitochondria probably suffer from increased oxidative 
stress. Adequately, the production of ROS in HtrA2 KO cells in response to rotenone 
and 6-OHDA was increased compared to WT cells (Nicoleta Moisoi, MRC Leicester; 
data not shown).
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treatment  with  anti-oxidants.  N-acetyl-L-cysteine  (NAC),  is widely  used  as  an  anti­
oxidant in cell culture as well as animal models (Molina-Jimenez et al. 2004; Park et al. 
2004),  and  it  functions  as  a  nucleophilic  ROS  scavenger  as  well  as  a  precursor  of 
intracellular cysteine and glutathione (GSH) (Weinander et al. 1994). Administration of 
NAC  to  the  newborn  pups  was  performed  by  oral  administration  (200mg/kg  body 
weight) from P6, in addition, the nursing mother received NAC in the drinking water. 
After  weaning  at  P20,  the  young  mice  continued  NAC  treatment  by  supplementing 
their drinking water with 1  mg/ml NAC. The onset and progression of the parkinsonian 
syndrome was delayed in NAC treated HtrA2 KO animals, but had no detectable effect 
on WT or Het mice. Notably, HtrA2 KO mice treated with NAC survived longer than 
HtrA2 KO mice treated with vehicle (Figure 4-10). This is the first evidence that HtrA2 
KO mice benefit from a reduction in oxidative stress by treatment with anti-oxidants.
Taken  together  these  results  indicate  that  loss  of HtrA2  in  mice  leads  to  increased 
oxidative stress, which is implicated in the development of the parkinsonian syndrome 
in the HtrA2 KO mice.
4.4  The protease inhibitor Ucf-101 induces cellular responses 
independently of its known target HtrA2
In order to inhibit HtrA2 activity in cells many studies have used the chemical inhibitor 
Ucf-lOl,  which  was  reported  as  a  specific  inhibitor  for  this  protease  (Cilenti  et  al. 
2003).  Ucf-lOl  is  a  cell-permeable,  furfurylidine-thiobarbituric  acid  compound  that 
competitively and reversibly inhibits HtrA2 protease activity ((Cilenti et al. 2003) and 
Figure 4-11 A).  It was  shown to  have  very  little activity  against various other  serine 
proteases and,  when tested  in caspase-9  null  fibroblasts,  was  found to  inhibit  HtrA2 
over-expression-induced cell death (Cilenti et al. 2003). On the assumption that it is a 
specific inhibitor of HtrA2, Ucf-lOl  has been employed to identify potential substrates 
of this protease (Cilenti  et al.  2004; Trencia et al.  2004) and to study  its role  in cell 
death (Blink et al. 2004; Cilenti et al. 2004; Goffredo et al. 2005; Liu et al. 2005). Ucf- 
lOl provides at least partial protection from cell death induction by cisplatin (Cilenti et 
al.  2004;  Cilenti  et al.  2004),  myocardial  ischemia and  reperfusion  (Liu et al.  2005; 
Bhuiyan  and  Fukunaga 2007),  TNFa  (Blink  et  al.  2004)  and  staurosporine  (Figure
1414-1 IB),  leading  to  the  assumption  that  HtrA2  plays  a  role  in  promoting  cell  death 
following these treatments.
Since siRNA against HtrA2 leads to an induction of CHOP mRNA level, inhibition of 
HtrA2 by Ucf-lOl  might have a similar effect. To test this, WT and as a control HtrA2 
KO  MEFs  were  incubated  with  Ucf-lOl  at  different  concentrations  and  incubation 
times,  and  the  levels of CHOP  mRNA  were  measured  by  RT  qPCR.  Tunicamycin, 
which inhibits N-linked glycosylation in the ER, was used as a positive control for the 
induction of CHOP. Surprisingly, Ucf-lOl by itself induced CHOP mRNA, both in WT 
and HtrA2 KO MEFs (Figure 4-12A). CHOP was already induced 2-fold after only  lh 
incubation with 20pM Ucf-lOl, rising to 5-8 fold at 2hrs. In addition, the expression of 
the TF ATF3, known to be inducible by a variety of stresses (for review see (Hai and 
Hartman 2001)), was measured. ATF3 was also induced by Ucf-lOl  in both WT and 
HtrA2 KO MEFs (Figure 4-12B). The increase in CHOP and ATF3 mRNA levels in 
response to UCF-101  treatment did not seem to be cell type specific, because similar 
results were seen in the murine neuroblastoma cell  line Neuro-2a (Figure 4-12C).  In 
line  with  the  previous  results  showing  a  stronger  stress  response  leading  to  up- 
regulation of CHOP mRNA levels in HtrA2 KO MEFs and in brain tissue ffom HtrA2 
KO animals, tunicamycin treatment led to 35-fold induction of CHOP in  HtrA2  KO 
MEFs, but only 20-fold in WT MEFs.
The induction of two TFs that are known to be responsive to stress, CHOP and ATF3, 
suggests that Ucf-lOl might trigger activation of stress pathways in cells. This action is 
independent of its ability to inhibit HtrA2, as the response is seen as strongly in HtrA2 
KO as in WT MEFs. The activation of cellular stress and other signalling pathways by 
Ucf-lOl  in WT and HtrA2 KO cells was determined using phospho-specific antibodies 
(Figure 4-13 A).  Phosphorylation of eIF2a is a well-documented mechanism of down- 
regulating protein synthesis under a variety of stress conditions (Figure  1-6B) (Holcik 
and  Sonenberg  2005).  The  stress-activated  protein  kinase/Jun-N-terminal  kinase 
SAPK/JNK  is potently and preferentially  activated by diverse environmental  stresses 
and  can also  be  phosphorylated  following  stimulation of a member  of the  germinal 
centre  kinase  (GCK)  family.  p38  MAP  kinase  participates  in  a  signalling  cascade 
controlling cellular responses to cytokines and stress. Both ERK1  and ERK2 function 
in a protein kinase cascade that plays a critical role in the regulation of cell growth and
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signals. All of these signalling pathways were activated in a time- and concentration- 
dependent manner by Ucf-lOl in WT and HtrA2 KO MEFs (Figure 4-13A).
Even  at  low  concentrations,  the  HtrA2  inhibitor  Ucf-lOl  seems  to  result  in  broad 
activation of cellular signalling pathways that is  independent of its ability  to  inhibit 
HtrA2 proteolytic activity. It is not clear how Ucf-lOl elicits such a pronounced overall 
stress response.  The most important implication of these findings is that the inhibitor 
Ucf-lOl  should  be  used  with  great  care  and  not  regarded  as  an  entirely  specific 
inhibitor of HtrA2. Several reports have assumed that all the biological effects of Ucf- 
101  reflect its inhibition of HtrA2  protease activity  (Blink et al.  2004;  Cilenti  et al. 
2004; Cilenti et al. 2004; Trencia et al.  2004; Gofffedo et al. 2005; Liu et al.  2005). 
Since  Ucf-lOl  can  induce  activation  of ERK  (Figure  4-13A),  it  is possible  that  its 
survival promoting actions could be mediated via this known anti-apoptotic pathway. 
Alternatively,  moderate  activation  of  various  stress-induced  pathways  has  been 
associated  with  cellular adaptation,  or conditioning,  and protection  from  subsequent 
challenge with death  stimuli,  so it is possible that the ability  of Ucf-lOl  to  activate 
these pathways might also contribute to  its reported protective effects.  A number of 
agents that  induce CHOP  are also  known to activate the NF-kB  pathway.  However, 
Ucf-lOl  is not able to activate this pathway: it fails to induce phosphorylation of IicBa 
under circumstances where TNFa gives a robust response (Figure 4-13B).
In addition to inhibiting HtrA2, Ucf-lOl  might affect other closely related proteases, 
such as HtrAl (Hu et al.  1998), HtrA3 (Nie et al. 2003) or HtrA4. The mRNA levels of 
these proteases in HtrA2 WT and KO MEFs were measured by RT qPCR. Primer pairs 
for each HtrA family member were designed, so that they did not align with any of the 
others.  HtrAl  and  HtrA4  mRNA  levels  were  similar  in  WT  and  HtrA2  KO  MEFs, 
however,  the  HtrA3  mRNA  level  was  70%  reduced  in  HtrA2  KO  MEFs  (Figure 
4-14A). Therefore HtrA3 is unlikely to be the target of Ucf-lOl  initiating the response 
seen equally in WT and HtrA2 KO MEFs. The down-regulation of HtrA3 expression in 
HtrA2  KO  MEFs  seems  to  be  an  attribute  of  the  MEF  cell  lines  used  for  this 
experiment, since HtrA3 expression levels did not vary in tissue from WT and HtrA2 
KO mice (data not shown).
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suggest that they  might also  be targeted by  Ucf-lOl,  it is  likely that they  have  very 
distinct function from HtrA2. None of these proteins are known to be mitochondrial or 
to have consensus mitochondrial import signals; HtrAl  and HtrA3 are reported to be 
secreted from cells (Hu et al. 1998; Tocharus et al. 2004), and the same seems to be the 
case  for  HtrA4  (Figure  4-14B).  Neither  HtrAl  nor  HtrA3  or  HtrA4  have  been 
implicated  in  protection  from  cell  death  or  stress  signalling.  A  single-nucleotide 
polymorphism has been identified in the HtrAl  promoter, which leads to an elevated 
level  of HtrAl  expression  and  increases  the  susceptibility  to  Age-related  Macular 
Degeneration causing irreversible vision loss (Dewan et al.  2006;  Yang et al.  2006). 
Even  if Ucf-lOl  was  eliciting  biological  effects  on  cells  through  the  inhibition  of 
HtrAl, HtrA3 or HtrA4 in addition to inhibition of HtrA2, it seemed unlikely that it 
will be able to provide meaningful information about HtrA2 function, given the evident 
functional  divergence  within  this  family.  Therefore,  Ucf-lOl  should  be  used  with 
caution to investigate HtrA2 function and its use should always be backed up by data 
from other approaches to the  ablation  of HtrA2  activity,  such as gene  knock out or 
RNA interference.
4.5  Discussion
The bacterial protease DegS is a critical mediator of a transcriptional stress response 
initiated  in  the  periplasmic  space  (Schlieker  et  al.  2004).  To  test  the  attractive 
hypothesis that HtrA2 might be mediating a stress signalling response in mitochondria, 
transcriptional  profiling  was  performed  to  identify  HtrA2-dependent  transcriptional 
changes.  WT  and  HtrA2  KO  MEFs  were  challenged  with  the  complex  I  inhibitor 
rotenone to induce mitochondrial stress. Cells lacking HtrA2 were previously shown to 
be more sensitive to this complex I inhibitor when mitochondrial morphology and cell 
death were examined (Figure 3-6 and Figure 3-7A). A higher number of transcriptional 
changes were detected in HtrA2  KO MEFs in response to rotenone treatment than in 
WT cells (Figure 4-2), which is in line with the previous results showing that loss of 
HtrA2 sensitises cells and their mitochondria to stress stimuli. Although 61  probe sets 
were differentially expressed in rotenone treated WT cells, but not in HtrA2 KO cells 
treated with rotenone (Figure 4-2C), only two of these were more than 1.5-fold induced 
by the treatment. One of the transcripts induced only in rotenone treated WT cells is a
144cDNA clone not  further characterised, the other one encodes  for AMP deaminase  3 
(AMPD3). Moreover, no functional signature of genes could be identified that was only 
modulated in WT cells in response to rotenone treatment but not in HtrA2 KO cells. 
Therefore,  an  HtrA2-dependent  transcriptional  response  similar  to  DegS  in  bacteria 
could  not  be  identified.  However,  most  of the  genes  modulated  by  rotenone  were 
identified in HtrA2 KO cells, whereas their transcriptional regulation in WT cells was 
not significant. Thus, rotenone-induced transcriptional changes were more pronounced 
in cells lacking HtrA2.
Subsequently, the expression of the TF CHOP was shown to be induced to a greater 
level in HtrA2 KO cells than in WT cells when stimulated with rotenone (Figure 4-3A 
and B).  Similarly, a greater induction of Gadd45a in HtrA2  KO than in WT cells in 
response  to  rotenone  was  verified  by  RT  qPCR  (data  not  shown).  Gadd45a  is  the 
strongest  up-regulated  gene  in  rotenone  treated  HtrA2  KO  MEFs  and  it  is  not 
significantly  modulated  in  WT  cells  that  are  treated  with  rotenone  (Table  4-1). 
Recently, Gadd45a has been implicated in epigenetic gene activation by inducing DNA 
demethylation (Barreto et al. 2007), and further investigation of its expression levels in 
HtrA2  KO brains might be of interest.  The induction of CHOP  in HtrA2  KO MEFs 
following  rotenone  treatment  could  point  to  an  increased  level  of  stress  in  these 
mitochondria, as CHOP was found to be implicated in a mitochondria-specific stress 
response (Zhao et al. 2002). This suggested the possibility that the function of HtrA2 
was  not  DegS-like  in  a  signalling  cascade,  but  more  akin  to  the  bacterial  protease 
DegP,  which  elicits  its  protective  function  by  refolding  or  degrading  unfolded 
accumulating  proteins.  The  lack  of HtrA2  would  lead  to  a higher level  of unfolded 
proteins  in  the  mitochondrial  intermembrane  space  and  therefore  the  threshold  for 
activation  of the  mitochondrial  stress  response  would  be  lower  in  HtrA2  KO  cells 
compared to the WT cells.
Interestingly, CHOP expression was higher in brain tissue from HtrA2  KO mice, but 
not in any other tissue tested (Figure 4-4A). This could potentially mirror a higher level 
of stress in brain due to an increased demand for mitochondrial function or a decreased 
capacity to cope with the stress elicited by  loss of HtrA2  function.  Furthermore,  the 
expression of CHOP in brains from HtrA2 Het animals was comparable to that of WT 
mice,  mirroring  the  fact,  that  no  neurodegeneration  or  locomotor  disabilities  are
145observed in HtrA2 Het mice.  CHOP expression is already higher in brains of HtrA2 
KO  animals  at  PI5  and  PI8,  suggesting  that  its  up-regulation  probably  precedes 
phenotypic alterations in mice devoid of HtrA2 (Figure 4-4B). However, the transcript 
levels of CHOP  were  similar  in  WT and  HtrA2  KO  brains  at  P8  (Nicoleta Moisoi, 
MRC Leicester; data not shown). Thus, the increase in CHOP expression level seems 
to correlate with the development of a parkinsonian syndrome in HtrA2 KO mice, and 
might be essential for the manifestation of this phenotype.
Transcriptional profiling of genes differentially expressed in brain tissue from HtrA2 
KO  mice  revealed  that,  besides  CHOP,  ATF3  and  Herp  mRNA  levels  were  also 
induced in these brains (Figure 4-8). CHOP and Herp are known to be dually regulated 
by the ER stress-specific and the shared branch of the UPR (Figure  1-6B) (Ma et al. 
2002;  Ma and Hendershot 2004).  Expression of ATF3  is increased following a wide 
range of stress stimuli.  Interestingly,  the induction of ATF3  transcript in response to 
amino  acid  deprivation  or  ER  stress  was  demonstrated  to  occur  by  mechanisms 
requiring eIF2a phosphorylation (Jiang et al.  2004). Thus, deregulation of the shared 
branch  of the  UPR  or  activation  of other  pathways  that  lead  to  phosphorylation  of 
eIF2a, and concomitantly stimulate translation of ATF4, could possibly be implicated 
in the cellular events resulting from loss of HtrA2 function.
Strikingly, a substantial proportion of genes that were expressed to a higher degree in 
brains from HtrA2 KO mice and also up-regulated in MEFs treated with rotenone, are 
likely  to  be  ATF4  target  genes  (Table  4-4).  Harding  and  colleagues  studied  the 
transcriptional  response  of ATF4  deficient  and  PERK  deficient  cells  to  ER  stress 
induced by tunicamycin,  and detected an  impairment of ATF4  deficient cells to  up- 
regulate the expression of genes involved in amino acid import, resistance to oxidative 
stress  and  glutathione  import  (Harding  et  al.  2003).  Additional  genes  have  been 
identified  in  other  studies  that  are  dependent  on  the  presence  of  ATF4  for  their 
induction (Vallejo et al.  1993; Fawcett et al.  1999; Siu et al. 2002; Ohoka et al. 2005). 
A high proportion of the up-regulated genes listed in Table 4-4 are not or only slightly 
increased in ATF4 deficient cells following stimulus with tunicamycin (Harding et al. 
2003).  Among  all  genes  identified  to  be  differentially  regulated  in  HtrA2  KO  brain 
(792 probe sets, 0.05 FDR; list on supplementary data CD), additional genes were up- 
regulated that  are  likely  to be  ATF4  target  genes.  Therefore,  from focussing  on the
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treatment in MEFs (Table 4-4), it was possible to identify a signature of ATF4 target 
genes within the up-regulated genes. Subsequently, extending the analysis to all genes 
differentially regulated in HtrA2 KO brain, strengthened the finding, that a signature of 
genes up-regulated in HtrA2 KO brain were previously reported to depend on ATF4.
Markedly, a C/EBP-ATF composite site had been characterised in the promoters of a 
subset of the ATF4 target genes up-regulated in HtrA2 KO brain. Transcription through 
this site was shown to be enhanced in response to amino acid starvation, ER stress and 
probably other stresses that lead to an increase of ATF4 protein (for review (Wek et al. 
2006)).  C/EBPp-ATF4  and  CHOP-ATF4  heterodimers  were  reported  to  enhance 
transcriptional  activity  (Ma et  al.  2002;  Ohoka et al.  2005),  whereas C/EBPp-ATF3 
heterodimers seemed to repress this site (Chen et al. 2004; Lopez et al. 2007). Analysis 
of the genomic  sequence  of the putative ATF4 target genes that are up-regulated  in 
HtrA2 KO brain, revealed C/EBP-ATF consensus sites in almost all of the genes (Table 
4-5).  These results strongly  support the hypothesis that deregulation of ATF4  might 
contribute  to  the  transcriptional  profile  in  brains  from  mice  lacking  HtrA2.  ATF4 
protein levels are regulated through phosphorylation of eIF2a on the translational level 
(Figure 1-6B). Therefore, investigation of the protein level of ATF4 in WT and HtrA2 
KO  brain  should  be  performed.  In  addition,  the  activity  of the  upstream  signalling 
pathways (the eIF2a kinases) can be studied using phospho-specific antibodies against 
PERK, GCN2 and PKR. Very preliminary results indicated, that ATF4 protein levels 
might  possibly  be  increased  in  HtrA2  KO  brain  (data  not  shown),  however,  no 
phosphorylation of PERK could be detected.
Gene expression profiling cannot differentiate between primary and secondary events 
and, therefore, the GeneChip analysis of brain tissue from HtrA2 mice at P29 may only 
provide a molecular fingerprint of late-stage processes due to loss of HtrA2. In order to 
avoid  transcriptional  differences  due  to  cellular  loss  in  the  HtrA2  KO  mice  brains, 
cortex tissue was chosen for this analysis.  In HtrA2 KO mice, the neurodegeneration 
can be detected in the posterior portion of the striatum which is part of the basal ganglia 
(Figure 3-3). It is not clear why these particular neurons die, but it is possible that these 
cells  rely  heavily  on  mitochondrial  function,  by  having  a  high  metabolic  rate  for
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regulation of CHOP was detected in all brain regions but not in other tissues of the 
HtrA2 KO mice that were tested (Figure 4-4). The signature of ATF4 target genes up- 
regulated  in HtrA2  KO brain has been reported to be  induced  following stimulation 
with neurotoxins in vitro (Ryu et al.  2002;  Holtz and O'Malley 2003) and for CHOP 
also in vivo (Silva et al. 2005). Therefore, a transient stimulus with neurotoxins such as 
6-OHDA  and  MPP+  modulates  the  same  genes  found  up-regulated  in  HtrA2  KO 
brains, suggesting that the identified genes are potentially important in the development 
of PD. Interestingly, the genes modulated by 6-OHDA and MPP+ treatment, but none 
of the  genes  induced  by  treatment  with  6-OHDA  only,  were  up-regulated  in brains 
from mice lacking HtrA2 (Holtz and O'Malley 2003). Thus, genes that can be regulated 
through  the  shared  branch  of the  UPR  are  induced  in  models  of PD  as  diverse  as 
neuronal cells stimulated with neurotoxins in vitro and HtrA2 KO mice in vivo.
Loss of HtrA2 in combination with cellular stress appears to modulate at least a subset 
of the genes differentially expressed in HtrA2 KO brain, since a signature of genes is 
similarly regulated in cells treated with rotenone (Table 4-4). Therefore, it is possible 
that  the  region  where  the  neuronal  loss  is  detected  is  more  sensitive  to  the 
transcriptional  changes  or  that  these  commence  earlier  and  consequently  lead  to 
cellular demise. The transcriptional profile detected in the cortex tissue of HtrA2 KO 
mice might indicate that this region could suffer from loss of cells at a later stage, if the 
animals lived longer.  Similarly,  if the HtrA2  KO mice survived longer, other tissues 
could  be  affected  from the  stress  leading  to  induction  of CHOP.  For example,  high 
metabolic activity in skeletal muscle resulting from intense training of the mice might 
cause up-regulation of CHOP transcript.
Transcriptional  profiling  from  human  post-mortem  brain  tissue  of PD  patients  and 
normal controls has been performed ((Papapetropoulos and McCorquodale 2007) and 
references  therein).  None  of these  studies  identified  a  signature  of genes  that  had 
previously  been reported from the  use of neurotoxin-induced cellular models of PD. 
However,  the  human  studies  used  mostly  tissue  from  the  SN,  suggesting  that 
transcriptional differences detected might be due to loss of cells in the  SN  from PD 
patients. In addition, the results seem to vary between different studies and none of the 
top  candidate  genes  were  identified  in  another  study.  Therefore,  transcriptional
148profiling performed on brain regions other than the SN might be necessary to identify 
candidate genes and pathways that are deregulated in human PD patients before cellular 
demise occurs.
The induction of CHOP expression has previously been implicated in a mitochondrial 
stress response  (Zhao  et al.  2002).  Zhao  and colleagues used  a mutant  version  of a 
mitochondrial  matrix  enzyme  that  could  not  fold  properly  and  accumulated  in  the 
mitochondria.  In  their  study,  the  authors  noted  the  transcriptional  up-regulation  of 
nuclear genes encoding mitochondrial  stress proteins such as Hsp60,  HsplO, mtDnaJ 
and  ClpP.  CHOP  in  association  with  C/EBPp  did  regulate  the  expression  of those 
mitochondrial stress proteins via a CHOP element in their promoters (Zhao et al. 2002). 
None of the mitochondrial  stress proteins was differentially  expressed  in HtrA2  KO 
brain,  suggesting that the  type of stress  in  cells that  lack  HtrA2  might be  different. 
Thus,  loss  of HtrA2  seems  to  elicit  a  different  sort  of stress  than  accumulation  of 
unfolded proteins.
HtrA2  KO  mice  probably  suffer  from  enhanced  levels  of  oxidative  stress  since 
mitochondrial lipids from HtrA2 KO mice show a higher content of peroxidised lipids 
than WT mitochondria (Table 4-6). Also, HtrA2 KO cells produce more ROS than WT 
cells in response to rotenone and 6-OHDA (data not shown). In addition, the phenotype 
of HtrA2 KO mice is delayed by treatment with anti-oxidants (Figure 4-10). Oxidative 
stress had been placed upstream of the induction of CHOP and ATF3 in response to 6- 
OHDA (Holtz et al.  2006).  Therefore,  loss of HtrA2 might lead to the production of 
ROS  itself or  might  diminish  the  capacity  of the  cells  to  counteract  ROS,  which 
subsequently causes induction of CHOP and potentially other stress-induced genes.
How  could  loss  of  HtrA2  lead  to  increased  production  of  ROS?  In  light  of  the 
homology  of HtrA2 to the bacterial proteases DegP and DegS, two scenarios can be 
proposed.  By  assuming  a  DegP-like  function  for  HtrA2  it  could  be  postulated  that 
HtrA2 would be involved in clearance of unfolded proteins in the intermembrane space 
of the mitochondria. Therefore,  loss of HtrA2 proteolytic function would result in the 
accumulation  of unfolded  proteins,  possibly  members  of the  respiratory  complexes, 
which would lead to impaired electron transport and generation of ROS. Analogous to 
a DegS-like function, mammalian HtrA2 could be responsible for transducing a signal
149from  the  mitochondria  to  the  nucleus  resulting  in  increased  expression  of  other 
proteases  or  chaperones,  that  would  help  to  maintain  the  mitochondria  free  from 
misfolded  proteins.  Loss  of  HtrA2  would  therefore  decrease  the  availability  of 
proteases and folding catalysts in the mitochondria and in turn lead to accumulation of 
aberrant  proteins,  impaired  electron  transport  and  generation  of ROS.  A  DegS-like 
function for HtrA2 would be predicted from the similarity of their domain and more 
importantly their closely related crystal structures (Li et al. 2002; Martins et al. 2003) 
and would be favoured over a DegP-like model. Furthermore, bacterial DegS is known 
to  induce  expression  of DegP  (Erickson  and  Gross  1989),  supporting  the  idea  that 
HtrA2  would  normally  lead  to  the  expression  of  other  proteases  involved  in 
mitochondrial maintenance.
An increased content of peroxidised lipids was identified in mitochondria isolated from 
liver and brain tissue of HtrA2 KO mice,  however,  an increase in CHOP expression 
level was only detected in brain tissue.  This observation could certainly indicate that 
the increased expression of CHOP is not connected to the generation of ROS in HtrA2 
KO mice, however, a more favourable explanation is that liver cells are less susceptible 
to the oxidative  stress and therefore up-regulation of CHOP  in  liver or other organs 
cannot be detected within the  life-span of the HtrA2  KO  animals.  Similar to  CHOP 
expression being exclusively up-regulated in brain tissue although all cells are exposed 
to  loss  of HtrA2,  the  systemic  treatment  of rats  with  low  doses  of rotenone  leads 
selectively  to  lesions  in  the  nigrostriatal  system  (Betarbet  et  al.  2000;  Sherer  et  al. 
2003).
Treatment of HtrA2 KO mice with anti-oxidants results in prolonged life-span (Figure
4-10) and is also beneficial for the locomotor activity of the HtrA2 KO mice (Nicoleta 
Moisoi,  Miguel  Martins,  MRC  Leicester).  It  will  be  interesting  to  measure  CHOP 
expression  levels  in  HtrA2  KO  mice treated  with anti-oxidants.  Preliminary analysis 
was  performed  on  P30  animals,  however,  the  level  of CHOP  expression  was  only 
slightly  reduced  in  HtrA2  KO  mice  treated  with  NAC  compared  to  vehicle  treated 
HtrA2 KO mice.  These analyses need to be repeated and more importantly extended 
over a time course. It is possible that measuring CHOP expression levels at P30 is too 
late in the development of the parkinsonian syndrome, even in HtrA2 KO mice treated 
with  anti-oxidants.  HtrA2  KO  mice  as  young  as  PI5  did  show  increased  levels  of
150CHOP transcript, however, P8 mice did not. Therefore, CHOP expression levels should 
be monitored between P10 and P20  in HtrA2 KO mice treated with anti-oxidants or 
vehicle.
Taken together the data indicates that HtrA2 deficient cells are more susceptible to the 
induction of the TF CHOP in response to rotenone treatment. Moreover, transcriptional 
profiling of brain tissue from mice lacking HtrA2 validated the increased expression of 
CHOP  and  revealed  up-regulation  of a  signature  of genes  known  to  be  regulated 
through the shared branch of the UPR, namely the stabilisation of the TF ATF4. These 
genes  appear to  be  characterised  by  C/EBP-ATF  composite  sites  for transcriptional 
regulation.  A similar signature of genes was reported to be up-regulated in neuronal 
cells  following  stimulation  with  neurotoxins.  Therefore,  different  models  used  for 
studying PD, such as in vitro cell systems challenged with neurotoxins and in vivo the 
HtrA2  KO  mice,  share  up-regulation  of a  specific  signature  of genes.  Interestingly, 
another pathway often deregulated in PD, proteasome inhibition, was reported to result 
in activation  of one  of the  eIF2a  kinases,  GCN2,  and  increased phosphorylation of 
eIF2a (Jiang and Wek 2005), which would possibly also lead to induction of an ATF4- 
dependent signature of genes. Thus, the induction of this signature of genes might be a 
common  underlying  theme  in  PD  and  the  study  of the  upstream  pathways  should 
provide meaningful insight into the cellular mechanisms involved in the development 
of PD.
151Figure 4-1. Transcriptional analysis of rotenone-induced stress response 
in cells lacking HtrA2 using microarray technology.
(A)  Schematic  outline  of  the  samples  processed  for  microarray  analysis. 
Primary  MEFs  were  isolated  and  at  passage  4  subjected  to  treatment  with 
vehicle  or  1^M  rotenone  for  4hrs.  3  replicates  were  performed.  RNA  was 
isolated and samples were processed for hybridisation to Affymetrix MOE430A 
GeneChips  (12  samples  in  total).  Raw  data was  normalised  using  RMA  and 
analysed  using  Genespring  software.  A  restriction  on  fold  change  of  1.2-fold 
was applied and probe sets that were differentially expressed were selected by 
statistical analysis using one-way ANOVA. Conditions that were compared are 
highlighted.  WT  ut to WT rot  (green)  and  KO  ut to  KO  rot (blue):  Probe sets 
identified to be regulated by rotenone in WT or KO MEFs were then compared 
(dashed  line).  To  identify basal differences  between the genotypes,  WT  ut to 
KO ut were analysed (orange). Abbreviations: untreated (ut), rot (rotenone). (B) 
Quality control of isolated total  RNA from the MEFs, the resulting synthesised 
cRNA and  fragmented  cRNA for hybridisation to the GeneChip.  The samples 
from replicate 2 shown are representative of all samples.
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F = fragmented cRNAFigure 4-2. Rotenone induces a greater number of transcriptional 
changes in cells lacking HtrA2.
Probe sets regulated upon rotenone treatment in either WT or HtrA2 KO MEFs 
were identified by applying a 0.15 FDR. (A) The number of probe sets that are 
up-  or  down-regulated  are  listed.  (B) The  number  of probe  sets within  each 
fold-range are shown. The number of probe sets only regulated in WT or HtrA2 
KO,  as well  as the  probe sets that are  changing  in  WT as well  as  HtrA2  KO 
upon  rotenone treatment are shown.  (C) Venn diagram  illustrating the overlap 
of probe sets regulated by rotenone in WT and HtrA2 KO MEFs.
154A   WT rot / WT
Figure 4-2
KOrot/KO
probe sets up 83
probe sets down 47
total 130
probe sets up 429
probe sets down 609
total 1038
□   only WT
□   WT and KO 
H   only KO
530
500  -
< />
400  - 370
a   300  -
u.
s
A   200  -
E
3
C
100  ■
42 45
1.5-1.2  1.2-1.5 1.5-2 2 -3 >3 3 -2 2-1.5
fold down-regulated fold  up-regulated
Changes by Rot 
in WT
Changes by Rot 
in KOTable 4-1. Genes regulated in HtrA2 KO MEFs upon rotenone treatment.
Shown are genes that are  1.6-fold or more up- or down-regulated in  HtrA2 KO 
MEFs  following  treatment  with  rotenone.  The  total  list  comprises  969  probe 
sets  and  can  be found  on  the  CD with  supplementary data.  The first column 
shows  whether  the  protein  is  mitochondrial  or  not  (based  on  the  published 
literature as well as the prediction programme pSORT II: http://psort.nibb.ac.jp). 
Up-regulated genes are shown in red and down-regulated genes in green.
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mito
MEF KO 
Rot/None Gene Title Gene Symbol
no 2.70 Growth arrest and DNA-damage-inducible 45 alpha Gadd45a
no 1.91 Glucosamine-6-phosphate deaminase 1 Gnpdal
no 1.91 RIKEN cDNA 1810008K03 gene ChaCI
no 1.86 C/EBP homologous protein CHOP
no 1.76 Stanniocalcin 2 Stc2
no 1.68 Folliculin Flcn
no 1.68 ATPase, H+ transporting, V1 subunit B, isoform 2 Atp6v1b2
yes 1.64 Adenylate kinase 3 alpha-like 1 Ak4
no 1.63 RIKEN cDNA 4933427C19 gene 5830411G16Rik
no 1.62 Forkhead box G1 Foxgl
yes 1.62 Glutamic pyruvate transaminase (A aminotransferase) 2 Gpt2
no 1.60 Activating transcription factor 4 Atf4
no 0.63 tripartite motif protein 16 Trim16
no 0.62 Heat shock protein 2 Hspa2
no 0.62
Endothelial differentiation, sphingolipid G-protein-coupled 
receptor, 3 Edg3
no 0.62 Splicing factor, arginine/serine-rich 2 (SC-35) Sfrs2
no 0.62 Protein phosphatase 1, regulatory subunit 10 Ppp1r10
no 0.62 Thioredoxin domain containing 11 Txndc11
no 0.62 Chemokine orphan receptor 1 Cmkorl
no 0.60 Insulin-like growth factor 1 igfi
no 0.60 Platelet derived growth factor receptor, alpha polypeptide Pdgfra
no 0.60 StAR-related lipid transfer (START) domain containing 4 Stard4
no 0.59
ELOVL family member 6, elongation of long chain fatty 
acids (yeast) Elovl6
no 0.58
A disintegrin-like and metalloprotease (reprolysin type) with 
thrombospondin type 1  motif, 1 Adamtsl
no 0.58 Tubulin, alpha 3 Tuba3
no 0.58 RIKEN CDNA6720475J19 gene 6720475J19Rik
no 0.58 Synaptopodin Synpo
0.56 Expressed sequence AI448196 AI448196
no 0.55
Male sterility domain containing 2 / putative fatty acyl 
reductase Mlstd2
no 0.55 Tubulin, beta 2b Tubb2b
no 0.54 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (3x) Hmgcsl
no 0.53 Sterol O-acyltransferase 1 Soatl
no 0.52 Heat shock protein 1B (2x) Hspalb
no 0.49 Isopentenyl-diphosphate delta isomerase (2x) Idi1
no 0.42 Tubulin, beta 3 Tubb3
no 0.41 ADP-ribosylation factor 2 Arf2Figure 4-3. Rotenone results in enhanced up-regulation of CHOP in cells 
lacking HtrA2. Transient down-regulation of HtrA2 leads to CHOP 
induction without further stress stimulus.
(A)  CHOP  is  up-regulated  in  primary  HtrA2  KO  MEFs  upon  treatment  with 
rotenone, but not in WT MEFs treated in the same manner. MEFs were treated 
with vehicle or 1  |iM rotenone for 4hrs,  RNA was isolated and cDNA was used 
as a template for qPCR analysis. Transcript levels of CHOP were normalised to 
Actiny RNA levels and are shown relative to vehicle treatment. (B) CHOP is up- 
regulated  in  immortalised  HtrA2  KO  MEFs  by  rotenone  treatment.  Short 
treatment  with  rotenone  does  not  induce  CHOP  expression  in  WT  cells, 
however  it  causes  nearly  2-fold  induction  in  cells  lacking  HtrA2.  Prolonged 
treatment  for  8hrs  with  rotenone  leads  to  a  2.7-fold  in  WT  and  a  3.9-fold 
increase in HtrA2 KO MEFs. MEFs were treated with vehicle,  25jaM  for 3hrs or 
10^M rotenone for 8hrs,  RNA was isolated and cDNA was used as a template 
for qPCR analysis. Transcript levels of CHOP were normalised to Actiny RNA 
levels and are shown relative to vehicle treatment. (C) CHOP mRNA is induced 
by  transient  down-regulation  of  HtrA2.  HtrA2  was  down-regulated  using 
SmartPool  siRNA  (Dharmacon)  in  Neuro-2a  neuroblastoma  cells,  and 
immortalised WT and HtrA2 KO MEFs.  RNA was isolated and cDNA was used 
as a template for qPCR analysis.  Transcript levels of HtrA2  and  CHOP were 
normalised to Actiny RNA levels and are shown  relative to control siRNA.  The 
p-value was  calculated  using  a  two-tailed  unpaired  t-test.  The  data  shown  in 
this figure represent the mean ± standard deviation, n=3.
158Expression to control
O
< D
C
ro
a>
m
o
cn  -*■ cn ro
ro
cn
m
-n
*
O
o
o
< — ► H
o
t  '
I
t- H — 1  
o
I
o
o
*— ♦ "
o
X
ro
□ □
0   I
1  =r 
o  >
- g   ro
W
5
Z
>
■ O
II
p
o -u
r
o
t
 
r
o
t
 
u
t
 
r
o
t
 
r
o
t
 
3
h
 
8
h
 
3
h
 
8
h
Expression to ut  ^
ro
*
o
cn cn o
C i-*
o * -►
c «-►
-1
o
00
o ro w
C
r-*-
F
i
g
u
r
e
 
4
-
3Figure 4-4. CHOP expression is induced in brain tissue from mice 
lacking HtrA2.
(A)  CHOP  is  up-regulated  in  HtrA2  KO  brain tissue.  WT and  littermate  HtrA2 
KO mice were culled  at P22  and  brain  (B),  heart (H),  kidney (K) and  liver (L) 
were snap frozen.  RNA was  isolated from these tissues and  cDNA was  used 
as a template for qPCR  analysis.  Transcript levels  of HtrA2  and  CHOP were 
normalised  to Actiny  RNA  levels  and  are  shown  relative to WT 2.  Error  bars 
represent ± standard deviation of two replicates. The results from two mice for 
each genotype are shown. (B) CHOP is up-regulated  in HtrA2  KO brain tissue 
from mice at P15,  P18,  P21,  P27 and  P31. WT and  littermate HtrA2  KO mice 
were  culled  at  the  indicated  age  and  the  brain  was  snap  frozen.  RNA  was 
isolated  and  cDNA  was  used  as  a  template  for  qPCR  analysis.  Transcript 
levels of CHOP were normalised to Actiny RNA levels and are shown relative to 
the  corresponding  WT  littermate.  Error  bars  represent  ±  standard  deviation, 
n=3.  (C)  Induction  of CHOP  in  different areas of the brain  of HtrA2  KO  mice. 
WT and  littermate HtrA2  KO mice were culled at P27, the brain was dissected 
and  cortex  (C),  cerebellum  (CB)  and  basal  ganglia  (BG)  were  snap  frozen. 
RNA was isolated from these brain regions and cDNA was used as a template 
for qPCR  analysis.  Transcript  levels  of HtrA2  and  CHOP were  normalised  to 
Actiny  RNA  levels  and  are  shown  relative  to  WT  1.  Error  bars  represent  ± 
standard  deviation  of  two  replicates.  The  results  from  two  mice  for  each 
genotype are shown.
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4Figure 4-5. Genes differentially expressed in untreated HtrA2 KO MEFs 
compared to WT.
Probe  sets  showing  different  expression  levels  between  untreated  WT  and 
HtrA2  KO  MEFs  were  identified  by  applying  a  0.05  FDR  threshold.  (A)  The 
number of probe sets that are up- or down-regulated are listed. (B) The number 
of probe  sets within  each  fold-range  up-  or down-regulated  in  HtrA2  KO  are 
shown. (C) Selected genes differentially expressed in WT and HtrA2 KO MEFs 
were validated  by qPCR.  RNA was isolated from  immortalised WT and  HtrA2 
KO  MEFs  and  cDNA was  used  as  a  template  for  qPCR  analysis.  Transcript 
levels  of target genes were  normalised  to Actiny  RNA  levels  and  are  shown 
relative to WT. Error bars represent ± standard deviation, n=3.
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MEF
KO/WT Gene Title Gene Symbol
2.45 matrix metalloproteinase 13 Mmp13
2.14 monooxygenase, DBH-like 1 Moxdl
1.84 nephroblastoma overexpressed gene Nov
1.74 dermatopontin Dpt
1.61 tissue factor pathway inhibitor 2 Tfpi2
1.58 RIKEN cDNA 1110055J05 gene 1110055J05Rik
1.56 matrix metalloproteinase 9 Mmp9
1.48 tumor necrosis factor receptor superfamily, member 5 Tnfrsf5
1.57 pleiotrophin Ptn
1.39 fibroblast activation protein Fap
1.52 phospholipase A 2,  groupvil  (piatetet-activating factor acetytiydrolase) Pla2g7
0.80 caveolin 2 Cav2
0.78 nephronectin Npnt
0.65 interleukin 1   receptor-like 1 1 1 1  rl1
0.64 gap junction membrane channel protein beta 3 Gjb3
0.62 cytokine receptor-like factor 1 Crlfl
0.61 aryl-hydrocarbon receptor Ahr
0.61 mannan-binding lectin serine protease 1 Maspl
0.59 RIKEN cDNA A030007L17 gene A030007L17Rik
0.56 WNT1   inducible signaling pathway protein 2 Wisp2
0.52 interleukin 1   receptor antagonist 111m
0.57 insulin-like growth factor binding protein 4 Igfbp4
0.47 stathmin-like 2 Stmb2
0.53 gap junction membrane channel protein beta 2 Gjb2
0.50 chemokine (C-X-C motif) ligand 14 Cxcl14
0.46 annexin A8 Anxa8
0.49 procollagen, type X, alpha 1 Col10a1
0.46 coagulation factor C homolog (Limulus polyphemus) Coch
0.46 fibromodulin Fmod
0.47 chemokine (C-X-C motif) ligand 5 CxcIS
0.38 HtrA2 serine protease HtrA2
0.24 aquaporin 1 Aqpi
Table 4-2.  Genes differentially expressed in HtrA2 KO MEFs.
Shown are genes that are  1.5-fold or more up- or downregu- 
lated. The total list comprises 298 probe sets (supplementary 
data  CD).  Up-regulated  genes  are  shown  in  red  and  down- 
regulated genes in green.Figure 4-6. Transcriptional profiling of brain tissue from mice lacking 
HtrA2.
(A) Schematic outline of the samples processed for GeneChip analysis. Brains 
of WT and  HtrA2 KO littermates were dissected to obtain cortex tissue at P29. 
RNA was isolated and samples were processed for hybridisation to Affymetrix 
Mouse  Genome  2.0  GeneChips  (6  samples  in  total,  3  replicates  for  each 
genotype).  Raw  data  was  normalised  using  RMA  and  analysed  within 
Bioconductor  software.  Probe  sets  that  were  differentially  expressed  were 
selected by statistical analysis using one-way ANOVA and a FDR threshold of 
0.05 or 0.01.  (B)  Quality control of isolated total  RNA for each sample  run on 
an Agilent Bioanalyser.  Numbers correspond to the replicate.  (C) Vulcano plot 
showing all probe sets.  Probe sets passing 0.05 FDR threshold are highlighted 
in red. The x-axis records the KO/WT log2 ratio for each probe set, vertical lines 
show 2-fold  up- or down-regulation of expression. The y-axis plots the FDR in 
-log units, horizontal lines show 0.01, 0.05 and 0.1  FDR threshold respectively. 
(D)  0 .05  FDR  threshold:  The  number  of  probe  sets  that  are  up-  or  down- 
regulated in HtrA2 KO cortex are listed. (E) 0.01  FDR threshold: The number of 
probe  sets that are  up-  or down-regulated  in  HtrA2  KO  cortex  are  listed.  (F) 
The  number of probe sets within  a certain fold-range are shown for 0.05  and 
0.01  FDR threshold. The lower threshold omits probe sets that are  1.2- to 1.5- 
fold differentially expressed.
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198
200  -
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160
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45
40  -
14
2-1.5  1.5-1.2  1.2-1.5  1.5-2 2-3 >3 > 3 3-2
fold down-regulated fold  up-regulatedTable 4-3. Genes differentially expressed in brains from mice lacking 
HtrA2.
Genes differentially expressed in brains from HtrA2 KO mice were identified by 
applying  a  0.05  FDR  threshold.  The  complete  list  comprises  792  probe  sets 
and  can  be  found  on  the  CD  with  supplementary  data.  Genes  differentially 
expressed above 2.5-fold are shown  in this table.  Genes passing a 0.01  FDR 
threshold  are  highlighted  in  bold  and  italics.  The first column  shows whether 
the protein is mitochondrial or not (based on the published literature as well as 
the  prediction  programme  pSORT  II:  http://psort.nibb.ac.jp).  Up-regulated 
genes are shown in red and down-regulated genes in green.
167Table 4-3
mito?
Brain
KO/WT Gene Title Gene Symbol
no 4.76
solute carrier family 7 (cationic amino 
acid transporter) Slc7a3 /  CAT3
no 4.44 cytochrome b5 reductase 1 CybSrl /  Nqo3a2
. 4.23 cDNA clone C230029M16 C230029M16
no 3.62 C/EBP homologous protein CHOP
no 3.41
alanine-glyoxylate aminotransferase 2- 
like 1 Agxt2l1
_ 3.10 cDNA clone UI-M-DJ2-bwb-i-13-0-UI
yes 3.03
serine hydroxymethyl transferase 2 
(mitochondrial) Shmt2
no 2.88
inter-alpha trypsin inhibitor, heavy chain 
3 Itih3
no 2.85 pyrroline-5-carboxylate reductase 1 Pycrl
no 2.84
interferon-induced protein with 
tetratricopeptide repeats 3 If  it3
2.78 RIKEN cDNA 9330179D12 gene 9330179D12Rik
no 2.74 ubiquitin specific peptidase 18 Usp18
no 2.73 RIKEN cDNA 1810010H24 gene 1810010H24Rik
no 2.73 RIKEN cDNA 4930546H06 gene 4930546H06Rik
no 2.73 RIKEN cDNA 1110018M03 gene 1110018M03Rik
yes 2.69
methylenetetrahydrofolate 
dehydrogenase (NAD+ dependent) Mthfd2
no 2.69 FEV (ETS oncogene family) Fev
no 2.65 RIKEN cDNA 2410006H16 gene 2410006H16Rik
_ 2.60 RNA,  U22 small nucleolar Rnu22
no 2.58
angiotensinogen (serpin peptidase 
inhibitor, clade A, member 8) Agt
no 2.51 RIKEN cDNA 2310005L22 gene 2310005L22Rik
no 0.38
immunoglobulin heavy chain 6 (heavy 
chain of IgM) lgh-6
no 0.37 prostaglandin-endoperoxide synthase 2 Ptgs2
no 0.37
isopentenyl-diphosphate delta 
isomerase Idi1
no 0.36 Dermokine Dmkn
no 0.31
activity regulated cytoskeletal-associated 
protein Arc
no 0.27 histone 2, H3c2 Hist2h3c2
no 0.21 homer homolog 1 (Drosophila) (2x) Homerl
yes 0.21 HtrA serine peptidase 2 HtrA2Figure 4-7. Stress response in brain tissue from mice lacking HtrA2 is
similar to stress response elicited by rotenone treatment in MEFs.
Expression  ratio of (A)  HtrA2 and  (B) CHOP plotted for each of the three WT 
and  HtrA2  KO  cortex  samples  used  for  GeneChip  analysis.  (C)  RT  qPCR 
analysis  of  these  samples.  Transcript  levels  of  HtrA2  and  CHOP  were 
normalised to Actiny RNA levels and are shown relative to WT replicate  1.  (D) 
Venn diagram showing the overlap of probe sets that were regulated  in  MEFs 
upon rotenone treatment (0.15 FDR) and probe sets differentially expressed in 
WT and HtrA2 KO cortex (0.05 FDR). (E) Venn diagram showing the overlap of 
probe sets that were  regulated  in  MEFs  upon  rotenone treatment (0.15  FDR) 
and probe sets differentially expressed in WT and HtrA2 KO cortex (0.01  FDR).
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724
Changes by Rot 
in
WT vs KO Brain
(0.01 FDR)Table 4-4. Genes differentially expressed in brain tissue from HtrA2 KO
mice and regulated upon rotenone treatment in MEFs.
List of genes compiled from the overlap  between  probe sets that are  induced 
by rotenone in MEFs (0.15 FDR) and probe sets differentially expressed in WT 
and  HtrA2  KO  cortex  (0.05  FDR).  When  more than  one probe set for a gene 
was present, the number of probe sets is indicated next to the gene title. Genes 
that were found up-regulated by rotenone in MEFs but down-regulated in HtrA2 
KO cortex,  or vice versa, were left out.  Genes  in  bold  and  italics also passed 
the 0.01  FDR threshold in the analysis of the cortex samples. The first column 
shows  whether  the  protein  is  mitochondrial  or  not  (based  on  the  published 
literature as well as the prediction programme pSORT II: http://psort.nibb.ac.jp). 
Up-regulated  genes  are  shown  in  red  and  down-regulated  genes  in  green. 
Several  of  the  genes  found  to  be  up-regulated  in  HtrA2  KO  cortex  and  in 
rotenone  treated  MEFs  have  been  previously  described  to  be  induced  in 
response to ER stress dependent on the TF ATF4 (marked by an arrow next to 
the gene symbol in the last column).
171Table 4-4
mito
Brain
KO/WT
MEF KO 
Rot/None Gene Title Gene Symbol
no 3.62 1.85 C/EBP homologous protein CHOP  < —
yes 3.04 1.25
serine hydroxymethyl transferase 
2 (mitochondrial) Shmt2
yes 2.70 1.32
methylene-THF dehydrogenase 
(NAD* dep), cyclohydrolase (2x) Mthfd2  < r -
no 2.29 1.91
ChaC, cation transport regulator­
like 1 (E. coli) ChaC1
no 2.16 1.32 plexin domain containing 1 Plxdcl
no 1.97 1.51
D site albumin promoter binding 
protein (2x) Dbp
no 1.92 1.21
eukaryotic translation initiation factor 
4E binding protein 1 Eif4ebp1  —
no 1.87 1.20
solute carrier family 7 (cationic aa 
transporter, y+ system), member 5 Slc7a5  < —
no 1.86 1.28
seryl-aminoacyl-tRNA synthetase 
(2x) Sars  < —
no 1.85 1.24 asparagine synthetase (2x) Asns  < —
no 1.75 1.29 phosphoserine phosphatase Psph  < —
no 1.68 1.22 sorbitol dehydrogenase Sord
yes 1.67 1.24
phosphoenolpyruvate carboxykinase 2 
(mitochondrial) Pck2  < —
no 1.67 1.33 Kruppel-like factor 5 Klf5
no 1.59 1.26 H2A histone family, member Y3 H2afy3
no 1.49 1.22
(glutamate/neutral aa transporter), 
member 4 Slc1a4
no 1.49 2.06 tribbles homolog 3 (Drosophila) Trib3  ^
no 1.44 1.33 activating transcription factor 3 Atf3  < —
no 1.39 1.30
sic 3 (activators of dibasic and neutral 
aa transport), member 2 Slc3a2 / Dnajc3
no 1.37 1.37 brain protein 1 3 Bri3
no 1.36 1.31 rhomboid domain containing 1 Rhbddl
no 1.33 1.21 vacuolar protein sorting 11  (yeast) Vps11
no 1.29 1.23 RIKEN cDNA 1810031K17 gene 1810031K17RikTable 4-4
mito
Brain
KO/WT
MEF KO 
Rot/None Gene Title Gene Symbol
no 0.78 0.75 ubiquitin associated protein 2-like Ubap2l
no 0.75 0.74 f-box only protein 9 Fbxo9
no 0.75 0.74 cAMP-regulated phosphoprotein 19 Arpp19
no 0.74 0.80 transmembrane protein 167 Tmem167
no 0.73 0.59
ELOVL family member 6, elongation of 
long chain fatty acids (yeast) Elovl6
no 0.72 0.70 transmembrane protein 119 Tmem119
no 0.72 0.82 histone 1, H2bp Hist1h2bp
no 0.71 0.75 regulator of G-protein signaling 4 Rgs4
no 0.70 0.80 apurinic/apyrimidinic endonuclease 2 Apex2
no 0.69 0.47 tubulin, beta 2c Tubb2c
no 0.68 0.70 tribbles homolog 2 (Drosophila) Trib2
no 0.68 0.82 RIKEN cDNA 1110057K04 gene 1110057K04Rik
no 0.67 0.66 tubulin, alpha 4 (2x) Tuba4
no 0.67 0.77 7-dehydrocholesterol reductase Dhcr7
no 0.63 0.82 cyclin D1 Ccndl
no 0.63 1.34 poliovirus receptor Pvr
yes? 0.59 0.68 mesoderm specific transcript Mest / Peg1
no 0.58 0.73 histone 2, H3c1 Hist2h3c1
no 0.56 0.72 squalene epoxidase Sqle
no 0.53 0.53 heat shock protein 1B (3x) Hspalb
no 0.52 0.57
HMG-CoA synthase 1 (soluble) 
(4x) Hmgcsl
no 0.48 0.66 low density lipoprotein receptor Ldlr
no 0.44 0.65
StAR-related lipid transfer 
(START) domain containing 4 (2x) Stard4
no 0.41 0.72 cytochrome P450, family 51 Cyp51
no 0.37 0.50
isopentenyi-diphosphate delta 
isomerase (2x) Idi1Figure 4-8. ATF3 and Herp are induced in brain tissue from mice lacking 
HtrA2.
ATF3 and  Herp are up-regulated  in  HtrA2  KO  brain tissue.  WT and  littermate 
HtrA2  KO  mice were  culled  at  P27,  the  brain  was  dissected  to  obtain  cortex 
and basal ganglia tissue which were snap frozen. RNA was isolated and cDNA 
was used as a template for qPCR analysis. Transcript levels of CHOP, ATF3, 
Herp,  KLF5 and  Hsp60 were  normalised to Actiny  RNA levels and  are shown 
relative to WT  1.  Error bars  represent ± standard  deviation  of two  replicates. 
The results from two mice for each genotype are shown. The p-values for the 
increase  in  Herp  expression  in  HtrA2  KO  mice  compared  to  WT  were 
calculated using a two-tailed unpaired t-test.
Figure 4-9. C/EBP-ATF composite sites.
Alignment  of C/EBP-ATF  composite  sites  (also  known  as AARE,  amino  acid 
response element or NRSE, nutrient-sensing response element) with its related 
elements, the variant ATF/CRE and palindromic C/EBP sites. The C/EBP-ATF 
composite sites in the promoters of CHOP, ATF3,  Herp, ASNS and TRB3 are 
shown, revealing the consensus sequence: TT(G/T)CATCA.
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variant ATF/CRE 
palindromic C/EBP 
CHOP promoter AARE 
ATF3 promoter 
Herp promoter 
ASNS promoter NRSE1 
TRB3 promoter AARETable 4-5. Presence of C/EBP-ATF composite sites in the sequence of 
selected genes that are higher expressed in brains from HtrA2 KO mice.
(A) Genes containing perfect C/EBP-ATF composite sites with no mismatch to 
the consensus sequence TT(G/T)CATCA. Alignment of the mouse with human 
sequence shows that all of the sites are conserved without any mismatch. (B) 
Genes  containing  C/EBP-ATF  composite  sites  with  one  mismatch  from  the 
consensus  sequence.  Alignment  of the  mouse  and  human  sequence  shows 
perfect  alignment  between  both.  The  mismatch  from  the  consensus  C/EBP- 
ATF composite site is highlighted in red.  For sites in TRB3, H2afy3 and Sord a 
mismatch was present in the mouse sequence, however, the human sequence 
did contain a perfect consensus site.
176Gene Symbol
C/EBP-ATF site 
(bp from TSS) sequence location
CHOP -318 TTGCATCA promoter
ASNS -50 TTTCATCA promoter
ATF3 60 TTGCATCA 5' UTR
Herp -183 TTGCATCA promoter
1406 TTGCATCA intron
4174 TTGCATCA intron
Shmt2 469 TTGCATCA intron
Mthfd2 -417 TTTCATCA promoter
ChaCI -884 TTGCATCA promoter
Slc7a5 9070 TTGCATCA intron
Sara 961 TTGCATCA intron
PSDh 8371 TTGCATCA 5' UTR
Stc2 -1632 TTTCATCA promoter
-952 TTGCATCA promoter
562 TTTCATCA intron
Btf3l4 -519 TTGCATCA promoter
Klf5 2407 TTGCATCA intron
Rhbddl -899 TTTCATCA 5' UTR
61.280 TTTCATCA intron
AARS -237 TTGCATCA promoter
NARS 8 TTGCATCA 5' UTR
MARS 9335 TTTCATCA intron
Brcal 42,463 TTTCATCA intron
TRB3 -22 TTACATCA 5' UTR
H2afv3 11.867 TTTTATCA 5' UTR
Sord 26,415 TTGCAGCA intron
6483 TTTCAGCA intron
Klf5 2035 TTTCATTA intron
Rhbddl -899 TTTCATCA 5' UTR
35.226 TTTCTTCA intron
Plxdcl 6466 TTTCATCT intron
22.222 TGTCATCA intron
Dbp -1893 CTTCATCA promoter
-1940 TTTCTTCA promoter
Erf4ebo1 -884 TTGCATGA promoter
Pck2 -103 TTACATCA promoter
Slc1a4 -2584 TGTCATCA 5' UTR
18,847 CTTCATCA intron
24.605 CTTCATCA exon
Vos11 3497 GTTCATCA exon
1810031 K17Rik -1120 TTTCTTCA promoter
2918 CTTCATCA exon
YARS -660 TTTCCTCA promoter
19,802 CTTCATCA intron
MARS -1714 TGTCATCA promoter
CARS 3751 TTGCTTCA intron
40.919 TTTCATCA intron
LARS 5,394 TTTTATCA intron
8,870 TTTCTTCA intron
9,204 TTGCCTCA intron
10.832 TTTCTTCA intron
Slc6a9/Glyt1 22 TTTCACCA 5' UTR
3364 CTTCATCA intron
Brcal 28.463 TTTAATCA intron
Grp75/Hspa9a -342 TTGCGTCA intronTable 4-6. Amount of peroxidised lipids is increased in mitochondria from 
mice lacking HtrA2.
Mitochondria  were  isolated  to  high  purity  from  WT  and  HtrA2  KO  livers. 
Quantitative  analysis was  performed  by  mass  spectrometry to  determine  the 
amount  of  peroxidised  lipids.  The  data  was  normalised  to  the  major 
phosphatidyl choline, that is PO-PC (m/z 758), which was in turn normalised to 
other reference ions like C-24 Ceramide (m/z 685). m/z:  mass-to-charge ratio. 
Mass spectrometry of the lipids was performed by Mauro D Esposti,  University 
of Manchester.
Figure 4-10. Anti-oxidant treatment of mice lacking HtrA2 delays their 
phenotype.
HtrA2  KO  mice were treated  post-birth with vehicle or NAC and their survival 
was monitored.  Directly after birth  until  P6 the mothers were fed with drinking 
water  containing  1  mg/ml  NAC.  From  P6  until  weaning  at  P20  the  pups  did 
receive oral administration of NAC (200mg/kg body weight). From P20 onwards 
the young  mice were fed with drinking water containing  1  mg/ml  NAC.  Control 
n=13,  NAC  treatment  n=7.  These  experiments  were  performed  by  Nicoleta 
Moisoi and Miguel Martins (MRC Leicester).
178Table 4-6
m/z peroxidised  lipids WT KO
301 arachidonate 16.6 40.1
331 lipoxin-like 8 43
353 lipoxin-like 7.8 53.2
365 ultraperoxidised arachidonate 170 280
381 ultraperoxidised arachidonate 25 106.7
Figure 4-10
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Age (post-natal days)Figure 4-11. Ucf-101  inhibits HtrA2 proteolytic activity and protects cells 
from death stimulus.
(A)  Ucf-101  inhibits  HtrA2  protease  activity.  Recombinant  HtrA2  was  pre­
incubated with the indicated concentrations of Ucf-101  for  15min  on  ice. After 
addition  of  the  fluorescent  substrate,  the  increase  in  fluorescence  was 
monitored  on  a  CytoFluor  multi-well  plate  reader  (PerSeptive  Biosystems). 
Protease  activity  (arbitrary fluorescence  units/min) were  determined  by  linear 
regression analysis of the data points corresponding to the maximum reaction 
rates  for  each  assay  condition.  The  relative  protease  activity  to  control  is 
shown.  Error  bars  represent  +  standard  deviation,  n=3.  (B)  Ucf-101  protects 
cells from staurosporine-induced cell death.  Immortalised WT MEFs were pre­
treated  with  50jiM  or  70^M  Ucf-101  for  20min,  then  vehicle  or  2j a M 
staurosporine were added for another 4hrs. Cells were harvested, stained with 
anti-Annexin V Alexa 647 and PI, and were analysed by FACS. The percent of 
Annexin  V-positive  cells  is  shown.  Error  bars  represent  ±  the  range  of  two 
determinations.
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HtrA2 KO MEFs.
(A) Ucf-101  induces CHOP and (B) ATF3 mRNA. Total RNA was isolated from 
HtrA2 WT and KO MEFs treated with vehicle or Ucf-101  for 1h or 2hrs or with 
tunicamycin  (Tunic) for 2hrs.  cDNA was synthesised  and  used  as a template 
for  qPCR  analysis.  Transcript  levels  of  (A)  CHOP  and  (B)  ATF3  were 
normalised  to  Actiny  RNA  levels  and  are  shown  relative  to  vehicle  treated 
control.  Error bars represent + the  range of two determinations.  (C)  Neuro-2a 
cells  were  treated  with  50nM  Ucf-101  for  4hrs.  RNA  was  harvested,  cDNA 
synthesised  and  used  as  a  template for  qPCR  analysis.  Transcript  levels  of 
CHOP and ATF3 were normalised to Actiny RNA levels and are shown relative 
to  vehicle  treated  control.  Error  bars  represent  ±  the  range  of  two 
determinations.
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(A)  Whole  cell  lysate was  prepared  from  HtrA2  WT  and  KO  MEFs  following 
treatment  with  vehicle,  Ucf-101,  tunicamycin  (Tunic,  2hrs)  or  thapsigargin 
(Thapsi, 30min). Proteins were separated on SDS-PAGE and detected with the 
indicated antibodies by Western blot. (B) NF-kB is not activated in response to 
Ucf-101.  WT andH2  KO MEFs were treated as in  (A),  in addition as a control 
for NF-kB activation cells were treated with TNFa for 5min.
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3Figure 4-14. Ucf-101  effect is probably not mediated through inhibition of 
other HtrA family members.
(A)  HtrA1,  HtrA3  and  HtrA4  transcript  levels  are  not  increased  in  HtrA2  KO 
MEFs compared to WT.  RNA was  isolated,  cDNA was synthesised  and  used 
as a template for qPCR analysis. Transcript levels of HtrA1,  HtrA3 and  HtrA4 
were normalised to Actiny RNA levels and are shown relative to WT. Error bars 
represent ± standard deviation  of replicates.  (B)  HtrA4  is secreted  from  cells. 
HEK293 cells were transfected with HtrA2 or HtrA4-HA expression constructs. 
The medium and cells were  harvested 48hrs after transfection,  processed for 
SDS-PAGE  and  Western  blot.  Primary  antibodies  used  for  detection  were 
against the HA tag of HtrA4-HA or HtrA2.
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Table 4-7. List of probe sets regulated in WT MEFs by rotenone 
treatment.
Probe  sets  modulated  by  rotenone treatment  in  WT  MEFs were  identified  by 
applying a 0.15 FDR threshold.
Table 4-8. List of probe sets regulated in HtrA2 KO MEFs by rotenone 
treatment.
Probe sets modulated by rotenone treatment in HtrA2 KO MEFs were identified 
by applying a 0.15 FDR threshold.
Table 4-9. List of genes differentially expressed in untreated HtrA2 KO 
MEFs compared to untreated WT MEFs.
Probe sets differentially expressed  in  untreated  HtrA2  KO  MEFs compared to 
untreated WT MEFs were identified by applying a 0.05 FDR threshold.
Table 4-10. List of genes differentially expressed in brain tissue from 
HtrA2 KO mice compared to WT controls.
Probes sets differentially expressed in HtrA2 KO cortex tissue compared to WT 
were identified by applying a 0.05 FDR threshold. Probe sets that withstand the 
0.01  FDR threshold are highlighted in bold.
Up-regulated genes are shown in red and down-regulated genes in green.
1885  Chapter  5:  HtrA2  is  regulated  by  PINK1,  a  kinase 
implicated in Parkinson’s disease
5.1  Introduction
Apart from HAX-1, all proteins reported to interact with or to be cleaved by HtrA2 are 
non-mitochondrial proteins (Suzuki et al. 2001; Cilenti et al. 2004; Gupta et al. 2004; 
Park et al. 2004; Trencia et al. 2004; Kuninaka et al. 2005; Sekine et al. 2005; Hong et 
al.  2006).  However,  HtrA2  function  seems  to  be  essential  for  protection  of 
mitochondrial  function  in  vivo  (Jones  et  al.  2003;  Martins  et  al.  2004),  therefore 
identification of proteins interacting with HtrA2  in the mitochondria might elucidate 
the pathway in which HtrA2 is involved. Unfortunately, the unequivocal identification 
of mitochondrial substrates of HtrA2 using the 2D DIGE approach was not successful 
(see  Chapter  3.7).  The  Tandem  Affinity  Purification  (TAP)  tag  system  allows  the 
purification of protein complexes under native conditions (Rigaut et al.  1999). In this 
chapter,  a  TAP  tagged  version  of HtrA2  is  generated  and  purified  complexes  are 
screened for the presence of mitochondrial proteins. This leads to the identification of a 
novel  interaction  partner  for  HtrA2,  the  PD-associated  putative  kinase  PINK1. 
Furthermore, HtrA2 is found to be phosphorylated and PINK1  appears to be important 
for this phosphorylation event to occur. Phosphorylation of HtrA2 is likely to modulate 
its  proteolytic  activity  and  this  might  contribute  to  increased  resistance  of cells  to 
stress-induced apoptosis.
5.2  PINK1 interacts with HtrA2
In  order  to  identify  interacting  proteins  of HtrA2,  the  TAP  tag  system  was  chosen 
(Rigaut  et  al.  1999).  The  TAP  tag  consists  of three  components.  The  first  element 
consists of tandem Protein A epitopes, which allows efficient recovery of the tagged 
protein  and  associated  components  by  affinity  purification  on  an  IgG-linked  bead 
matrix. This is followed by a cleavage site for the TEV protease, which allows specific 
elution from the matrix under native conditions. The second element in the tag consists 
of a calmodulin binding protein (CBP) epitope, which allows a second round of affinity 
purification  on  a  calmodulin-coated  bead  matrix.  After  washing,  bound  material  is 
again eluted under native conditions, this time by a chelation of Ca2+ ions with EGTA. 
The  eluted  tagged  proteins,  together  with  any  co-purifying  proteins,  can  then  be
189analysed by SDS-PAGE followed either by Western blotting or mass spectrometry.
A TAP tag was added to the C-terminus of full length HtrA2, and the catalytic serine 
was mutated to alanine (S306A) in order to abolish the proteolytic activity of HtrA2 
which  could  interfere  with the  purification  process  by  cleaving  interacting  proteins. 
HtrA2-TAP was stably expressed in HEK293 cells, and HtrA2 along with interacting 
proteins was purified. Using 33  antibodies raised against a range of 28 mitochondrial 
proteins as well as an anti-XIAP antibody as a positive control, the purified fraction 
containing  HtrA2  was  analysed  by  Western  blotting  (Table  5-1).  HAX-1,  a protein 
previously  shown to  interact  with  HtrA2  (Cilenti  et al.  2004)  was  found  to  be  co­
purified, as well as XIAP, demonstrating the validity of this approach (Figure 5-1 A). 
From the proteins tested,  one other protein was found to  co-purify  with  HtrA2,  the 
putative mitochondrial kinase PINK1  (Figure 5-1B). Mutations in the PINK1  gene are 
associated with the recessive parkinsonism locus PARK6 (Table  1-1).  Initially, three 
pedigrees were described with identified mutations: a G309D point substitution in one 
family and a truncation mutation (W437X)  in two additional families (Valente et al. 
2004).  Subsequently,  several  studies  have  described  other  point  mutations  or 
truncations (Figure  1-7) (Hatano et al.  2004;  Rogaeva et al.  2004; Rohe  et al.  2004; 
Bonifati et al. 2005; Li et al. 2005). Given that dysfunction in both HtrA2 and PINK1 
have been associated with neuronal degeneration in mammals, the putative interaction 
between  these  two  might  be  physiologically  important.  To  confirm  the  interaction 
between endogenous PINK1  and HtrA2,  endogenous HtrA2 was immunoprecipitated 
from  lysates  prepared  from  WT  and  HtrA2  KO  MEFs.  When  purified  HtrA2 
immunoprecipitates  were  probed  with  an  anti-PINKl  antibody,  endogenous  PINK1 
could  be  detected  in  complexes  purified  from  WT  but  not  from  HtrA2  KO  MEFs, 
further  confirming  the  specificity  of  the  interaction  (Figure  5-1C).  Next,  co- 
immunoprecipitation experiments from  lysates prepared from cells  subjected to  sub- 
cellular  fractionation  were  performed.  Such  experiments  showed  that the  interaction 
between  endogenous  HtrA2  and  exogenously  expressed  PINK1  is  detected 
predominantly  in  mitochondria-enriched  fractions  indicating  that  the  interaction  is 
likely to occur in the mitochondria (Figure 5-ID).
1905.3  HtrA2  is  phosphorylated  on  serine  142  in  response  to 
MEKK3 activation
A mutation screen of the HtrA2 gene performed in German PD patients recently led to 
the  identification  of  a  heterozygous  G399S  mutation  as  well  as  an  A141S 
polymorphism that was associated with the disease (Strauss et al. 2005). The identified 
mutations localise to domains previously shown to be important in the regulation of the 
proteolytic activity of HtrA2 (Martins et al. 2003), namely the PDZ domain and the N- 
terminal  portion  of the  mature  form  of HtrA2,  respectively.  An  analysis  using  the 
Scansite algorithm (Obenauer et al. 2003) (www.scansite.mit.edu) indicates that SI42 
and  S400,  residues that  lie  immediately  adjacent to  the  mutations  found  in the  PD 
patients, are putative phosphorylation sites for proline-directed serine/threonine kinases 
(Figure 5-2A). According to Scansite, SI42 is a putative phosphorylation site for Cdc2, 
Cdk5, ERK1  and p38, and S400 is a putative phosphorylation site for Cdc2 and Cdk5. 
Alignment of HtrA2 homologues of different species shows that SI42  and S400  are 
conserved in human, rodents and chicken, and in addition S400 is further conserved in 
fly and baker’s yeast (Figure 5-2B).
Subsequently,  antibodies  that  specifically  recognise  HtrA2  phospho-peptides  were 
raised.  Peptides  surrounding  SI42  and  S400  were  synthesised  incorporating  a 
phoshporylated serine at these sites. The phospho-specific S400 HtrA2 antibody did not 
recognise  S400,  however,  the  phospho-specific  SI42  HtrA2  antibody  showed  an 
unambiguous signal when used for Western blotting.  The specificity of the phospho- 
S142 antibody was tested on lysates from cells over-expressing WT and SI42A mutant 
HtrA2  (Figure  5-3C),  and  additionally  on  recombinant  HtrA2  that  had  been 
phosphorylated  in  vitro  using  p38y  (data  not  shown).  To  test  if  HtrA2  could  be 
phosphorylated  on  SI42,  HEK293  and  NIH  3T3  cell  lines  expressing  4-hydroxy- 
tamoxifen  (40H-Tx)  inducible  versions  of  MEKK3,  Akt  and  Raf  (AMEKK3:ER, 
myrAkt:ER,  ARaf-DD:ER)  were  employed.  Lysates  were  then  prepared  from  cells 
where  MEKK3,  Akt and  Raf had been activated with 40H-Tx and probed  with the 
phospho-S142 HtrA2 (P-HtrA2) antibody. These experiments showed that activation of 
MEKK3,  but  not  Akt  or  Raf,  induced  efficient  phosphorylation  of HtrA2  on  SI42 
(Figure 5-2C). Activation of downstream signalling pathways of MEKK3, Akt and Raf 
were  detected by  determining  the phosphorylation  status of Akt,  ERK1/2,  JNK  and
191p38. Induction of MEKK3  resulted in strong activation of p38 and JNK and weaker 
activation  of ERK,  whereas  Raf induction  led  to  strong  activation  of ERK1/2  and 
weaker activation of JNK and p38 (Figure 5-2C).
The compound BIRB796 is a broad-spectrum inhibitor of all p38 MAPK isoforms in 
vitro  and  in vivo  (Kuma et al.  2005).  To test  if chemical  inhibition  of p38  affected 
MEKK3-dependent  phosphorylation  of HtrA2,  AMEKK3:ER  expressing  cells  were 
treated with increasing concentrations of BIRB796  and the levels of phosphorylated 
HtrA2  and  p38  were  analysed.  These  experiments  showed  that  pre-treatment  with 
BIRB796 partially decreased the levels of detected P-p38 and P-HtrA2, suggesting that 
p38 activity might be important for the phosphorylation of HtrA2 (Figure 5-2D).
To test whether purified HtrA2 could be phosphorylated by any of the four isoforms of 
p38, in vitro kinase assays using recombinant HtrA2 and p38 were performed. These 
experiments revealed that HtrA2 could be predominantly phosphorylated by p38y and 
also by p38p although not by the two  other p38  isoforms p38a and p386 (data not 
shown, Helene Plun-Favreau). In order to determine the position of the phosphorylation 
sites  on  HtrA2  in  these  in  vitro  assays,  mass  spectrometric  analysis  of  in  vitro 
phosphorylated HtrA2 by p38y was performed. This analysis detected a phospho-serine 
at positions 137 and 142 (data not shown). Since SI37 is not conserved in other species 
than human (Figure 5-2B), this site was not analysed any further. Due to the behaviour 
of the  S400-containing  peptide  in  mass  spectrometric  analysis,  the  phosphorylation 
state of this site could not be addressed directly.
It is possible that PINK1, previously  shown to interact with HtrA2 (Figure  5-1) and 
reported to possess kinase activity (Beilina et al. 2005; Silvestri et al. 2005; Sim et al. 
2006), might phosphorylate HtrA2 directly. In order to determine if PINK1  is able to 
phosphorylate  HtrA2,  in  vitro  kinase  assays  using  purified  PINK1  produced  in  a 
baculovirus expression system were performed. However, the in vitro kinase activity of 
PINK1  was  relatively  weak,  and  a  theoretically  kinase  inactive  mutant  of  PINK1 
(K219D, abolishing one of the catalytically active residues) exhibited similar activity 
towards HtrA2 (data not  shown),  suggesting that co-purifying proteins might exhibit 
this activity rather than PINK1 itself. From these assays it is not possible to conclude if
192PINK1 can phosphorylate HtrA2 directly.
5.4  PINK1 modulates the levels of phosphorylated HtrA2
The data presented so far suggest that HtrA2 physically interacts with PINK1  and that 
activation  of  MEKK3  is  involved  in  a  signalling  pathway  that  leads  to  HtrA2 
phosphorylation.  Therefore,  PINK1  could  modulate  the  phosphorylation  of  HtrA2 
induced  by  MEKK3.  For  the  purpose  of down-regulating  PINK1,  siRNA  targeting 
PINK1 was employed, which led to a significant decrease of both PINK1 transcript and 
protein levels (Figure 5-3A). Down-regulation of PINK1  also resulted in a decrease in 
HtrA2 phosphorylation level, suggesting that PINK1  is capable of modulating HtrA2 
phosphorylation (Figure 5-3B). Over-expression of PINK1 protein together with WT or 
SI42A HtrA2 showed loss of the P-HtrA2 signal when SI42A HtrA2 was expressed 
(Figure  5-3C).  Next,  the  role  of  PINK1  in  the  modulation  of  MEKK3-induced 
phosphorylation of HtrA2 was assessed. Activation of MEKK3 in cells where PINK1 
was down-regulated led to a clear decrease in the level of P-HtrA2 compared to control 
siRNA transfected cells (Figure 5-3D), suggesting that PINK1 could be implicated in a 
signalling  pathway  leading  to  phosphorylation  of  HtrA2  that  can  be  induced  by 
MEKK3.
If PINK1  plays a role in phosphorylation of HtrA2 in vivo, the phosphorylation status 
of HtrA2 might be altered in PD patients carrying mutant PINK1. Initially, a range of 
human brain regions (cortex, striatum (caudate nucleus and putamen), SN, cerebellum) 
were  screened  for  P-HtrA2,  and  it  was  detected  most  prominently  in  the  caudate 
nucleus, which is the medial part of the striatum (data not shown). Next, the levels of 
phosphorylated HtrA2 in the caudate of brains with idiopathic PD and brains with PD 
associated with  mutations  in the  PINK1  gene  (Y431H  and  C575R)  were  compared. 
This analysis revealed a striking decrease in P-HtrA2 in brain tissue from PD patients 
with PINK l mutations compared to idiopathic PD (Figure 5-3 E).
5.5  Mutations  mimicking phosphorylated HtrA2  enhance  its 
protease activity
To determine whether HtrA2 phosphorylation might affect its proteolytic activity, SI42 
and S400 of HtrA2 were mutated into aspartate to mimic phosphorylation of these sites.
193The activity of these phospho-mimic mutants was compared to WT HtrA2 in an in vitro 
protease  assay  previously  described  (Martins  et  al.  2003).  Comparison  of the  basal 
activity  of  WT,  S142D  and  S400D  mutants,  revealed  that  both  phospho-mimic 
mutations induced a marked increase in the ability of HtrA2 to cleave the fluorogenic 
substrate peptide.  The proteolytic  activity  of HtrA2  is  increased  about  2-fold  in the 
S142D phospho-mimic mutant and 3-fold in case of the S400D mutant (Figure 5-4A). 
To control for the effect of introducing any mutation at residues SI42 and S400 rather 
than  an  effect  specific  to  the  phospho-mimetic  aspartate,  these  residues  were 
additionally mutated to an alanine. Both, SI42A and S400A, showed markedly lower 
protease activity when compared to their phospho-mimic counterparts (Figure 5-4A). 
Quality control on the different HtrA2 mutants was performed by SDS-PAGE analysis 
(Figure 5-4A) and gel filtration (data not shown). Furthermore, the proteolytic activity 
of HtrA2 can be activated by engagement of its PDZ domain by PDZ-binding peptides 
or by interaction of its mature N-terminus with XIAP (Martins et al. 2003). Therefore, 
the ability of these stimuli to activate the phospho-mimic mutants of HtrA2 was tested. 
The optimal HtrA2 PDZ domain-interacting peptide, termed PDZopt,  and also XIAP 
both caused a major increase  in the reaction rate and  loss of the  initial time  lag for 
cleavage of the HtrA2  substrate peptide by  WT  HtrA2  (Figure  5-4B).  However, the 
protease  activity  of the  S400D  mutant  of HtrA2,  and  to  a  lesser  extent the  S142D 
mutant,  is  already close to  its  maximum rate  without any  stimulus  and  can be only 
minimally activated further by PDZopt or XIAP (Figure 5-4C).  When the amount of 
the phospho-mimic mutants in this assay was titrated down, so that their activity was 
similar to that of a higher concentration of WT HtrA2, the PDZopt peptide or XIAP 
still only minimally activated their proteolytic activity (Figure 5-4B, shown only for 
S400D), demonstrating the sensitivity of the assay.
The  PDZ  domain  of HtrA2  usually  restrains  the  protease  activity,  possibly  through 
restricting  access  to  the  catalytic  centre  (Li  et  al.  2002;  Martins  et  al.  2003)  or 
alternatively  by  trapping  a  flexible  activator  binding  loop  (L3  loop)  in  an  inactive 
conformation (Wilken et al.  2004).  Binding of peptides to the PDZ domain probably 
results in a conformational change that improves substrate access to the catalytic centre 
(Wilken et al.  2004). The data presented here would suggest that phosphorylation of 
HtrA2  in the  PDZ  domain  might  lead  to  a  similar  conformational  effect.  Likewise,
194binding of XIAP to the N-terminus of mature HtrA2 leads to its activation (Martins et 
al. 2003), therefore phosphorylation on SI42 close to its mature N-terminus might have 
a similar effect.
5.6  Establishment of ex vivo HtrA2 protease assay
In order to measure the proteolytic activity of HtrA2 ex vivo, the protease assay was 
tested  on  exogenously  expressed  or  endogenous  HtrA2  immunoprecipitated  from 
HtrA2 KO MEFs or HEK293 cells. Over-expression of active or catalytically inactive 
(S306A) HtrA2 in cells lacking HtrA2, followed by immunoprecipitation and in vitro 
protease assay showed that this assay worked on HtrA2 ex vivo, albeit the assay time 
needed  to  be  longer  to  reach  maximal  activity  (Figure  5-5A).  No  unspecific 
background  activity  of  co-purifying  proteins  was  detectable,  suggesting  that 
immunoprecipitates of HtrA2 were clean. Endogenous HtrA2 immunoprecipitated from 
HEK293 cells could also be subjected to this assay, and its proteolytic activity could be 
increased by incubation with the PDZopt peptide or XIAP (Figure 5-5B). However, the 
activation of the proteolytic activity of immunoprecipitated HtrA2 was much smaller 
than  the  activation  that  could  be  achieved  using  recombinant  WT  HtrA2  (compare 
Figure 5-5B with Figure 5-4B).
Then, WT or S400D HtrA2 was over-expressed in HEK293  cells and the proteolytic 
activity  of immunoprecipitated  HtrA2  was  measured  subsequently.  This  experiment 
revealed that  S400D  HtrA2  was  activated to  a  lesser extent by  the  PDZopt peptide 
compared to WT HtrA2 (Figure 5-5C), confirming the data obtained previously using 
recombinant  HtrA2  proteins.  Thus,  ex vivo  HtrA2 protease  activity  can be  analysed 
similarly to recombinant HtrA2.
5.7  Activation  of  HtrA2  proteolytic  activity  by  MEKK3 
induction cannot be measured
The  phosphorylation  of at  least  SI42  of HtrA2  could  be  induced  by  activation  of 
MEKK3 (Figure 5-2C and Figure 5-3D), and phospho-mimic mutants of recombinant 
HtrA2 displayed higher basal activity and decreased activation by the PDZopt peptide 
and XIAP than WT HtrA2 (Figure 5-4). In order to test if activation of MEKK3 could 
activate endogenous HtrA2,  HEK293  cells expressing AMEKK3:ER were  stimulated
195with  vehicle  or  40H-Tx  to  activate  this  signalling  pathway  and  induce  HtrA2 
phosphorylation.  Half of the  immunoprecipitated  HtrA2  of each  sample  was  then 
incubated  with  the  PDZopt  peptide  or  XIAP  to  stimulate  the  proteolytic  activity. 
However, neither a difference in the proteolytic rate of HtrA2 from MEKK3 stimulated 
cells nor a difference  in the  ability  of PDZopt or XIAP to  activate  HtrA2  could be 
detected (Figure 5-6A).
As previously noted, the proteolytic activity of ex vivo HtrA2 could not be activated by 
PDZ engagement or binding to XIAP to the same extent as recombinant WT HtrA2. 
Therefore,  HtrA2  might  be  constitutively  phosphorylated  in  cells.  However, 
phosphatase treatment of immunoprecipitated HtrA2 did not lead to a reduction of its 
basal activity (Figure 5-6B). Nevertheless, the protease assay might reach its limit of 
sensitivity  when assaying  immunoprecipitated  HtrA2,  therefore,  it is not possible to 
conclude whether phosphorylation of HtrA2 in vivo increases its proteolytic activity or 
not.
5.8  PINK1 influences HtrA2 activity in vivo
Induction of HtrA2 phosphorylation by activation of MEKK3 did not reveal an increase 
in HtrA2 activity ex vivo. Besides MEKK3  activation, the over-expression of PINK1 
might  induce  phosphorylation  of  HtrA2.  Therefore,  WT  or  S142A/S400A  mutant 
HtrA2 was immunoprecipitated from HtrA2 KO cells co-transfected with vector or a 
PINK1  expression construct. Immunoprecipitated samples were split and half of each 
was incubated with the PDZopt peptide. Interestingly, PINK1 expression did reduce the 
ability of PDZopt to activate WT HtrA2, but not S142A/S400A mutant HtrA2 (Figure 
5-6C),  suggesting that these  sites could potentially  be phosphorylated in response to 
PINK1 over-expression and therefore decrease the effect of activating stimuli on HtrA2 
protease activity similar to the effect observed with the phospho-mimic mutants (Figure 
5-4C and Figure 5-5C).
5.9  Over-expression of PINK1 protects WT, but not HtrA2 KO 
cells from toxic stimuli
The data presented so far suggests that PINK1  might modulate the activity of HtrA2 
through  influencing  its phosphorylation  status.  Over-expression  of PINK1  has  been
196reported to protect SH-SY5Y cells from apoptosis induced by the proteasome inhibitor 
MG-132  (Valente  et  al.  2004)  and  staurosporine  (Petit  et  al.  2005).  If PINK1  acts 
upstream  of HtrA2  in  a  mitochondrial  pathway  responsible  for  resistance  to  stress, 
over-expression  of  this  kinase  in  cells  devoid  of  HtrA2  might  not  elicit  such  a 
significant response as in WT cells. Therefore, the effect of PINK1 over-expression in 
WT and HtrA2 KO MEFs on stress-induced apoptosis was studied.  Although PINK1 
could protect WT MEFs from MG-132 or staurosporine-induced apoptosis, its ability to 
protect HtrA2  KO MEFs was decreased  compared to  WT  (Figure  5-7).  In  contrast, 
when PINK1  expression was  decreased  using  PINK 1-specific  siRNA,  a decrease  in 
viability and mitochondrial membrane potential were observed in WT, but not in HtrA2 
KO MEFs (data not shown, Miguel Martins, MRC Leicester), supporting the data from 
the over-expression of PINK 1  (Figure 5-7).
Taken together, these results suggest that PINK1, possibly through phosphorylation and 
subsequent increased proteolytic activity of HtrA2, is able to protect cells from stress- 
induced mitochondrial dysfunction and stress-induced apoptosis.
5.10  Discussion
Eight nuclear genes are known to carry mutations that cause PD, encoding a-synuclein, 
parkin, UCHL1, PINK1, DJ-1, LRRK2, ATP13A2 and HtrA2 (Table 1-1) (Farrer 2006; 
Ramirez et al. 2006). Mutation or altered expression of these proteins contributes to PD 
pathogenesis  through  partly  overlapping  mechanisms  that  result  in  mitochondrial 
impairment, oxidative stress, and protein mishandling. Consistent with the development 
of a parkinsonian syndrome  in mice  lacking HtrA2  function,  a polymorphism and a 
mutation resulting in single amino acid changes in HtrA2 that appear to dampen the 
activation of its proteolytic activity were identified to be associated with the PARK13 
locus (Strauss et al. 2005). These studies suggest that loss of function of HtrA2 leads to 
neuronal  cell  death,  possibly  due  to mitochondrial  dysfunction,  both  in  mice  and in 
humans. Since then, several other mutations linked to PD have been identified in HtrA2 
(personal  communication,  Reijko  Kruger).  The  A141S  polymorphism  and  G399S 
mutation  in  HtrA2  localise  to  domains  previously  shown  to  be  important  in  the 
regulation of the proteolytic activity of HtrA2 (Martins et al. 2002). In addition, these 
residues  are  adjacent to two putative phosphorylation  sites  in the protein,  SI42  and
197S400,  suggesting  that  these  sites  might  play  a  major  role  in  the  regulation  of the 
enzymatic activity of HtrA2.
PINK1  was identified as a new binding partner of HtrA2 using the TAP tag system to 
affinity  purify  interacting  proteins.  Furthermore,  HtrA2  could  be  phosphorylated  in 
vitro by p38y and p38{3, and preliminary data indicates that p38y might phosphorylate 
both  sites,  SI42  and  S400  in vitro  (personal  communication,  Helene  Plun-Favreau). 
Activation of the MEKK3 signalling pathway led to phosphorylation of HtrA2 at least 
on SI42 in vivo (Figure 5-2C), and chemical inhibition of p38 reduced the MEKK3- 
induced phosphorylation of HtrA2 (Figure 5-2D). Moreover, PINK1  was required for 
this phosphorylation to occur (Figure 5-3D) and mutations in PINK1 decreased HtrA2 
phosphorylation  on  SI42  in  human  brain  samples  from  PD  patients  (Figure  5-3E). 
Unfortunately, the sequence around S400 of HtrA2 is relatively hydrophobic and does 
not work well as an immunogen in rabbits. Therefore it was not possible to generate an 
antibody  specific  for phospho-S400  HtrA2  and  address  its  phosphorylation  in  vivo. 
Interestingly, HtrA2 mutants mimicking phosphorylation on SI42 and S400 showed an 
increase in their protease activity (Figure 5-4).
It  has  been  hypothesised  that  PINK1  may  phosphorylate  mitochondrial  proteins  in 
response to cellular stress, protecting against mitochondrial dysfunction (Valente et al. 
2004). It is possible that HtrA2 is a substrate for PINK1, therefore the PINK1  kinase 
activity towards HtrA2 in an in vitro assay was measured. However, the weak kinase 
activity of bacterially expressed PINK1 (Beilina et al. 2005; Silvestri et al. 2005; Sim et 
al. 2006) could not be improved by using a baculoviral system. Moreover, although an 
apparent autophosphorylation activity of PINK1  and activity towards HtrA2 could be 
detected,  this  was  also  seen  with  a  kinase  inactive  K219D  mutant  of the  protein, 
suggesting that the kinase activity observed most likely belonged to a contaminant of 
the preparation (data not  shown).  PINK1  could  entirely  lack kinase activity,  despite 
having  a  strong  predicted  kinase  domain  sequence.  Alternatively,  PINK1  might  not 
fold  properly  in  the  insect  cell  system  used  or  some  essential  cofactors  might  be 
missing  from the  purified preparation.  A  relatively  likely  explanation  would be that 
PINK1  needs to  be  activated  in  order to  exhibit  substantial  kinase  activity.  Akt  for 
example  only  exhibits  kinase  activity  when  the  cells  are  stimulated  with  serum  or 
dephosphorylation is inhibited by okadaic acid (Andjelkovic et al.  1996). However, if a
198“correct” stimulus to activate PINK1 exists, it has not been identified yet. Thus, it is not 
possible to conclude that PINK1 phosphorylates HtrA2 directly.
Why might PINK1 expression be necessary for HtrA2 phosphorylation to occur (Figure 
5-3B  and  D)?  One  possibility,  suggested  by  the  data  presented,  is  that  HtrA2 
phosphorylation is mediated by a kinase activated in the MEKK3  signalling pathway 
(potentially p38, Figure 5-2C and D), but is dependent on the interaction of HtrA2 with 
PINK1, possibly reflecting the existence of a multimeric complex. Another possibility 
is  that  PINK1  is  indeed  a  kinase,  but  the  “correct”  stimulus  to  activate  its  kinase 
activity in vitro has not been identified. In this case, PINK1 might phosphorylate HtrA2 
directly  and  PINK1  activity  could  be  modulated  by  the  MEKK3  pathway. 
Alternatively,  PINK1  might  be  upstream  of  another  kinase  responsible  for 
phosphorylating HtrA2 and be involved in its activation. In vivo, the phosphorylation of 
HtrA2  might require recruitment of this kinase to  the  mitochondria,  or alternatively 
could  occur  in  the  cytosol  before  HtrA2  is  imported  into  the  mitochondria.  The 
interaction between PINK1  and  HtrA2  was predominantly detected in mitochondria- 
enriched fractions. However, both over-expressed full length mitochondrial and mature 
cytosolic  HtrA2  could be phosphorylated on  SI42  when MEKK3  was activated and 
this  occurred  in  a  PINK 1-dependent  manner  (data  not  shown),  suggesting  that  the 
phosphorylation might occur prior to import of HtrA2 into the mitochondria.
Being located just next to the cleavage motif site (A 134 is the N-terminus of mature 
HtrA2),  phosphorylation  on  SI42  could  also  impact  on  the  processing  of  HtrA2. 
Indeed,  data  from  several  groups  have  revealed  that  Alzheimer’s  amyloid  precursor 
protein  (APP)  processing can  be regulated  by phosphorylation  and phosphorylation- 
dependent events and it is now widely accepted that abnormal processing of APP can 
contribute  significantly  to  Alzheimer's  disease  (for  review  (da  Cruz  e  Silva  et  al.
2004)). In order to address the impact of SI42 phosphorylation on processing of HtrA2 
to  its  mature  form,  mitochondria  import  assays  need  to  be  performed.  Preliminary 
experiments suggested that over-expression of WT and S142D HtrA2 in cells did not 
reveal a difference in the ratio of full length to mature form of HtrA2 (data not shown).
Since the notion that HtA2 is a pro-apoptotic protein analogous to Drosophila Reaper 
family proteins  has been thrown  into  doubt by the parkinsonian phenotype  of mice
199lacking HtrA2 function and its protective function in cells subjected to stress (Jones et 
al. 2003; Martins et al. 2004), it is attractive to speculate that human HtrA2 might act 
more  like  its bacterial  homologues  DegS  and  DegP.  HtrA2  could  degrade  unfolded 
proteins,  performing  crucial  functions  with  regard  to  protein  quality  control  in  the 
intermembrane space of the mitochondria, in a similar manner to DegP. Alternatively, 
HtrA2  could  transduce  a  stress  adaptive  signal,  like  DegS  (for review,  (Young  and 
Hartl  2003)).  Thus,  the  proteolytic  activity  of HtrA2  is  critical  for  its  protective 
function. Phosphorylation of HtrA2 appeared to regulate its proteolytic activity, since 
HtrA2 mutants mimicking phosphorylation on SI42 and S400 showed an increase in 
their protease activity (Figure 5-4A), concomitant with a reduction in the ability of the 
PDZopt  peptide  and  XIAP  to  activate  HtrA2  protease  activity  (Figure  5-4B  and  C, 
Figure  5-5C).  This  suggests  that  phosphorylation  of  HtrA2  might  lead  to 
conformational  changes  facilitating  its  protease  activity.  However,  in  these 
experiments, HtrA2 proteins engineered with a serine to aspartate mutation, to mimic 
phosphorylation at the sites of interest, were used. Therefore, it is crucial to show that 
“real”  phosphorylation  can  have  the  same  impact  on  HtrA2  proteolytic  activity. 
Unfortunately, although activation of the MEKK3 signalling pathway led to increase of 
HtrA2 phosphorylated on SI42, neither the basal activity nor the induction in HtrA2 
activity by activating stimuli were altered when HtrA2 was isolated from cells in which 
MEKK3 had been induced (Figure 5-6A). It is possible, that the protease assay is not 
sensitive enough to detect subtle changes in HtrA2 activity when isolated ex vivo.  In 
line with this,  the ability of the  PDZopt peptide or XIAP to activate HtrA2  isolated 
from cells is much reduced compared to recombinant WT HtrA2 (compare Figure 5-5B 
with  Figure  5-4B).  The  latter  observation,  however,  might  also  suggest  that  HtrA2 
could  be  constitutively  phosphorylated  in  cells  thereby  diminishing  the  increase  in 
HtrA2 activity that can be achieved by  activating  stimuli.  Nevertheless,  phosphatase 
treatment of HtrA2 isolated from cells did not change its basal activity (Figure 5-6B), 
reinforcing  the  hypothesis  that  the  protease  assay  is  not  sensitive  enough  for 
immunoprecipitated  HtrA2.  HtrA2  isolated  in  this  way  possibly  suffers  from  steric 
hindrance  resulting  from  the  binding  of the  antibodies,  thereby  fixing  HtrA2  in  a 
particular  position  and  reducing  the  flexibility  of  structural  changes  to  occur. 
Nevertheless, the first evidence that PINK1  might indeed regulate HtrA2  activity  in 
vivo  comes  from  experiments  over-expressing  PINK1  prior  to  measuring  HtrA2
200activity ex vivo (Figure 5-6C). In line with this is the observation that over-expression 
of PINK1  cannot protect HtrA2 KO cells to the same extent as WT cells from stress- 
induced apoptosis, placing HtrA2 downstream of PINK1 function (Figure 5-7).
Previously,  it was reported that both A141S  and  G399S  PD-associated mutations in 
HtrA2  resulted  in  reduced  ability  of the  PDZopt  peptide  or  XIAP  to  activate  its 
protease activity (Strauss et al. 2005). The influence of these PD-associated mutations 
on the phosphorylation of the  adjacent  sites  (SI42  and  S400)  is clearly  an  area for 
further investigation. Mutation of A141S creates a new potential phosphorylation site 
for proline-directed serine/threonine kinases on this residue. However, A141 is not well 
conserved  across  different  species.  In  rodents  this  residue  is  a  threonine,  already 
providing  such  a potential  phosphorylation  site  (Figure  5-2B)  and  preliminary  data 
indicates that A141S  has no  effect on  SI42  phosphorylation  in vitro.  However,  the 
G399  sequence  is  well  conserved  and  G399S  mutation  in  HtrA2  might  lead  to 
decreased  phosphorylation  of this  site  in  vitro.  A  defect  in  phosphorylation  due  to 
G399S mutation and therefore impaired modulation of HtrA2 proteolytic activity could 
explain the increased mitochondrial dysfunction and sensitivity to stress-induced cell 
death of this mutant when over-expressed (Strauss et al. 2005).
The  PD-associated  mutations  in  PINK1,  C575R  and  Y431H,  resulted  in  a  robust 
decrease  in  the  levels  of phosphorylated  HtrA2  on  position  SI42  in  human  brains 
(Figure 5-3E). The study of these human brains is clearly important for confirming the 
relevance of the interaction of HtrA2 and PINK1  in vivo in human PD patients.  The 
brains  of  patients  with  mutations  in  the  PINK1  gene  are  morphologically 
indistinguishable  from  sporadic  PD  and  exhibit  the  pathological  hallmarks  of 
dopaminergic  neuronal  cell  loss  in  the  SN  and  the  presence  of  Lewy  bodies.  In 
addition,  there  is  no  difference  in  the  expression  of PINK1  protein  in  these  brains 
compared to brains with sporadic  PD  (Gandhi  et al.  2006).  The  Y431H  and  C575R 
mutations in PINK1  are thought to  influence the putative kinase activity  (Sim et al. 
2006). Over-expression of both PINK1 mutants resulted in a significant decrease in the 
mitochondrial membrane potential compared to WT PINK1 on exposure of the cells to 
proteasomal stress (Abou-Sleiman et al. 2006), suggesting that both mutations have a 
major pathogenic effect on PINK1 function. Neither the C575R nor the Y431H mutant 
of PINK 1  have lost their ability to interact with HtrA2 in vitro (data not shown, Helene
201Plun-Favreau), thus supporting the idea that PINK1  possibly functions as a kinase in 
vivo  to  phosphorylate  HtrA2  and  that  its  kinase  activity  towards  HtrA2  could  be 
impaired by the PD mutations.
The results from the study in human brain highlight another important controversy in 
PD  pathogenesis:  it  has  not  yet  been  clear  whether  heterozygous  mutations  in  the 
recessive  genes  associated  with  PD  are  sufficient  to  cause  disease.  Classically,  as 
mutations in PINK1  cause an autosomal recessive form of PD the carriage of a single 
heterozygous  mutation  would  be  considered  to  be  of  no  phenotypic  significance. 
However,  several  groups  have  shown  that  there  is  a  higher  rate  of heterozygous 
mutations  in  PD  patients  compared  to  controls  (Abou-Sleiman  et  al.  2006). 
Furthermore heterozygous carriers of PINK 1   mutations have a demonstrable reduction
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in  fluorodopa uptake in the striatum, a marker for dopaminergic dysfunction (Khan et 
al.  2002).  Therefore,  there  is  accumulating  but  circumstantial  evidence  that  single 
heterozygous mutations represent a significant risk factor for developing disease in the 
presence  of  particular  stress.  For  the  first  time,  functional  data  to  support  this 
hypothesis  is  provided:  in  the  presence  of  a  PD-inducing  stress,  a  heterozygous 
mutation  in  the  PINK1  gene  is  able  to  exert  a  significant  functional  effect  on  the 
phosphorylation of HtrA2, presumably via a haploinsufficiency mechanism.
The  identification  of  PINK1  binding  to  HtrA2  demonstrates  a  direct  molecular 
interaction between two  genes  implicated  in  PD.  Uniquely,  it is the  only  functional 
interaction that has been validated in vitro, in vivo and in human PD brains. In parallel 
to the presented data in this thesis, genetic analyses of HtrA2 and PINK1  function in 
Drosophila place HtrA2 downstream of PINK1  and Parkin (unpublished data, Ruhena 
Begum  et  al.,  Cancer  Research  UK).  Thus,  both  HtrA2  and  PINK1  proteins  are 
genetically linked, suggesting that they could be part of the same signalling pathway. 
The identification of HtrA2  and PINK1  being involved in a common pathway  is the 
first  step  in  elucidating  the  molecular  players  around  the  mitochondrial  function  of 
HtrA2,  and  in  understanding  how  loss  of  HtrA2  function  can  lead  to  increased 
sensitivity  to mitochondrial  stress.  Further study  of this pathway might help explain 
how mitochondrial dysfunction leads to neuronal death in the SN of PD patients.
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Company Antigen
Detected in 
HtrA2-TAP eluate
Santa Cruz Biotechnology ANT No
Santa Cruz, BD Transduction Bad No
Stressgen, Calbiochem Bak No
Mito Science,  Imgenex Bax No
Pharmingen, Santa Cruz Bcl-2 No
BD Transduction Laboratories Bcl-XL No
Abeam Bif-1 No
Santa Cruz Biotechnology Blk No
Santa Cruz Biotechnology Bim No
Calbiochem Bnip3L No
Molecular Probes Complexl 17kD subunit No
Molecular Probes Complexlll (UQCRC1) No
Molecular Probes ComplexV subunit alpha No
Molecular Probes ComplexV subunit beta No
Molecular Probes ComplexV subunit d No
Molecular Probes ComplexV subunit OSCP No
Molecular Probes ComplexV inh. Protein No
Mito Science ComplexV No
Pharmingen Cytochrome c No
V. Dawson DJ-1 No
Stressgen Grp-75 No
BD Transduction Laboratories HAX-1 Yes
Santa Cruz Biotechnology Hrk No
Stressgen Hsp-60 No
CRUK generated PINK1 Yes
Abeam Prohibitin No
CRUK generated Smac No
Calbiochem VDAC No
Santa Cruz Biotechnology VDAC2 No
BD Transcution Laboratories XIAP Yes
Table 5-1.  TAP  epitope-tagged  HtrA2  was  purified  from  HEK293  cells 
stably expressing the fusion  protein,  resolved by SDS-PAGE 
and  probed  with  antibodies  raised  against  mitochondrial 
proteins.Figure 5-1. PINK1  interacts with HtrA2.
(A)  TAP  purification  of  HtrA2  shows  interaction  with  XIAP  and  HAX-1.  TAP 
epitope-tagged  HtrA2  or  TAP  alone  were  purified  from  stable  HEK293  cell 
lines,  resolved  by  SDS-PAGE  and  probed  with  anti-XlAP  or  anti-HAX-1 
antibodies.  (B)  TAP  purification  of HtrA2  identifies  PINK1  as  a  novel  binding 
partner. Following each step of the purification, a sample was kept for Western 
blotting  with  anti-PINK1  antibody:  Lane  1,  lysate  from  HEK293  HtrA2-TAP 
stable  cell  line.  Lane 2,  IgG  flow through  (FT).  Lane  3,  TEV eluate.  Lane  4, 
calmodulin  flow  through  (CaM  FT).  Lane  5,  final  eluate.  (C)  Co- 
immunoprecipitation  of endogenous  PINK1  with  endogenous  HtrA2.  Lysates 
prepared from WT and HtrA2 KO MEFs were subjected to immunoprecipitation 
with  anti-HtrA2  antibody  and  purified  proteins  were  subjected  to  Western 
blotting with  biotinylated anti-PINK1  antibody.  Lysates derived from  HtrA2  KO 
MEFs  demonstrate  that  in  the  absence  of  HtrA2,  no  PINK1  purification  is 
achieved.  Duplicates for the  co-immunoprecipitation  of PINK1  with  HtrA2  are 
shown. Asterisks denotes IgG background band. (D) Co-immunoprecipitation of 
HtrA2 with  PINK1  occurs  in  mitochondria-enriched  fractions.  PINK1-Myc was 
expressed in HEK293 cells. Cytosol- and mitochondria-enriched fractions were 
subjected  to  immunoprecipitation  with  anti-HtrA2  antibody.  Detection  was 
performed  with  anti-Myc  or  anti-HtrA2  antibody.  Asterisk  denotes  IgG 
background band.
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HtrA2-TAPFigure 5-2. HtrA2 is phosphorylated upon MEKK3 activation.
(A)  Schematic  representation  of  human  HtrA2.  The  IBM  present  in  the  N- 
terminus of mature HtrA2 is indicated in blue. Also shown are residues mutated 
in  PD  (green)  and  potential  stress  kinase  phosphorylation  sites  (red).  TM, 
transmembrane  domain.  (B)  Alignment  of  HtrA2  homologues  showing 
conservation  of S142  and  S400.  (C)  HtrA2  is  phosphorylated  on  S142  upon 
activation  of  MEKK3,  and  p38  is  predominantly  activated  in  these  cells. 
Inducible versions of MEKK3  (AMEKK3:ER), Akt (myrAkt:ER)  and  Raf (ARaf- 
DD:ER) were stably expressed  in  HEK293,  NIH3T3 and  NIH3T3,  respectively. 
These cells were transfected with full length HtrA2. After over night (o/n) 40H- 
Tx activation of MEKK3, Akt and  Raf in these cell lines,  lysates were analysed 
by  SDS-PAGE  followed  by  Western  blot  with  anti-phospho-S142  HtrA2  (P- 
HtrA2) antibody. After stripping, the membrane was re-probed using anti-HtrA2 
antibody.  To  assess  activation  of downstream  signalling  pathways,  Western 
blot with anti-P-Akt,  anti-P-ERK1/2,  anti-P-JNK and  anti-P-p38 antibodies was 
performed.  (D)  Inhibition  of  p38  decreases  40H-Tx  induced  HtrA2 
phosphorylation.  HEK293/AMEKK3:ER  cells  were  transfected  with  full  length 
HtrA2 for 48hrs.  After one  hour pre-treatment with  BIRB796  and  o/n  40H-Tx 
activation  of  MEKK3,  lysates  were  analysed  by  SDS-PAGE  followed  by 
Western  blotting  with  anti-P-HtrA2  and  anti-P-p38  antibodies.  After  stripping, 
membranes were re-probed using anti-HtrA2 and anti-p38 antibodies.
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p38Figure 5-3. PINK1  is necessary for HtrA2 phosphorylation to occur.
(A)  Down-regulation  of  endogenous  PINK1  mRNA  and  protein  levels  by 
PINK1 -specific  siRNA  in  SH-SY5Y  cells.  The  Western  blot  shows  full  length 
and  processed  forms  of  the  PINK1  protein.  (B)  Endogenous  HtrA2 
phosphorylation  on  S142  is  decreased  in  the  absence  of  PINK1.  Control  or 
PINK1  siRNA  was  transfected  into  SH-SY5Y  and  mitochondria-enriched 
fractions  were  analysed  by  SDS-PAGE  followed  by  Western  blot  with  the 
antibody against P-HtrA2. After stripping,  the membrane was re-probed  using 
anti-HtrA2 antibody. (C) Over-expression of PINK1  reveals phosphorylation on 
S142 of HtrA2.  Full length WT or S142A HtrA2 were co-expressed with PINK1 
in SH-SY5Y cells and lysates subjected to Western blot using anti-P-HtrA2 and 
anti-HtrA2  antibodies.  (D)  Down-regulation  of  endogenous  PINK1  by  siRNA 
inhibits HtrA2 phosphorylation on S142 upon 40H-Tx activation of MEKK3. Full 
length  WT  and  S142A  HtrA2  expression  constructs  and  control  or  PINK1- 
specific siRNA were  co-transfected  into  HEK293/AMEKK3:ER cells that were 
treated with vehicle or 40H-Tx o/n. Cell lystates were subjected to Western blot 
with  anti-P-HtrA2  and  anti-HtrA2  antibodies.  (E)  HtrA2  is  phosphorylated  on 
S142  in  PD  brains.  Human  brain  tissue  samples  from  the  caudate  nucleus 
(which  is part of the striatum) carrying a mutation  in the  PINK1  gene (C575R 
and Y431H PINK1) or idiopathic PD (IPD) brains were analysed by SDS-PAGE 
followed  by  Western  blot  with  anti-P-HtrA2,  anti-HtrA2  or  anti-PINK1 
antibodies.  The  data  in  (B-E)  of this  figure  was  generated  by  Helene  Plun- 
Favreau.
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3Figure 5-4. Phosphorylation-mimics of S142 and S400 of HtrA2 increase
its proteolytic activity.
(A)  Mutation  of  S142  or  S400  into  aspartate  to  mimic  phosphorylation 
increases  the  proteolytic  activity  of  recombinant  HtrA2.  Kinetics  of  the 
proteolytic  activity  of  recombinant  HtrA2  were  monitored  by  measuring  the 
increase  in  fluorescence  resulting  from  HtrA2  substrate  cleavage.  Protease 
activity  (AFU/min)  was  determined  by  linear  regression  analysis  of the  data 
points corresponding to the maximum  reaction  rates for each assay condition 
(Vmax). Protease activity of WT HtrA2, as well as S142D and S400D phospho- 
mimic mutants  is displayed.  Serine to alanine mutations at the  phospho-sites 
show no significant effect compared to the WT protein. Mean values ± SD of 4- 
6 data points are represented. Statistically significant values (one-way ANOVA 
with  Bonferroni post-test,  compared to WT HtrA2) are indicated:  *** P <0.001. 
In parallel, SDS-PAGE was performed and stained with colloidal Coomassie to 
show the  recombinant  HtrA2  proteins.  AFU,  arbitrary  fluorescence  units.  (B) 
Proteolytic activity of HtrA2  is  increased  with  PDZ engagement or binding  to 
XIAP,  however,  phospho-mimic mutants cannot be activated  as much  as WT 
HtrA2. WT (circles) or S400D (triangles) HtrA2 (black) were pre-incubated with 
the PDZ-interacting peptide PDZopt (blue) or XIAP recombinant protein (green) 
for 15min at room temperature before addition of the fluorescent substrate. The 
amount of S400D HtrA2 was reduced in order to show the same rate of activity 
as  WT  HtrA2  in  the  experiment  shown.  (C)  Activation  of  HtrA2  proteolytic 
activity  through  PDZ  engagement  and  XIAP  is  reduced  in  the  S142D  and 
S400D  mutants.  Proteasfe  activity  (AFU/min)  was  determined  by  linear 
regression analysis of the data points corresponding to the maximum reaction 
rates for each  assay condition.  The fold  of activation  achieved  by  incubation 
with PDZopt peptide or XIAP for each protein is displayed. Error bars represent 
+ the range of two determinations.
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Fold activationFigure 5-5. Establishment of ex vivo HtrA2 protease assay.
(A)  I mm u noprecipitated  HtrA2  exhibits  proteolytic  activity  in  the  in  vitro 
protease  assay.  HtrA2  KO  MEFs were  transfected  with  vector,  WT  HtrA2  or 
catalytically  inactive  S306A  HtrA2  expression  constructs.  HtrA2  was 
immunoprecipitated  from  cell  lysates  and  the  washed  Protein  A  bead  matrix 
containing  purified  HtrA2  was  subjected  to  the  protease  assay,  measuring 
cleavage of the HtrA2 fluorescent substrate peptide.  Non-specific background 
proteolytic activity could not be detected in lysates from vector or S306A HtrA2 
transfected cells.  (B)  Immunoprecipitated  HtrA2 can  be activated  by the  PDZ- 
binding  peptide  (PDZopt)  as  well  as  XIAP.  Endogenous  HtrA2  was 
immunoprecipitated  from  HEK293  cells,  and  incubated  with  PDZopt or XIAP, 
which  resulted  in stimulation  of the proteolytic activity of HtrA2.  (C)  Phospho- 
mimic S400D HtrA2 is activated less by the PDZopt peptide than WT HtrA2 ex 
vivo.  Both  HtrA2 constructs were expressed  in  HEK293 cells, the half of each 
immunoprecipitates was  incubated  with  PDZopt and  kinetics  of HtrA2  activity 
were  measured.  Protease  activity  (AFU/min)  was  determined  by  linear 
regression analysis of the data points corresponding to the maximum reaction 
rates for each  assay condition.  The fold  of activation  achieved  by  incubation 
with  PDZopt peptide for each  protein  is displayed.  Error bars represent + the 
range of two determinations.
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1.2  1.4 1.6Figure 5-6. PINK1  influences HtrA2 proteolytic activity in vivo.
(A) Activation of MEKK3 does not activate basal  HtrA2 proteolytic activity and 
does  not  decrease  the  ability  of  PDZopt  or  XIAP  to  activate  HtrA2  activity. 
Endogenous  HtrA2  was  immunoprecipitated  from  HEK293  cells  stably 
expressing  AMEKK3:ER,  which  had  been  stimulated  with  vehicle  or 40H-Tx 
o/n.  Immunoprecipitates  were  incubated  with  PDZopt  or  XIAP  and  HtrA2 
proteolytic activity was measured.  (B) Phosphatase treatment of ex vivo HtrA2 
does  not  alter  its  basal  activity.  Endogenous  HtrA2  was  immunoprecipitated 
from  HEK293  cells  and  incubated  with  recombinant  protein  phosphatase  2A 
(PP2A),  X  phosphatase  or  buffer  alone  to  dephosphorylate  HtrA2,  before 
measuring  its  proteolytic  activity.  (C)  Over-expression  of  PINK1  reduces  the 
ability  of  PDZopt  to  activate  WT  HtrA2,  but  not  S142A/S400A  HtrA2  which 
cannot be  phosphorylated  on  these  sites.  WT  HtrA2  (HtrA2,  HtrA2-Flag)  and 
S142A/S400A  HtrA2  were  co-expressed  with  vector  or  PINK1  in  HtrA2  KO 
MEFs.  Immunoprecipitated  HtrA2  was  incubated  with  PDZopt and  proteolytic 
activity was  measured.  Protease activity (AFU/min)  was determined  by  linear 
regression analysis of the data points corresponding to the maximum reaction 
rates for each  assay condition.  The fold  of activation  achieved  by  incubation 
with PDZopt peptide for each protein is displayed. The data shown represents 
the mean ± the range of two determinations.
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endo HtrA2 +XIAPFigure 5-7. PINK1  protects WT, but not HtrA2 KO cells from stress- 
induced apoptosis.
Over-expression of PINK1  protects WT more effectively than  HtrA2  KO MEFs 
from  stress-induced  apoptosis.  Farnesylated  EGFP  was  co-transfected  with 
vector  or  PINK1-myc  expression  construct,  cells were treated  with  VM   MG- 
132 for 24hrs or 2^M staurosporine (STS) for 3hrs and the number of Annexin 
V positive cells within the EGFP positive population was determined by FACS. 
The data shown represents the mean ± the range of two determinations.
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KO6  Chapter 6: Final Discussion
6.1  Loss  of  HtrA2  in  mice  leads  to  the  development  of  a 
parkinsonian syndrome
When  the  mammalian  IBM-containing  proteins  Smac  and  HtrA2  were  initially 
identified through their ability to interact with XIAP (Du et al. 2000; Verhagen et al. 
2000; Suzuki et al. 2001; Hegde et al. 2002; Martins et al. 2002; van Loo et al. 2002; 
Verhagen et al. 2002), it appeared likely that they would exhibit pro-apoptotic function 
involving release  from mitochondria following apoptotic  insult.  Once  in the  cytosol, 
the proteins were thought to act together to block the caspase  inhibitory  function of 
IAPs, thus promoting caspase activation and apoptosis. While over-expression of Smac 
or  HtrA2  might  promote  caspase-mediated  apoptotic  death  and  also,  in  the  case  of 
HtrA2, caspase-independent cell death, the significance of the endogenous proteins in 
these pathways has been much less clear. The data presented in Chapter 3 indicate that 
the complete loss of expression of HtrA2 protein in vivo, including its IBM, does not 
result in resistance to cell death, as one might expect from deletion of a pro-apoptotic 
protein.  It  has  been  reported  that  many  mitochondrial  proteins  might  have  an  N- 
terminal IBM (Verhagen et al. 2007). Therefore, severe mitochondrial damage would 
cause release of many proteins with the ability to antagonise IAPs, in addition to just 
Smac  and  HtrA2,  so  that  loss  of the  IBMs  of these  two  proteins  may  have  little 
detectable  impact  on  IAP  activity.  In  contrast  to  showing  resistance  to  cell  death, 
neuronal cell populations isolated from HtrA2 KO mice were more sensitive than WT 
controls  to  excitotoxicity-induced  death  in  response  to  glutamate  (Figure  3-7C). 
Similarly,  non-neuronal  cell  types  such as  fibroblasts from the  HtrA2  KO  mice also 
showed increased sensitivity to induction of cell death by specific drugs, for instance 
the complex I  inhibitor rotenone, the ER stressor tunicamycin and H2O2 which elicits 
oxidative  stress  (Figure  3-7A).  The  increase  in cell  death  in  animals  lacking  HtrA2 
function and absence of protection from apoptosis suggests that HtrA2 is an essential 
gene required for mitochondrial function, rather than a pro-apoptotic regulator.
The  phenotype  of  the  HtrA2  KO  mice  displays  some  similarity  to  patients  with 
parkinsonian  neurodegeneration,  such  as  resting  tremor,  rigidity,  bradykinesia  and 
postural instability. Moreover, complete loss of HtrA2 protein has a very similar effect
218to that of only loss of HtrA2 serine protease activity: HtrA2 KO and Mnd2 mice both 
die  prematurely  at  around  30  to  40  days  of age  due  to  a  progressive  neurological 
disorder caused by death of a population of striatal neurons (Jones et al. 2003; Martins 
et al. 2004). Since the Mnd2 mice display the same phenotype as the HtrA2 KO mice, 
it appears that the proteolytic activity of HtrA2 is critical for its correct mitochondrial 
function.
Analysis  of brains  from  HtrA2  KO  animals  reveals  a  selective  loss  of a  neuronal 
population  in  the  striatum,  concomitantly  with  selective  loss  of  terminals  of  the 
nigrostriatal pathway, just lateral of the thalamus in a relatively posteriomedial portion 
of  the  basal  ganglia  (Figure  3-3A  and  F).  In  humans,  PD  is  characterised  by 
degeneration of the neural connection between the SN and the striatum. The striatum 
receives  its  dopaminergic  input  from  neurons  of  the  SNpc  via  this  nigrostriatal 
pathway. Progressive degeneration of the nigrostriatal dopaminergic pathway results in 
profound striatal dopamine deficiency, leading to the described motor deficiencies (for 
review (Fahn 2003)). The clinical symptoms of PD arise by a threshold effect, whereby 
denervation of the striatum by dopaminergic neuronal loss reduces dopamine levels to 
below 70% of wild type (Bemheimer et al. 1973). Thus, loss of the neuronal population 
in the striatum of HtrA2 KO mice is likely to lead to the locomotor deficits observed in 
HtrA2  KO  mice.  Additionally,  these  neurons  are  already  lost  at  P20,  where  no 
phenotypic  alterations  in  the  mice  are  detectable.  This  suggests  that  neuronal  loss 
precedes the full development of the parkinsonian syndrome in HtrA2 KO mice, and is 
in line with the described threshold effect in human PD patients.
Why  are  certain  neurons  more  susceptible  to  the  loss  of HtrA2?  In  rats  systemic 
administration of rotenone results in mild but  systemic  complex I  inhibition and can 
produce a progressive model of parkinsonism (Betarbet et al. 2000; Sherer et al. 2003). 
When a degenerative lesion results, it is selective to the nigrostriatal system, indicative 
of the vulnerability of this neuronal population to oxidative stress. In the case of human 
PD  patients,  there  is  circumstantial  evidence  that  SN  dopamine  neurons  are  under 
greater  metabolic  stress,  and  this  potentially  provides  an  explanation  for  why  these 
neurons  are  selectively  susceptible  to  mitochondrial  toxins  and  why  they  are  more 
likely to degenerate in PD (Greene et al. 2005). In line with these observations are the 
results in Chapter 3, which show that a population of striatal neurons in mice appears to
219be specifically sensitive to the loss of HtrA2. Therefore, neurons and in particular these 
striatal neurons might push their mitochondria to the limit of energy generation with 
the concomitant enhanced ROS production and stress.
6.1.1  Rodent models of PD
Rodent  models  of  parkinsonism  aim  to  reproduce  key  pathogenic  features  of the 
syndrome including movement disorder induced by the progressive loss of dopminergic 
neurons  in  the  SN,  accompanied  by  the  formation  of a-synuclein  containing  Lewy 
body  inclusions.  Despite  the  creation  of many  chemically  induced  and  genetically 
engineered models, there is none that accurately demonstrates these features.
One of the first acute models was created using 6-OHDA administration in rats which 
causes  depletion  of  striatal  and  SN  neurons  through  oxidative  stress,  providing 
fundamental  insights  into  basal  ganglia  physiology.  Bilateral  injection  into  both 
hemispheres of the striatum results in akinesia (absence of movement) and unilateral 
injection  in  asymmetric  circling  motor  behavior.  Lewy  body  formation  was  not 
observed in the 6-OHDA model (Jeon et al. 1995).
Mitochondrial complex  I  inhibitors such as MPTP and rotenone have provided more 
progressive models of disease when chronically administered at low dose, resulting in 
degeneration  of the  nigrostriatal  pathway.  MPTP  administration  in  mice  results  in 
symptoms  of akinesia  and  rigidity  (Sedelis  et  al.  2001),  and  transgenic  mice  over­
expressing a-synuclein have increased sensitivity to MPTP, suggesting that genetic and 
environmental causes may converge (Song et al. 2004).
Chronic  administration  of rotenone  in  rats  results  not  only  in  degeneration  of the 
nigrostriatal  pathway,  but also  in the  appearance  of Lewy  body-like  inclusions.  The 
animals show symptoms of akinesia, rigidity and tremor, thus recapitulating most of the 
mechanisms thought to be important in PD pathogenesis (Betarbet et al. 2000; Sherer et 
al. 2003).
Genetic  mutations  identified  in  familial  parkinsonism  have  provided  new  tools  to 
implicate and understand the molecular pathways affected.
a-synuclein  mutations  and  multiplications  are  dominantly  inherited  and  gain-of- 
function. A vast number of mice over-expressing WT or mutant a-synuclein have been
220generated. Some of these show pathological and behavioural impairments that worsen 
with age and are reminiscent of PD patients. These impairments include a reduction in 
dopaminergic  nerve  terminals  in  the  striatum,  neuronal  inclusions  containing  a- 
synuclein, and motor abnormalities (for review (Fleming et al. 2005)).
PD mutations in Parkin, DJ-1 and PINK1 are recessively inherited and loss-of-function. 
Parkin  deficient  mice  show  no  overt  loss  of neurons  in  the  SN  or  striatum,  but 
relatively subtle alterations were identified, including increased extracellular dopamine 
concentration and reduced excitability of neurons in the striatum.  Interestingly, these 
mice  show  a  reduction  in  weight  gain,  mitochondrial  respiration  and  antioxidant 
capacity, and increased oxidative damage in the ventral midbrain (Palacino et al. 2004). 
The  behavioural  phenotype  of the  Parkin  KO  mice  is  modest  by  exhibiting  a mild 
reduction in locomotor activity and ability. Therefore, Parkin deficient mice are useful 
to identify the early effects of a PD-causing mutation in vivo (for review (Fleming et al.
2005)).
Similar  to  Parkin  KO  mice,  DJ-1  deficient  mice  show  no  loss  of  nigrostriatal 
dopaminergic neurons, but they exhibit increased striatal dopamine levels and up-take 
rates. Behaviourally, DJ-1 KO mice display subtle deficits such as decreased locomotor 
activity.
Mice deficient for PINK1 are being characterised, and they show no overt neuronal loss 
or behavioural phenotype. However, a decrease in dopamine release has been identified 
that appears to result in impairment of long-term potentiation and depression in striatal 
neurons  (Jie  Shen,  Keystone  Symposium  “Molecular  Mechanisms  of 
Neurodegeneration 2007”).
The  HtrA2  KO mice  exhibit a very  strong phenotype with reduction in weight gain 
(Figure  3-2B)  and  the  progressive  development  of motor  deficits  such  as  tremor, 
rigidity, postural instability and bradykinesia or akinesia. This phenotype develops over 
a short period of only  10 days and thereby allows the  study of the late stages of the 
disease. Pathologically, the HtrA2 KO mice suffer from loss of a population of striatal 
neurons  (Figure  3-3E)  concomitant  with  a  reduction  in  nerve  terminals  of  the 
nigrostriatal  pathway  in  the  posterior  portion  of the  striatum  (Figure  3-3F).  Neither 
neuronal  loss  in  the  SNpc  (Figure  3-3G)  nor  Lewy  body-like  aggregates  could  be 
detected.  In  human  PD,  non-motor  symptoms  clearly  precede  the  onset  of
221parkinsonism,  and  this  is  also  the  case  in  the  HtrA2  KO  animals  since  the  striatal 
neuron loss is evident already at P20. Therefore, further study of the HtrA2 KO mice at 
earlier time points would be needed to determine when the neuronal loss occurs. None 
of the  mice  deleted  for  one  of the  recessive  PD  genes,  Parkin,  DJ-1  and  PINK1, 
exhibits neuronal  loss in the SNpc  or striatum and severe motor deficits  such as the 
HtrA2  KO  mice.  Some  of  the  a-synuclein  transgenic  mice  show  a  reduction  in 
dopaminergic nerve terminals in the striatum similar to HtrA2 KO mice, however their 
motor deficits are not as severe as the deficits of the HtrA2 KO mice. Therefore, loss of 
HtrA2  in mice results in a relatively  strong model  of parkinsonism  compared to the 
other  genetic  mouse  models  of PD,  and  they  represent  a  useful  model  for  further 
studies because they have pathology and behavioural  impairments reminiscent of the 
pathology and symptoms observed in patients with PD.
6.2  Loss  of HtrA2  leads  to  a  stress-induced  transcriptional 
response
Transcriptional  profiling  was  performed  to  identify  HtrA2-dependent  transcriptional 
changes.  WT  and  HtrA2  KO  MEFs  were  challenged  with  the  complex  I  inhibitor 
rotenone to  induce mitochondrial  stress.  A higher number of transcriptional  changes 
were detected in HtrA2 KO MEFs in response to rotenone treatment than in WT cells 
(Figure 4-2C).  Although a subset of genes  were  differentially  expressed  in rotenone 
treated  WT  cells,  but  not  in  HtrA2  KO  cells  treated  with  rotenone,  no  functional 
signature of genes could be identified that was only modulated in WT cells in response 
to  rotenone  treatment  but not  in  HtrA2  KO  cells.  Most  of the  genes  modulated  by 
rotenone were identified in HtrA2 KO cells, whereas their transcriptional regulation in 
WT cells was not significant (Figure 4-2C). The stress-inducible TF CHOP as well as 
Gadd45a  were  among  those  transcripts  being  significantly  induced  by  rotenone 
treatment in HtrA2  KO cells but not in WT cells in the GeneChip analysis, and their 
enhanced expression in HtrA2 KO cells following rotenone treatment was confirmed 
by RT qPCR analysis (Figure 4-3A,  B  and data not shown).  Recently,  Gadd45a has 
been implicated in epigenetic gene activation by inducing DNA demethylation (Barreto 
et al. 2007), and further investigation of its expression levels in HtrA2 KO brains might 
be  of  interest.  The  induction  of  CHOP  in  HtrA2  KO  MEFs  following  rotenone 
treatment could point to an increased level of stress in these mitochondria,  as CHOP
222was  found  to  be  implicated  in  a  mitochondria-specific  stress  response  (Zhao  et  al. 
2002).  Interestingly,  CHOP  expression  was  higher  in  brain  tissue  from  HtrA2  KO 
mice, but not in any other tissue tested (Figure 4-4A), potentially mirroring a higher 
level  of stress  in  brain due to  an  increased  demand  for mitochondrial  function or a 
decreased  capacity  to  cope  with  the  stress  elicited  by  loss  of  HtrA2  function. 
Furthermore,  the  increase  in  CHOP  expression  level  seems  to  correlate  with  the 
development of a parkinsonian syndrome in HtrA2 KO mice (Figure 4-4B and Figure 
3-2B) and might be essential for the manifestation of this phenotype.
Transcriptional profiling of genes differentially expressed in brain tissue from HtrA2 
KO  mice  revealed  that,  besides  CHOP,  ATF3  and  Herp  mRNA  levels  were  also 
induced in these brains (Figure 4 8). CHOP and Herp are known to be dually regulated 
by the ER stress-specific and the shared branch of the UPR (Figure  1   6B) (Ma et al. 
2002; Ma and Hendershot 2004).  Expression of ATF3  is increased following a wide 
range of stress stimuli.  Interestingly,  the induction of ATF3  transcript in response to 
amino  acid  deprivation  or  ER  stress  was  demonstrated  to  occur  by  mechanisms 
requiring eIF2a phosphorylation (Jiang et al. 2004). Thus, deregulation of the shared 
branch  of the  UPR or  activation  of other  pathways  that  lead  to  phosphorylation  of 
eIF2a, and concomitantly stimulate translation of ATF4, could possibly be implicated 
in the cellular events resulting from loss of HtrA2 function.
The induction of CHOP expression has previously been implicated in a mitochondrial 
stress response  (Zhao  et  al.  2002).  Zhao  and colleagues used  a mutant  version  of a 
mitochondrial  matrix  enzyme  that  could  not  fold  properly  and  accumulated  in  the 
mitochondria.  In  their  study,  the  authors  noted  the  transcriptional  up-regulation  of 
nuclear genes encoding mitochondrial  stress proteins such as Hsp60,  HsplO,  mtDnaJ 
and  ClpP.  CHOP  in  association  with  C/EBPp  did  regulate  the  expression  of those 
mitochondrial stress proteins via a CHOP element in their promoters (Zhao et al. 2002). 
None of the  mitochondrial  stress proteins  was differentially  expressed  in  HtrA2  KO 
brain,  suggesting  that  the  type of stress  in  cells that  lack  HtrA2  might be  different. 
Thus,  loss  of HtrA2  seems  to  elicit  a  different  sort  of stress  than  accumulation  of 
unfolded proteins.
2236.2.1  Potential  deregulation  of  the  ATF4  pathway  in  HtrA2  KO 
animals
Strikingly,  a subset of genes that  were  expressed to  a higher degree  in  brains  from 
HtrA2  KO  mice  were  previously  reported  to  dependent  on  the  TF  ATF4  for 
transcriptional up-regulation (Vallejo et al.  1993; Fawcett et al.  1999; Siu et al. 2002; 
Harding et al. 2003; Ohoka et al. 2005). Markedly, a C/EBP-ATF composite site had 
been characterised in the promoters of a subset of these genes, namely CHOP, ATF3, 
Herp, ASNS and TRB3. Analysis of the genomic sequence of the putative ATF4 target 
genes that are up-regulated in HtrA2 KO brain, revealed C/EBP-ATF consensus sites in 
almost all of the genes (Table 4-5). These results strongly support the hypothesis that 
deregulation of ATF4 might contribute to the transcriptional profile in brains from mice 
lacking HtrA2. ATF4 protein levels are regulated through phosphorylation of eIF2a on 
the translational  level  (Figure  1-6B).  Therefore,  investigation of the protein  level  of 
ATF4 in WT and HtrA2 KO brain should be performed. In addition, the activity of the 
upstream  signalling  pathways  (the  eIF2a  kinases)  can  be  studied  using  phospho- 
specific antibodies against PERK, GCN2 and PKR. Interestingly, proteasome inhibition 
was reported to result in activation of GCN2 and increased phosphorylation of eIF2a 
(Jiang  and  Wek  2005),  suggesting  that  deregulation  of this  pathway  might  not  be 
uncommon in the cellular events leading to development of PD.
Gene expression profiling cannot differentiate between primary and secondary events 
and, therefore, the GeneChip analysis of brain tissue from HtrA2 mice at P29 may only 
provide a molecular fingerprint of late-stage processes due to loss of HtrA2. However, 
the signature of ATF4 target genes up-regulated in HtrA2 KO brain has been reported 
to be induced in cellular models of PD following stimulation with neurotoxins in vitro 
(treatment  of MEFs  with  rotenone  in  this  thesis,  and  (Ryu  et  al.  2002;  Holtz  and 
O'Malley 2003)) and for CHOP also in vivo (Silva et al. 2005). Therefore, a transient 
stimulus with  neurotoxins  such  as rotenone,  6-OHDA  or MPP+  modulates the  same 
genes found up-regulated in HtrA2 KO brains, suggesting that the identified genes are 
potentially important in the development of PD.
Interestingly, the genes modulated by 6-OHDA and MPP+ treatment, but none of the 
genes induced by treatment with 6-OHDA but not MPP+, were up-regulated in brains
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this study, the transcriptional changes induced by MPP+ or 6-OHDA treatment in the 
dopaminergic cell line MN9D were measured. Whereas 6-OHDA led to the induction 
of ER chaperones and other genes that are associated with the ER stress-specific branch 
of the UPR, MPP+ did not. However, both, 6-OHDA and MPP+ caused transcriptional 
up-regulation of a set of genes that are induced downstream of the shared branch of the 
UPR, as most of these genes were described previously to be induced in response to ER 
stress dependent on the presence of ATF4 (Harding et al. 2003). Therefore, the authors 
proposed  that  6-OHDA  is  activating  all  three  signalling  pathways  of  the  UPR, 
IRE1/XBP-1,  ATF6 and PERK,  whereas MPP+  is only  activating the  PERK branch 
(Figure  1-6B) (Holtz and O'Malley 2003). In line with this were the observations that 
arsenite  exposure  of  primary  neuronal  cells  led  to  the  up-regulation  of  CHOP 
expression without a concurrent activation of ER-specific signalling pathways of the 
UPR (Mengesdorf et al. 2002).
What are the cellular events leading to 6-OHDA- and MPP+-induced toxicity? Both 
MPP+  and  6-OHDA  can  inhibit  complex  I  of the  respiratory  chain,  however,  the 
cellular events and the type of cell death induced by these toxins appear to be different. 
MPP+ accumulates in mitochondria due to the energy-dependent electrical gradient that 
is maintained across the mitochondria membrane. Once accumulated in mitochondria, 
MPP+  inhibits  complex  I  of the  electron  transport  chain,  at  or  near  the  rotenone 
sensitive site.  Blockade of mitochondrial respiration has two cytotoxic consequences. 
First,  it impairs mitochondrial energy supply resulting in decreased intracellular ATP 
and NAD+ contents and ATP/ADP ratio (Storch et al. 2000). In line with this are the 
observations, that glucose or fructose decrease MPP+-mediated toxicity by providing 
energy for anaerobic metabolism via glycolysis, and inhibition of glycolysis increases 
MPP+-induced cell death (Wu et al.  1996; Mazzio and Soliman 2003). A recent study 
suggests  that  inhibition  of complex  I  is  not  solely  involved  in  eliciting  cell  death. 
Indeed,  disruption  of Ca2+  homeostasis  appears  to  play  an  additional  role  in  MPP+ 
toxicity.  This results in an elevation of intracellular Ca2+, leading to the activation of 
Ca2+-dependent  enzymes,  for  example,  protein  kinase  and  calpains  I  and  II,  which 
disturbs  the  normal  cell  function,  resulting  in  cellular  damage  (Lee  et  al.  2006). 
Second,  MPP+  appears to  support the  occurrence  of oxidative  stress.  This  notion  is
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mitochondrial respiratory chain and energy production will probably cause leakage or 
generation of oxyradicals and subsequent oxidative stress, so that the two processes are 
probably inexorably linked. However, a series of experiments comparing 6-OHDA and 
MPP+ toxicity showed, that generation of ROS seemed to play an essential role in 6- 
OHDA-mediated apoptosis, but there was no evidence of this in the setting of MPP+- 
induced cell death (Wu et al.  1996; Fonck and Baudry 2001; Han et al.  2003). Thus, 
MPP+-induced  toxicity  has  been  primarily  attributed  to  its  effect  on  mitochondrial 
energy  metabolism,  rather  than  increased  oxidative  stress.  The  neurotoxicity  of 6- 
OHDA is believed to be related primarily to production of ROS since, in contrast to 
MPP+, anti-oxidants can attenuate 6-OHDA-induced cell death (Han et al. 2003) and 
inhibition of glycolysis has not adverse effect (Wu et al.  1996). Only 6-OHDA, but not 
MPP+,  treatment  results  in  activation  of  caspases  and  morphological  changes 
associated with apoptosis, probably because MPP+ more effectively depletes cellular 
energy than 6-OHDA, therefore, only 6-OHDA-treated cells retain sufficient energy to 
execute apoptosis (Choi et al. 1999; Lotharius et al.  1999).
Transcriptional up-regulated genes in the dopaminergic cell  line MN9D that were in 
common to  treatment  with  both  MPP+  and  6-OHDA  (Table  I  (Holtz and  O'Malley 
2003)) were found to be induced in brains from HtrA2 KO mice. None of the genes 
associated with the ER stress-specific branch of the UPR that were induced only by 6- 
OHDA  treatment  (Table  II  (Holtz and  O'Malley  2003))  were  up-regulated  in brains 
from  HtrA2  KO  mice.  Which  conclusions  about  HtrA2  could  be  drawn  from  the 
knowledge about the cellular events that lead to 6-OHDA- and MPP+-induced toxicity? 
Loss  of  HtrA2  causes  mitochondrial  dysfunction,  potentially  leading  to  impaired 
respiration and concomitant energy deficits as well as generation of ROS. In addition, 
intracellular Ca2+ homeostasis might be deregulated upon loss of HtrA2. It is possible 
that loss of HtrA2, similar to MPP+, primarily leads to impaired mitochondrial energy 
supply  resulting  in  decreased  intracellular  ATP  content.  Primary  WT  or  HtrA2  KO 
MEFs did not exhibit differences in metabolic activity when challenged with CCCP, 
rotenone or tunicamycin as determined by an MTT assay (Figure 3-5C-E), suggesting 
that  loss  of HtrA2  in  MEFs  might  not  result  in  metabolic  defects.  Analysis  of the 
mitochondrial  electron  transport  chain  at  the  biochemical  level  in  extracts  prepared
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compromise of the function of complexes I, II, III or IV when enzymatic activities were 
normalised against the activity of the mitochondrial matrix enzyme citrate synthase, to 
account  for  differences  in  mitochondrial  density  in  the  samples.  However,  extracts 
prepared from the basal ganglia of HtrA2 KO animals showed a decrease of the yield 
of  mitochondrial  citrate  synthase,  indicating  that  mitochondrial  density  might  be 
reduced in these tissue samples (Martins et al. 2004). Preliminary data using an oxygen 
electrode  to  measure  oxygen  consumption  in  brain  revealed  that  the  oxygen 
consumption going through complexes II,  III  and IV  is reduced in HtrA2  KO tissue 
compared to  WT (Nicoleta Moisoi,  MRC Leicester).  Thus, mitochondrial respiration 
might be impaired in brains from HtrA2 KO mice. Disruption of the Ca2+ homeostasis 
appears to play an additional role in MPP+ toxicity.  Mitochondrial Ca2+ homeostasis 
seems to  be  similar in  WT  and  HtrA2  KO  cells (Nicoleta Moisoi,  MRC  Leicester), 
however,  the  study  of intracellular and  ER  Ca2+  homeostasis needs to  be extended. 
Both toxins, MPP+ and 6-OHDA, will cause oxidative stress albeit 6-OHDA might be 
more potent to induce ROS. Therefore, a lower level of ROS generation could result in 
activation of only the  shared  branch  of the  UPR (PERK,  eIF2a),  as  in the  case  for 
MPP+, and higher levels of ROS might lead to signalling through all branches of the 
UPR as in the case for 6-OHDA (IRE1/XBP-1, ATF6,  PERK).  Thus,  loss of HtrA2 
might  result  in  relatively  mild  ROS  generation,  thereby  inducing  genes  that  can  be 
regulated through the shared branch of the UPR.
6.2.2  Loss of HtrA2 leads to oxidative stress
HtrA2  KO  mice  probably  suffer  from  enhanced  levels  of  oxidative  stress  since 
mitochondrial lipids from HtrA2 KO mice show a higher content of peroxidised lipids 
than WT mitochondria (Table 4-6). Also, HtrA2 KO cells produce more ROS than WT 
cells in response to rotenone and 6-OHDA (data not shown). In addition, the phenotype 
of HtrA2  KO mice can be  delayed  by  treatment with an anti-oxidant  (Figure 4-10). 
Oxidative  stress  had  been  placed  upstream  of the  induction of CHOP  and  ATF3  in 
response to 6-OHDA (Holtz et al.  2006).  Therefore,  loss of HtrA2 might lead to the 
production of ROS itself or might diminish the capacity of the cells to counteract ROS, 
which subsequently causes induction of CHOP and other stress-induced genes.
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liver and brain tissue of HtrA2  KO mice,  however, an increase in CHOP expression 
level was only detected in brain tissue.  This observation could certainly indicate that 
the increased expression of CHOP is not connected to the generation of ROS in HtrA2 
KO mice, however, a more favourable explanation is that liver cells are less susceptible 
to the oxidative  stress and therefore  up-regulation of CHOP  in  liver or other organs 
cannot be detected within the  life-span of the HtrA2  KO animals.  Similar to  CHOP 
expression being exclusively up-regulated in brain tissue although all cells are exposed 
to  loss  of HtrA2,  the  systemic  treatment  of rats  with  low  doses  of rotenone  leads 
selectively  to  lesions  in  the  nigrostriatal  system  (Betarbet  et  al.  2000;  Sherer  et  al. 
2003). In line with the observation that CHOP expression is selectively induced in the 
brain of HtrA2 KO mice, mitochondria isolated from the brains of WT and HtrA2 KO 
mice rather than liver mitochondria might result in the unambiguous identification of 
HtrA2 substrates in the 2D DIGE approach.
Treatment of HtrA2 KO mice with anti-oxidants results in prolonged life-span (Figure
4-10) and is also beneficial for the locomotor activity of the HtrA2 KO mice (Nicoleta 
Moisoi,  Miguel  Martins,  MRC  Leicester).  It  will  be  interesting  to  measure  CHOP 
expression  levels  in HtrA2  KO mice treated with anti-oxidants.  Preliminary analysis 
was  performed  on  P30  animals,  however,  the  level  of CHOP  expression  was  only 
slightly  reduced  in  HtrA2  KO  mice  treated  with NAC  compared  to  vehicle  treated 
HtrA2  KO  mice  (data  not  shown).  These  analyses  need  to  be  repeated  and  more 
importantly  extended  over  a  time  course.  It  is  possible  that  measuring  CHOP 
expression levels at P30 is too late in the development of the parkinsonian syndrome, 
even in HtrA2 KO mice treated with anti-oxidants.  HtrA2 KO mice as young as PI5 
did show increased  levels of CHOP transcript, however,  P8 mice did not.  Therefore, 
CHOP expression levels should be monitored between P10 and P20 in HtrA2 KO mice 
treated with anti-oxidants or vehicle.
Taken together expression profiling of brains from HtrA2 deficient mice  identified a 
signature of genes that appear to be characterised by C/EBP-ATF composite sites for 
transcriptional  regulation.  These  genes  are  up-regulated  in  cells  stimulated  with 
neurotoxins and thought to be regulated through phosphorylation of eIF2a leading to 
an increase of ATF4 protein. Therefore, different models used for studying PD, such as
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up-regulation of a specific signature of genes, suggesting that their up-regulation might 
be a common underlying theme in PD.
6.3  HtrA2 and Parkinson’s disease
Eight nuclear genes are known to carry mutations that cause PD, encoding a-synuclein, 
parkin, UCHL1, PINK1, DJ-1, LRRK2, ATP13A2 and HtrA2 (Table 1-1) (Farrer 2006; 
Ramirez et al. 2006). Mutation or altered expression of these proteins contributes to PD 
pathogenesis  through  partly  overlapping  mechanisms  that  result  in  mitochondrial 
impairment, oxidative stress, and protein mishandling. Consistent with the development 
of a parkinsonian  syndrome  in mice  lacking  HtrA2  function,  a polymorphism and a 
mutation resulting in single amino acid changes in HtrA2 that appear to dampen the 
activation of its proteolytic activity were identified to be associated with the PARK 13 
locus (Strauss et al. 2005). These studies suggest that loss of function of HtrA2 leads to 
neuronal  cell  death,  possibly  due  to  mitochondrial  dysfunction,  both in  mice  and  in 
humans. Since then, several other mutations linked to PD have been identified in HtrA2 
(personal  communication,  Reijko  Kruger).  The  A141S  polymorphism  and  G399S 
mutation in HtrA2 were found to be heterozygous in sporadic PD patients, therefore it 
is not  possible  to  conclude  from  the  inheritance  pattern whether the  HtrA2  locus  is 
dominant  or  recessive.  The  fact  that  the  heterozygous  mutation  appears  to  be 
pathogenic  would  suggest  that  it  is  inherited  in  a  dominant  manner,  however,  the 
mutation seems to be loss-of-function and therefore a heterozygous mutation could act 
as  haploinsufficiency  which  would  suggest  that  it  is  recessive.  In  mice,  only 
homozygous  loss  of HtrA2  results  in  the  development  of a parkinsonian  syndrome 
suggesting that loss of HtrA2 activity  is recessive in mice.  Targeted knock in of the 
G399S mutation in mice would be needed to address the effect and inheritance pattern 
of this PD-associated mutation.
The  A141S  polymorphism  and  G399S  mutation  in  HtrA2  localise  to  domains 
previously shown to be important in the regulation of the proteolytic activity of HtrA2, 
namely  the  N-terminal  portion  of the  mature  form  of HtrA2  and  the  PDZ  domain, 
respectively (Martins et al. 2002). Interestingly, analysis using the Scansite algorithm 
(Obenauer et al. 2003) (www.scansite.mit.edu) indicates that SI42 and S400, residues
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phosphorylation  sites  for  proline-directed  serine/threonine  kinases  (Figure  5-2A), 
suggesting that these sites might play a major role in the regulation of the enzymatic 
activity  of HtrA2.  Alignment  of HtrA2  homologues  of different  species  shows  that 
SI42 and S400 are conserved in human, rodents and chicken, and in addition S400 is 
further conserved in Drosophila and Sacharomyces cerevisiae (Figure 5-2B).
6.3.1  PINK1 is upstream of HtrA2 and regulates its activity
The  mitochondrial  kinase  PINK1  was  identified as  a new binding  partner of HtrA2 
using the TAP tag system to affinity purify interacting proteins.  Mutations in PINK1 
were  reported  to  account  for  the  PARK6  locus  of  familial  PD  and  it  has  been 
hypothesised  that  PINK1  may  phosphorylate  mitochondrial  proteins  in  response  to 
cellular  stress,  protecting  against  mitochondrial  dysfunction  (Valente  et  al.  2004). 
HtrA2 might be a direct substrate of PINK1, however, the kinase activity of PINK1  in 
in vitro kinase assays was very low, thus, it is not possible to conclude whether PINK1 
phosphorylates HtrA2  directly.  However,  HtrA2 could be phosphorylated in vitro by 
p38y  and  p38f$,  and  preliminary  data  indicates  that  p38y  might  phosphorylate  both 
sites, SI42 and S400 in vitro (personal communication, Helene Plun-Favreau).
Activation of the MEKK3 signalling pathway led to phosphorylation of HtrA2 at least 
on SI42 in vivo (Figure 5-2C), and chemical inhibition of p38 reduced the MEKK3- 
induced phosphorylation of HtrA2 (Figure 5-2D). Moreover, PINK1  was required for 
this phosphorylation to occur (Figure 5-3D) and mutations in PINK1  decreased HtrA2 
phosphorylation  on  SI42  in  human  brain  samples  from  PD  patients  (Figure  5-3E). 
Unfortunately, the sequence around S400 of HtrA2 is relatively hydrophobic and does 
not work well as an immunogen in rabbits. Therefore it was not possible to generate an 
antibody  specific  for  phospho-S400  HtrA2  and  address  its  phosphorylation  in  vivo. 
Interestingly, HtrA2 mutants mimicking phosphorylation on SI42 and S400 showed an 
increase in their protease activity (Figure 5-4).
Why might PINK1 expression be necessary for HtrA2 phosphorylation to occur (Figure 
5-3B  and  D)?  One  possibility,  suggested  by  the  data  presented,  is  that  HtrA2 
phosphorylation is mediated by a kinase activated in the MEKK3  signalling pathway 
(potentially p38, Figure 5-2C and D), but is dependent on the interaction of HtrA2 with
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is  that  PINK1  is  indeed  a  kinase,  but  the  “correct”  stimulus  to  activate  its  kinase 
activity in vitro has not been identified. In this case, PINK1 might phosphorylate HtrA2 
directly  and  PINK1  kinase  activity  could  be  modulated  by  the  MEKK3  pathway. 
Alternatively,  PINK1  might  be  upstream  of  another  kinase  responsible  for 
phosphorylating HtrA2 and be involved in its activation. In vivo, the phosphorylation of 
HtrA2  might  require recruitment  of this kinase to  the  mitochondria,  or alternatively 
could  occur  in  the  cytosol  before  HtrA2  is  imported  into  the  mitochondrial 
intermembrane space. The interaction between PINK1  and HtrA2 was predominantly 
detected in mitochondria-enriched fractions. However, both over-expressed full length 
mitochondrial  and  mature  cytosolic  HtrA2  could  be  phosphorylated  on  SI42  when 
MEKK3  was  activated  and  this  occurred  in  a  PINK 1-dependent  manner  (data  not 
shown), suggesting that the phosphorylation might occur prior to import of HtrA2 into 
the mitochondria.
Phosphorylation  of HtrA2  appears  to  regulate  its  proteolytic  activity,  since  HtrA2 
mutants mimicking phosphorylation  on  SI42  and  S400  showed  an  increase  in their 
protease activity in vitro (Figure 5-4A), concomitant with a reduction in the ability of 
the PDZopt peptide and XIAP to activate HtrA2 protease activity (Figure 5-4B and C, 
Figure  5-5C).  This  suggests  that  phosphorylation  of  HtrA2  might  lead  to 
conformational  changes  facilitating  its  protease  activity.  However,  in  these 
experiments, HtrA2 proteins engineered with a serine to aspartate mutation, to mimic 
phosphorylation at the sites of interest, were used. Therefore, it is crucial to show that 
“real” phosphorylation can have the same impact on HtrA2 proteolytic activity.  First 
evidence  that  PINK1  might  indeed  regulate  HtrA2  activity  in  vivo  comes  from 
experiments over-expressing PINK1  prior to measuring HtrA2 activity ex vivo (Figure
5-6C). In line with this is the observation that over-expression of PINK 1  cannot protect 
HtrA2 KO cells to the same extent as WT cells from stress-induced apoptosis, placing 
HtrA2 downstream of PINK 1  function (Figure 5-7).
Previously,  it was reported that both A141S  and  G399S  PD-associated mutations  in 
HtrA2  resulted  in  reduced  ability  of the  PDZopt  peptide  or  XIAP  to  activate  its 
protease activity (Strauss et al. 2005). The influence of these PD-associated mutations 
on the phosphorylation  of the  adjacent  sites  (SI42  and  S400)  is  clearly  an  area for
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for proline-directed serine/threonine kinases on this residue. However, A141 is not well 
conserved  across  different  species.  In  rodents  this  residue  is  a  threonine,  already 
providing  such  a  potential  phosphorylation  site  (Figure  5-2B)  and  preliminary  data 
indicates that  A141S  has no  effect  on  SI42  phosphorylation  in  vitro.  However,  the 
G399  sequence  is  well  conserved  and  G399S  mutation  in  HtrA2  might  lead  to 
decreased  phosphorylation  of this  site  in  vitro.  A  defect  in  phosphorylation  due  to 
G399S mutation and therefore impaired modulation of HtrA2 proteolytic activity could 
explain the increased mitochondrial dysfunction and sensitivity to stress-induced cell 
death of this mutant when over-expressed (Strauss et al. 2005).
The  PD-associated  mutations  in  PINK1,  C575R  and  Y431H,  resulted  in  a  robust 
decrearse  in  the  levels  of phosphorylated  HtrA2  at  position  SI42  in  human  brains 
(Figure 5-3E). The study of these human brains is clearly important for confirming the 
relevance of the interaction of HtrA2 and PINK1 in vivo in human PD patients. Neither 
the  C575R nor the  Y431H  mutant of PINK1  have  lost their ability  to  interact  with 
HtrA2  in vitro (data not shown,  Helene Plun-Favreau), thus supporting the idea that 
PINK1 possibly functions as a kinase in vivo to phosphorylate HtrA2 and that its kinase 
activity towards HtrA2 could be impaired by the PD mutations. Alternatively, through 
interaction with HtrA2, these PINK1  mutants might be acting as dominant negatives 
and therefore prevent WT PINK1 from binding and exerting its effect on HtrA2.
The  identification  of  PINK1  binding  to  HtrA2  demonstrates  a  direct  molecular 
interaction  between two  genes  implicated  in  PD.  Uniquely,  it  is the  only  functional 
interaction that has been validated in vitro, in vivo and in human PD brains. In parallel 
to the presented data in this thesis, genetic analyses of HtrA2 and PINK1  function in 
Drosophila place HtrA2 downstream of PINK1  and Parkin (unpublished data, Ruhena 
Begum  et  al.,  Cancer  Research  UK).  Thus,  both  HtrA2  and  PINK1  proteins  are 
genetically linked, suggesting that they could be part of the same signalling pathway.
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Mammalian  HtrA2  may  function  to  protect  mitochondria  from  certain  stresses  in  a 
manner similar to the homologous stress-adaptive proteins DegP and DegS in bacteria.
6.4.1  HtrA2 function akin to bacterial DegP
DegP  is  localised  in  the  periplasmic  space,  where  it  controls  bacterial  thermal  and 
oxidative  tolerance  by  acting  as  a  chaperone  at  normal  temperatures.  At  elevated 
temperatures,  the  chaperone  transforms  into  an  active  endoprotease  that  degrades 
damaged  and  misfolded  proteins  (Spiess  et  al.  1999).  If HtrA2  functions  similar to 
DegP, mitochondria from HtrA2 KO mice may be unable to degrade unfolded proteins 
in  the  intermembrane  space  under  conditions  of cell  stress  and  these  could  form 
aggregates that would directly compromise the maintenance of the mitochondria.
Evidence  for  an  evolutionary  conservation  of  this  function  is  provided  by  the 
observation  that  the  protein  level  of HtrA2  appears  to  be  increased  following  heat 
shock  of  human  neuroblastoma  SH-SY5Y  cells  (Gray  et  al.  2000),  and  that  the 
proteolytic activity of recombinant HtrA2 is significantly elevated upon heat shock in 
vitro (Martins et al.  2003).  However, the data showing an increase of HtrA2 protein 
levels was obtained using an antibody that recognised an apparently nuclear form of 
HtrA2 and has subsequently not been validated. In addition, chaperone activity similar 
to DegP has not been identified for HtrA2.
In contrast to mammalian HtrA2, bacterial DegP protease possesses two PDZ domains 
and does not contain a transmembrane segment (Figure 1-2B). Whereas HtrA2 is active 
as a trimer, DegP forms a hexameric structure (Figure 1-3B and D). In addition, in the 
inactive  conformation, the catalytic  centre of DegP  is sterically  blocked  by  a trio of 
loops from the surrounding protein,  and the catalytic triad is distorted away  from an 
active configuration (Krojer et al. 2002). However, in HtrA2 the proteolytic active sites 
are  in  conformation  poised  for  catalysis  (Li  et  al.  2002).  DegP  shows  substrate 
specificity for aliphatic amino acids at the PI  position (Kolmar et al.  1996), similar to 
HtrA2 and DegS. However, DegP exhibits no preference for any amino acid at the PI’ 
position, which is in contrast to HtrA2 that favours an alanine or serine at this position 
(Martins et al. 2003; Walle et al. 2007). In addition, DegP cleaves substrates which are
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whereas HtrA2 has a rather narrow cleavage site preference (Walle et al. 2007).
The induction of CHOP in HtrA2 KO MEFs following rotenone treatment and in brains 
of  HtrA2  KO  mice  probably  points  to  an  increased  level  of  stress  in  these 
mitochondria. This suggests the possibility that the function of HtrA2 is not DegS-like 
in a signalling cascade, but more akin to the bacterial protease DegP, which elicits its 
protective function by refolding or degrading unfolded accumulating proteins. The lack 
of  HtrA2  would  lead  to  a  higher  level  of unfolded  proteins  in  the  mitochondrial 
intermembrane  space  and therefore the threshold for activation of the  mitochondrial 
stress response would be lower in HtrA2 KO cells compared to the WT cells.
How could loss of HtrA2 lead to increased production of ROS if HtrA2 had DegP-like 
function?  HtrA2  would  be  involved  in  clearance  of  unfolded  proteins  in  the 
intermembrane  space  of  the  mitochondria.  Therefore,  loss  of  HtrA2  proteolytic 
function would result in the accumulation of unfolded proteins, possibly members of 
the  respiratory  complexes,  which  would  lead  to  impaired  electron  transport  and 
generation of ROS (Figure 6-IB).
6.4.2  HtrA2 function akin to bacterial DegS
The bacterial protease DegS  is a critical mediator of a transcriptional stress response 
initiated  in  the  periplasmic  space  (Schlieker  et  al.  2004).  If HtrA2  acts  like  DegS 
(Walsh  et  al.  2003),  loss  of HtrA2  may  result  in  an  inability  to  mount an  adaptive 
transcriptional  response under stress  conditions that cause protein unfolding,  leaving 
the mitochondria unable to maintain normal function and rendering the cells prone to 
either necrotic or apoptotic death (Figure 6-1 A).
A DegS-like function for HtrA2 would be clearly predicted from the similarity of their 
domain and more importantly their closely related crystal structures (Figure  1-2B and 
Figure  1-3B and C) (Li et al. 2002; Martins et al. 2003). The catalytic centre of both 
proteases is slightly distorted in the inactive conformation, and their catalytic activity 
can  be  regulated  by  the  PDZ  domains  (Li  et  al.  2002;  Wilken  et  al.  2004).  It  is 
interesting to note that DegS cleaves RseA between a valine and a serine (Walsh et al. 
2003). Similarly, human and mouse HtrA2 have a preference for valine at PI  position
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suggests that conservation between DegS and HtrA2 is also present at the biochemical 
level.  Moreover,  HtrA2  has  a rather  narrow cleavage  site preference  (Martins et al. 
2003;  Walle et al.  2007),  further supporting the notion that HtrA2 cleaves substrates 
specifically similar to DegS.
While the structural and biochemical similarity between HtrA2 and DegS is evident, it 
has so far not been possible to identify mitochondrial mammalian homologues of other 
downstream components of the bacterial periplasmic stress response system. Bacterial 
RseP,  a rhomboid-like metalloprotease that is responsible for the second cleavage of 
the  transmembrane  receptor  RseA  (Kanehara  et  al.  2002),  is  a  homologue  of the 
mammalian  S2P protease  in the Golgi  network.  S2P possesses like bacterial  RseP  a 
PDZ domain, and it is interesting to note that the residue corresponding to S400 in the 
PDZ domain of HtrA2  is conserved in the PDZ domain of S2P,  suggesting that this 
residue might be important for the regulation of a number of PDZ domain-containing 
proteases.  S2P  participates  in  proteolytic  activation  of membrane-tethered  TFs  like 
SREBP in response to low cholesterol levels (Sakai et al.  1996) and ATF6 in response 
to unfolded proteins in the ER (see Chapter 1.5.1, (Ye et al. 2000)). Cleavage of these 
substrates is also preceded by cleavage through another protease, the ER localised SIP 
(Sakai et al.  1998; Ye et al. 2000). However, there is no apparent sequence similarity 
between mammalian  SIP and bacterial  DegS  or mammalian HtrA2,  although all  are 
serine  proteases.  Even  though  S2P  appears  to  be  the  mammalian  homologue  of 
bacterial RseP, the localisation of S2P in the Golgi network suggests that it cannot be 
the functional homologue of RseP in a putative stress response pathway downstream of 
HtrA2 in the mitochondria.
The  rotenone-mediated  induction  of CHOP  in  HtrA2  KO  MEFs  and  the  increased 
expression of CHOP in brains of HtrA2 KO mice probably points to an increased level 
of stress in these mitochondria. An HtrA2-dependent transcriptional response following 
rotenone treatment could not be identified. At a first glance, this seems to suggest that 
the function of HtrA2  is not DegS-like in a signalling cascade,  but more akin to the 
bacterial  protease  DegP.  However,  a  role  for  HtrA2  in  actively  signalling  in  a 
mitochondrial  stress  response  cannot  be  excluded  from  the  data.  It  is  possible  that 
rotenone  might  not  be  the  “correct”  stimulus  to  induce  HtrA2-dependent  stress
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their mitochondria to this stress stimulus (Figure 3-6 and Figure 3-7A).  Furthermore, 
rotenone might induce a variety of stress  signalling pathways that could overlay the 
HtrA2-dependent signature in WT cells.
How could  loss  of HtrA2  lead  to  increased  production  of ROS  if it had  DegS-like 
function in the mitochondria? Analogous to a DegS-like function, mammalian HtrA2 
could  be  responsible  for transducing  a  signal  from  the  mitochondria to  the  nucleus 
resulting in increased expression of other proteases or chaperones, that would help to 
maintain the mitochondria free from misfolded proteins. Loss of HtrA2 would therefore 
decrease the availability of proteases and folding catalysts in the mitochondria and in 
turn  lead  to  accumulation  of  aberrant  proteins,  impaired  electron  transport  and 
generation  of ROS  (Figure  6-IB).  In  addition,  bacterial  DegS  is  known  to  induce 
expression of DegP (Erickson and Gross  1989), supporting the idea that HtrA2 would 
normally  lead  to  the  expression  of  other  proteases  involved  in  mitochondrial 
maintenance, thereby protecting against oxidative stress.
The  PINK 1-dependent  phosphorylation  of  HtrA2  seems  likely  to  influence  its 
proteolytic activity. This observation might support a DegS-like model for HtrA2, since 
DegS  activity  is  also  regulated  by  an  upstream  component,  rather  than  an 
environmental stimulus, heat shock, as in the case for DegP protease activity. DegS is 
activated by engagement of its PDZ domain by binding to C-terminal motifs of OMPs. 
Phosphorylation of HtrA2 in the PDZ domain might lead to a similar conformational 
effect.  Likewise,  binding  of XIAP  to  the  N-terminus  of mature  HtrA2  leads  to  its 
activation (Martins et al. 2003), therefore phosphorylation on SI42 close to its mature 
N-terminus might have a similar effect.
Taken together,  whether HtrA2  has inherited a function similar to bacterial  DegP or 
DegS in mammalian mitochondria is not clear. A DegS-like function for HtrA2 would 
be predicted  from the  similarity  of their closely  related crystal  structures and of the 
regulation of their proteolytic activity (Li et al. 2002; Martins et al. 2003) and would be 
favoured over a DegP-like model.
2366.5  Concluding remarks and future directions
During the last years, progress has been made to understand the physiological role of 
HtrA2  in the  mitochondria.  Especially,  the  characterisation  of the  phenotype  of the 
HtrA2 KO and Mnd2 mice was important to highlight HtrA2’s role as being protective 
rather  than  pro-apoptotic  (see  Chapter  3,  (Jones  et  al.  2003;  Martins  et  al.  2004)). 
Analogous to the bacterial protease DegS, HtrA2 was proposed to function in a putative 
mitochondrial stress response pathway inherited from bacteria (Figure 6-1 A).
From  the  data  presented  in  this  thesis,  it  is  possible  to  postulate  that  PINK1  acts 
upstream of HtrA2 and regulates HtrA2 activity through phosphorylation (see Chapter 
5).  Enhanced  HtrA2  activity  is  thought  to  protect  cells  from  stress-induced  death. 
Decreased phosphorylation of HtrA2 in human PD patients with PINK1  mutations and 
potentially also in patients with HtrA2 mutation will probably lead to deregulation of 
HtrA2 protease activity. This could possibly impair signalling of a mitochondrial stress 
response pathway and/or trigger a stress response similar to the response seen in brains 
of HtrA2 KO animals.
In the future,  it will  be crucial  to  determine whether HtrA2  is a direct  substrate  for 
PINK1  kinase  activity  and/or  whether  other  kinases  could  be  involved  in  the 
phosphorylation  of HtrA2.  The  activtion  of the  MEKK3-p38  pathway  leads  to  an 
increase in HtrA2 phosphorylation on SI42 in vivo, therefore, the activity of PINK 1   in 
these settings should be studied.
The phosphorylation of HtrA2 on SI42 has been shown to occur in vitro and in vivo, 
however,  little is known about phosphorylation on S400,  a potential phosphorylation 
site  within  the  PDZ  domain  of HtrA2.  In  an  in  vitro  kinase  assay  using  a  peptide 
surrounding  S400,  this  site  can  be  phosphorylated  (data  not  shown).  However,  for 
technical reasons it has not been possible to determine phosphorylation on S400 of full 
length  or  mature  HtrA2.  It  should  be  fairly  interesting  to  find  out  whether 
phosphorylation does occur in vivo on S400 of HtrA2. In addition, it will be important 
to  study  the  impact  of the  polymorphism  and  mutation  identified  in  HtrA2  in  PD 
patients,  SI41A  and  G399S  (Strauss  et  al.  2005),  on  the  phosphorylation  and 
proteolytic activity of HtrA2.
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these animals. In addition, loss of HtrA2 results in oxidative stress, and at least a subset 
of genes  up-regulated  in  brains  from  HtrA2  KO  animals  have  been  reported  to  be 
induced  by  oxidative  stress.  The  TF  CHOP  has  taken  a central  role  in cellular  and 
animal models of PD  induced by  neurotoxins (Ryu et al.  2002;  Holtz and O'Malley 
2003; Silva et al. 2005), and it is induced in brains of HtrA2 KO mice. Thus, loss of 
HtrA2  is  the  first  genetic  mouse  model  of PD  that  shows  up-regulation  of CHOP, 
interestingly specifically in the brains of HtrA2 KO mice. CHOP has been implicated 
as  a  mediator  of apoptosis  in  the  context  of oxidative  stress  (Guyton  et  al.  1996; 
Mengesdorf et  al.  2002),  suggesting  that  up-regulation  of CHOP  might  ultimately 
contribute to enhanced cell death. Therefore a model can be proposed, whereby HtrA2 
function decreases oxidative stress, however, upon loss of HtrA2 increased oxidative 
stress would result in expression of CHOP and modulation of a number of other genes 
leading to cell death (Figure 6-IB).
Anti-oxidant treatment of the HtrA2 KO mice alleviates their phenotype and oxidative 
stress  has  been  implicated  in  the  up-regulation  of  CHOP.  Therefore,  it  will  be 
important to monitor CHOP expression levels in anti-oxidant treated HtrA2 KO mice. 
This will shed light on the role of CHOP in the development of the phenotype of the 
HtrA2 KO mice. However, it is possible that, although sustained CHOP expression has 
been  shown  to  promote  apoptosis  (for  review  (Oyadomari  and  Mori  2004)),  initial 
activation of CHOP  could  have  a protective  effect  (Zinszner et al.  1998)  similar to 
moderate  activation  of  various  stress-induced  signalling  pathways.  Therefore,  the 
interpretation of the time course of CHOP expression in anti-oxidant treated HtrA2 KO 
mice could be complicated.
Furthermore, to address the role of CHOP in the development of the phenotype of the 
HtrA2 KO mice, the HtrA2 KO mice could be crossed to CHOP deficient mice. CHOP 
KO mice have already been generated,  and they appear phenotypically normal,  have 
normal fertility and reproductive behaviour, but they are defective in the development 
of apoptosis in response to ER stress elicited by tunicamycin (Zinszner et al.  1998). 
Absence of CHOP might delay the development of the parkinsonian syndrome in the 
HtrA2 KO mice.
CHOP can be transcriptionally induced by activation of eIF2a kinases and subsequent
238induction of ATF4 protein level (Figure  1-6B). Therefore, investigation of the protein 
level of ATF4 and the phosphorylation status of eIF2a  in WT and HtrA2 KO brain 
should be performed. In addition, the activity of the upstream signalling pathways (the 
eIF2a kinases) can be studied using phospho-specific antibodies against PERK, GCN2 
and PKR.
A signature of genes was identified to be up-regulated in HtrA2 KO brain that contain 
C/EBP-ATF  composite  sites  (Table  4-5).  Therefore,  it  would  be  interesting  to 
investigate whether transcription through this site is enhanced in the absence of HtrA2. 
In addition, immunodepletion of ATF4, CHOP, C/EBP{3 and other TFs might suppress 
this enhanced transcriptional activity and thereby could lead to the identification of the 
TFs responsible for activation of the C/EBP-ATF composite site upon loss of HtrA2.
The  HtrA2  KO  mice  and  neurotoxin-induced  mouse  models  of  PD  exhibit  up- 
regulation of CHOP, however, other genetic PD mouse models have not been examined 
for their CHOP expression  levels.  Therefore,  it would be  interesting to  obtain brain 
tissue  from  a-synuclein  over-expressing,  and  Parkin,  PINK1  and  DJ-1  KO  mice  to 
determine CHOP expression levels in these. Furthermore, it would be very important to 
test human PD patients for CHOP expression in order to verify CHOP as a common 
underlying theme in the human disease. Most of the dopaminergic neurons in the SNpc 
are lost when the PD patients die, making the comparision with the same tissue from 
normal humans quite difficult.  Therefore,  other brain regions that do not suffer from 
cell loss in PD patients have to be tested as well.
The  characterisation  of transcriptional  changes  in  mice  lacking  HtrA2  identified  a 
signature  of  genes  potentially  representing  a  common  underlying  theme  in  the 
development  of  PD.  The  identification  of  HtrA2  and  PINK1  being  involved  in  a 
common  pathway  is  the  first  step  in  elucidating  the  molecular  players  around  the 
mitochondrial  function  of  HtrA2.  Thus,  further  study  of this  pathway  might  help 
explain how mitochondrial dysfunction leads to neuronal death in patients with PD.
239Figure 6-1. Model for HtrA2 function.
(A) A putative mitochondrial stress signalling  pathway inherited from  bacteria. 
Model for  HtrA2  in  a  signalling  pathway  akin to  bacterial  DegS  protease.  (B) 
HtrA2 activity is necessary to decrease oxidative stress, and HtrA2 activity can 
be regulated by PINK1.  Loss of HtrA2 would cause increased oxidative stress, 
leading to transcriptional up-regulation of CHOP, ATF3 and modulation of other 
genes.  Increased  expression  of  CHOP  has  been  reported  to  contribute  to 
enhanced  cell  death.  Model  akin  to  DegS:  HtrA2  could  be  involved  in  a 
signalling cascade responsible for the expression of mitochondrial chaperones 
and  proteases,  thereby  decreasing  the  load  of unfolded  proteins,  preventing 
oxidative  stress and  cell  death.  Loss of HtrA2  would  lead  to accumulation  of 
aberrant proteins, which could impair electron transport of the respiratory chain 
and cause oxidative stress. Model akin to DegP: HtrA2 could be responsible for 
degrading unfolded proteins, thereby preventing their accumulation which could 
lead to oxidative stress.
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